Separate indirect from direct evidence (SIDE) using back-calculation method
serious-arrhythmias

Random effects model: 

                                           comparison k prop   nma         95%-CI direct        95%-CI indir.            95%-CI   RoR           95%-CI     z p-value
                      Afatinib:Afatinib + Cetuximab 1 1.00  2.96 [0.12;  73.82]   2.96 [0.12; 73.82]      .                 .     .                .     .       .
                   Afatinib:Afatinib + HMGCR inhibitors 1 1.00  3.38 [0.13;  86.01]   3.38 [0.13; 86.01]      .                 .     .                .     .       .
                                Afatinib:Almonertinib 0    0  0.67 [0.04;  11.86]      .             .   0.67 [0.04;     11.86]     .                .     .       .
                    Afatinib:Amivantamab  +  Lazertinib 0    0  0.77 [0.06;   9.31]      .             .   0.77 [0.06;      9.31]     .                .     .       .
                                Afatinib:Chemotherapy 1 0.16  1.09 [0.30;   4.00]   0.16 [0.01;  3.97]   1.59 [0.38;      6.58]  0.10 [0.00;     3.37] -1.28  0.2002
                                 Afatinib:Dacomitinib 0    0  2.77 [0.62;  12.38]      .             .   2.77 [0.62;     12.38]     .                .     .       .
                              Afatinib:DHFR inhibitor 0    0  1.48 [0.16;  13.55]      .             .   1.48 [0.16;     13.55]     .                .     .       .
                                   Afatinib:Erlotinib 1 0.71  1.55 [0.58;   4.14]   2.56 [0.80;  8.23]   0.45 [0.07;      2.80]  5.70 [0.65;    50.02]  1.57  0.1164
                      Afatinib:Erlotinib + chemotherapy 0    0  0.82 [0.12;   5.39]      .             .   0.82 [0.12;      5.39]     .                .     .       .
                    Afatinib:Erlotinib + HER3 inhibitor 0    0  1.54 [0.21;  11.17]      .             .   1.54 [0.21;     11.17]     .                .     .       .
                     Afatinib:Erlotinib + IGF-1R inhibitor 0    0  1.27 [0.23;   7.19]      .             .   1.27 [0.23;      7.19]     .                .     .       .
                     Afatinib:Erlotinib + MET inhibitor 0    0  1.76 [0.43;   7.23]      .             .   1.76 [0.43;      7.23]     .                .     .       .
                    Afatinib:Erlotinib + antiangiogenesis 0    0  1.59 [0.42;   6.11]      .             .   1.59 [0.42;      6.11]     .                .     .       .
                               Afatinib:Furmonertinib 0    0  0.94 [0.13;   6.72]      .             .   0.94 [0.13;      6.72]     .                .     .       .
                                   Afatinib:Gefitinib 1 0.24  1.35 [0.28;   6.52]   0.33 [0.01;  8.14]   2.11 [0.34;     12.93]  0.16 [0.00;     6.22] -0.99  0.3232
                         Afatinib:Gefitinib/Erlotinib 0    0  2.26 [0.30;  17.18]      .             .   2.26 [0.30;     17.18]     .                .     .       .
                                  Afatinib:Lazertinib 0    0  0.79 [0.08;   8.33]      .             .   0.79 [0.08;      8.33]     .                .     .       .
                                 Afatinib:Osimertinib 0    0  1.29 [0.26;   6.41]      .             .   1.29 [0.26;      6.41]     .                .     .       .
                    Afatinib:Osimertinib + chemotherapy 0    0  0.64 [0.04;  11.61]      .             .   0.64 [0.04;     11.61]     .                .     .       .
                  Afatinib:Osimertinib + antiangiogenesis 0    0  0.21 [0.01;   3.02]      .             .   0.21 [0.01;      3.02]     .                .     .       .
                                     Afatinib:Placebo 1 0.36  3.11 [0.86;  11.31]   2.52 [0.29; 21.72]   3.51 [0.70;     17.53]  0.72 [0.05;    10.58] -0.24  0.8098
                                 Afatinib:Rociletinib 0    0  1.52 [0.08;  29.50]      .             .   1.52 [0.08;     29.50]     .                .     .       .
                              Afatinib:antiangiogenesis 0    0  0.36 [0.10;   1.36]      .             .   0.36 [0.10;      1.36]     .                .     .       .
                                Afatinib:Zorifertinib 0    0  0.84 [0.07;   9.51]      .             .   0.84 [0.07;      9.51]     .                .     .       .
     Afatinib + Cetuximab:Afatinib + HMGCR inhibitors 0    0  1.14 [0.01; 109.20]      .             .   1.14 [0.01;    109.20]     .                .     .       .
                  Afatinib + Cetuximab:Almonertinib 0    0  0.22 [0.00;  16.83]      .             .   0.22 [0.00;     16.83]     .                .     .       .
      Afatinib + Cetuximab:Amivantamab  +  Lazertinib 0    0  0.26 [0.00;  15.20]      .             .   0.26 [0.00;     15.20]     .                .     .       .
                  Afatinib + Cetuximab:Chemotherapy 0    0  0.37 [0.01;  11.81]      .             .   0.37 [0.01;     11.81]     .                .     .       .
                   Afatinib + Cetuximab:Dacomitinib 0    0  0.93 [0.03;  32.39]      .             .   0.93 [0.03;     32.39]     .                .     .       .
                Afatinib + Cetuximab:DHFR inhibitor 0    0  0.50 [0.01;  24.79]      .             .   0.50 [0.01;     24.79]     .                .     .       .
                     Afatinib + Cetuximab:Erlotinib 0    0  0.52 [0.02;  15.06]      .             .   0.52 [0.02;     15.06]     .                .     .       .
        Afatinib + Cetuximab:Erlotinib + chemotherapy 0    0  0.28 [0.01;  11.45]      .             .   0.28 [0.01;     11.45]     .                .     .       .
      Afatinib + Cetuximab:Erlotinib + HER3 inhibitor 0    0  0.52 [0.01;  22.65]      .             .   0.52 [0.01;     22.65]     .                .     .       .
       Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor 0    0  0.43 [0.01;  16.54]      .             .   0.43 [0.01;     16.54]     .                .     .       .
       Afatinib + Cetuximab:Erlotinib + MET inhibitor 0    0  0.59 [0.02;  19.89]      .             .   0.59 [0.02;     19.89]     .                .     .       .
      Afatinib + Cetuximab:Erlotinib + antiangiogenesis 0    0  0.54 [0.02;  17.52]      .             .   0.54 [0.02;     17.52]     .                .     .       .
                 Afatinib + Cetuximab:Furmonertinib 0    0  0.32 [0.01;  13.77]      .             .   0.32 [0.01;     13.77]     .                .     .       .
                     Afatinib + Cetuximab:Gefitinib 0    0  0.45 [0.01;  16.30]      .             .   0.45 [0.01;     16.30]     .                .     .       .
           Afatinib + Cetuximab:Gefitinib/Erlotinib 0    0  0.76 [0.02;  34.14]      .             .   0.76 [0.02;     34.14]     .                .     .       .
                    Afatinib + Cetuximab:Lazertinib 0    0  0.27 [0.00;  14.38]      .             .   0.27 [0.00;     14.38]     .                .     .       .
                   Afatinib + Cetuximab:Osimertinib 0    0  0.43 [0.01;  15.79]      .             .   0.43 [0.01;     15.79]     .                .     .       .
      Afatinib + Cetuximab:Osimertinib + chemotherapy 0    0  0.22 [0.00;  16.40]      .             .   0.22 [0.00;     16.40]     .                .     .       .
    Afatinib + Cetuximab:Osimertinib + antiangiogenesis 0    0  0.07 [0.00;   4.61]      .             .   0.07 [0.00;      4.61]     .                .     .       .
                       Afatinib + Cetuximab:Placebo 0    0  1.05 [0.03;  33.55]      .             .   1.05 [0.03;     33.55]     .                .     .       .
                   Afatinib + Cetuximab:Rociletinib 0    0  0.51 [0.01;  40.64]      .             .   0.51 [0.01;     40.64]     .                .     .       .
                Afatinib + Cetuximab:antiangiogenesis 0    0  0.12 [0.00;   3.96]      .             .   0.12 [0.00;      3.96]     .                .     .       .
                  Afatinib + Cetuximab:Zorifertinib 0    0  0.28 [0.01;  15.88]      .             .   0.28 [0.01;     15.88]     .                .     .       .
               Afatinib + HMGCR inhibitors:Almonertinib 0    0  0.20 [0.00;  14.99]      .             .   0.20 [0.00;     14.99]     .                .     .       .
   Afatinib + HMGCR inhibitors:Amivantamab  +  Lazertinib 0    0  0.23 [0.00;  13.56]      .             .   0.23 [0.00;     13.56]     .                .     .       .
               Afatinib + HMGCR inhibitors:Chemotherapy 0    0  0.32 [0.01;  10.56]      .             .   0.32 [0.01;     10.56]     .                .     .       .
                Afatinib + HMGCR inhibitors:Dacomitinib 0    0  0.82 [0.02;  28.96]      .             .   0.82 [0.02;     28.96]     .                .     .       .
             Afatinib + HMGCR inhibitors:DHFR inhibitor 0    0  0.44 [0.01;  22.13]      .             .   0.44 [0.01;     22.13]     .                .     .       .
                  Afatinib + HMGCR inhibitors:Erlotinib 0    0  0.46 [0.02;  13.48]      .             .   0.46 [0.02;     13.48]     .                .     .       .
     Afatinib + HMGCR inhibitors:Erlotinib + chemotherapy 0    0  0.24 [0.01;  10.23]      .             .   0.24 [0.01;     10.23]     .                .     .       .
   Afatinib + HMGCR inhibitors:Erlotinib + HER3 inhibitor 0    0  0.45 [0.01;  20.23]      .             .   0.45 [0.01;     20.23]     .                .     .       .
    Afatinib + HMGCR inhibitors:Erlotinib + IGF-1R inhibitor 0    0  0.38 [0.01;  14.78]      .             .   0.38 [0.01;     14.78]     .                .     .       .
    Afatinib + HMGCR inhibitors:Erlotinib + MET inhibitor 0    0  0.52 [0.02;  17.78]      .             .   0.52 [0.02;     17.78]     .                .     .       .
   Afatinib + HMGCR inhibitors:Erlotinib + antiangiogenesis 0    0  0.47 [0.01;  15.67]      .             .   0.47 [0.01;     15.67]     .                .     .       .
              Afatinib + HMGCR inhibitors:Furmonertinib 0    0  0.28 [0.01;  12.30]      .             .   0.28 [0.01;     12.30]     .                .     .       .
                  Afatinib + HMGCR inhibitors:Gefitinib 0    0  0.40 [0.01;  14.57]      .             .   0.40 [0.01;     14.57]     .                .     .       .
        Afatinib + HMGCR inhibitors:Gefitinib/Erlotinib 0    0  0.67 [0.01;  30.49]      .             .   0.67 [0.01;     30.49]     .                .     .       .
                 Afatinib + HMGCR inhibitors:Lazertinib 0    0  0.24 [0.00;  12.83]      .             .   0.24 [0.00;     12.83]     .                .     .       .
                Afatinib + HMGCR inhibitors:Osimertinib 0    0  0.38 [0.01;  14.11]      .             .   0.38 [0.01;     14.11]     .                .     .       .
   Afatinib + HMGCR inhibitors:Osimertinib + chemotherapy 0    0  0.19 [0.00;  14.62]      .             .   0.19 [0.00;     14.62]     .                .     .       .
 Afatinib + HMGCR inhibitors:Osimertinib + antiangiogenesis 0    0  0.06 [0.00;   4.11]      .             .   0.06 [0.00;      4.11]     .                .     .       .
                    Afatinib + HMGCR inhibitors:Placebo 0    0  0.92 [0.03;  30.01]      .             .   0.92 [0.03;     30.01]     .                .     .       .
                Afatinib + HMGCR inhibitors:Rociletinib 0    0  0.45 [0.01;  36.21]      .             .   0.45 [0.01;     36.21]     .                .     .       .
             Afatinib + HMGCR inhibitors:antiangiogenesis 0    0  0.11 [0.00;   3.54]      .             .   0.11 [0.00;      3.54]     .                .     .       .
               Afatinib + HMGCR inhibitors:Zorifertinib 0    0  0.25 [0.00;  14.17]      .             .   0.25 [0.00;     14.17]     .                .     .       .
                Almonertinib:Amivantamab  +  Lazertinib 0    0  1.16 [0.04;  36.15]      .             .   1.16 [0.04;     36.15]     .                .     .       .
                            Almonertinib:Chemotherapy 0    0  1.64 [0.10;  25.75]      .             .   1.64 [0.10;     25.75]     .                .     .       .
                             Almonertinib:Dacomitinib 0    0  4.15 [0.20;  85.93]      .             .   4.15 [0.20;     85.93]     .                .     .       .
                          Almonertinib:DHFR inhibitor 0    0  2.23 [0.07;  69.39]      .             .   2.23 [0.07;     69.39]     .                .     .       .
                               Almonertinib:Erlotinib 0    0  2.32 [0.14;  38.62]      .             .   2.32 [0.14;     38.62]     .                .     .       .
                  Almonertinib:Erlotinib + chemotherapy 0    0  1.22 [0.05;  29.22]      .             .   1.22 [0.05;     29.22]     .                .     .       .
                Almonertinib:Erlotinib + HER3 inhibitor 0    0  2.31 [0.09;  62.29]      .             .   2.31 [0.09;     62.29]     .                .     .       .
                 Almonertinib:Erlotinib + IGF-1R inhibitor 0    0  1.91 [0.08;  44.63]      .             .   1.91 [0.08;     44.63]     .                .     .       .
                 Almonertinib:Erlotinib + MET inhibitor 0    0  2.64 [0.13;  52.42]      .             .   2.64 [0.13;     52.42]     .                .     .       .
                Almonertinib:Erlotinib + antiangiogenesis 0    0  2.39 [0.12;  45.95]      .             .   2.39 [0.12;     45.95]     .                .     .       .
                           Almonertinib:Furmonertinib 0    0  1.42 [0.10;  20.58]      .             .   1.42 [0.10;     20.58]     .                .     .       .
                               Almonertinib:Gefitinib 1 1.00  2.02 [0.18;  22.43]   2.02 [0.18; 22.43]      .                 .     .                .     .       .
                     Almonertinib:Gefitinib/Erlotinib 0    0  3.40 [0.13;  86.44]      .             .   3.40 [0.13;     86.44]     .                .     .       .
                              Almonertinib:Lazertinib 0    0  1.19 [0.04;  31.84]      .             .   1.19 [0.04;     31.84]     .                .     .       .
                             Almonertinib:Osimertinib 0    0  1.93 [0.10;  38.45]      .             .   1.93 [0.10;     38.45]     .                .     .       .
                Almonertinib:Osimertinib + chemotherapy 0    0  0.97 [0.02;  44.89]      .             .   0.97 [0.02;     44.89]     .                .     .       .
              Almonertinib:Osimertinib + antiangiogenesis 0    0  0.31 [0.01;  12.37]      .             .   0.31 [0.01;     12.37]     .                .     .       .
                                 Almonertinib:Placebo 0    0  4.67 [0.25;  87.92]      .             .   4.67 [0.25;     87.92]     .                .     .       .
                             Almonertinib:Rociletinib 0    0  2.27 [0.04; 120.27]      .             .   2.27 [0.04;    120.27]     .                .     .       .
                          Almonertinib:antiangiogenesis 0    0  0.54 [0.03;   9.73]      .             .   0.54 [0.03;      9.73]     .                .     .       .
                            Almonertinib:Zorifertinib 0    0  1.26 [0.04;  41.73]      .             .   1.26 [0.04;     41.73]     .                .     .       .
                Amivantamab  +  Lazertinib:Chemotherapy 0    0  1.41 [0.13;  15.59]      .             .   1.41 [0.13;     15.59]     .                .     .       .
                 Amivantamab  +  Lazertinib:Dacomitinib 0    0  3.58 [0.26;  49.31]      .             .   3.58 [0.26;     49.31]     .                .     .       .
              Amivantamab  +  Lazertinib:DHFR inhibitor 0    0  1.92 [0.09;  43.19]      .             .   1.92 [0.09;     43.19]     .                .     .       .
                   Amivantamab  +  Lazertinib:Erlotinib 0    0  2.00 [0.18;  22.11]      .             .   2.00 [0.18;     22.11]     .                .     .       .
      Amivantamab  +  Lazertinib:Erlotinib + chemotherapy 0    0  1.06 [0.06;  18.06]      .             .   1.06 [0.06;     18.06]     .                .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor 0    0  1.99 [0.10;  38.17]      .             .   1.99 [0.10;     38.17]     .                .     .       .
     Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor 0    0  1.65 [0.10;  26.87]      .             .   1.65 [0.10;     26.87]     .                .     .       .
     Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor 0    0  2.28 [0.17;  30.86]      .             .   2.28 [0.17;     30.86]     .                .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis 0    0  2.06 [0.16;  26.92]      .             .   2.06 [0.16;     26.92]     .                .     .       .
               Amivantamab  +  Lazertinib:Furmonertinib 0    0  1.22 [0.08;  18.55]      .             .   1.22 [0.08;     18.55]     .                .     .       .
                   Amivantamab  +  Lazertinib:Gefitinib 0    0  1.74 [0.15;  20.32]      .             .   1.74 [0.15;     20.32]     .                .     .       .
         Amivantamab  +  Lazertinib:Gefitinib/Erlotinib 0    0  2.93 [0.26;  33.48]      .             .   2.93 [0.26;     33.48]     .                .     .       .
                  Amivantamab  +  Lazertinib:Lazertinib 1 0.94  1.03 [0.18;   5.88]   0.76 [0.13;  4.57] 145.39 [0.11; 199205.50]  0.01 [0.00;     8.89] -1.38  0.1662
                 Amivantamab  +  Lazertinib:Osimertinib 1 0.86  1.67 [0.20;  13.58]   3.06 [0.32; 29.58]   0.05 [0.00;     11.29] 67.69 [0.17; 26419.55]  1.38  0.1662
    Amivantamab  +  Lazertinib:Osimertinib + chemotherapy 0    0  0.83 [0.03;  20.29]      .             .   0.83 [0.03;     20.29]     .                .     .       .
  Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis 0    0  0.27 [0.01;   5.40]      .             .   0.27 [0.01;      5.40]     .                .     .       .
                     Amivantamab  +  Lazertinib:Placebo 0    0  4.03 [0.39;  42.15]      .             .   4.03 [0.39;     42.15]     .                .     .       .
                 Amivantamab  +  Lazertinib:Rociletinib 0    0  1.96 [0.05;  78.48]      .             .   1.96 [0.05;     78.48]     .                .     .       .
              Amivantamab  +  Lazertinib:antiangiogenesis 0    0  0.47 [0.04;   5.92]      .             .   0.47 [0.04;      5.92]     .                .     .       .
                Amivantamab  +  Lazertinib:Zorifertinib 0    0  1.08 [0.07;  17.47]      .             .   1.08 [0.07;     17.47]     .                .     .       .
                             Chemotherapy:Dacomitinib 0    0  2.53 [0.54;  11.96]      .             .   2.53 [0.54;     11.96]     .                .     .       .
                          Chemotherapy:DHFR inhibitor 0    0  1.36 [0.14;  12.84]      .             .   1.36 [0.14;     12.84]     .                .     .       .
                               Chemotherapy:Erlotinib 4 0.59  1.42 [0.49;   4.08]   1.11 [0.28;  4.41]   2.01 [0.38;     10.50]  0.55 [0.06;     4.76] -0.54  0.5902
                  Chemotherapy:Erlotinib + chemotherapy 1 0.56  0.75 [0.13;   4.15]   0.97 [0.10;  9.58]   0.53 [0.04;      7.12]  1.84 [0.06;    58.59]  0.35  0.7294
                Chemotherapy:Erlotinib + HER3 inhibitor 0    0  1.41 [0.19;  10.61]      .             .   1.41 [0.19;     10.61]     .                .     .       .
                 Chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  1.17 [0.20;   6.87]      .             .   1.17 [0.20;      6.87]     .                .     .       .
                 Chemotherapy:Erlotinib + MET inhibitor 0    0  1.61 [0.37;   6.98]      .             .   1.61 [0.37;      6.98]     .                .     .       .
                Chemotherapy:Erlotinib + antiangiogenesis 0    0  1.46 [0.36;   5.91]      .             .   1.46 [0.36;      5.91]     .                .     .       .
                           Chemotherapy:Furmonertinib 0    0  0.86 [0.15;   5.10]      .             .   0.86 [0.15;      5.10]     .                .     .       .
                               Chemotherapy:Gefitinib 2 0.64  1.23 [0.32;   4.69]   1.37 [0.26;  7.30]   1.03 [0.11;      9.41]  1.33 [0.08;    21.40]  0.20  0.8403
                     Chemotherapy:Gefitinib/Erlotinib 0    0  2.07 [0.30;  14.38]      .             .   2.07 [0.30;     14.38]     .                .     .       .
                              Chemotherapy:Lazertinib 0    0  0.73 [0.08;   6.87]      .             .   0.73 [0.08;      6.87]     .                .     .       .
                             Chemotherapy:Osimertinib 1 0.43  1.18 [0.27;   5.23]   0.68 [0.07;  6.61]   1.78 [0.25;     12.81]  0.38 [0.02;     7.75] -0.63  0.5312
                Chemotherapy:Osimertinib + chemotherapy 0    0  0.59 [0.03;   9.99]      .             .   0.59 [0.03;      9.99]     .                .     .       .
              Chemotherapy:Osimertinib + antiangiogenesis 0    0  0.19 [0.01;   2.59]      .             .   0.19 [0.01;      2.59]     .                .     .       .
                                 Chemotherapy:Placebo 0    0  2.85 [0.72;  11.25]      .             .   2.85 [0.72;     11.25]     .                .     .       .
                             Chemotherapy:Rociletinib 0    0  1.39 [0.07;  27.69]      .             .   1.39 [0.07;     27.69]     .                .     .       .
                          Chemotherapy:antiangiogenesis 0    0  0.33 [0.09;   1.28]      .             .   0.33 [0.09;      1.28]     .                .     .       .
                            Chemotherapy:Zorifertinib 0    0  0.77 [0.07;   8.08]      .             .   0.77 [0.07;      8.08]     .                .     .       .
                           Dacomitinib:DHFR inhibitor 0    0  0.54 [0.05;   5.36]      .             .   0.54 [0.05;      5.36]     .                .     .       .
                                Dacomitinib:Erlotinib 1 0.85  0.56 [0.17;   1.81]   0.66 [0.19;  2.37]   0.21 [0.01;      4.40]  3.11 [0.12;    82.87]  0.68  0.4979
                   Dacomitinib:Erlotinib + chemotherapy 0    0  0.30 [0.04;   2.24]      .             .   0.30 [0.04;      2.24]     .                .     .       .
                 Dacomitinib:Erlotinib + HER3 inhibitor 0    0  0.56 [0.07;   4.46]      .             .   0.56 [0.07;      4.46]     .                .     .       .
                  Dacomitinib:Erlotinib + IGF-1R inhibitor 0    0  0.46 [0.07;   2.91]      .             .   0.46 [0.07;      2.91]     .                .     .       .
                  Dacomitinib:Erlotinib + MET inhibitor 0    0  0.64 [0.13;   3.00]      .             .   0.64 [0.13;      3.00]     .                .     .       .
                 Dacomitinib:Erlotinib + antiangiogenesis 0    0  0.58 [0.13;   2.55]      .             .   0.58 [0.13;      2.55]     .                .     .       .
                            Dacomitinib:Furmonertinib 0    0  0.34 [0.04;   3.02]      .             .   0.34 [0.04;      3.02]     .                .     .       .
                                Dacomitinib:Gefitinib 0    0  0.49 [0.08;   3.06]      .             .   0.49 [0.08;      3.06]     .                .     .       .
                      Dacomitinib:Gefitinib/Erlotinib 0    0  0.82 [0.09;   7.19]      .             .   0.82 [0.09;      7.19]     .                .     .       .
                               Dacomitinib:Lazertinib 0    0  0.29 [0.02;   3.49]      .             .   0.29 [0.02;      3.49]     .                .     .       .
                              Dacomitinib:Osimertinib 0    0  0.47 [0.08;   2.78]      .             .   0.47 [0.08;      2.78]     .                .     .       .
                 Dacomitinib:Osimertinib + chemotherapy 0    0  0.23 [0.01;   4.66]      .             .   0.23 [0.01;      4.66]     .                .     .       .
               Dacomitinib:Osimertinib + antiangiogenesis 0    0  0.08 [0.00;   1.22]      .             .   0.08 [0.00;      1.22]     .                .     .       .
                                  Dacomitinib:Placebo 1 0.28  1.13 [0.26;   4.95]   0.50 [0.03;  8.03]   1.56 [0.27;      8.96]  0.32 [0.01;     8.56] -0.68  0.4979
                              Dacomitinib:Rociletinib 0    0  0.55 [0.03;  11.41]      .             .   0.55 [0.03;     11.41]     .                .     .       .
                           Dacomitinib:antiangiogenesis 0    0  0.13 [0.03;   0.58]      .             .   0.13 [0.03;      0.58]     .                .     .       .
                             Dacomitinib:Zorifertinib 0    0  0.30 [0.02;   3.89]      .             .   0.30 [0.02;      3.89]     .                .     .       .
                             DHFR inhibitor:Erlotinib 1 1.00  1.04 [0.14;   7.55]   1.04 [0.14;  7.55]      .                 .     .                .     .       .
                DHFR inhibitor:Erlotinib + chemotherapy 0    0  0.55 [0.04;   7.30]      .             .   0.55 [0.04;      7.30]     .                .     .       .
              DHFR inhibitor:Erlotinib + HER3 inhibitor 0    0  1.03 [0.08;  14.27]      .             .   1.03 [0.08;     14.27]     .                .     .       .
               DHFR inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.86 [0.07;   9.82]      .             .   0.86 [0.07;      9.82]     .                .     .       .
               DHFR inhibitor:Erlotinib + MET inhibitor 0    0  1.18 [0.13;  10.96]      .             .   1.18 [0.13;     10.96]     .                .     .       .
              DHFR inhibitor:Erlotinib + antiangiogenesis 0    0  1.07 [0.12;   9.50]      .             .   1.07 [0.12;      9.50]     .                .     .       .
                         DHFR inhibitor:Furmonertinib 0    0  0.64 [0.04;   9.63]      .             .   0.64 [0.04;      9.63]     .                .     .       .
                             DHFR inhibitor:Gefitinib 0    0  0.91 [0.08;  10.55]      .             .   0.91 [0.08;     10.55]     .                .     .       .
                   DHFR inhibitor:Gefitinib/Erlotinib 0    0  1.52 [0.10;  23.93]      .             .   1.52 [0.10;     23.93]     .                .     .       .
                            DHFR inhibitor:Lazertinib 0    0  0.54 [0.03;  10.78]      .             .   0.54 [0.03;     10.78]     .                .     .       .
                           DHFR inhibitor:Osimertinib 0    0  0.87 [0.07;  10.14]      .             .   0.87 [0.07;     10.14]     .                .     .       .
              DHFR inhibitor:Osimertinib + chemotherapy 0    0  0.43 [0.01;  13.53]      .             .   0.43 [0.01;     13.53]     .                .     .       .
            DHFR inhibitor:Osimertinib + antiangiogenesis 0    0  0.14 [0.01;   3.66]      .             .   0.14 [0.01;      3.66]     .                .     .       .
                               DHFR inhibitor:Placebo 0    0  2.10 [0.22;  20.40]      .             .   2.10 [0.22;     20.40]     .                .     .       .
                           DHFR inhibitor:Rociletinib 0    0  1.02 [0.03;  31.51]      .             .   1.02 [0.03;     31.51]     .                .     .       .
                        DHFR inhibitor:antiangiogenesis 0    0  0.24 [0.03;   2.17]      .             .   0.24 [0.03;      2.17]     .                .     .       .
                          DHFR inhibitor:Zorifertinib 0    0  0.56 [0.03;  12.05]      .             .   0.56 [0.03;     12.05]     .                .     .       .
                     Erlotinib:Erlotinib + chemotherapy 2 0.74  0.53 [0.10;   2.78]   0.41 [0.06;  2.86]   1.06 [0.04;     27.29]  0.39 [0.01;    17.17] -0.49  0.6260
                   Erlotinib:Erlotinib + HER3 inhibitor 1 1.00  0.99 [0.18;   5.55]   0.99 [0.18;  5.55]      .                 .     .                .     .       .
                    Erlotinib:Erlotinib + IGF-1R inhibitor 2 1.00  0.82 [0.20;   3.41]   0.82 [0.20;  3.41]      .                 .     .                .     .       .
                    Erlotinib:Erlotinib + MET inhibitor 3 1.00  1.14 [0.41;   3.14]   1.14 [0.41;  3.14]      .                 .     .                .     .       .
                   Erlotinib:Erlotinib + antiangiogenesis 4 1.00  1.03 [0.41;   2.57]   1.03 [0.41;  2.57]      .                 .     .                .     .       .
                              Erlotinib:Furmonertinib 0    0  0.61 [0.09;   3.93]      .             .   0.61 [0.09;      3.93]     .                .     .       .
                                  Erlotinib:Gefitinib 0    0  0.87 [0.20;   3.71]      .             .   0.87 [0.20;      3.71]     .                .     .       .
                        Erlotinib:Gefitinib/Erlotinib 0    0  1.46 [0.22;   9.91]      .             .   1.46 [0.22;      9.91]     .                .     .       .
                                 Erlotinib:Lazertinib 0    0  0.51 [0.05;   4.91]      .             .   0.51 [0.05;      4.91]     .                .     .       .
                                Erlotinib:Osimertinib 0    0  0.83 [0.19;   3.58]      .             .   0.83 [0.19;      3.58]     .                .     .       .
                   Erlotinib:Osimertinib + chemotherapy 0    0  0.42 [0.02;   6.94]      .             .   0.42 [0.02;      6.94]     .                .     .       .
                 Erlotinib:Osimertinib + antiangiogenesis 0    0  0.14 [0.01;   1.79]      .             .   0.14 [0.01;      1.79]     .                .     .       .
                                    Erlotinib:Placebo 3 0.49  2.01 [0.66;   6.17]   2.60 [0.52; 12.89]   1.58 [0.33;      7.55]  1.64 [0.18;    15.44]  0.44  0.6633
                                Erlotinib:Rociletinib 1 1.00  0.98 [0.06;  16.11]   0.98 [0.06; 16.11]      .                 .     .                .     .       .
                             Erlotinib:antiangiogenesis 2 0.92  0.23 [0.09;   0.59]   0.30 [0.11;  0.77]   0.01 [0.00;      0.39] 20.71 [0.67;   638.73]  1.73  0.0832
                               Erlotinib:Zorifertinib 0    0  0.54 [0.05;   5.59]      .             .   0.54 [0.05;      5.59]     .                .     .       .
      Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor 0    0  1.88 [0.17;  20.63]      .             .   1.88 [0.17;     20.63]     .                .     .       .
       Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  1.56 [0.17;  13.93]      .             .   1.56 [0.17;     13.93]     .                .     .       .
       Erlotinib + chemotherapy:Erlotinib + MET inhibitor 0    0  2.16 [0.31;  15.13]      .             .   2.16 [0.31;     15.13]     .                .     .       .
      Erlotinib + chemotherapy:Erlotinib + antiangiogenesis 0    0  1.95 [0.29;  13.03]      .             .   1.95 [0.29;     13.03]     .                .     .       .
                 Erlotinib + chemotherapy:Furmonertinib 0    0  1.16 [0.11;  12.41]      .             .   1.16 [0.11;     12.41]     .                .     .       .
                     Erlotinib + chemotherapy:Gefitinib 0    0  1.65 [0.21;  13.00]      .             .   1.65 [0.21;     13.00]     .                .     .       .
           Erlotinib + chemotherapy:Gefitinib/Erlotinib 0    0  2.77 [0.24;  32.10]      .             .   2.77 [0.24;     32.10]     .                .     .       .
                    Erlotinib + chemotherapy:Lazertinib 0    0  0.97 [0.06;  14.70]      .             .   0.97 [0.06;     14.70]     .                .     .       .
                   Erlotinib + chemotherapy:Osimertinib 0    0  1.58 [0.19;  13.04]      .             .   1.58 [0.19;     13.04]     .                .     .       .
      Erlotinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.79 [0.03;  19.39]      .             .   0.79 [0.03;     19.39]     .                .     .       .
    Erlotinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.26 [0.01;   5.16]      .             .   0.26 [0.01;      5.16]     .                .     .       .
                       Erlotinib + chemotherapy:Placebo 0    0  3.82 [0.54;  26.91]      .             .   3.82 [0.54;     26.91]     .                .     .       .
                   Erlotinib + chemotherapy:Rociletinib 0    0  1.86 [0.07;  48.25]      .             .   1.86 [0.07;     48.25]     .                .     .       .
                Erlotinib + chemotherapy:antiangiogenesis 0    0  0.44 [0.07;   2.92]      .             .   0.44 [0.07;      2.92]     .                .     .       .
                  Erlotinib + chemotherapy:Zorifertinib 0    0  1.03 [0.06;  16.72]      .             .   1.03 [0.06;     16.72]     .                .     .       .
     Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.83 [0.09;   7.74]      .             .   0.83 [0.09;      7.74]     .                .     .       .
     Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor 0    0  1.15 [0.16;   8.45]      .             .   1.15 [0.16;      8.45]     .                .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis 0    0  1.04 [0.15;   7.28]      .             .   1.04 [0.15;      7.28]     .                .     .       .
               Erlotinib + HER3 inhibitor:Furmonertinib 0    0  0.61 [0.05;   7.76]      .             .   0.61 [0.05;      7.76]     .                .     .       .
                   Erlotinib + HER3 inhibitor:Gefitinib 0    0  0.88 [0.09;   8.32]      .             .   0.88 [0.09;      8.32]     .                .     .       .
         Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib 0    0  1.47 [0.11;  19.33]      .             .   1.47 [0.11;     19.33]     .                .     .       .
                  Erlotinib + HER3 inhibitor:Lazertinib 0    0  0.52 [0.03;   8.85]      .             .   0.52 [0.03;      8.85]     .                .     .       .
                 Erlotinib + HER3 inhibitor:Osimertinib 0    0  0.84 [0.09;   8.00]      .             .   0.84 [0.09;      8.00]     .                .     .       .
    Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy 0    0  0.42 [0.02;  11.35]      .             .   0.42 [0.02;     11.35]     .                .     .       .
  Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis 0    0  0.14 [0.01;   3.04]      .             .   0.14 [0.01;      3.04]     .                .     .       .
                     Erlotinib + HER3 inhibitor:Placebo 0    0  2.03 [0.26;  15.81]      .             .   2.03 [0.26;     15.81]     .                .     .       .
                 Erlotinib + HER3 inhibitor:Rociletinib 0    0  0.99 [0.04;  26.41]      .             .   0.99 [0.04;     26.41]     .                .     .       .
              Erlotinib + HER3 inhibitor:antiangiogenesis 0    0  0.24 [0.03;   1.66]      .             .   0.24 [0.03;      1.66]     .                .     .       .
                Erlotinib + HER3 inhibitor:Zorifertinib 0    0  0.54 [0.03;   9.92]      .             .   0.54 [0.03;      9.92]     .                .     .       .
      Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor 0    0  1.38 [0.24;   7.93]      .             .   1.38 [0.24;      7.93]     .                .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis 0    0  1.25 [0.23;   6.79]      .             .   1.25 [0.23;      6.79]     .                .     .       .
                Erlotinib + IGF-1R inhibitor:Furmonertinib 0    0  0.74 [0.07;   7.73]      .             .   0.74 [0.07;      7.73]     .                .     .       .
                    Erlotinib + IGF-1R inhibitor:Gefitinib 0    0  1.06 [0.14;   8.06]      .             .   1.06 [0.14;      8.06]     .                .     .       .
          Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib 0    0  1.78 [0.16;  19.30]      .             .   1.78 [0.16;     19.30]     .                .     .       .
                   Erlotinib + IGF-1R inhibitor:Lazertinib 0    0  0.62 [0.04;   9.00]      .             .   0.62 [0.04;      9.00]     .                .     .       .
                  Erlotinib + IGF-1R inhibitor:Osimertinib 0    0  1.01 [0.13;   7.76]      .             .   1.01 [0.13;      7.76]     .                .     .       .
     Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy 0    0  0.51 [0.02;  11.84]      .             .   0.51 [0.02;     11.84]     .                .     .       .
   Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis 0    0  0.16 [0.01;   3.14]      .             .   0.16 [0.01;      3.14]     .                .     .       .
                      Erlotinib + IGF-1R inhibitor:Placebo 0    0  2.45 [0.40;  14.96]      .             .   2.45 [0.40;     14.96]     .                .     .       .
                  Erlotinib + IGF-1R inhibitor:Rociletinib 0    0  1.19 [0.05;  27.54]      .             .   1.19 [0.05;     27.54]     .                .     .       .
               Erlotinib + IGF-1R inhibitor:antiangiogenesis 0    0  0.28 [0.05;   1.55]      .             .   0.28 [0.05;      1.55]     .                .     .       .
                 Erlotinib + IGF-1R inhibitor:Zorifertinib 0    0  0.66 [0.04;  10.13]      .             .   0.66 [0.04;     10.13]     .                .     .       .
     Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis 0    0  0.91 [0.23;   3.55]      .             .   0.91 [0.23;      3.55]     .                .     .       .
                Erlotinib + MET inhibitor:Furmonertinib 0    0  0.54 [0.06;   4.47]      .             .   0.54 [0.06;      4.47]     .                .     .       .
                    Erlotinib + MET inhibitor:Gefitinib 0    0  0.76 [0.13;   4.49]      .             .   0.76 [0.13;      4.49]     .                .     .       .
          Erlotinib + MET inhibitor:Gefitinib/Erlotinib 0    0  1.29 [0.15;  11.22]      .             .   1.29 [0.15;     11.22]     .                .     .       .
                   Erlotinib + MET inhibitor:Lazertinib 0    0  0.45 [0.04;   5.37]      .             .   0.45 [0.04;      5.37]     .                .     .       .
                  Erlotinib + MET inhibitor:Osimertinib 0    0  0.73 [0.12;   4.32]      .             .   0.73 [0.12;      4.32]     .                .     .       .
     Erlotinib + MET inhibitor:Osimertinib + chemotherapy 0    0  0.37 [0.02;   7.29]      .             .   0.37 [0.02;      7.29]     .                .     .       .
   Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis 0    0  0.12 [0.01;   1.91]      .             .   0.12 [0.01;      1.91]     .                .     .       .
                      Erlotinib + MET inhibitor:Placebo 0    0  1.77 [0.39;   8.02]      .             .   1.77 [0.39;      8.02]     .                .     .       .
                  Erlotinib + MET inhibitor:Rociletinib 0    0  0.86 [0.04;  16.94]      .             .   0.86 [0.04;     16.94]     .                .     .       .
               Erlotinib + MET inhibitor:antiangiogenesis 0    0  0.21 [0.05;   0.81]      .             .   0.21 [0.05;      0.81]     .                .     .       .
                 Erlotinib + MET inhibitor:Zorifertinib 0    0  0.48 [0.04;   6.07]      .             .   0.48 [0.04;      6.07]     .                .     .       .
               Erlotinib + antiangiogenesis:Furmonertinib 0    0  0.59 [0.07;   4.72]      .             .   0.59 [0.07;      4.72]     .                .     .       .
                   Erlotinib + antiangiogenesis:Gefitinib 0    0  0.84 [0.15;   4.69]      .             .   0.84 [0.15;      4.69]     .                .     .       .
         Erlotinib + antiangiogenesis:Gefitinib/Erlotinib 0    0  1.42 [0.17;  11.84]      .             .   1.42 [0.17;     11.84]     .                .     .       .
                  Erlotinib + antiangiogenesis:Lazertinib 0    0  0.50 [0.04;   5.70]      .             .   0.50 [0.04;      5.70]     .                .     .       .
                 Erlotinib + antiangiogenesis:Osimertinib 0    0  0.81 [0.14;   4.52]      .             .   0.81 [0.14;      4.52]     .                .     .       .
    Erlotinib + antiangiogenesis:Osimertinib + chemotherapy 0    0  0.40 [0.02;   7.79]      .             .   0.40 [0.02;      7.79]     .                .     .       .
  Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.13 [0.01;   2.04]      .             .   0.13 [0.01;      2.04]     .                .     .       .
                     Erlotinib + antiangiogenesis:Placebo 0    0  1.95 [0.46;   8.29]      .             .   1.95 [0.46;      8.29]     .                .     .       .
                 Erlotinib + antiangiogenesis:Rociletinib 0    0  0.95 [0.05;  18.10]      .             .   0.95 [0.05;     18.10]     .                .     .       .
              Erlotinib + antiangiogenesis:antiangiogenesis 0    0  0.23 [0.06;   0.83]      .             .   0.23 [0.06;      0.83]     .                .     .       .
                Erlotinib + antiangiogenesis:Zorifertinib 0    0  0.53 [0.04;   6.46]      .             .   0.53 [0.04;      6.46]     .                .     .       .
                              Furmonertinib:Gefitinib 1 1.00  1.42 [0.44;   4.58]   1.42 [0.44;  4.58]      .                 .     .                .     .       .
                    Furmonertinib:Gefitinib/Erlotinib 0    0  2.40 [0.21;  27.99]      .             .   2.40 [0.21;     27.99]     .                .     .       .
                             Furmonertinib:Lazertinib 0    0  0.84 [0.07;  10.46]      .             .   0.84 [0.07;     10.46]     .                .     .       .
                            Furmonertinib:Osimertinib 0    0  1.36 [0.16;  11.39]      .             .   1.36 [0.16;     11.39]     .                .     .       .
               Furmonertinib:Osimertinib + chemotherapy 0    0  0.68 [0.03;  16.88]      .             .   0.68 [0.03;     16.88]     .                .     .       .
             Furmonertinib:Osimertinib + antiangiogenesis 0    0  0.22 [0.01;   4.50]      .             .   0.22 [0.01;      4.50]     .                .     .       .
                                Furmonertinib:Placebo 0    0  3.30 [0.43;  25.44]      .             .   3.30 [0.43;     25.44]     .                .     .       .
                            Furmonertinib:Rociletinib 0    0  1.61 [0.06;  46.33]      .             .   1.61 [0.06;     46.33]     .                .     .       .
                         Furmonertinib:antiangiogenesis 0    0  0.38 [0.05;   2.75]      .             .   0.38 [0.05;      2.75]     .                .     .       .
                           Furmonertinib:Zorifertinib 0    0  0.89 [0.05;  14.56]      .             .   0.89 [0.05;     14.56]     .                .     .       .
                        Gefitinib:Gefitinib/Erlotinib 0    0  1.68 [0.19;  14.63]      .             .   1.68 [0.19;     14.63]     .                .     .       .
                                 Gefitinib:Lazertinib 1 0.49  0.59 [0.06;   5.51]   3.00 [0.12; 74.09]   0.13 [0.01;      2.87] 23.51 [0.27;  2053.29]  1.38  0.1662
                                Gefitinib:Osimertinib 0    0  0.96 [0.16;   5.64]      .             .   0.96 [0.16;      5.64]     .                .     .       .
                   Gefitinib:Osimertinib + chemotherapy 0    0  0.48 [0.02;   9.51]      .             .   0.48 [0.02;      9.51]     .                .     .       .
                 Gefitinib:Osimertinib + antiangiogenesis 0    0  0.16 [0.01;   2.49]      .             .   0.16 [0.01;      2.49]     .                .     .       .
                                    Gefitinib:Placebo 0    0  2.31 [0.43;  12.39]      .             .   2.31 [0.43;     12.39]     .                .     .       .
                                Gefitinib:Rociletinib 0    0  1.13 [0.05;  26.39]      .             .   1.13 [0.05;     26.39]     .                .     .       .
                             Gefitinib:antiangiogenesis 1 0.31  0.27 [0.05;   1.32]   0.03 [0.00;  0.57]   0.69 [0.10;      4.70]  0.05 [0.00;     1.49] -1.73  0.0832
                               Gefitinib:Zorifertinib 0    0  0.62 [0.05;   7.92]      .             .   0.62 [0.05;      7.92]     .                .     .       .
                       Gefitinib/Erlotinib:Lazertinib 0    0  0.35 [0.03;   3.78]      .             .   0.35 [0.03;      3.78]     .                .     .       .
                      Gefitinib/Erlotinib:Osimertinib 1 1.00  0.57 [0.16;   1.97]   0.57 [0.16;  1.97]      .                 .     .                .     .       .
         Gefitinib/Erlotinib:Osimertinib + chemotherapy 0    0  0.28 [0.02;   4.27]      .             .   0.28 [0.02;      4.27]     .                .     .       .
       Gefitinib/Erlotinib:Osimertinib + antiangiogenesis 0    0  0.09 [0.01;   1.09]      .             .   0.09 [0.01;      1.09]     .                .     .       .
                          Gefitinib/Erlotinib:Placebo 0    0  1.38 [0.24;   8.01]      .             .   1.38 [0.24;      8.01]     .                .     .       .
                      Gefitinib/Erlotinib:Rociletinib 0    0  0.67 [0.02;  19.91]      .             .   0.67 [0.02;     19.91]     .                .     .       .
                   Gefitinib/Erlotinib:antiangiogenesis 0    0  0.16 [0.02;   1.30]      .             .   0.16 [0.02;      1.30]     .                .     .       .
                     Gefitinib/Erlotinib:Zorifertinib 1 1.00  0.37 [0.10;   1.41]   0.37 [0.10;  1.41]      .                 .     .                .     .       .
                               Lazertinib:Osimertinib 1 0.71  1.62 [0.21;  12.32]   4.05 [0.36; 44.89]   0.17 [0.00;      7.44] 23.51 [0.27;  2053.29]  1.38  0.1662
                  Lazertinib:Osimertinib + chemotherapy 0    0  0.81 [0.03;  18.85]      .             .   0.81 [0.03;     18.85]     .                .     .       .
                Lazertinib:Osimertinib + antiangiogenesis 0    0  0.26 [0.01;   5.00]      .             .   0.26 [0.01;      5.00]     .                .     .       .
                                   Lazertinib:Placebo 0    0  3.92 [0.42;  36.62]      .             .   3.92 [0.42;     36.62]     .                .     .       .
                               Lazertinib:Rociletinib 0    0  1.91 [0.05;  69.61]      .             .   1.91 [0.05;     69.61]     .                .     .       .
                            Lazertinib:antiangiogenesis 0    0  0.46 [0.04;   4.98]      .             .   0.46 [0.04;      4.98]     .                .     .       .
                              Lazertinib:Zorifertinib 0    0  1.05 [0.07;  16.12]      .             .   1.05 [0.07;     16.12]     .                .     .       .
                 Osimertinib:Osimertinib + chemotherapy 1 1.00  0.50 [0.05;   5.55]   0.50 [0.05;  5.55]      .                 .     .                .     .       .
               Osimertinib:Osimertinib + antiangiogenesis 2 1.00  0.16 [0.02;   1.37]   0.16 [0.02;  1.37]      .                 .     .                .     .       .
                                  Osimertinib:Placebo 2 0.76  2.42 [0.69;   8.45]   2.69 [0.64; 11.33]   1.73 [0.14;     21.93]  1.56 [0.08;    28.78]  0.30  0.7668
                              Osimertinib:Rociletinib 0    0  1.18 [0.05;  27.65]      .             .   1.18 [0.05;     27.65]     .                .     .       .
                           Osimertinib:antiangiogenesis 0    0  0.28 [0.05;   1.53]      .             .   0.28 [0.05;      1.53]     .                .     .       .
                             Osimertinib:Zorifertinib 0    0  0.65 [0.10;   4.03]      .             .   0.65 [0.10;      4.03]     .                .     .       .
  Osimertinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.32 [0.01;   8.10]      .             .   0.32 [0.01;      8.10]     .                .     .       .
                     Osimertinib + chemotherapy:Placebo 0    0  4.83 [0.32;  72.82]      .             .   4.83 [0.32;     72.82]     .                .     .       .
                 Osimertinib + chemotherapy:Rociletinib 0    0  2.35 [0.04; 124.62]      .             .   2.35 [0.04;    124.62]     .                .     .       .
              Osimertinib + chemotherapy:antiangiogenesis 0    0  0.56 [0.03;  10.65]      .             .   0.56 [0.03;     10.65]     .                .     .       .
                Osimertinib + chemotherapy:Zorifertinib 0    0  1.30 [0.06;  26.63]      .             .   1.30 [0.06;     26.63]     .                .     .       .
                   Osimertinib + antiangiogenesis:Placebo 0    0 14.88 [1.25; 176.58]      .             .  14.88 [1.25;    176.58]     .                .     .       .
               Osimertinib + antiangiogenesis:Rociletinib 0    0  7.24 [0.16; 327.20]      .             .   7.24 [0.16;    327.20]     .                .     .       .
            Osimertinib + antiangiogenesis:antiangiogenesis 0    0  1.73 [0.11;  26.36]      .             .   1.73 [0.11;     26.36]     .                .     .       .
              Osimertinib + antiangiogenesis:Zorifertinib 0    0  4.00 [0.24;  66.31]      .             .   4.00 [0.24;     66.31]     .                .     .       .
                                  Rociletinib:Placebo 0    0  2.05 [0.10;  41.92]      .             .   2.05 [0.10;     41.92]     .                .     .       .
                               antiangiogenesis:Placebo 0    0  8.60 [2.06;  35.95]      .             .   8.60 [2.06;     35.95]     .                .     .       .
                                 Zorifertinib:Placebo 0    0  3.72 [0.41;  34.05]      .             .   3.72 [0.41;     34.05]     .                .     .       .
                           Rociletinib:antiangiogenesis 0    0  0.24 [0.01;   4.56]      .             .   0.24 [0.01;      4.56]     .                .     .       .
                             Rociletinib:Zorifertinib 0    0  0.55 [0.01;  21.17]      .             .   0.55 [0.01;     21.17]     .                .     .       .
                          antiangiogenesis:Zorifertinib 0    0  2.31 [0.19;  27.85]      .             .   2.31 [0.19;     27.85]     .                .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

serious-heart failure

Random effects model: 

                                          comparison k prop   nma          95%-CI direct        95%-CI    indir.               95%-CI    RoR             95%-CI     z p-value
                               Afatinib:Almonertinib 0    0  2.62 [0.03;  211.69]      .             .      2.62 [0.03; 2.116900e + 02]      .                  .     .       .
                   Afatinib:Amivantamab  +  Lazertinib 0    0  1.74 [0.14;   21.60]      .             .      1.74 [0.14; 2.160000e + 01]      .                  .     .       .
                               Afatinib:Chemotherapy 1 0.39  0.68 [0.09;    5.03]   0.16 [0.01;  3.87]      1.73 [0.14; 2.216000e + 01]   0.09 [0.00;       5.43] -1.15  0.2501
                                Afatinib:Dacomitinib 0    0  0.71 [0.03;   15.01]      .             .      0.71 [0.03; 1.501000e + 01]      .                  .     .       .
                                  Afatinib:Erlotinib 1 0.72  0.71 [0.20;    2.54]   0.75 [0.17;  3.39]      0.60 [0.05; 6.760000e + 00]   1.26 [0.07;      21.81]  0.16  0.8744
                     Afatinib:Erlotinib + chemotherapy 0    0  1.41 [0.09;   21.91]      .             .      1.41 [0.09; 2.191000e + 01]      .                  .     .       .
                   Afatinib:Erlotinib + HER3 inhibitor 0    0  0.28 [0.01;    7.53]      .             .      0.28 [0.01; 7.530000e + 00]      .                  .     .       .
                    Afatinib:Erlotinib + IGF-1R inhibitor 0    0  0.70 [0.03;   14.98]      .             .      0.70 [0.03; 1.498000e + 01]      .                  .     .       .
                    Afatinib:Erlotinib + MET inhibitor 0    0  0.48 [0.08;    2.88]      .             .      0.48 [0.08; 2.880000e + 00]      .                  .     .       .
                    Afatinib:Erlotinib + MMP inhibitor 0    0  0.23 [0.01;    7.31]      .             .      0.23 [0.01; 7.310000e + 00]      .                  .     .       .
                   Afatinib:Erlotinib + antiangiogenesis 0    0  0.60 [0.12;    3.07]      .             .      0.60 [0.12; 3.070000e + 00]      .                  .     .       .
                                  Afatinib:Gefitinib 0    0  0.87 [0.04;   17.57]      .             .      0.87 [0.04; 1.757000e + 01]      .                  .     .       .
                        Afatinib:Gefitinib/Erlotinib 0    0  5.53 [0.32;   96.50]      .             .      5.53 [0.32; 9.650000e + 01]      .                  .     .       .
                     Afatinib:Gefitinib + chemotherapy 0    0  0.28 [0.00;   22.61]      .             .      0.28 [0.00; 2.261000e + 01]      .                  .     .       .
                   Afatinib:Gefitinib + PARP inhibitor 0    0  0.29 [0.00;   23.39]      .             .      0.29 [0.00; 2.339000e + 01]      .                  .     .       .
                                   Afatinib:Icotinib 0    0  0.12 [0.00;    8.42]      .             .      0.12 [0.00; 8.420000e + 00]      .                  .     .       .
                                 Afatinib:Lazertinib 0    0  1.08 [0.08;   15.13]      .             .      1.08 [0.08; 1.513000e + 01]      .                  .     .       .
                                Afatinib:Osimertinib 0    0  0.78 [0.11;    5.41]      .             .      0.78 [0.11; 5.410000e + 00]      .                  .     .       .
                   Afatinib:Osimertinib + chemotherapy 0    0  0.09 [0.00;    2.86]      .             .      0.09 [0.00; 2.860000e + 00]      .                  .     .       .
                 Afatinib:Osimertinib + antiangiogenesis 0    0  0.15 [0.00;    5.57]      .             .      0.15 [0.00; 5.570000e + 00]      .                  .     .       .
                                    Afatinib:Placebo 1 0.48  1.15 [0.25;    5.25]   2.01 [0.22; 18.11]      0.70 [0.09; 5.650000e + 00]   2.88 [0.14;      59.99]  0.68  0.4941
                             Afatinib:antiangiogenesis 0    0  0.08 [0.00;    1.93]      .             .      0.08 [0.00; 1.930000e + 00]      .                  .     .       .
               Almonertinib:Amivantamab  +  Lazertinib 0    0  0.67 [0.01;   56.11]      .             .      0.67 [0.01; 5.611000e + 01]      .                  .     .       .
                           Almonertinib:Chemotherapy 0    0  0.26 [0.00;   16.16]      .             .      0.26 [0.00; 1.616000e + 01]      .                  .     .       .
                            Almonertinib:Dacomitinib 0    0  0.27 [0.00;   48.07]      .             .      0.27 [0.00; 4.807000e + 01]      .                  .     .       .
                              Almonertinib:Erlotinib 0    0  0.27 [0.00;   21.48]      .             .      0.27 [0.00; 2.148000e + 01]      .                  .     .       .
                 Almonertinib:Erlotinib + chemotherapy 0    0  0.54 [0.00;   80.38]      .             .      0.54 [0.00; 8.038000e + 01]      .                  .     .       .
               Almonertinib:Erlotinib + HER3 inhibitor 0    0  0.11 [0.00;   21.84]      .             .      0.11 [0.00; 2.184000e + 01]      .                  .     .       .
                Almonertinib:Erlotinib + IGF-1R inhibitor 0    0  0.27 [0.00;   47.95]      .             .      0.27 [0.00; 4.795000e + 01]      .                  .     .       .
                Almonertinib:Erlotinib + MET inhibitor 0    0  0.18 [0.00;   17.29]      .             .      0.18 [0.00; 1.729000e + 01]      .                  .     .       .
                Almonertinib:Erlotinib + MMP inhibitor 0    0  0.09 [0.00;   20.01]      .             .      0.09 [0.00; 2.001000e + 01]      .                  .     .       .
               Almonertinib:Erlotinib + antiangiogenesis 0    0  0.23 [0.00;   20.47]      .             .      0.23 [0.00; 2.047000e + 01]      .                  .     .       .
                              Almonertinib:Gefitinib 1 1.00  0.33 [0.01;    8.23]   0.33 [0.01;  8.23]         .                    .      .                  .     .       .
                    Almonertinib:Gefitinib/Erlotinib 0    0  2.11 [0.02;  233.96]      .             .      2.11 [0.02; 2.339600e + 02]      .                  .     .       .
                 Almonertinib:Gefitinib + chemotherapy 0    0  0.11 [0.00;    9.95]      .             .      0.11 [0.00; 9.950000e + 00]      .                  .     .       .
               Almonertinib:Gefitinib + PARP inhibitor 0    0  0.11 [0.00;   10.29]      .             .      0.11 [0.00; 1.029000e + 01]      .                  .     .       .
                               Almonertinib:Icotinib 0    0  0.05 [0.00;    3.73]      .             .      0.05 [0.00; 3.730000e + 00]      .                  .     .       .
                             Almonertinib:Lazertinib 0    0  0.41 [0.01;   25.45]      .             .      0.41 [0.01; 2.545000e + 01]      .                  .     .       .
                            Almonertinib:Osimertinib 0    0  0.30 [0.00;   20.07]      .             .      0.30 [0.00; 2.007000e + 01]      .                  .     .       .
               Almonertinib:Osimertinib + chemotherapy 0    0  0.03 [0.00;    5.52]      .             .      0.03 [0.00; 5.520000e + 00]      .                  .     .       .
             Almonertinib:Osimertinib + antiangiogenesis 0    0  0.06 [0.00;   10.38]      .             .      0.06 [0.00; 1.038000e + 01]      .                  .     .       .
                                Almonertinib:Placebo 0    0  0.44 [0.01;   33.02]      .             .      0.44 [0.01; 3.302000e + 01]      .                  .     .       .
                         Almonertinib:antiangiogenesis 0    0  0.03 [0.00;    5.84]      .             .      0.03 [0.00; 5.840000e + 00]      .                  .     .       .
               Amivantamab  +  Lazertinib:Chemotherapy 0    0  0.39 [0.03;    4.94]      .             .      0.39 [0.03; 4.940000e + 00]      .                  .     .       .
                Amivantamab  +  Lazertinib:Dacomitinib 0    0  0.41 [0.01;   16.72]      .             .      0.41 [0.01; 1.672000e + 01]      .                  .     .       .
                  Amivantamab  +  Lazertinib:Erlotinib 0    0  0.41 [0.03;    4.82]      .             .      0.41 [0.03; 4.820000e + 00]      .                  .     .       .
     Amivantamab  +  Lazertinib:Erlotinib + chemotherapy 0    0  0.81 [0.03;   25.94]      .             .      0.81 [0.03; 2.594000e + 01]      .                  .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor 0    0  0.16 [0.00;    8.04]      .             .      0.16 [0.00; 8.040000e + 00]      .                  .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor 0    0  0.40 [0.01;   16.68]      .             .      0.40 [0.01; 1.668000e + 01]      .                  .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor 0    0  0.27 [0.02;    4.41]      .             .      0.27 [0.02; 4.410000e + 00]      .                  .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor 0    0  0.13 [0.00;    7.62]      .             .      0.13 [0.00; 7.620000e + 00]      .                  .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis 0    0  0.34 [0.02;    5.00]      .             .      0.34 [0.02; 5.000000e + 00]      .                  .     .       .
                  Amivantamab  +  Lazertinib:Gefitinib 0    0  0.50 [0.02;   10.71]      .             .      0.50 [0.02; 1.071000e + 01]      .                  .     .       .
        Amivantamab  +  Lazertinib:Gefitinib/Erlotinib 0    0  3.17 [0.22;   45.56]      .             .      3.17 [0.22; 4.556000e + 01]      .                  .     .       .
     Amivantamab  +  Lazertinib:Gefitinib + chemotherapy 0    0  0.16 [0.00;   13.52]      .             .      0.16 [0.00; 1.352000e + 01]      .                  .     .       .
   Amivantamab  +  Lazertinib:Gefitinib + PARP inhibitor 0    0  0.17 [0.00;   13.99]      .             .      0.17 [0.00; 1.399000e + 01]      .                  .     .       .
                   Amivantamab  +  Lazertinib:Icotinib 0    0  0.07 [0.00;    5.05]      .             .      0.07 [0.00; 5.050000e + 00]      .                  .     .       .
                 Amivantamab  +  Lazertinib:Lazertinib 1 0.91  0.62 [0.06;    6.16]   1.01 [0.09; 11.22]      0.00 [0.00; 8.210000e + 00] 313.13 [0.09; 1141796.16]  1.37  0.1697
                Amivantamab  +  Lazertinib:Osimertinib 1 0.99  0.45 [0.09;    2.30]   0.40 [0.08;  2.09] 251456.40 [0.00; 4.355616e + 13]   0.00 [0.00;     298.70] -1.37  0.1697
   Amivantamab  +  Lazertinib:Osimertinib + chemotherapy 0    0  0.05 [0.00;    1.40]      .             .      0.05 [0.00; 1.400000e + 00]      .                  .     .       .
 Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis 0    0  0.09 [0.00;    2.74]      .             .      0.09 [0.00; 2.740000e + 00]      .                  .     .       .
                    Amivantamab  +  Lazertinib:Placebo 0    0  0.66 [0.08;    5.80]      .             .      0.66 [0.08; 5.800000e + 00]      .                  .     .       .
             Amivantamab  +  Lazertinib:antiangiogenesis 0    0  0.05 [0.00;    2.10]      .             .      0.05 [0.00; 2.100000e + 00]      .                  .     .       .
                            Chemotherapy:Dacomitinib 0    0  1.03 [0.03;   31.13]      .             .      1.03 [0.03; 3.113000e + 01]      .                  .     .       .
                              Chemotherapy:Erlotinib 1 0.38  1.03 [0.14;    7.44]   2.77 [0.11; 68.50]      0.57 [0.05; 6.920000e + 00]   4.90 [0.08;     286.10]  0.77  0.4440
                 Chemotherapy:Erlotinib + chemotherapy 0    0  2.07 [0.09;   47.09]      .             .      2.07 [0.09; 4.709000e + 01]      .                  .     .       .
               Chemotherapy:Erlotinib + HER3 inhibitor 0    0  0.40 [0.01;   15.25]      .             .      0.40 [0.01; 1.525000e + 01]      .                  .     .       .
                Chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  1.03 [0.03;   31.07]      .             .      1.03 [0.03; 3.107000e + 01]      .                  .     .       .
                Chemotherapy:Erlotinib + MET inhibitor 0    0  0.69 [0.07;    7.26]      .             .      0.69 [0.07; 7.260000e + 00]      .                  .     .       .
                Chemotherapy:Erlotinib + MMP inhibitor 0    0  0.34 [0.01;   14.60]      .             .      0.34 [0.01; 1.460000e + 01]      .                  .     .       .
               Chemotherapy:Erlotinib + antiangiogenesis 0    0  0.88 [0.10;    8.08]      .             .      0.88 [0.10; 8.080000e + 00]      .                  .     .       .
                              Chemotherapy:Gefitinib 1 0.66  1.28 [0.10;   17.11]   0.34 [0.01;  8.44]     15.81 [0.19; 1.329080e + 03]   0.02 [0.00;       5.14] -1.37  0.1697
                    Chemotherapy:Gefitinib/Erlotinib 0    0  8.08 [0.45;  146.37]      .             .      8.08 [0.45; 1.463700e + 02]      .                  .     .       .
                 Chemotherapy:Gefitinib + chemotherapy 0    0  0.41 [0.01;   25.32]      .             .      0.41 [0.01; 2.532000e + 01]      .                  .     .       .
               Chemotherapy:Gefitinib + PARP inhibitor 0    0  0.42 [0.01;   26.20]      .             .      0.42 [0.01; 2.620000e + 01]      .                  .     .       .
                               Chemotherapy:Icotinib 0    0  0.18 [0.00;    9.32]      .             .      0.18 [0.00; 9.320000e + 00]      .                  .     .       .
                             Chemotherapy:Lazertinib 0    0  1.57 [0.12;   19.85]      .             .      1.57 [0.12; 1.985000e + 01]      .                  .     .       .
                            Chemotherapy:Osimertinib 1 0.43  1.14 [0.15;    8.35]   0.41 [0.02;  8.53]      2.46 [0.18; 3.445000e + 01]   0.17 [0.00;       9.26] -0.88  0.3806
               Chemotherapy:Osimertinib + chemotherapy 0    0  0.13 [0.00;    4.31]      .             .      0.13 [0.00; 4.310000e + 00]      .                  .     .       .
             Chemotherapy:Osimertinib + antiangiogenesis 0    0  0.22 [0.01;    8.38]      .             .      0.22 [0.01; 8.380000e + 00]      .                  .     .       .
                                Chemotherapy:Placebo 0    0  1.69 [0.23;   12.56]      .             .      1.69 [0.23; 1.256000e + 01]      .                  .     .       .
                         Chemotherapy:antiangiogenesis 0    0  0.12 [0.00;    3.94]      .             .      0.12 [0.00; 3.940000e + 00]      .                  .     .       .
                               Dacomitinib:Erlotinib 1 1.00  1.00 [0.06;   16.04]   1.00 [0.06; 16.04]         .                    .      .                  .     .       .
                  Dacomitinib:Erlotinib + chemotherapy 0    0  2.00 [0.05;   79.67]      .             .      2.00 [0.05; 7.967000e + 01]      .                  .     .       .
                Dacomitinib:Erlotinib + HER3 inhibitor 0    0  0.39 [0.01;   24.10]      .             .      0.39 [0.01; 2.410000e + 01]      .                  .     .       .
                 Dacomitinib:Erlotinib + IGF-1R inhibitor 0    0  1.00 [0.02;   50.51]      .             .      1.00 [0.02; 5.051000e + 01]      .                  .     .       .
                 Dacomitinib:Erlotinib + MET inhibitor 0    0  0.67 [0.03;   14.22]      .             .      0.67 [0.03; 1.422000e + 01]      .                  .     .       .
                 Dacomitinib:Erlotinib + MMP inhibitor 0    0  0.32 [0.00;   22.71]      .             .      0.32 [0.00; 2.271000e + 01]      .                  .     .       .
                Dacomitinib:Erlotinib + antiangiogenesis 0    0  0.85 [0.04;   16.30]      .             .      0.85 [0.04; 1.630000e + 01]      .                  .     .       .
                               Dacomitinib:Gefitinib 0    0  1.23 [0.02;   72.41]      .             .      1.23 [0.02; 7.241000e + 01]      .                  .     .       .
                     Dacomitinib:Gefitinib/Erlotinib 0    0  7.81 [0.15;  409.69]      .             .      7.81 [0.15; 4.096900e + 02]      .                  .     .       .
                  Dacomitinib:Gefitinib + chemotherapy 0    0  0.39 [0.00;   70.42]      .             .      0.39 [0.00; 7.042000e + 01]      .                  .     .       .
                Dacomitinib:Gefitinib + PARP inhibitor 0    0  0.41 [0.00;   72.84]      .             .      0.41 [0.00; 7.284000e + 01]      .                  .     .       .
                                Dacomitinib:Icotinib 0    0  0.17 [0.00;   26.96]      .             .      0.17 [0.00; 2.696000e + 01]      .                  .     .       .
                              Dacomitinib:Lazertinib 0    0  1.52 [0.03;   68.62]      .             .      1.52 [0.03; 6.862000e + 01]      .                  .     .       .
                             Dacomitinib:Osimertinib 0    0  1.10 [0.04;   31.53]      .             .      1.10 [0.04; 3.153000e + 01]      .                  .     .       .
                Dacomitinib:Osimertinib + chemotherapy 0    0  0.12 [0.00;   10.38]      .             .      0.12 [0.00; 1.038000e + 01]      .                  .     .       .
              Dacomitinib:Osimertinib + antiangiogenesis 0    0  0.21 [0.00;   19.75]      .             .      0.21 [0.00; 1.975000e + 01]      .                  .     .       .
                                 Dacomitinib:Placebo 0    0  1.63 [0.07;   37.06]      .             .      1.63 [0.07; 3.706000e + 01]      .                  .     .       .
                          Dacomitinib:antiangiogenesis 0    0  0.11 [0.00;    6.31]      .             .      0.11 [0.00; 6.310000e + 00]      .                  .     .       .
                    Erlotinib:Erlotinib + chemotherapy 1 1.00  2.00 [0.18;   22.59]   2.00 [0.18; 22.59]         .                    .      .                  .     .       .
                  Erlotinib:Erlotinib + HER3 inhibitor 1 1.00  0.39 [0.02;    8.24]   0.39 [0.02;  8.24]         .                    .      .                  .     .       .
                   Erlotinib:Erlotinib + IGF-1R inhibitor 1 1.00  1.00 [0.06;   16.01]   1.00 [0.06; 16.01]         .                    .      .                  .     .       .
                   Erlotinib:Erlotinib + MET inhibitor 2 1.00  0.67 [0.19;    2.39]   0.67 [0.19;  2.39]         .                    .      .                  .     .       .
                   Erlotinib:Erlotinib + MMP inhibitor 1 1.00  0.32 [0.01;    8.09]   0.32 [0.01;  8.09]         .                    .      .                  .     .       .
                  Erlotinib:Erlotinib + antiangiogenesis 5 1.00  0.85 [0.31;    2.35]   0.85 [0.31;  2.35]         .                    .      .                  .     .       .
                                 Erlotinib:Gefitinib 0    0  1.23 [0.06;   24.29]      .             .      1.23 [0.06; 2.429000e + 01]      .                  .     .       .
                       Erlotinib:Gefitinib/Erlotinib 0    0  7.81 [0.46;  131.66]      .             .      7.81 [0.46; 1.316600e + 02]      .                  .     .       .
                    Erlotinib:Gefitinib + chemotherapy 0    0  0.39 [0.00;   31.48]      .             .      0.39 [0.00; 3.148000e + 01]      .                  .     .       .
                  Erlotinib:Gefitinib + PARP inhibitor 0    0  0.41 [0.01;   32.58]      .             .      0.41 [0.01; 3.258000e + 01]      .                  .     .       .
                                  Erlotinib:Icotinib 0    0  0.17 [0.00;   11.72]      .             .      0.17 [0.00; 1.172000e + 01]      .                  .     .       .
                                Erlotinib:Lazertinib 0    0  1.52 [0.11;   20.67]      .             .      1.52 [0.11; 2.067000e + 01]      .                  .     .       .
                               Erlotinib:Osimertinib 0    0  1.10 [0.17;    7.26]      .             .      1.10 [0.17; 7.260000e + 00]      .                  .     .       .
                  Erlotinib:Osimertinib + chemotherapy 0    0  0.12 [0.00;    3.93]      .             .      0.12 [0.00; 3.930000e + 00]      .                  .     .       .
                Erlotinib:Osimertinib + antiangiogenesis 0    0  0.21 [0.01;    7.65]      .             .      0.21 [0.01; 7.650000e + 00]      .                  .     .       .
                                   Erlotinib:Placebo 3 0.60  1.63 [0.39;    6.84]   2.50 [0.39; 15.87]      0.86 [0.09; 8.310000e + 00]   2.90 [0.16;      53.93]  0.71  0.4762
                            Erlotinib:antiangiogenesis 1 1.00  0.11 [0.01;    2.08]   0.11 [0.01;  2.08]         .                    .      .                  .     .       .
     Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor 0    0  0.20 [0.00;    9.60]      .             .      0.20 [0.00; 9.600000e + 00]      .                  .     .       .
      Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  0.50 [0.01;   19.87]      .             .      0.50 [0.01; 1.987000e + 01]      .                  .     .       .
      Erlotinib + chemotherapy:Erlotinib + MET inhibitor 0    0  0.34 [0.02;    5.19]      .             .      0.34 [0.02; 5.190000e + 00]      .                  .     .       .
      Erlotinib + chemotherapy:Erlotinib + MMP inhibitor 0    0  0.16 [0.00;    9.11]      .             .      0.16 [0.00; 9.110000e + 00]      .                  .     .       .
     Erlotinib + chemotherapy:Erlotinib + antiangiogenesis 0    0  0.42 [0.03;    5.88]      .             .      0.42 [0.03; 5.880000e + 00]      .                  .     .       .
                    Erlotinib + chemotherapy:Gefitinib 0    0  0.62 [0.01;   28.75]      .             .      0.62 [0.01; 2.875000e + 01]      .                  .     .       .
          Erlotinib + chemotherapy:Gefitinib/Erlotinib 0    0  3.91 [0.09;  161.55]      .             .      3.91 [0.09; 1.615500e + 02]      .                  .     .       .
       Erlotinib + chemotherapy:Gefitinib + chemotherapy 0    0  0.20 [0.00;   29.44]      .             .      0.20 [0.00; 2.944000e + 01]      .                  .     .       .
     Erlotinib + chemotherapy:Gefitinib + PARP inhibitor 0    0  0.20 [0.00;   30.46]      .             .      0.20 [0.00; 3.046000e + 01]      .                  .     .       .
                     Erlotinib + chemotherapy:Icotinib 0    0  0.09 [0.00;   11.21]      .             .      0.09 [0.00; 1.121000e + 01]      .                  .     .       .
                   Erlotinib + chemotherapy:Lazertinib 0    0  0.76 [0.02;   26.79]      .             .      0.76 [0.02; 2.679000e + 01]      .                  .     .       .
                  Erlotinib + chemotherapy:Osimertinib 0    0  0.55 [0.03;   11.87]      .             .      0.55 [0.03; 1.187000e + 01]      .                  .     .       .
     Erlotinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.06 [0.00;    4.21]      .             .      0.06 [0.00; 4.210000e + 00]      .                  .     .       .
   Erlotinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.11 [0.00;    8.04]      .             .      0.11 [0.00; 8.040000e + 00]      .                  .     .       .
                      Erlotinib + chemotherapy:Placebo 0    0  0.82 [0.05;   13.63]      .             .      0.82 [0.05; 1.363000e + 01]      .                  .     .       .
               Erlotinib + chemotherapy:antiangiogenesis 0    0  0.06 [0.00;    2.50]      .             .      0.06 [0.00; 2.500000e + 00]      .                  .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor 0    0  2.55 [0.04;  157.90]      .             .      2.55 [0.04; 1.579000e + 02]      .                  .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor 0    0  1.72 [0.06;   46.86]      .             .      1.72 [0.06; 4.686000e + 01]      .                  .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor 0    0  0.83 [0.01;   69.96]      .             .      0.83 [0.01; 6.996000e + 01]      .                  .     .       .
   Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis 0    0  2.17 [0.09;   54.13]      .             .      2.17 [0.09; 5.413000e + 01]      .                  .     .       .
                  Erlotinib + HER3 inhibitor:Gefitinib 0    0  3.16 [0.04;  224.84]      .             .      3.16 [0.04; 2.248400e + 02]      .                  .     .       .
        Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib 0    0 20.03 [0.31; 1278.76]      .             .     20.03 [0.31; 1.278760e + 03]      .                  .     .       .
     Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy 0    0  1.01 [0.00;  210.10]      .             .      1.01 [0.00; 2.101000e + 02]      .                  .     .       .
   Erlotinib + HER3 inhibitor:Gefitinib + PARP inhibitor 0    0  1.04 [0.01;  217.32]      .             .      1.04 [0.01; 2.173200e + 02]      .                  .     .       .
                   Erlotinib + HER3 inhibitor:Icotinib 0    0  0.45 [0.00;   80.78]      .             .      0.45 [0.00; 8.078000e + 01]      .                  .     .       .
                 Erlotinib + HER3 inhibitor:Lazertinib 0    0  3.90 [0.07;  215.78]      .             .      3.90 [0.07; 2.157800e + 02]      .                  .     .       .
                Erlotinib + HER3 inhibitor:Osimertinib 0    0  2.82 [0.08;  101.75]      .             .      2.82 [0.08; 1.017500e + 02]      .                  .     .       .
   Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy 0    0  0.31 [0.00;   31.72]      .             .      0.31 [0.00; 3.172000e + 01]      .                  .     .       .
 Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis 0    0  0.54 [0.00;   60.17]      .             .      0.54 [0.00; 6.017000e + 01]      .                  .     .       .
                    Erlotinib + HER3 inhibitor:Placebo 0    0  4.18 [0.14;  121.51]      .             .      4.18 [0.14; 1.215100e + 02]      .                  .     .       .
             Erlotinib + HER3 inhibitor:antiangiogenesis 0    0  0.29 [0.00;   19.63]      .             .      0.29 [0.00; 1.963000e + 01]      .                  .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor 0    0  0.67 [0.03;   14.29]      .             .      0.67 [0.03; 1.429000e + 01]      .                  .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor 0    0  0.33 [0.00;   22.81]      .             .      0.33 [0.00; 2.281000e + 01]      .                  .     .       .
    Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis 0    0  0.85 [0.04;   16.38]      .             .      0.85 [0.04; 1.638000e + 01]      .                  .     .       .
                   Erlotinib + IGF-1R inhibitor:Gefitinib 0    0  1.24 [0.02;   72.74]      .             .      1.24 [0.02; 7.274000e + 01]      .                  .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib 0    0  7.84 [0.15;  411.58]      .             .      7.84 [0.15; 4.115800e + 02]      .                  .     .       .
      Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy 0    0  0.40 [0.00;   70.72]      .             .      0.40 [0.00; 7.072000e + 01]      .                  .     .       .
    Erlotinib + IGF-1R inhibitor:Gefitinib + PARP inhibitor 0    0  0.41 [0.00;   73.16]      .             .      0.41 [0.00; 7.316000e + 01]      .                  .     .       .
                    Erlotinib + IGF-1R inhibitor:Icotinib 0    0  0.18 [0.00;   27.08]      .             .      0.18 [0.00; 2.708000e + 01]      .                  .     .       .
                  Erlotinib + IGF-1R inhibitor:Lazertinib 0    0  1.53 [0.03;   68.94]      .             .      1.53 [0.03; 6.894000e + 01]      .                  .     .       .
                 Erlotinib + IGF-1R inhibitor:Osimertinib 0    0  1.10 [0.04;   31.68]      .             .      1.10 [0.04; 3.168000e + 01]      .                  .     .       .
    Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy 0    0  0.12 [0.00;   10.42]      .             .      0.12 [0.00; 1.042000e + 01]      .                  .     .       .
  Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis 0    0  0.21 [0.00;   19.84]      .             .      0.21 [0.00; 1.984000e + 01]      .                  .     .       .
                     Erlotinib + IGF-1R inhibitor:Placebo 0    0  1.64 [0.07;   37.24]      .             .      1.64 [0.07; 3.724000e + 01]      .                  .     .       .
              Erlotinib + IGF-1R inhibitor:antiangiogenesis 0    0  0.11 [0.00;    6.34]      .             .      0.11 [0.00; 6.340000e + 00]      .                  .     .       .
     Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor 0    0  0.48 [0.02;   15.33]      .             .      0.48 [0.02; 1.533000e + 01]      .                  .     .       .
    Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis 0    0  1.26 [0.25;    6.43]      .             .      1.26 [0.25; 6.430000e + 00]      .                  .     .       .
                   Erlotinib + MET inhibitor:Gefitinib 0    0  1.84 [0.07;   46.84]      .             .      1.84 [0.07; 4.684000e + 01]      .                  .     .       .
         Erlotinib + MET inhibitor:Gefitinib/Erlotinib 0    0 11.63 [0.53;  257.21]      .             .     11.63 [0.53; 2.572100e + 02]      .                  .     .       .
      Erlotinib + MET inhibitor:Gefitinib + chemotherapy 0    0  0.59 [0.01;   56.10]      .             .      0.59 [0.01; 5.610000e + 01]      .                  .     .       .
    Erlotinib + MET inhibitor:Gefitinib + PARP inhibitor 0    0  0.61 [0.01;   58.04]      .             .      0.61 [0.01; 5.804000e + 01]      .                  .     .       .
                    Erlotinib + MET inhibitor:Icotinib 0    0  0.26 [0.00;   21.04]      .             .      0.26 [0.00; 2.104000e + 01]      .                  .     .       .
                  Erlotinib + MET inhibitor:Lazertinib 0    0  2.26 [0.12;   41.21]      .             .      2.26 [0.12; 4.121000e + 01]      .                  .     .       .
                 Erlotinib + MET inhibitor:Osimertinib 0    0  1.64 [0.17;   15.91]      .             .      1.64 [0.17; 1.591000e + 01]      .                  .     .       .
    Erlotinib + MET inhibitor:Osimertinib + chemotherapy 0    0  0.18 [0.00;    7.32]      .             .      0.18 [0.00; 7.320000e + 00]      .                  .     .       .
  Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis 0    0  0.31 [0.01;   14.16]      .             .      0.31 [0.01; 1.416000e + 01]      .                  .     .       .
                     Erlotinib + MET inhibitor:Placebo 0    0  2.43 [0.36;   16.47]      .             .      2.43 [0.36; 1.647000e + 01]      .                  .     .       .
              Erlotinib + MET inhibitor:antiangiogenesis 0    0  0.17 [0.01;    4.04]      .             .      0.17 [0.01; 4.040000e + 00]      .                  .     .       .
    Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis 0    0  2.61 [0.09;   76.34]      .             .      2.61 [0.09; 7.634000e + 01]      .                  .     .       .
                   Erlotinib + MMP inhibitor:Gefitinib 0    0  3.81 [0.05;  305.30]      .             .      3.81 [0.05; 3.053000e + 02]      .                  .     .       .
         Erlotinib + MMP inhibitor:Gefitinib/Erlotinib 0    0 24.09 [0.33; 1741.63]      .             .     24.09 [0.33; 1.741630e + 03]      .                  .     .       .
      Erlotinib + MMP inhibitor:Gefitinib + chemotherapy 0    0  1.22 [0.01;  278.55]      .             .      1.22 [0.01; 2.785500e + 02]      .                  .     .       .
    Erlotinib + MMP inhibitor:Gefitinib + PARP inhibitor 0    0  1.26 [0.01;  288.12]      .             .      1.26 [0.01; 2.881200e + 02]      .                  .     .       .
                    Erlotinib + MMP inhibitor:Icotinib 0    0  0.54 [0.00;  107.38]      .             .      0.54 [0.00; 1.073800e + 02]      .                  .     .       .
                  Erlotinib + MMP inhibitor:Lazertinib 0    0  4.69 [0.07;  295.15]      .             .      4.69 [0.07; 2.951500e + 02]      .                  .     .       .
                 Erlotinib + MMP inhibitor:Osimertinib 0    0  3.39 [0.08;  141.24]      .             .      3.39 [0.08; 1.412400e + 02]      .                  .     .       .
    Erlotinib + MMP inhibitor:Osimertinib + chemotherapy 0    0  0.37 [0.00;   42.67]      .             .      0.37 [0.00; 4.267000e + 01]      .                  .     .       .
  Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis 0    0  0.65 [0.01;   80.79]      .             .      0.65 [0.01; 8.079000e + 01]      .                  .     .       .
                     Erlotinib + MMP inhibitor:Placebo 0    0  5.03 [0.15;  170.17]      .             .      5.03 [0.15; 1.701700e + 02]      .                  .     .       .
              Erlotinib + MMP inhibitor:antiangiogenesis 0    0  0.35 [0.00;   26.68]      .             .      0.35 [0.00; 2.668000e + 01]      .                  .     .       .
                  Erlotinib + antiangiogenesis:Gefitinib 0    0  1.46 [0.06;   33.94]      .             .      1.46 [0.06; 3.394000e + 01]      .                  .     .       .
        Erlotinib + antiangiogenesis:Gefitinib/Erlotinib 0    0  9.22 [0.46;  185.60]      .             .      9.22 [0.46; 1.856000e + 02]      .                  .     .       .
     Erlotinib + antiangiogenesis:Gefitinib + chemotherapy 0    0  0.47 [0.01;   41.74]      .             .      0.47 [0.01; 4.174000e + 01]      .                  .     .       .
   Erlotinib + antiangiogenesis:Gefitinib + PARP inhibitor 0    0  0.48 [0.01;   43.19]      .             .      0.48 [0.01; 4.319000e + 01]      .                  .     .       .
                   Erlotinib + antiangiogenesis:Icotinib 0    0  0.21 [0.00;   15.62]      .             .      0.21 [0.00; 1.562000e + 01]      .                  .     .       .
                 Erlotinib + antiangiogenesis:Lazertinib 0    0  1.80 [0.11;   29.54]      .             .      1.80 [0.11; 2.954000e + 01]      .                  .     .       .
                Erlotinib + antiangiogenesis:Osimertinib 0    0  1.30 [0.15;   11.07]      .             .      1.30 [0.15; 1.107000e + 01]      .                  .     .       .
   Erlotinib + antiangiogenesis:Osimertinib + chemotherapy 0    0  0.14 [0.00;    5.37]      .             .      0.14 [0.00; 5.370000e + 00]      .                  .     .       .
 Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.25 [0.01;   10.40]      .             .      0.25 [0.01; 1.040000e + 01]      .                  .     .       .
                    Erlotinib + antiangiogenesis:Placebo 0    0  1.92 [0.33;   11.16]      .             .      1.92 [0.33; 1.116000e + 01]      .                  .     .       .
             Erlotinib + antiangiogenesis:antiangiogenesis 0    0  0.13 [0.01;    2.92]      .             .      0.13 [0.01; 2.920000e + 00]      .                  .     .       .
                       Gefitinib:Gefitinib/Erlotinib 0    0  6.33 [0.20;  199.05]      .             .      6.33 [0.20; 1.990500e + 02]      .                  .     .       .
                    Gefitinib:Gefitinib + chemotherapy 1 1.00  0.32 [0.01;    7.92]   0.32 [0.01;  7.92]         .                    .      .                  .     .       .
                  Gefitinib:Gefitinib + PARP inhibitor 1 1.00  0.33 [0.01;    8.20]   0.33 [0.01;  8.20]         .                    .      .                  .     .       .
                                  Gefitinib:Icotinib 1 1.00  0.14 [0.01;    2.76]   0.14 [0.01;  2.76]         .                    .      .                  .     .       .
                                Gefitinib:Lazertinib 1 0.66  1.23 [0.09;   16.55]   0.33 [0.01;  8.15]     15.21 [0.18; 1.274970e + 03]   0.02 [0.00;       5.14] -1.37  0.1697
                               Gefitinib:Osimertinib 0    0  0.89 [0.06;   13.71]      .             .      0.89 [0.06; 1.371000e + 01]      .                  .     .       .
                  Gefitinib:Osimertinib + chemotherapy 0    0  0.10 [0.00;    5.37]      .             .      0.10 [0.00; 5.370000e + 00]      .                  .     .       .
                Gefitinib:Osimertinib + antiangiogenesis 0    0  0.17 [0.00;   10.32]      .             .      0.17 [0.00; 1.032000e + 01]      .                  .     .       .
                                   Gefitinib:Placebo 0    0  1.32 [0.07;   23.80]      .             .      1.32 [0.07; 2.380000e + 01]      .                  .     .       .
                            Gefitinib:antiangiogenesis 0    0  0.09 [0.00;    5.90]      .             .      0.09 [0.00; 5.900000e + 00]      .                  .     .       .
          Gefitinib/Erlotinib:Gefitinib + chemotherapy 0    0  0.05 [0.00;    5.61]      .             .      0.05 [0.00; 5.610000e + 00]      .                  .     .       .
        Gefitinib/Erlotinib:Gefitinib + PARP inhibitor 0    0  0.05 [0.00;    5.81]      .             .      0.05 [0.00; 5.810000e + 00]      .                  .     .       .
                        Gefitinib/Erlotinib:Icotinib 0    0  0.02 [0.00;    2.12]      .             .      0.02 [0.00; 2.120000e + 00]      .                  .     .       .
                      Gefitinib/Erlotinib:Lazertinib 0    0  0.19 [0.01;    3.49]      .             .      0.19 [0.01; 3.490000e + 00]      .                  .     .       .
                     Gefitinib/Erlotinib:Osimertinib 1 1.00  0.14 [0.02;    1.15]   0.14 [0.02;  1.15]         .                    .      .                  .     .       .
        Gefitinib/Erlotinib:Osimertinib + chemotherapy 0    0  0.02 [0.00;    0.57]      .             .      0.02 [0.00; 5.700000e-01]      .                  .     .       .
      Gefitinib/Erlotinib:Osimertinib + antiangiogenesis 0    0  0.03 [0.00;    1.10]      .             .      0.03 [0.00; 1.100000e + 00]      .                  .     .       .
                         Gefitinib/Erlotinib:Placebo 0    0  0.21 [0.02;    2.68]      .             .      0.21 [0.02; 2.680000e + 00]      .                  .     .       .
                  Gefitinib/Erlotinib:antiangiogenesis 0    0  0.01 [0.00;    0.84]      .             .      0.01 [0.00; 8.400000e-01]      .                  .     .       .
     Gefitinib + chemotherapy:Gefitinib + PARP inhibitor 0    0  1.03 [0.01;   97.04]      .             .      1.03 [0.01; 9.704000e + 01]      .                  .     .       .
                     Gefitinib + chemotherapy:Icotinib 0    0  0.44 [0.01;   35.14]      .             .      0.44 [0.01; 3.514000e + 01]      .                  .     .       .
                   Gefitinib + chemotherapy:Lazertinib 0    0  3.86 [0.06;  239.99]      .             .      3.86 [0.06; 2.399900e + 02]      .                  .     .       .
                  Gefitinib + chemotherapy:Osimertinib 0    0  2.79 [0.04;  189.31]      .             .      2.79 [0.04; 1.893100e + 02]      .                  .     .       .
     Gefitinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.31 [0.00;   52.00]      .             .      0.31 [0.00; 5.200000e + 01]      .                  .     .       .
   Gefitinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.54 [0.00;   97.86]      .             .      0.54 [0.00; 9.786000e + 01]      .                  .     .       .
                      Gefitinib + chemotherapy:Placebo 0    0  4.14 [0.05;  311.37]      .             .      4.14 [0.05; 3.113700e + 02]      .                  .     .       .
               Gefitinib + chemotherapy:antiangiogenesis 0    0  0.28 [0.00;   55.04]      .             .      0.28 [0.00; 5.504000e + 01]      .                  .     .       .
                   Gefitinib + PARP inhibitor:Icotinib 0    0  0.43 [0.01;   34.10]      .             .      0.43 [0.01; 3.410000e + 01]      .                  .     .       .
                 Gefitinib + PARP inhibitor:Lazertinib 0    0  3.74 [0.06;  232.92]      .             .      3.74 [0.06; 2.329200e + 02]      .                  .     .       .
                Gefitinib + PARP inhibitor:Osimertinib 0    0  2.70 [0.04;  183.72]      .             .      2.70 [0.04; 1.837200e + 02]      .                  .     .       .
   Gefitinib + PARP inhibitor:Osimertinib + chemotherapy 0    0  0.30 [0.00;   50.44]      .             .      0.30 [0.00; 5.044000e + 01]      .                  .     .       .
 Gefitinib + PARP inhibitor:Osimertinib + antiangiogenesis 0    0  0.52 [0.00;   94.93]      .             .      0.52 [0.00; 9.493000e + 01]      .                  .     .       .
                    Gefitinib + PARP inhibitor:Placebo 0    0  4.01 [0.05;  302.17]      .             .      4.01 [0.05; 3.021700e + 02]      .                  .     .       .
             Gefitinib + PARP inhibitor:antiangiogenesis 0    0  0.28 [0.00;   53.39]      .             .      0.28 [0.00; 5.339000e + 01]      .                  .     .       .
                                 Icotinib:Lazertinib 0    0  8.71 [0.17;  450.45]      .             .      8.71 [0.17; 4.504500e + 02]      .                  .     .       .
                                Icotinib:Osimertinib 0    0  6.30 [0.11;  356.73]      .             .      6.30 [0.11; 3.567300e + 02]      .                  .     .       .
                   Icotinib:Osimertinib + chemotherapy 0    0  0.69 [0.00;  101.30]      .             .      0.69 [0.00; 1.013000e + 02]      .                  .     .       .
                 Icotinib:Osimertinib + antiangiogenesis 0    0  1.21 [0.01;  191.06]      .             .      1.21 [0.01; 1.910600e + 02]      .                  .     .       .
                                    Icotinib:Placebo 0    0  9.34 [0.15;  589.42]      .             .      9.34 [0.15; 5.894200e + 02]      .                  .     .       .
                             Icotinib:antiangiogenesis 0    0  0.64 [0.00;  107.64]      .             .      0.64 [0.00; 1.076400e + 02]      .                  .     .       .
                              Lazertinib:Osimertinib 1 0.84  0.72 [0.10;    5.23]   0.40 [0.05;  3.44]     18.40 [0.12; 2.801800e + 03]   0.02 [0.00;       5.14] -1.37  0.1697
                 Lazertinib:Osimertinib + chemotherapy 0    0  0.08 [0.00;    2.72]      .             .      0.08 [0.00; 2.720000e + 00]      .                  .     .       .
               Lazertinib:Osimertinib + antiangiogenesis 0    0  0.14 [0.00;    5.29]      .             .      0.14 [0.00; 5.290000e + 00]      .                  .     .       .
                                  Lazertinib:Placebo 0    0  1.07 [0.10;   11.50]      .             .      1.07 [0.10; 1.150000e + 01]      .                  .     .       .
                           Lazertinib:antiangiogenesis 0    0  0.07 [0.00;    3.70]      .             .      0.07 [0.00; 3.700000e + 00]      .                  .     .       .
                Osimertinib:Osimertinib + chemotherapy 1 1.00  0.11 [0.01;    2.05]   0.11 [0.01;  2.05]         .                    .      .                  .     .       .
              Osimertinib:Osimertinib + antiangiogenesis 1 1.00  0.19 [0.01;    4.07]   0.19 [0.01;  4.07]         .                    .      .                  .     .       .
                                 Osimertinib:Placebo 2 0.85  1.48 [0.35;    6.29]   0.82 [0.17;  3.95]     41.52 [0.99; 1.734570e + 03]   0.02 [0.00;       1.14] -1.90  0.0577
                          Osimertinib:antiangiogenesis 0    0  0.10 [0.00;    3.30]      .             .      0.10 [0.00; 3.300000e + 00]      .                  .     .       .
 Osimertinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  1.75 [0.03;  120.10]      .             .      1.75 [0.03; 1.201000e + 02]      .                  .     .       .
                    Osimertinib + chemotherapy:Placebo 0    0 13.49 [0.52;  352.84]      .             .     13.49 [0.52; 3.528400e + 02]      .                  .     .       .
             Osimertinib + chemotherapy:antiangiogenesis 0    0  0.93 [0.01;   87.37]      .             .      0.93 [0.01; 8.737000e + 01]      .                  .     .       .
                  Osimertinib + antiangiogenesis:Placebo 0    0  7.71 [0.26;  226.01]      .             .      7.71 [0.26; 2.260100e + 02]      .                  .     .       .
           Osimertinib + antiangiogenesis:antiangiogenesis 0    0  0.53 [0.01;   54.23]      .             .      0.53 [0.01; 5.423000e + 01]      .                  .     .       .
                              antiangiogenesis:Placebo 0    0 14.56 [0.56;  377.89]      .             .     14.56 [0.56; 3.778900e + 02]      .                  .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

serious-hypertension

Random effects model: 

                                          comparison  k prop   nma          95%-CI direct         95%-CI indir.          95%-CI    RoR           95%-CI     z p-value
                     Afatinib:Afatinib + Cetuximab  1 1.00  2.96 [0.12;   74.78]   2.96 [0.12;  74.78]      .               .      .                .     .       .
                               Afatinib:Chemotherapy  0    0  0.21 [0.01;    4.65]      .              .   0.21 [0.01;    4.65]      .                .     .       .
                                Afatinib:Dacomitinib  0    0  0.80 [0.07;    9.84]      .              .   0.80 [0.07;    9.84]      .                .     .       .
                                  Afatinib:Erlotinib  1 0.46  0.89 [0.10;    7.85]   0.34 [0.01;   8.36]   2.03 [0.11;   38.94]   0.16 [0.00;    12.96] -0.81  0.4180
                    Afatinib:Erlotinib + IGF-1R inhibitor  0    0  0.30 [0.01;   14.35]      .              .   0.30 [0.01;   14.35]      .                .     .       .
                    Afatinib:Erlotinib + MET inhibitor  0    0  0.30 [0.01;   14.49]      .              .   0.30 [0.01;   14.49]      .                .     .       .
                   Afatinib:Erlotinib + antiangiogenesis  0    0  0.15 [0.02;    1.39]      .              .   0.15 [0.02;    1.39]      .                .     .       .
                                  Afatinib:Gefitinib  1 0.45  0.45 [0.05;    3.86]   0.33 [0.01;   8.25]   0.57 [0.03;   10.44]   0.58 [0.01;    43.97] -0.25  0.8026
                        Afatinib:Gefitinib/Erlotinib  0    0  0.79 [0.02;   34.13]      .              .   0.79 [0.02;   34.13]      .                .     .       .
                     Afatinib:Gefitinib + chemotherapy  0    0  0.41 [0.04;    3.76]      .              .   0.41 [0.04;    3.76]      .                .     .       .
                   Afatinib:Gefitinib + antiangiogenesis  0    0  0.01 [0.00;    0.16]      .              .   0.01 [0.00;    0.16]      .                .     .       .
                                 Afatinib:Lazertinib  0    0  0.34 [0.01;    9.09]      .              .   0.34 [0.01;    9.09]      .                .     .       .
                                Afatinib:Osimertinib  0    0  0.53 [0.02;   14.28]      .              .   0.53 [0.02;   14.28]      .                .     .       .
                   Afatinib:Osimertinib + chemotherapy  0    0  0.16 [0.00;   17.36]      .              .   0.16 [0.00;   17.36]      .                .     .       .
                 Afatinib:Osimertinib + antiangiogenesis  0    0  0.21 [0.01;    6.99]      .              .   0.21 [0.01;    6.99]      .                .     .       .
                                    Afatinib:Placebo  1 0.48  0.42 [0.05;    3.84]   1.51 [0.06;  37.62]   0.13 [0.01;    2.79]  11.64 [0.14;   993.96]  1.08  0.2795
                             Afatinib:antiangiogenesis  0    0  0.04 [0.00;    0.35]      .              .   0.04 [0.00;    0.35]      .                .     .       .
                 Afatinib + Cetuximab:Chemotherapy  0    0  0.07 [0.00;    6.18]      .              .   0.07 [0.00;    6.18]      .                .     .       .
                  Afatinib + Cetuximab:Dacomitinib  0    0  0.27 [0.00;   16.12]      .              .   0.27 [0.00;   16.12]      .                .     .       .
                    Afatinib + Cetuximab:Erlotinib  0    0  0.30 [0.01;   14.75]      .              .   0.30 [0.01;   14.75]      .                .     .       .
      Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor  0    0  0.10 [0.00;   15.54]      .              .   0.10 [0.00;   15.54]      .                .     .       .
      Afatinib + Cetuximab:Erlotinib + MET inhibitor  0    0  0.10 [0.00;   15.69]      .              .   0.10 [0.00;   15.69]      .                .     .       .
     Afatinib + Cetuximab:Erlotinib + antiangiogenesis  0    0  0.05 [0.00;    2.58]      .              .   0.05 [0.00;    2.58]      .                .     .       .
                    Afatinib + Cetuximab:Gefitinib  0    0  0.15 [0.00;    7.31]      .              .   0.15 [0.00;    7.31]      .                .     .       .
          Afatinib + Cetuximab:Gefitinib/Erlotinib  0    0  0.27 [0.00;   38.03]      .              .   0.27 [0.00;   38.03]      .                .     .       .
       Afatinib + Cetuximab:Gefitinib + chemotherapy  0    0  0.14 [0.00;    6.91]      .              .   0.14 [0.00;    6.91]      .                .     .       .
     Afatinib + Cetuximab:Gefitinib + antiangiogenesis  0    0  0.00 [0.00;    0.27]      .              .   0.00 [0.00;    0.27]      .                .     .       .
                   Afatinib + Cetuximab:Lazertinib  0    0  0.12 [0.00;   11.51]      .              .   0.12 [0.00;   11.51]      .                .     .       .
                  Afatinib + Cetuximab:Osimertinib  0    0  0.18 [0.00;   18.00]      .              .   0.18 [0.00;   18.00]      .                .     .       .
     Afatinib + Cetuximab:Osimertinib + chemotherapy  0    0  0.05 [0.00;   16.03]      .              .   0.05 [0.00;   16.03]      .                .     .       .
   Afatinib + Cetuximab:Osimertinib + antiangiogenesis  0    0  0.07 [0.00;    8.27]      .              .   0.07 [0.00;    8.27]      .                .     .       .
                      Afatinib + Cetuximab:Placebo  0    0  0.14 [0.00;    7.07]      .              .   0.14 [0.00;    7.07]      .                .     .       .
               Afatinib + Cetuximab:antiangiogenesis  0    0  0.01 [0.00;    0.64]      .              .   0.01 [0.00;    0.64]      .                .     .       .
                            Chemotherapy:Dacomitinib  0    0  3.89 [0.16;   92.96]      .              .   3.89 [0.16;   92.96]      .                .     .       .
                              Chemotherapy:Erlotinib  2 1.00  4.32 [0.46;   40.22]   4.32 [0.46;  40.22]      .               .      .                .     .       .
                Chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  1.43 [0.03;   71.78]      .              .   1.43 [0.03;   71.78]      .                .     .       .
                Chemotherapy:Erlotinib + MET inhibitor  0    0  1.45 [0.03;   72.45]      .              .   1.45 [0.03;   72.45]      .                .     .       .
               Chemotherapy:Erlotinib + antiangiogenesis  0    0  0.75 [0.08;    7.14]      .              .   0.75 [0.08;    7.14]      .                .     .       .
                              Chemotherapy:Gefitinib  0    0  2.16 [0.12;   39.55]      .              .   2.16 [0.12;   39.55]      .                .     .       .
                    Chemotherapy:Gefitinib/Erlotinib  0    0  3.84 [0.05;  277.86]      .              .   3.84 [0.05;  277.86]      .                .     .       .
                 Chemotherapy:Gefitinib + chemotherapy  0    0  1.97 [0.10;   37.87]      .              .   1.97 [0.10;   37.87]      .                .     .       .
               Chemotherapy:Gefitinib + antiangiogenesis  0    0  0.07 [0.00;    1.51]      .              .   0.07 [0.00;    1.51]      .                .     .       .
                             Chemotherapy:Lazertinib  0    0  1.66 [0.04;   77.08]      .              .   1.66 [0.04;   77.08]      .                .     .       .
                            Chemotherapy:Osimertinib  0    0  2.57 [0.05;  123.85]      .              .   2.57 [0.05;  123.85]      .                .     .       .
               Chemotherapy:Osimertinib + chemotherapy  0    0  0.79 [0.00;  128.99]      .              .   0.79 [0.00;  128.99]      .                .     .       .
             Chemotherapy:Osimertinib + antiangiogenesis  0    0  1.00 [0.02;   58.66]      .              .   1.00 [0.02;   58.66]      .                .     .       .
                                Chemotherapy:Placebo  0    0  2.02 [0.10;   42.60]      .              .   2.02 [0.10;   42.60]      .                .     .       .
                         Chemotherapy:antiangiogenesis  0    0  0.18 [0.02;    2.10]      .              .   0.18 [0.02;    2.10]      .                .     .       .
                               Dacomitinib:Erlotinib  0    0  1.11 [0.12;   10.61]      .              .   1.11 [0.12;   10.61]      .                .     .       .
                 Dacomitinib:Erlotinib + IGF-1R inhibitor  0    0  0.37 [0.01;   18.72]      .              .   0.37 [0.01;   18.72]      .                .     .       .
                 Dacomitinib:Erlotinib + MET inhibitor  0    0  0.37 [0.01;   18.90]      .              .   0.37 [0.01;   18.90]      .                .     .       .
                Dacomitinib:Erlotinib + antiangiogenesis  0    0  0.19 [0.02;    1.86]      .              .   0.19 [0.02;    1.86]      .                .     .       .
                               Dacomitinib:Gefitinib  1 1.00  0.56 [0.16;    1.99]   0.56 [0.16;   1.99]      .               .      .                .     .       .
                     Dacomitinib:Gefitinib/Erlotinib  0    0  0.99 [0.02;   39.77]      .              .   0.99 [0.02;   39.77]      .                .     .       .
                  Dacomitinib:Gefitinib + chemotherapy  0    0  0.51 [0.13;    2.03]      .              .   0.51 [0.13;    2.03]      .                .     .       .
                Dacomitinib:Gefitinib + antiangiogenesis  0    0  0.02 [0.00;    0.09]      .              .   0.02 [0.00;    0.09]      .                .     .       .
                              Dacomitinib:Lazertinib  0    0  0.43 [0.02;    8.55]      .              .   0.43 [0.02;    8.55]      .                .     .       .
                             Dacomitinib:Osimertinib  0    0  0.66 [0.03;   16.48]      .              .   0.66 [0.03;   16.48]      .                .     .       .
                Dacomitinib:Osimertinib + chemotherapy  0    0  0.20 [0.00;   20.50]      .              .   0.20 [0.00;   20.50]      .                .     .       .
              Dacomitinib:Osimertinib + antiangiogenesis  0    0  0.26 [0.01;    8.11]      .              .   0.26 [0.01;    8.11]      .                .     .       .
                                 Dacomitinib:Placebo  0    0  0.52 [0.05;    5.65]      .              .   0.52 [0.05;    5.65]      .                .     .       .
                          Dacomitinib:antiangiogenesis  0    0  0.05 [0.01;    0.40]      .              .   0.05 [0.01;    0.40]      .                .     .       .
                   Erlotinib:Erlotinib + IGF-1R inhibitor  1 1.00  0.33 [0.01;    8.27]   0.33 [0.01;   8.27]      .               .      .                .     .       .
                   Erlotinib:Erlotinib + MET inhibitor  1 1.00  0.33 [0.01;    8.34]   0.33 [0.01;   8.34]      .               .      .                .     .       .
                  Erlotinib:Erlotinib + antiangiogenesis 11 0.98  0.17 [0.12;    0.25]   0.17 [0.12;   0.24]   0.69 [0.04;   11.72]   0.24 [0.01;     4.21] -0.97  0.3311
                                 Erlotinib:Gefitinib  0    0  0.50 [0.08;    3.22]      .              .   0.50 [0.08;    3.22]      .                .     .       .
                       Erlotinib:Gefitinib/Erlotinib  0    0  0.89 [0.02;   34.34]      .              .   0.89 [0.02;   34.34]      .                .     .       .
                    Erlotinib:Gefitinib + chemotherapy  0    0  0.46 [0.07;    3.17]      .              .   0.46 [0.07;    3.17]      .                .     .       .
                  Erlotinib:Gefitinib + antiangiogenesis  0    0  0.02 [0.00;    0.13]      .              .   0.02 [0.00;    0.13]      .                .     .       .
                                Erlotinib:Lazertinib  0    0  0.38 [0.02;    8.73]      .              .   0.38 [0.02;    8.73]      .                .     .       .
                               Erlotinib:Osimertinib  0    0  0.60 [0.03;   14.14]      .              .   0.60 [0.03;   14.14]      .                .     .       .
                  Erlotinib:Osimertinib + chemotherapy  0    0  0.18 [0.00;   17.85]      .              .   0.18 [0.00;   17.85]      .                .     .       .
                Erlotinib:Osimertinib + antiangiogenesis  0    0  0.23 [0.01;    6.98]      .              .   0.23 [0.01;    6.98]      .                .     .       .
                                   Erlotinib:Placebo  1 0.46  0.47 [0.06;    3.74]   0.11 [0.01;   2.37]   1.61 [0.09;   27.55]   0.07 [0.00;     4.49] -1.25  0.2097
                            Erlotinib:antiangiogenesis  2 0.63  0.04 [0.01;    0.12]   0.07 [0.02;   0.25]   0.02 [0.00;    0.10]   3.65 [0.42;    31.93]  1.17  0.2413
     Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor  0    0  1.01 [0.01;   95.59]      .              .   1.01 [0.01;   95.59]      .                .     .       .
    Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis  0    0  0.52 [0.02;   13.27]      .              .   0.52 [0.02;   13.27]      .                .     .       .
                   Erlotinib + IGF-1R inhibitor:Gefitinib  0    0  1.51 [0.04;   62.26]      .              .   1.51 [0.04;   62.26]      .                .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib  0    0  2.69 [0.02;  349.57]      .              .   2.69 [0.02;  349.57]      .                .     .       .
      Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy  0    0  1.38 [0.03;   58.96]      .              .   1.38 [0.03;   58.96]      .                .     .       .
    Erlotinib + IGF-1R inhibitor:Gefitinib + antiangiogenesis  0    0  0.05 [0.00;    2.29]      .              .   0.05 [0.00;    2.29]      .                .     .       .
                  Erlotinib + IGF-1R inhibitor:Lazertinib  0    0  1.16 [0.01;  102.80]      .              .   1.16 [0.01;  102.80]      .                .     .       .
                 Erlotinib + IGF-1R inhibitor:Osimertinib  0    0  1.80 [0.02;  164.33]      .              .   1.80 [0.02;  164.33]      .                .     .       .
    Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy  0    0  0.55 [0.00;  149.05]      .              .   0.55 [0.00;  149.05]      .                .     .       .
  Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis  0    0  0.70 [0.01;   75.72]      .              .   0.70 [0.01;   75.72]      .                .     .       .
                     Erlotinib + IGF-1R inhibitor:Placebo  0    0  1.41 [0.03;   65.06]      .              .   1.41 [0.03;   65.06]      .                .     .       .
              Erlotinib + IGF-1R inhibitor:antiangiogenesis  0    0  0.13 [0.00;    3.68]      .              .   0.13 [0.00;    3.68]      .                .     .       .
    Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis  0    0  0.52 [0.02;   13.11]      .              .   0.52 [0.02;   13.11]      .                .     .       .
                   Erlotinib + MET inhibitor:Gefitinib  0    0  1.50 [0.04;   61.49]      .              .   1.50 [0.04;   61.49]      .                .     .       .
         Erlotinib + MET inhibitor:Gefitinib/Erlotinib  0    0  2.66 [0.02;  345.41]      .              .   2.66 [0.02;  345.41]      .                .     .       .
      Erlotinib + MET inhibitor:Gefitinib + chemotherapy  0    0  1.36 [0.03;   58.24]      .              .   1.36 [0.03;   58.24]      .                .     .       .
    Erlotinib + MET inhibitor:Gefitinib + antiangiogenesis  0    0  0.05 [0.00;    2.27]      .              .   0.05 [0.00;    2.27]      .                .     .       .
                  Erlotinib + MET inhibitor:Lazertinib  0    0  1.15 [0.01;  101.57]      .              .   1.15 [0.01;  101.57]      .                .     .       .
                 Erlotinib + MET inhibitor:Osimertinib  0    0  1.78 [0.02;  162.36]      .              .   1.78 [0.02;  162.36]      .                .     .       .
    Erlotinib + MET inhibitor:Osimertinib + chemotherapy  0    0  0.55 [0.00;  147.30]      .              .   0.55 [0.00;  147.30]      .                .     .       .
  Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis  0    0  0.69 [0.01;   74.81]      .              .   0.69 [0.01;   74.81]      .                .     .       .
                     Erlotinib + MET inhibitor:Placebo  0    0  1.40 [0.03;   64.26]      .              .   1.40 [0.03;   64.26]      .                .     .       .
              Erlotinib + MET inhibitor:antiangiogenesis  0    0  0.12 [0.00;    3.64]      .              .   0.12 [0.00;    3.64]      .                .     .       .
                  Erlotinib + antiangiogenesis:Gefitinib  0    0  2.90 [0.44;   19.04]      .              .   2.90 [0.44;   19.04]      .                .     .       .
        Erlotinib + antiangiogenesis:Gefitinib/Erlotinib  0    0  5.16 [0.13;  201.44]      .              .   5.16 [0.13;  201.44]      .                .     .       .
     Erlotinib + antiangiogenesis:Gefitinib + chemotherapy  0    0  2.64 [0.37;   18.73]      .              .   2.64 [0.37;   18.73]      .                .     .       .
   Erlotinib + antiangiogenesis:Gefitinib + antiangiogenesis  0    0  0.09 [0.01;    0.79]      .              .   0.09 [0.01;    0.79]      .                .     .       .
                 Erlotinib + antiangiogenesis:Lazertinib  0    0  2.23 [0.10;   51.23]      .              .   2.23 [0.10;   51.23]      .                .     .       .
                Erlotinib + antiangiogenesis:Osimertinib  0    0  3.45 [0.14;   83.09]      .              .   3.45 [0.14;   83.09]      .                .     .       .
   Erlotinib + antiangiogenesis:Osimertinib + chemotherapy  0    0  1.06 [0.01;  104.46]      .              .   1.06 [0.01;  104.46]      .                .     .       .
 Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  1.33 [0.04;   41.01]      .              .   1.33 [0.04;   41.01]      .                .     .       .
                    Erlotinib + antiangiogenesis:Placebo  0    0  2.71 [0.33;   22.16]      .              .   2.71 [0.33;   22.16]      .                .     .       .
             Erlotinib + antiangiogenesis:antiangiogenesis  1 0.35  0.24 [0.08;    0.70]   0.11 [0.02;   0.68]   0.36 [0.10;    1.36]   0.31 [0.03;     2.93] -1.02  0.3094
                       Gefitinib:Gefitinib/Erlotinib  0    0  1.78 [0.06;   56.98]      .              .   1.78 [0.06;   56.98]      .                .     .       .
                    Gefitinib:Gefitinib + chemotherapy  2 1.00  0.91 [0.53;    1.57]   0.91 [0.53;   1.57]      .               .      .                .     .       .
                  Gefitinib:Gefitinib + antiangiogenesis  2 1.00  0.03 [0.01;    0.09]   0.03 [0.01;   0.09]      .               .      .                .     .       .
                                Gefitinib:Lazertinib  1 0.71  0.77 [0.05;   11.57]   3.00 [0.12;  75.06]   0.03 [0.00;    4.19] 110.45 [0.28; 43687.31]  1.54  0.1231
                               Gefitinib:Osimertinib  0    0  1.19 [0.06;   22.76]      .              .   1.19 [0.06;   22.76]      .                .     .       .
                  Gefitinib:Osimertinib + chemotherapy  0    0  0.36 [0.00;   30.80]      .              .   0.36 [0.00;   30.80]      .                .     .       .
                Gefitinib:Osimertinib + antiangiogenesis  0    0  0.46 [0.02;   11.43]      .              .   0.46 [0.02;   11.43]      .                .     .       .
                                   Gefitinib:Placebo  1 0.39  0.93 [0.12;    7.03]   0.32 [0.01;   8.10]   1.85 [0.14;   24.78]   0.17 [0.00;    10.90] -0.83  0.4082
                            Gefitinib:antiangiogenesis  1 0.71  0.08 [0.01;    0.48]   0.06 [0.01;   0.51]   0.15 [0.01;    3.95]   0.42 [0.01;    19.70] -0.44  0.6565
          Gefitinib/Erlotinib:Gefitinib + chemotherapy  0    0  0.51 [0.02;   17.15]      .              .   0.51 [0.02;   17.15]      .                .     .       .
        Gefitinib/Erlotinib:Gefitinib + antiangiogenesis  0    0  0.02 [0.00;    0.67]      .              .   0.02 [0.00;    0.67]      .                .     .       .
                      Gefitinib/Erlotinib:Lazertinib  0    0  0.43 [0.02;   11.32]      .              .   0.43 [0.02;   11.32]      .                .     .       .
                     Gefitinib/Erlotinib:Osimertinib  1 1.00  0.67 [0.11;    4.13]   0.67 [0.11;   4.13]      .               .      .                .     .       .
        Gefitinib/Erlotinib:Osimertinib + chemotherapy  0    0  0.21 [0.00;    8.98]      .              .   0.21 [0.00;    8.98]      .                .     .       .
      Gefitinib/Erlotinib:Osimertinib + antiangiogenesis  0    0  0.26 [0.03;    2.38]      .              .   0.26 [0.03;    2.38]      .                .     .       .
                         Gefitinib/Erlotinib:Placebo  0    0  0.53 [0.02;   13.76]      .              .   0.53 [0.02;   13.76]      .                .     .       .
                  Gefitinib/Erlotinib:antiangiogenesis  0    0  0.05 [0.00;    1.81]      .              .   0.05 [0.00;    1.81]      .                .     .       .
     Gefitinib + chemotherapy:Gefitinib + antiangiogenesis  0    0  0.04 [0.01;    0.11]      .              .   0.04 [0.01;    0.11]      .                .     .       .
                   Gefitinib + chemotherapy:Lazertinib  0    0  0.84 [0.05;   13.43]      .              .   0.84 [0.05;   13.43]      .                .     .       .
                  Gefitinib + chemotherapy:Osimertinib  0    0  1.31 [0.06;   26.31]      .              .   1.31 [0.06;   26.31]      .                .     .       .
     Gefitinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.40 [0.00;   35.01]      .              .   0.40 [0.00;   35.01]      .                .     .       .
   Gefitinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.51 [0.02;   13.16]      .              .   0.51 [0.02;   13.16]      .                .     .       .
                      Gefitinib + chemotherapy:Placebo  0    0  1.03 [0.13;    8.31]      .              .   1.03 [0.13;    8.31]      .                .     .       .
               Gefitinib + chemotherapy:antiangiogenesis  0    0  0.09 [0.01;    0.57]      .              .   0.09 [0.01;    0.57]      .                .     .       .
                 Gefitinib + antiangiogenesis:Lazertinib  0    0 23.91 [1.32;  434.59]      .              .  23.91 [1.32;  434.59]      .                .     .       .
                Gefitinib + antiangiogenesis:Osimertinib  0    0 37.05 [1.63;  843.02]      .              .  37.05 [1.63;  843.02]      .                .     .       .
   Gefitinib + antiangiogenesis:Osimertinib + chemotherapy  0    0 11.36 [0.12; 1078.72]      .              .  11.36 [0.12; 1078.72]      .                .     .       .
 Gefitinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0 14.33 [0.49;  417.80]      .              .  14.33 [0.49;  417.80]      .                .     .       .
                    Gefitinib + antiangiogenesis:Placebo  0    0 29.07 [3.02;  279.76]      .              .  29.07 [3.02;  279.76]      .                .     .       .
             Gefitinib + antiangiogenesis:antiangiogenesis  0    0  2.58 [0.34;   19.58]      .              .   2.58 [0.34;   19.58]      .                .     .       .
                              Lazertinib:Osimertinib  1 0.71  1.55 [0.10;   23.34]   6.05 [0.24; 151.07]   0.05 [0.00;    8.47] 110.45 [0.28; 43687.31]  1.54  0.1231
                 Lazertinib:Osimertinib + chemotherapy  0    0  0.48 [0.01;   34.35]      .              .   0.48 [0.01;   34.35]      .                .     .       .
               Lazertinib:Osimertinib + antiangiogenesis  0    0  0.60 [0.03;   11.97]      .              .   0.60 [0.03;   11.97]      .                .     .       .
                                  Lazertinib:Placebo  0    0  1.22 [0.06;   23.29]      .              .   1.22 [0.06;   23.29]      .                .     .       .
                           Lazertinib:antiangiogenesis  0    0  0.11 [0.00;    2.38]      .              .   0.11 [0.00;    2.38]      .                .     .       .
                Osimertinib:Osimertinib + chemotherapy  1 1.00  0.31 [0.01;    8.41]   0.31 [0.01;   8.41]      .               .      .                .     .       .
              Osimertinib:Osimertinib + antiangiogenesis  3 1.00  0.39 [0.11;    1.38]   0.39 [0.11;   1.38]      .               .      .                .     .       .
                                 Osimertinib:Placebo  1 0.71  0.78 [0.05;   11.82]   3.06 [0.12;  76.43]   0.03 [0.00;    4.29] 110.45 [0.28; 43687.31]  1.54  0.1231
                          Osimertinib:antiangiogenesis  0    0  0.07 [0.00;    1.67]      .              .   0.07 [0.00;    1.67]      .                .     .       .
 Osimertinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  1.26 [0.04;   43.77]      .              .   1.26 [0.04;   43.77]      .                .     .       .
                    Osimertinib + chemotherapy:Placebo  0    0  2.56 [0.04;  184.98]      .              .   2.56 [0.04;  184.98]      .                .     .       .
             Osimertinib + chemotherapy:antiangiogenesis  0    0  0.23 [0.00;   22.33]      .              .   0.23 [0.00;   22.33]      .                .     .       .
                  Osimertinib + antiangiogenesis:Placebo  0    0  2.03 [0.10;   40.51]      .              .   2.03 [0.10;   40.51]      .                .     .       .
           Osimertinib + antiangiogenesis:antiangiogenesis  0    0  0.18 [0.01;    5.50]      .              .   0.18 [0.01;    5.50]      .                .     .       .
                              antiangiogenesis:Placebo  0    0 11.29 [1.32;   96.71]      .              .  11.29 [1.32;   96.71]      .                .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

serious-Vascular Toxicity

Random effects model: 

                                               comparison  k prop   nma          95%-CI direct         95%-CI indir.          95%-CI  RoR        95%-CI     z p-value
                          Afatinib:Afatinib + Cetuximab  1 1.00  0.38 [0.07;    1.99]   0.38 [0.07;   1.99]      .               .    .             .     .       .
                                    Afatinib:Almonertinib  0    0  0.06 [0.00;    1.05]      .              .   0.06 [0.00;    1.05]    .             .     .       .
                        Afatinib:Amivantamab  +  Lazertinib  0    0  0.26 [0.10;    0.65]      .              .   0.26 [0.10;    0.65]    .             .     .       .
                                    Afatinib:Chemotherapy  2 0.29  0.85 [0.44;    1.61]   0.58 [0.18;   1.92]   0.99 [0.46;    2.12] 0.59 [0.14;  2.44] -0.73  0.4676
                                     Afatinib:Dacomitinib  0    0  1.40 [0.62;    3.18]      .              .   1.40 [0.62;    3.18]    .             .     .       .
                                  Afatinib:DHFR inhibitor  0    0  1.16 [0.07;   19.90]      .              .   1.16 [0.07;   19.90]    .             .     .       .
                                       Afatinib:Erlotinib  1 0.60  1.21 [0.70;    2.10]   1.01 [0.50;   2.05]   1.60 [0.67;    3.82] 0.63 [0.21;  1.93] -0.81  0.4193
                   Afatinib:Erlotinib + Autophagy inhibitor  0    0  3.73 [0.14;   99.00]      .              .   3.73 [0.14;   99.00]    .             .     .       .
                          Afatinib:Erlotinib + chemotherapy  0    0  1.59 [0.51;    4.99]      .              .   1.59 [0.51;    4.99]    .             .     .       .
                        Afatinib:Erlotinib + COX2 inhibitor  0    0  3.77 [0.14;   99.22]      .              .   3.77 [0.14;   99.22]    .             .     .       .
                          Afatinib:Erlotinib + ER inhibitor  0    0  0.24 [0.01;    5.32]      .              .   0.24 [0.01;    5.32]    .             .     .       .
                        Afatinib:Erlotinib + HER3 inhibitor  0    0  1.83 [0.36;    9.26]      .              .   1.83 [0.36;    9.26]    .             .     .       .
                         Afatinib:Erlotinib + HGF inhibitor  0    0  0.38 [0.01;   11.01]      .              .   0.38 [0.01;   11.01]    .             .     .       .
                         Afatinib:Erlotinib + IGF-1R inhibitor  0    0  0.33 [0.08;    1.35]      .              .   0.33 [0.08;    1.35]    .             .     .       .
                         Afatinib:Erlotinib + MET inhibitor  0    0  1.27 [0.65;    2.49]      .              .   1.27 [0.65;    2.49]    .             .     .       .
                         Afatinib:Erlotinib + MMP inhibitor  0    0  2.46 [0.40;   15.08]      .              .   2.46 [0.40;   15.08]    .             .     .       .
                        Afatinib:Erlotinib + antiangiogenesis  0    0  0.87 [0.46;    1.67]      .              .   0.87 [0.46;    1.67]    .             .     .       .
                                       Afatinib:Gefitinib  1 0.50  1.51 [0.78;    2.95]   1.92 [0.75;   4.95]   1.19 [0.46;    3.07] 1.61 [0.42;  6.13]  0.70  0.4861
                             Afatinib:Gefitinib/Erlotinib  0    0  2.58 [0.68;    9.83]      .              .   2.58 [0.68;    9.83]    .             .     .       .
                          Afatinib:Gefitinib + chemotherapy  0    0  0.57 [0.14;    2.39]      .              .   0.57 [0.14;    2.39]    .             .     .       .
                                      Afatinib:Lazertinib  0    0  0.67 [0.26;    1.73]      .              .   0.67 [0.26;    1.73]    .             .     .       .
                                     Afatinib:Osimertinib  0    0  0.97 [0.42;    2.23]      .              .   0.97 [0.42;    2.23]    .             .     .       .
                        Afatinib:Osimertinib + chemotherapy  0    0  0.36 [0.10;    1.38]      .              .   0.36 [0.10;    1.38]    .             .     .       .
                      Afatinib:Osimertinib + antiangiogenesis  0    0  1.97 [0.29;   13.40]      .              .   1.97 [0.29;   13.40]    .             .     .       .
                                         Afatinib:Placebo  1 0.19  1.47 [0.77;    2.83]   3.33 [0.74;  14.89]   1.21 [0.59;    2.51] 2.74 [0.52; 14.49]  1.19  0.2356
                                     Afatinib:Rociletinib  0    0  1.19 [0.07;   20.59]      .              .   1.19 [0.07;   20.59]    .             .     .       .
                                  Afatinib:antiangiogenesis  0    0  0.75 [0.33;    1.72]      .              .   0.75 [0.33;    1.72]    .             .     .       .
                      Afatinib + Cetuximab:Almonertinib  0    0  0.15 [0.01;    4.34]      .              .   0.15 [0.01;    4.34]    .             .     .       .
          Afatinib + Cetuximab:Amivantamab  +  Lazertinib  0    0  0.68 [0.10;    4.60]      .              .   0.68 [0.10;    4.60]    .             .     .       .
                      Afatinib + Cetuximab:Chemotherapy  0    0  2.25 [0.38;   13.46]      .              .   2.25 [0.38;   13.46]    .             .     .       .
                       Afatinib + Cetuximab:Dacomitinib  0    0  3.72 [0.58;   23.92]      .              .   3.72 [0.58;   23.92]    .             .     .       .
                    Afatinib + Cetuximab:DHFR inhibitor  0    0  3.09 [0.11;   83.35]      .              .   3.09 [0.11;   83.35]    .             .     .       .
                         Afatinib + Cetuximab:Erlotinib  0    0  3.22 [0.56;   18.67]      .              .   3.22 [0.56;   18.67]    .             .     .       .
     Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor  0    0  9.93 [0.25;  393.02]      .              .   9.93 [0.25;  393.02]    .             .     .       .
            Afatinib + Cetuximab:Erlotinib + chemotherapy  0    0  4.23 [0.56;   32.00]      .              .   4.23 [0.56;   32.00]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + COX2 inhibitor  0    0 10.04 [0.26;  394.24]      .              .  10.04 [0.26;  394.24]    .             .     .       .
            Afatinib + Cetuximab:Erlotinib + ER inhibitor  0    0  0.64 [0.02;   21.54]      .              .   0.64 [0.02;   21.54]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + HER3 inhibitor  0    0  4.87 [0.48;   49.87]      .              .   4.87 [0.48;   49.87]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + HGF inhibitor  0    0  1.01 [0.02;   43.30]      .              .   1.01 [0.02;   43.30]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor  0    0  0.87 [0.10;    7.76]      .              .   0.87 [0.10;    7.76]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + MET inhibitor  0    0  3.38 [0.56;   20.45]      .              .   3.38 [0.56;   20.45]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + MMP inhibitor  0    0  6.54 [0.56;   76.91]      .              .   6.54 [0.56;   76.91]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + antiangiogenesis  0    0  2.32 [0.39;   13.91]      .              .   2.32 [0.39;   13.91]    .             .     .       .
                         Afatinib + Cetuximab:Gefitinib  0    0  4.03 [0.67;   24.31]      .              .   4.03 [0.67;   24.31]    .             .     .       .
               Afatinib + Cetuximab:Gefitinib/Erlotinib  0    0  6.87 [0.81;   58.25]      .              .   6.87 [0.81;   58.25]    .             .     .       .
            Afatinib + Cetuximab:Gefitinib + chemotherapy  0    0  1.51 [0.17;   13.70]      .              .   1.51 [0.17;   13.70]    .             .     .       .
                        Afatinib + Cetuximab:Lazertinib  0    0  1.79 [0.26;   12.19]      .              .   1.79 [0.26;   12.19]    .             .     .       .
                       Afatinib + Cetuximab:Osimertinib  0    0  2.58 [0.40;   16.68]      .              .   2.58 [0.40;   16.68]    .             .     .       .
          Afatinib + Cetuximab:Osimertinib + chemotherapy  0    0  0.97 [0.11;    8.21]      .              .   0.97 [0.11;    8.21]    .             .     .       .
        Afatinib + Cetuximab:Osimertinib + antiangiogenesis  0    0  5.24 [0.41;   66.56]      .              .   5.24 [0.41;   66.56]    .             .     .       .
                           Afatinib + Cetuximab:Placebo  0    0  3.91 [0.65;   23.49]      .              .   3.91 [0.65;   23.49]    .             .     .       .
                       Afatinib + Cetuximab:Rociletinib  0    0  3.16 [0.12;   86.09]      .              .   3.16 [0.12;   86.09]    .             .     .       .
                    Afatinib + Cetuximab:antiangiogenesis  0    0  2.00 [0.31;   12.85]      .              .   2.00 [0.31;   12.85]    .             .     .       .
                    Almonertinib:Amivantamab  +  Lazertinib  0    0  4.49 [0.23;   87.33]      .              .   4.49 [0.23;   87.33]    .             .     .       .
                                Almonertinib:Chemotherapy  0    0 14.86 [0.81;  274.00]      .              .  14.86 [0.81;  274.00]    .             .     .       .
                                 Almonertinib:Dacomitinib  0    0 24.61 [1.27;  477.64]      .              .  24.61 [1.27;  477.64]    .             .     .       .
                              Almonertinib:DHFR inhibitor  0    0 20.44 [0.36; 1152.74]      .              .  20.44 [0.36; 1152.74]    .             .     .       .
                                   Almonertinib:Erlotinib  0    0 21.29 [1.15;  392.90]      .              .  21.29 [1.15;  392.90]    .             .     .       .
               Almonertinib:Erlotinib + Autophagy inhibitor  0    0 65.59 [0.84; 5094.15]      .              .  65.59 [0.84; 5094.15]    .             .     .       .
                      Almonertinib:Erlotinib + chemotherapy  0    0 27.94 [1.28;  609.99]      .              .  27.94 [1.28;  609.99]    .             .     .       .
                    Almonertinib:Erlotinib + COX2 inhibitor  0    0 66.32 [0.86; 5116.29]      .              .  66.32 [0.86; 5116.29]    .             .     .       .
                      Almonertinib:Erlotinib + ER inhibitor  0    0  4.21 [0.06;  286.34]      .              .   4.21 [0.06;  286.34]    .             .     .       .
                    Almonertinib:Erlotinib + HER3 inhibitor  0    0 32.18 [1.20;  863.60]      .              .  32.18 [1.20;  863.60]    .             .     .       .
                     Almonertinib:Erlotinib + HGF inhibitor  0    0  6.69 [0.08;  554.68]      .              .   6.69 [0.08;  554.68]    .             .     .       .
                     Almonertinib:Erlotinib + IGF-1R inhibitor  0    0  5.75 [0.24;  140.19]      .              .   5.75 [0.24;  140.19]    .             .     .       .
                     Almonertinib:Erlotinib + MET inhibitor  0    0 22.34 [1.18;  423.11]      .              .  22.34 [1.18;  423.11]    .             .     .       .
                     Almonertinib:Erlotinib + MMP inhibitor  0    0 43.20 [1.46; 1280.70]      .              .  43.20 [1.46; 1280.70]    .             .     .       .
                    Almonertinib:Erlotinib + antiangiogenesis  0    0 15.34 [0.81;  288.89]      .              .  15.34 [0.81;  288.89]    .             .     .       .
                                   Almonertinib:Gefitinib  1 1.00 26.60 [1.57;  452.28]  26.60 [1.57; 452.28]      .               .    .             .     .       .
                         Almonertinib:Gefitinib/Erlotinib  0    0 45.36 [1.99; 1032.41]      .              .  45.36 [1.99; 1032.41]    .             .     .       .
                      Almonertinib:Gefitinib + chemotherapy  0    0 10.01 [0.45;  223.34]      .              .  10.01 [0.45;  223.34]    .             .     .       .
                                  Almonertinib:Lazertinib  0    0 11.84 [0.61;  228.14]      .              .  11.84 [0.61;  228.14]    .             .     .       .
                                 Almonertinib:Osimertinib  0    0 17.06 [0.90;  324.37]      .              .  17.06 [0.90;  324.37]    .             .     .       .
                    Almonertinib:Osimertinib + chemotherapy  0    0  6.39 [0.28;  145.49]      .              .   6.39 [0.28;  145.49]    .             .     .       .
                  Almonertinib:Osimertinib + antiangiogenesis  0    0 34.59 [1.14; 1051.63]      .              .  34.59 [1.14; 1051.63]    .             .     .       .
                                     Almonertinib:Placebo  0    0 25.86 [1.39;  479.38]      .              .  25.86 [1.39;  479.38]    .             .     .       .
                                 Almonertinib:Rociletinib  0    0 20.86 [0.37; 1187.98]      .              .  20.86 [0.37; 1187.98]    .             .     .       .
                              Almonertinib:antiangiogenesis  0    0 13.19 [0.67;  259.63]      .              .  13.19 [0.67;  259.63]    .             .     .       .
                    Amivantamab  +  Lazertinib:Chemotherapy  0    0  3.31 [1.41;    7.77]      .              .   3.31 [1.41;    7.77]    .             .     .       .
                     Amivantamab  +  Lazertinib:Dacomitinib  0    0  5.48 [1.91;   15.69]      .              .   5.48 [1.91;   15.69]    .             .     .       .
                  Amivantamab  +  Lazertinib:DHFR inhibitor  0    0  4.55 [0.24;   84.80]      .              .   4.55 [0.24;   84.80]    .             .     .       .
                       Amivantamab  +  Lazertinib:Erlotinib  0    0  4.74 [1.95;   11.55]      .              .   4.74 [1.95;   11.55]    .             .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor  0    0 14.60 [0.51;  417.27]      .              .  14.60 [0.51;  417.27]    .             .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + chemotherapy  0    0  6.22 [1.62;   23.82]      .              .   6.22 [1.62;   23.82]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + COX2 inhibitor  0    0 14.77 [0.52;  418.24]      .              .  14.77 [0.52;  418.24]    .             .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + ER inhibitor  0    0  0.94 [0.04;   22.50]      .              .   0.94 [0.04;   22.50]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor  0    0  7.16 [1.23;   41.89]      .              .   7.16 [1.23;   41.89]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + HGF inhibitor  0    0  1.49 [0.05;   46.30]      .              .   1.49 [0.05;   46.30]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor  0    0  1.28 [0.26;    6.21]      .              .   1.28 [0.26;    6.21]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor  0    0  4.98 [1.88;   13.15]      .              .   4.98 [1.88;   13.15]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor  0    0  9.62 [1.38;   67.26]      .              .   9.62 [1.38;   67.26]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis  0    0  3.42 [1.31;    8.88]      .              .   3.42 [1.31;    8.88]    .             .     .       .
                       Amivantamab  +  Lazertinib:Gefitinib  0    0  5.92 [2.45;   14.33]      .              .   5.92 [2.45;   14.33]    .             .     .       .
             Amivantamab  +  Lazertinib:Gefitinib/Erlotinib  0    0 10.10 [3.13;   32.61]      .              .  10.10 [3.13;   32.61]    .             .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + chemotherapy  0    0  2.23 [0.47;   10.48]      .              .   2.23 [0.47;   10.48]    .             .     .       .
                      Amivantamab  +  Lazertinib:Lazertinib  1 0.90  2.64 [1.43;    4.86]   2.73 [1.43;   5.20]   1.89 [0.26;   13.76] 1.45 [0.18; 11.67]  0.35  0.7290
                     Amivantamab  +  Lazertinib:Osimertinib  1 0.94  3.80 [2.23;    6.46]   3.71 [2.15;   6.41]   5.56 [0.60;   51.27] 0.67 [0.07;  6.57] -0.35  0.7290
        Amivantamab  +  Lazertinib:Osimertinib + chemotherapy  0    0  1.42 [0.44;    4.60]      .              .   1.42 [0.44;    4.60]    .             .     .       .
      Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis  0    0  7.70 [1.26;   46.95]      .              .   7.70 [1.26;   46.95]    .             .     .       .
                         Amivantamab  +  Lazertinib:Placebo  0    0  5.76 [2.40;   13.82]      .              .   5.76 [2.40;   13.82]    .             .     .       .
                     Amivantamab  +  Lazertinib:Rociletinib  0    0  4.64 [0.25;   87.72]      .              .   4.64 [0.25;   87.72]    .             .     .       .
                  Amivantamab  +  Lazertinib:antiangiogenesis  0    0  2.94 [0.99;    8.68]      .              .   2.94 [0.99;    8.68]    .             .     .       .
                                 Chemotherapy:Dacomitinib  0    0  1.66 [0.72;    3.80]      .              .   1.66 [0.72;    3.80]    .             .     .       .
                              Chemotherapy:DHFR inhibitor  0    0  1.38 [0.08;   23.59]      .              .   1.38 [0.08;   23.59]    .             .     .       .
                                   Chemotherapy:Erlotinib  6 0.60  1.43 [0.82;    2.51]   1.16 [0.56;   2.40]   1.96 [0.81;    4.75] 0.59 [0.19;  1.87] -0.89  0.3738
               Chemotherapy:Erlotinib + Autophagy inhibitor  0    0  4.41 [0.17;  117.33]      .              .   4.41 [0.17;  117.33]    .             .     .       .
                      Chemotherapy:Erlotinib + chemotherapy  0    0  1.88 [0.59;    5.94]      .              .   1.88 [0.59;    5.94]    .             .     .       .
                    Chemotherapy:Erlotinib + COX2 inhibitor  0    0  4.46 [0.17;  117.58]      .              .   4.46 [0.17;  117.58]    .             .     .       .
                      Chemotherapy:Erlotinib + ER inhibitor  0    0  0.28 [0.01;    6.30]      .              .   0.28 [0.01;    6.30]    .             .     .       .
                    Chemotherapy:Erlotinib + HER3 inhibitor  0    0  2.16 [0.43;   11.00]      .              .   2.16 [0.43;   11.00]    .             .     .       .
                     Chemotherapy:Erlotinib + HGF inhibitor  0    0  0.45 [0.02;   13.04]      .              .   0.45 [0.02;   13.04]    .             .     .       .
                     Chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  0.39 [0.09;    1.60]      .              .   0.39 [0.09;    1.60]    .             .     .       .
                     Chemotherapy:Erlotinib + MET inhibitor  0    0  1.50 [0.76;    2.98]      .              .   1.50 [0.76;    2.98]    .             .     .       .
                     Chemotherapy:Erlotinib + MMP inhibitor  0    0  2.91 [0.47;   17.90]      .              .   2.91 [0.47;   17.90]    .             .     .       .
                    Chemotherapy:Erlotinib + antiangiogenesis  0    0  1.03 [0.53;    2.00]      .              .   1.03 [0.53;    2.00]    .             .     .       .
                                   Chemotherapy:Gefitinib  4 0.38  1.79 [0.90;    3.54]   1.56 [0.51;   4.74]   1.95 [0.82;    4.61] 0.80 [0.20;  3.28] -0.31  0.7580
                         Chemotherapy:Gefitinib/Erlotinib  0    0  3.05 [0.85;   10.90]      .              .   3.05 [0.85;   10.90]    .             .     .       .
                      Chemotherapy:Gefitinib + chemotherapy  0    0  0.67 [0.16;    2.85]      .              .   0.67 [0.16;    2.85]    .             .     .       .
                                  Chemotherapy:Lazertinib  0    0  0.80 [0.33;    1.92]      .              .   0.80 [0.33;    1.92]    .             .     .       .
                                 Chemotherapy:Osimertinib  1 0.54  1.15 [0.55;    2.37]   1.46 [0.54;   3.92]   0.86 [0.30;    2.53] 1.69 [0.39;  7.26]  0.70  0.4818
                    Chemotherapy:Osimertinib + chemotherapy  0    0  0.43 [0.12;    1.54]      .              .   0.43 [0.12;    1.54]    .             .     .       .
                  Chemotherapy:Osimertinib + antiangiogenesis  0    0  2.33 [0.36;   15.17]      .              .   2.33 [0.36;   15.17]    .             .     .       .
                                     Chemotherapy:Placebo  0    0  1.74 [0.89;    3.40]      .              .   1.74 [0.89;    3.40]    .             .     .       .
                                 Chemotherapy:Rociletinib  0    0  1.40 [0.08;   24.41]      .              .   1.40 [0.08;   24.41]    .             .     .       .
                              Chemotherapy:antiangiogenesis  0    0  0.89 [0.38;    2.05]      .              .   0.89 [0.38;    2.05]    .             .     .       .
                               Dacomitinib:DHFR inhibitor  0    0  0.83 [0.05;   14.56]      .              .   0.83 [0.05;   14.56]    .             .     .       .
                                    Dacomitinib:Erlotinib  2 0.67  0.87 [0.45;    1.68]   0.64 [0.28;   1.44]   1.57 [0.50;    4.95] 0.41 [0.10;  1.66] -1.25  0.2101
                Dacomitinib:Erlotinib + Autophagy inhibitor  0    0  2.67 [0.10;   72.23]      .              .   2.67 [0.10;   72.23]    .             .     .       .
                       Dacomitinib:Erlotinib + chemotherapy  0    0  1.14 [0.34;    3.78]      .              .   1.14 [0.34;    3.78]    .             .     .       .
                     Dacomitinib:Erlotinib + COX2 inhibitor  0    0  2.70 [0.10;   72.39]      .              .   2.70 [0.10;   72.39]    .             .     .       .
                       Dacomitinib:Erlotinib + ER inhibitor  0    0  0.17 [0.01;    3.88]      .              .   0.17 [0.01;    3.88]    .             .     .       .
                     Dacomitinib:Erlotinib + HER3 inhibitor  0    0  1.31 [0.25;    6.90]      .              .   1.31 [0.25;    6.90]    .             .     .       .
                      Dacomitinib:Erlotinib + HGF inhibitor  0    0  0.27 [0.01;    8.03]      .              .   0.27 [0.01;    8.03]    .             .     .       .
                      Dacomitinib:Erlotinib + IGF-1R inhibitor  0    0  0.23 [0.05;    1.01]      .              .   0.23 [0.05;    1.01]    .             .     .       .
                      Dacomitinib:Erlotinib + MET inhibitor  0    0  0.91 [0.42;    1.96]      .              .   0.91 [0.42;    1.96]    .             .     .       .
                      Dacomitinib:Erlotinib + MMP inhibitor  0    0  1.76 [0.28;   11.19]      .              .   1.76 [0.28;   11.19]    .             .     .       .
                     Dacomitinib:Erlotinib + antiangiogenesis  0    0  0.62 [0.29;    1.32]      .              .   0.62 [0.29;    1.32]    .             .     .       .
                                    Dacomitinib:Gefitinib  1 0.13  1.08 [0.45;    2.60]   1.98 [0.18;  22.02]   0.99 [0.38;    2.53] 2.01 [0.15; 26.69]  0.53  0.5962
                          Dacomitinib:Gefitinib/Erlotinib  0    0  1.84 [0.45;    7.60]      .              .   1.84 [0.45;    7.60]    .             .     .       .
                       Dacomitinib:Gefitinib + chemotherapy  0    0  0.41 [0.09;    1.91]      .              .   0.41 [0.09;    1.91]    .             .     .       .
                                   Dacomitinib:Lazertinib  0    0  0.48 [0.17;    1.40]      .              .   0.48 [0.17;    1.40]    .             .     .       .
                                  Dacomitinib:Osimertinib  0    0  0.69 [0.27;    1.81]      .              .   0.69 [0.27;    1.81]    .             .     .       .
                     Dacomitinib:Osimertinib + chemotherapy  0    0  0.26 [0.06;    1.07]      .              .   0.26 [0.06;    1.07]    .             .     .       .
                   Dacomitinib:Osimertinib + antiangiogenesis  0    0  1.41 [0.20;   10.13]      .              .   1.41 [0.20;   10.13]    .             .     .       .
                                      Dacomitinib:Placebo  1 0.41  1.05 [0.51;    2.16]   1.65 [0.53;   5.10]   0.77 [0.30;    1.97] 2.13 [0.49;  9.26]  1.01  0.3130
                                  Dacomitinib:Rociletinib  0    0  0.85 [0.05;   15.07]      .              .   0.85 [0.05;   15.07]    .             .     .       .
                               Dacomitinib:antiangiogenesis  0    0  0.54 [0.22;    1.33]      .              .   0.54 [0.22;    1.33]    .             .     .       .
                                 DHFR inhibitor:Erlotinib  1 1.00  1.04 [0.06;   16.89]   1.04 [0.06;  16.89]      .               .    .             .     .       .
             DHFR inhibitor:Erlotinib + Autophagy inhibitor  0    0  3.21 [0.04;  228.78]      .              .   3.21 [0.04;  228.78]    .             .     .       .
                    DHFR inhibitor:Erlotinib + chemotherapy  0    0  1.37 [0.07;   26.42]      .              .   1.37 [0.07;   26.42]    .             .     .       .
                  DHFR inhibitor:Erlotinib + COX2 inhibitor  0    0  3.24 [0.05;  229.75]      .              .   3.24 [0.05;  229.75]    .             .     .       .
                    DHFR inhibitor:Erlotinib + ER inhibitor  0    0  0.21 [0.00;   12.82]      .              .   0.21 [0.00;   12.82]    .             .     .       .
                  DHFR inhibitor:Erlotinib + HER3 inhibitor  0    0  1.57 [0.07;   37.70]      .              .   1.57 [0.07;   37.70]    .             .     .       .
                   DHFR inhibitor:Erlotinib + HGF inhibitor  0    0  0.33 [0.00;   24.94]      .              .   0.33 [0.00;   24.94]    .             .     .       .
                   DHFR inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.28 [0.01;    6.10]      .              .   0.28 [0.01;    6.10]    .             .     .       .
                   DHFR inhibitor:Erlotinib + MET inhibitor  0    0  1.09 [0.07;   18.21]      .              .   1.09 [0.07;   18.21]    .             .     .       .
                   DHFR inhibitor:Erlotinib + MMP inhibitor  0    0  2.11 [0.08;   56.10]      .              .   2.11 [0.08;   56.10]    .             .     .       .
                  DHFR inhibitor:Erlotinib + antiangiogenesis  0    0  0.75 [0.05;   12.43]      .              .   0.75 [0.05;   12.43]    .             .     .       .
                                 DHFR inhibitor:Gefitinib  0    0  1.30 [0.07;   22.93]      .              .   1.30 [0.07;   22.93]    .             .     .       .
                       DHFR inhibitor:Gefitinib/Erlotinib  0    0  2.22 [0.10;   48.02]      .              .   2.22 [0.10;   48.02]    .             .     .       .
                    DHFR inhibitor:Gefitinib + chemotherapy  0    0  0.49 [0.02;   11.29]      .              .   0.49 [0.02;   11.29]    .             .     .       .
                                DHFR inhibitor:Lazertinib  0    0  0.58 [0.03;   10.86]      .              .   0.58 [0.03;   10.86]    .             .     .       .
                               DHFR inhibitor:Osimertinib  0    0  0.83 [0.05;   15.04]      .              .   0.83 [0.05;   15.04]    .             .     .       .
                  DHFR inhibitor:Osimertinib + chemotherapy  0    0  0.31 [0.01;    6.77]      .              .   0.31 [0.01;    6.77]    .             .     .       .
                DHFR inhibitor:Osimertinib + antiangiogenesis  0    0  1.69 [0.06;   49.13]      .              .   1.69 [0.06;   49.13]    .             .     .       .
                                   DHFR inhibitor:Placebo  0    0  1.26 [0.07;   21.50]      .              .   1.26 [0.07;   21.50]    .             .     .       .
                               DHFR inhibitor:Rociletinib  0    0  1.02 [0.02;   53.00]      .              .   1.02 [0.02;   53.00]    .             .     .       .
                            DHFR inhibitor:antiangiogenesis  0    0  0.65 [0.04;   11.19]      .              .   0.65 [0.04;   11.19]    .             .     .       .
                  Erlotinib:Erlotinib + Autophagy inhibitor  1 1.00  3.08 [0.12;   78.02]   3.08 [0.12;  78.02]      .               .    .             .     .       .
                         Erlotinib:Erlotinib + chemotherapy  3 1.00  1.31 [0.48;    3.58]   1.31 [0.48;   3.58]      .               .    .             .     .       .
                       Erlotinib:Erlotinib + COX2 inhibitor  1 1.00  3.11 [0.12;   78.18]   3.11 [0.12;  78.18]      .               .    .             .     .       .
                         Erlotinib:Erlotinib + ER inhibitor  1 1.00  0.20 [0.01;    4.18]   0.20 [0.01;   4.18]      .               .    .             .     .       .
                       Erlotinib:Erlotinib + HER3 inhibitor  1 1.00  1.51 [0.33;    6.94]   1.51 [0.33;   6.94]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + HGF inhibitor  1 1.00  0.31 [0.01;    8.68]   0.31 [0.01;   8.68]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + IGF-1R inhibitor  3 1.00  0.27 [0.07;    0.99]   0.27 [0.07;   0.99]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + MET inhibitor  5 1.00  1.05 [0.71;    1.55]   1.05 [0.71;   1.55]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + MMP inhibitor  1 1.00  2.03 [0.36;   11.43]   2.03 [0.36;  11.43]      .               .    .             .     .       .
                       Erlotinib:Erlotinib + antiangiogenesis 12 0.97  0.72 [0.51;    1.02]   0.69 [0.48;   0.98]   2.82 [0.40;   20.01] 0.24 [0.03;  1.79] -1.39  0.1658
                                      Erlotinib:Gefitinib  0    0  1.25 [0.63;    2.48]      .              .   1.25 [0.63;    2.48]    .             .     .       .
                            Erlotinib:Gefitinib/Erlotinib  0    0  2.13 [0.58;    7.82]      .              .   2.13 [0.58;    7.82]    .             .     .       .
                         Erlotinib:Gefitinib + chemotherapy  0    0  0.47 [0.11;    1.99]      .              .   0.47 [0.11;    1.99]    .             .     .       .
                                     Erlotinib:Lazertinib  0    0  0.56 [0.22;    1.38]      .              .   0.56 [0.22;    1.38]    .             .     .       .
                                    Erlotinib:Osimertinib  0    0  0.80 [0.37;    1.74]      .              .   0.80 [0.37;    1.74]    .             .     .       .
                       Erlotinib:Osimertinib + chemotherapy  0    0  0.30 [0.08;    1.10]      .              .   0.30 [0.08;    1.10]    .             .     .       .
                     Erlotinib:Osimertinib + antiangiogenesis  0    0  1.62 [0.24;   10.79]      .              .   1.62 [0.24;   10.79]    .             .     .       .
                                        Erlotinib:Placebo  3 0.59  1.21 [0.73;    2.03]   0.70 [0.36;   1.37]   2.69 [1.20;    6.04] 0.26 [0.09;  0.75] -2.51  0.0122
                                    Erlotinib:Rociletinib  1 1.00  0.98 [0.06;   16.11]   0.98 [0.06;  16.11]      .               .    .             .     .       .
                                 Erlotinib:antiangiogenesis  2 0.87  0.62 [0.33;    1.15]   0.67 [0.35;   1.30]   0.35 [0.06;    1.98] 1.94 [0.30; 12.54]  0.70  0.4852
     Erlotinib + Autophagy inhibitor:Erlotinib + chemotherapy  0    0  0.43 [0.01;   12.57]      .              .   0.43 [0.01;   12.57]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + COX2 inhibitor  0    0  1.01 [0.01;   97.07]      .              .   1.01 [0.01;   97.07]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + ER inhibitor  0    0  0.06 [0.00;    5.47]      .              .   0.06 [0.00;    5.47]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + HER3 inhibitor  0    0  0.49 [0.01;   17.49]      .              .   0.49 [0.01;   17.49]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + HGF inhibitor  0    0  0.10 [0.00;   10.49]      .              .   0.10 [0.00;   10.49]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.09 [0.00;    2.86]      .              .   0.09 [0.00;    2.86]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor  0    0  0.34 [0.01;    8.83]      .              .   0.34 [0.01;    8.83]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MMP inhibitor  0    0  0.66 [0.02;   25.74]      .              .   0.66 [0.02;   25.74]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis  0    0  0.23 [0.01;    6.04]      .              .   0.23 [0.01;    6.04]    .             .     .       .
                  Erlotinib + Autophagy inhibitor:Gefitinib  0    0  0.41 [0.01;   11.04]      .              .   0.41 [0.01;   11.04]    .             .     .       .
        Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib  0    0  0.69 [0.02;   22.54]      .              .   0.69 [0.02;   22.54]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy  0    0  0.15 [0.00;    5.26]      .              .   0.15 [0.00;    5.26]    .             .     .       .
                 Erlotinib + Autophagy inhibitor:Lazertinib  0    0  0.18 [0.01;    5.19]      .              .   0.18 [0.01;    5.19]    .             .     .       .
                Erlotinib + Autophagy inhibitor:Osimertinib  0    0  0.26 [0.01;    7.22]      .              .   0.26 [0.01;    7.22]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy  0    0  0.10 [0.00;    3.18]      .              .   0.10 [0.00;    3.18]    .             .     .       .
 Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis  0    0  0.53 [0.01;   22.33]      .              .   0.53 [0.01;   22.33]    .             .     .       .
                    Erlotinib + Autophagy inhibitor:Placebo  0    0  0.39 [0.01;   10.40]      .              .   0.39 [0.01;   10.40]    .             .     .       .
                Erlotinib + Autophagy inhibitor:Rociletinib  0    0  0.32 [0.00;   22.89]      .              .   0.32 [0.00;   22.89]    .             .     .       .
             Erlotinib + Autophagy inhibitor:antiangiogenesis  0    0  0.20 [0.01;    5.40]      .              .   0.20 [0.01;    5.40]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + COX2 inhibitor  0    0  2.37 [0.08;   69.43]      .              .   2.37 [0.08;   69.43]    .             .     .       .
            Erlotinib + chemotherapy:Erlotinib + ER inhibitor  0    0  0.15 [0.01;    3.74]      .              .   0.15 [0.01;    3.74]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor  0    0  1.15 [0.19;    7.15]      .              .   1.15 [0.19;    7.15]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + HGF inhibitor  0    0  0.24 [0.01;    7.68]      .              .   0.24 [0.01;    7.68]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  0.21 [0.04;    1.07]      .              .   0.21 [0.04;    1.07]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + MET inhibitor  0    0  0.80 [0.27;    2.35]      .              .   0.80 [0.27;    2.35]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + MMP inhibitor  0    0  1.55 [0.21;   11.42]      .              .   1.55 [0.21;   11.42]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + antiangiogenesis  0    0  0.55 [0.19;    1.59]      .              .   0.55 [0.19;    1.59]    .             .     .       .
                         Erlotinib + chemotherapy:Gefitinib  0    0  0.95 [0.28;    3.21]      .              .   0.95 [0.28;    3.21]    .             .     .       .
               Erlotinib + chemotherapy:Gefitinib/Erlotinib  0    0  1.62 [0.31;    8.40]      .              .   1.62 [0.31;    8.40]    .             .     .       .
            Erlotinib + chemotherapy:Gefitinib + chemotherapy  0    0  0.36 [0.06;    2.08]      .              .   0.36 [0.06;    2.08]    .             .     .       .
                        Erlotinib + chemotherapy:Lazertinib  0    0  0.42 [0.11;    1.64]      .              .   0.42 [0.11;    1.64]    .             .     .       .
                       Erlotinib + chemotherapy:Osimertinib  0    0  0.61 [0.17;    2.17]      .              .   0.61 [0.17;    2.17]    .             .     .       .
          Erlotinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.23 [0.04;    1.18]      .              .   0.23 [0.04;    1.18]    .             .     .       .
        Erlotinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  1.24 [0.15;   10.56]      .              .   1.24 [0.15;   10.56]    .             .     .       .
                           Erlotinib + chemotherapy:Placebo  0    0  0.93 [0.30;    2.86]      .              .   0.93 [0.30;    2.86]    .             .     .       .
                       Erlotinib + chemotherapy:Rociletinib  0    0  0.75 [0.04;   14.63]      .              .   0.75 [0.04;   14.63]    .             .     .       .
                    Erlotinib + chemotherapy:antiangiogenesis  0    0  0.47 [0.15;    1.54]      .              .   0.47 [0.15;    1.54]    .             .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + ER inhibitor  0    0  0.06 [0.00;    5.37]      .              .   0.06 [0.00;    5.37]    .             .     .       .
        Erlotinib + COX2 inhibitor:Erlotinib + HER3 inhibitor  0    0  0.49 [0.01;   17.16]      .              .   0.49 [0.01;   17.16]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + HGF inhibitor  0    0  0.10 [0.00;   10.31]      .              .   0.10 [0.00;   10.31]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.09 [0.00;    2.81]      .              .   0.09 [0.00;    2.81]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + MET inhibitor  0    0  0.34 [0.01;    8.66]      .              .   0.34 [0.01;    8.66]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + MMP inhibitor  0    0  0.65 [0.02;   25.25]      .              .   0.65 [0.02;   25.25]    .             .     .       .
        Erlotinib + COX2 inhibitor:Erlotinib + antiangiogenesis  0    0  0.23 [0.01;    5.92]      .              .   0.23 [0.01;    5.92]    .             .     .       .
                       Erlotinib + COX2 inhibitor:Gefitinib  0    0  0.40 [0.01;   10.82]      .              .   0.40 [0.01;   10.82]    .             .     .       .
             Erlotinib + COX2 inhibitor:Gefitinib/Erlotinib  0    0  0.68 [0.02;   22.10]      .              .   0.68 [0.02;   22.10]    .             .     .       .
          Erlotinib + COX2 inhibitor:Gefitinib + chemotherapy  0    0  0.15 [0.00;    5.16]      .              .   0.15 [0.00;    5.16]    .             .     .       .
                      Erlotinib + COX2 inhibitor:Lazertinib  0    0  0.18 [0.01;    5.08]      .              .   0.18 [0.01;    5.08]    .             .     .       .
                     Erlotinib + COX2 inhibitor:Osimertinib  0    0  0.26 [0.01;    7.08]      .              .   0.26 [0.01;    7.08]    .             .     .       .
        Erlotinib + COX2 inhibitor:Osimertinib + chemotherapy  0    0  0.10 [0.00;    3.12]      .              .   0.10 [0.00;    3.12]    .             .     .       .
      Erlotinib + COX2 inhibitor:Osimertinib + antiangiogenesis  0    0  0.52 [0.01;   21.92]      .              .   0.52 [0.01;   21.92]    .             .     .       .
                         Erlotinib + COX2 inhibitor:Placebo  0    0  0.39 [0.01;   10.20]      .              .   0.39 [0.01;   10.20]    .             .     .       .
                     Erlotinib + COX2 inhibitor:Rociletinib  0    0  0.31 [0.00;   22.49]      .              .   0.31 [0.00;   22.49]    .             .     .       .
                  Erlotinib + COX2 inhibitor:antiangiogenesis  0    0  0.20 [0.01;    5.29]      .              .   0.20 [0.01;    5.29]    .             .     .       .
          Erlotinib + ER inhibitor:Erlotinib + HER3 inhibitor  0    0  7.64 [0.25;  231.47]      .              .   7.64 [0.25;  231.47]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + HGF inhibitor  0    0  1.59 [0.02;  144.26]      .              .   1.59 [0.02;  144.26]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + IGF-1R inhibitor  0    0  1.37 [0.05;   37.71]      .              .   1.37 [0.05;   37.71]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MET inhibitor  0    0  5.31 [0.24;  114.98]      .              .   5.31 [0.24;  114.98]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MMP inhibitor  0    0 10.26 [0.31;  342.10]      .              .  10.26 [0.31;  342.10]    .             .     .       .
          Erlotinib + ER inhibitor:Erlotinib + antiangiogenesis  0    0  3.64 [0.17;   78.52]      .              .   3.64 [0.17;   78.52]    .             .     .       .
                         Erlotinib + ER inhibitor:Gefitinib  0    0  6.32 [0.28;  144.12]      .              .   6.32 [0.28;  144.12]    .             .     .       .
               Erlotinib + ER inhibitor:Gefitinib/Erlotinib  0    0 10.77 [0.39;  297.01]      .              .  10.77 [0.39;  297.01]    .             .     .       .
            Erlotinib + ER inhibitor:Gefitinib + chemotherapy  0    0  2.38 [0.08;   69.51]      .              .   2.38 [0.08;   69.51]    .             .     .       .
                        Erlotinib + ER inhibitor:Lazertinib  0    0  2.81 [0.12;   67.88]      .              .   2.81 [0.12;   67.88]    .             .     .       .
                       Erlotinib + ER inhibitor:Osimertinib  0    0  4.05 [0.17;   94.35]      .              .   4.05 [0.17;   94.35]    .             .     .       .
          Erlotinib + ER inhibitor:Osimertinib + chemotherapy  0    0  1.52 [0.06;   41.86]      .              .   1.52 [0.06;   41.86]    .             .     .       .
        Erlotinib + ER inhibitor:Osimertinib + antiangiogenesis  0    0  8.22 [0.23;  297.91]      .              .   8.22 [0.23;  297.91]    .             .     .       .
                           Erlotinib + ER inhibitor:Placebo  0    0  6.14 [0.28;  135.52]      .              .   6.14 [0.28;  135.52]    .             .     .       .
                       Erlotinib + ER inhibitor:Rociletinib  0    0  4.95 [0.08;  311.52]      .              .   4.95 [0.08;  311.52]    .             .     .       .
                    Erlotinib + ER inhibitor:antiangiogenesis  0    0  3.13 [0.14;   70.44]      .              .   3.13 [0.14;   70.44]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + HGF inhibitor  0    0  0.21 [0.01;    8.02]      .              .   0.21 [0.01;    8.02]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.18 [0.02;    1.33]      .              .   0.18 [0.02;    1.33]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor  0    0  0.69 [0.14;    3.35]      .              .   0.69 [0.14;    3.35]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor  0    0  1.34 [0.13;   13.46]      .              .   1.34 [0.13;   13.46]    .             .     .       .
        Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis  0    0  0.48 [0.10;    2.28]      .              .   0.48 [0.10;    2.28]    .             .     .       .
                       Erlotinib + HER3 inhibitor:Gefitinib  0    0  0.83 [0.16;    4.40]      .              .   0.83 [0.16;    4.40]    .             .     .       .
             Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib  0    0  1.41 [0.19;   10.46]      .              .   1.41 [0.19;   10.46]    .             .     .       .
          Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy  0    0  0.31 [0.04;    2.54]      .              .   0.31 [0.04;    2.54]    .             .     .       .
                      Erlotinib + HER3 inhibitor:Lazertinib  0    0  0.37 [0.06;    2.17]      .              .   0.37 [0.06;    2.17]    .             .     .       .
                     Erlotinib + HER3 inhibitor:Osimertinib  0    0  0.53 [0.10;    2.93]      .              .   0.53 [0.10;    2.93]    .             .     .       .
        Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy  0    0  0.20 [0.03;    1.47]      .              .   0.20 [0.03;    1.47]    .             .     .       .
      Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis  0    0  1.08 [0.09;   12.23]      .              .   1.08 [0.09;   12.23]    .             .     .       .
                         Erlotinib + HER3 inhibitor:Placebo  0    0  0.80 [0.16;    4.02]      .              .   0.80 [0.16;    4.02]    .             .     .       .
                     Erlotinib + HER3 inhibitor:Rociletinib  0    0  0.65 [0.03;   15.72]      .              .   0.65 [0.03;   15.72]    .             .     .       .
                  Erlotinib + HER3 inhibitor:antiangiogenesis  0    0  0.41 [0.08;    2.12]      .              .   0.41 [0.08;    2.12]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.86 [0.02;   30.40]      .              .   0.86 [0.02;   30.40]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MET inhibitor  0    0  3.34 [0.12;   94.38]      .              .   3.34 [0.12;   94.38]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MMP inhibitor  0    0  6.45 [0.15;  272.38]      .              .   6.45 [0.15;  272.38]    .             .     .       .
         Erlotinib + HGF inhibitor:Erlotinib + antiangiogenesis  0    0  2.29 [0.08;   64.48]      .              .   2.29 [0.08;   64.48]    .             .     .       .
                        Erlotinib + HGF inhibitor:Gefitinib  0    0  3.98 [0.13;  117.83]      .              .   3.98 [0.13;  117.83]    .             .     .       .
              Erlotinib + HGF inhibitor:Gefitinib/Erlotinib  0    0  6.78 [0.19;  239.47]      .              .   6.78 [0.19;  239.47]    .             .     .       .
           Erlotinib + HGF inhibitor:Gefitinib + chemotherapy  0    0  1.50 [0.04;   55.82]      .              .   1.50 [0.04;   55.82]    .             .     .       .
                       Erlotinib + HGF inhibitor:Lazertinib  0    0  1.77 [0.06;   55.25]      .              .   1.77 [0.06;   55.25]    .             .     .       .
                      Erlotinib + HGF inhibitor:Osimertinib  0    0  2.55 [0.08;   77.01]      .              .   2.55 [0.08;   77.01]    .             .     .       .
         Erlotinib + HGF inhibitor:Osimertinib + chemotherapy  0    0  0.96 [0.03;   33.75]      .              .   0.96 [0.03;   33.75]    .             .     .       .
       Erlotinib + HGF inhibitor:Osimertinib + antiangiogenesis  0    0  5.17 [0.11;  235.97]      .              .   5.17 [0.11;  235.97]    .             .     .       .
                          Erlotinib + HGF inhibitor:Placebo  0    0  3.86 [0.13;  111.09]      .              .   3.86 [0.13;  111.09]    .             .     .       .
                      Erlotinib + HGF inhibitor:Rociletinib  0    0  3.12 [0.04;  239.67]      .              .   3.12 [0.04;  239.67]    .             .     .       .
                   Erlotinib + HGF inhibitor:antiangiogenesis  0    0  1.97 [0.07;   57.65]      .              .   1.97 [0.07;   57.65]    .             .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor  0    0  3.88 [1.00;   15.14]      .              .   3.88 [1.00;   15.14]    .             .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor  0    0  7.51 [0.86;   65.46]      .              .   7.51 [0.86;   65.46]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis  0    0  2.67 [0.69;   10.27]      .              .   2.67 [0.69;   10.27]    .             .     .       .
                        Erlotinib + IGF-1R inhibitor:Gefitinib  0    0  4.62 [1.06;   20.17]      .              .   4.62 [1.06;   20.17]    .             .     .       .
              Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib  0    0  7.88 [1.25;   49.72]      .              .   7.88 [1.25;   49.72]    .             .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy  0    0  1.74 [0.25;   12.17]      .              .   1.74 [0.25;   12.17]    .             .     .       .
                       Erlotinib + IGF-1R inhibitor:Lazertinib  0    0  2.06 [0.42;   10.09]      .              .   2.06 [0.42;   10.09]    .             .     .       .
                      Erlotinib + IGF-1R inhibitor:Osimertinib  0    0  2.97 [0.65;   13.51]      .              .   2.97 [0.65;   13.51]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy  0    0  1.11 [0.18;    7.01]      .              .   1.11 [0.18;    7.01]    .             .     .       .
       Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis  0    0  6.01 [0.60;   59.89]      .              .   6.01 [0.60;   59.89]    .             .     .       .
                          Erlotinib + IGF-1R inhibitor:Placebo  0    0  4.49 [1.11;   18.25]      .              .   4.49 [1.11;   18.25]    .             .     .       .
                      Erlotinib + IGF-1R inhibitor:Rociletinib  0    0  3.63 [0.17;   79.58]      .              .   3.63 [0.17;   79.58]    .             .     .       .
                   Erlotinib + IGF-1R inhibitor:antiangiogenesis  0    0  2.29 [0.54;    9.70]      .              .   2.29 [0.54;    9.70]    .             .     .       .
          Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor  0    0  1.93 [0.33;   11.38]      .              .   1.93 [0.33;   11.38]    .             .     .       .
         Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis  0    0  0.69 [0.41;    1.16]      .              .   0.69 [0.41;    1.16]    .             .     .       .
                        Erlotinib + MET inhibitor:Gefitinib  0    0  1.19 [0.54;    2.62]      .              .   1.19 [0.54;    2.62]    .             .     .       .
              Erlotinib + MET inhibitor:Gefitinib/Erlotinib  0    0  2.03 [0.52;    7.90]      .              .   2.03 [0.52;    7.90]    .             .     .       .
           Erlotinib + MET inhibitor:Gefitinib + chemotherapy  0    0  0.45 [0.10;    2.00]      .              .   0.45 [0.10;    2.00]    .             .     .       .
                       Erlotinib + MET inhibitor:Lazertinib  0    0  0.53 [0.20;    1.43]      .              .   0.53 [0.20;    1.43]    .             .     .       .
                      Erlotinib + MET inhibitor:Osimertinib  0    0  0.76 [0.32;    1.82]      .              .   0.76 [0.32;    1.82]    .             .     .       .
         Erlotinib + MET inhibitor:Osimertinib + chemotherapy  0    0  0.29 [0.07;    1.11]      .              .   0.29 [0.07;    1.11]    .             .     .       .
       Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis  0    0  1.55 [0.22;   10.70]      .              .   1.55 [0.22;   10.70]    .             .     .       .
                          Erlotinib + MET inhibitor:Placebo  0    0  1.16 [0.61;    2.21]      .              .   1.16 [0.61;    2.21]    .             .     .       .
                      Erlotinib + MET inhibitor:Rociletinib  0    0  0.93 [0.06;   15.78]      .              .   0.93 [0.06;   15.78]    .             .     .       .
                   Erlotinib + MET inhibitor:antiangiogenesis  0    0  0.59 [0.28;    1.23]      .              .   0.59 [0.28;    1.23]    .             .     .       .
         Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis  0    0  0.36 [0.06;    2.07]      .              .   0.36 [0.06;    2.07]    .             .     .       .
                        Erlotinib + MMP inhibitor:Gefitinib  0    0  0.62 [0.10;    3.96]      .              .   0.62 [0.10;    3.96]    .             .     .       .
              Erlotinib + MMP inhibitor:Gefitinib/Erlotinib  0    0  1.05 [0.12;    9.14]      .              .   1.05 [0.12;    9.14]    .             .     .       .
           Erlotinib + MMP inhibitor:Gefitinib + chemotherapy  0    0  0.23 [0.02;    2.21]      .              .   0.23 [0.02;    2.21]    .             .     .       .
                       Erlotinib + MMP inhibitor:Lazertinib  0    0  0.27 [0.04;    1.93]      .              .   0.27 [0.04;    1.93]    .             .     .       .
                      Erlotinib + MMP inhibitor:Osimertinib  0    0  0.39 [0.06;    2.63]      .              .   0.39 [0.06;    2.63]    .             .     .       .
         Erlotinib + MMP inhibitor:Osimertinib + chemotherapy  0    0  0.15 [0.02;    1.29]      .              .   0.15 [0.02;    1.29]    .             .     .       .
       Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis  0    0  0.80 [0.06;   10.40]      .              .   0.80 [0.06;   10.40]    .             .     .       .
                          Erlotinib + MMP inhibitor:Placebo  0    0  0.60 [0.10;    3.64]      .              .   0.60 [0.10;    3.64]    .             .     .       .
                      Erlotinib + MMP inhibitor:Rociletinib  0    0  0.48 [0.02;   12.98]      .              .   0.48 [0.02;   12.98]    .             .     .       .
                   Erlotinib + MMP inhibitor:antiangiogenesis  0    0  0.31 [0.05;    1.92]      .              .   0.31 [0.05;    1.92]    .             .     .       .
                       Erlotinib + antiangiogenesis:Gefitinib  0    0  1.73 [0.80;    3.74]      .              .   1.73 [0.80;    3.74]    .             .     .       .
             Erlotinib + antiangiogenesis:Gefitinib/Erlotinib  0    0  2.96 [0.77;   11.37]      .              .   2.96 [0.77;   11.37]    .             .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + chemotherapy  0    0  0.65 [0.15;    2.88]      .              .   0.65 [0.15;    2.88]    .             .     .       .
                      Erlotinib + antiangiogenesis:Lazertinib  0    0  0.77 [0.29;    2.05]      .              .   0.77 [0.29;    2.05]    .             .     .       .
                     Erlotinib + antiangiogenesis:Osimertinib  0    0  1.11 [0.48;    2.60]      .              .   1.11 [0.48;    2.60]    .             .     .       .
        Erlotinib + antiangiogenesis:Osimertinib + chemotherapy  0    0  0.42 [0.11;    1.60]      .              .   0.42 [0.11;    1.60]    .             .     .       .
      Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  2.26 [0.33;   15.46]      .              .   2.26 [0.33;   15.46]    .             .     .       .
                         Erlotinib + antiangiogenesis:Placebo  0    0  1.69 [0.91;    3.14]      .              .   1.69 [0.91;    3.14]    .             .     .       .
                     Erlotinib + antiangiogenesis:Rociletinib  0    0  1.36 [0.08;   22.85]      .              .   1.36 [0.08;   22.85]    .             .     .       .
                  Erlotinib + antiangiogenesis:antiangiogenesis  1 0.19  0.86 [0.43;    1.70]   0.43 [0.09;   2.06]   1.01 [0.47;    2.17] 0.42 [0.07;  2.42] -0.96  0.3347
                            Gefitinib:Gefitinib/Erlotinib  0    0  1.71 [0.46;    6.37]      .              .   1.71 [0.46;    6.37]    .             .     .       .
                         Gefitinib:Gefitinib + chemotherapy  3 1.00  0.38 [0.11;    1.34]   0.38 [0.11;   1.34]      .               .    .             .     .       .
                                     Gefitinib:Lazertinib  1 0.52  0.44 [0.19;    1.04]   0.39 [0.12;   1.25]   0.52 [0.15;    1.80] 0.74 [0.13;  4.08] -0.35  0.7290
                                    Gefitinib:Osimertinib  0    0  0.64 [0.29;    1.43]      .              .   0.64 [0.29;    1.43]    .             .     .       .
                       Gefitinib:Osimertinib + chemotherapy  0    0  0.24 [0.06;    0.90]      .              .   0.24 [0.06;    0.90]    .             .     .       .
                     Gefitinib:Osimertinib + antiangiogenesis  0    0  1.30 [0.19;    8.74]      .              .   1.30 [0.19;    8.74]    .             .     .       .
                                        Gefitinib:Placebo  2 0.29  0.97 [0.48;    1.97]   1.82 [0.49;   6.78]   0.75 [0.33;    1.74] 2.41 [0.51; 11.47]  1.11  0.2684
                                    Gefitinib:Rociletinib  0    0  0.78 [0.04;   14.01]      .              .   0.78 [0.04;   14.01]    .             .     .       .
                                 Gefitinib:antiangiogenesis  0    0  0.50 [0.20;    1.25]      .              .   0.50 [0.20;    1.25]    .             .     .       .
               Gefitinib/Erlotinib:Gefitinib + chemotherapy  0    0  0.22 [0.04;    1.38]      .              .   0.22 [0.04;    1.38]    .             .     .       .
                           Gefitinib/Erlotinib:Lazertinib  0    0  0.26 [0.08;    0.90]      .              .   0.26 [0.08;    0.90]    .             .     .       .
                          Gefitinib/Erlotinib:Osimertinib  1 1.00  0.38 [0.13;    1.07]   0.38 [0.13;   1.07]      .               .    .             .     .       .
             Gefitinib/Erlotinib:Osimertinib + chemotherapy  0    0  0.14 [0.03;    0.62]      .              .   0.14 [0.03;    0.62]    .             .     .       .
           Gefitinib/Erlotinib:Osimertinib + antiangiogenesis  0    0  0.76 [0.10;    5.75]      .              .   0.76 [0.10;    5.75]    .             .     .       .
                              Gefitinib/Erlotinib:Placebo  0    0  0.57 [0.16;    2.07]      .              .   0.57 [0.16;    2.07]    .             .     .       .
                          Gefitinib/Erlotinib:Rociletinib  0    0  0.46 [0.02;   10.08]      .              .   0.46 [0.02;   10.08]    .             .     .       .
                       Gefitinib/Erlotinib:antiangiogenesis  0    0  0.29 [0.07;    1.23]      .              .   0.29 [0.07;    1.23]    .             .     .       .
                        Gefitinib + chemotherapy:Lazertinib  0    0  1.18 [0.26;    5.47]      .              .   1.18 [0.26;    5.47]    .             .     .       .
                       Gefitinib + chemotherapy:Osimertinib  0    0  1.70 [0.38;    7.67]      .              .   1.70 [0.38;    7.67]    .             .     .       .
          Gefitinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.64 [0.10;    3.99]      .              .   0.64 [0.10;    3.99]    .             .     .       .
        Gefitinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  3.46 [0.35;   34.16]      .              .   3.46 [0.35;   34.16]    .             .     .       .
                           Gefitinib + chemotherapy:Placebo  0    0  2.58 [0.60;   11.06]      .              .   2.58 [0.60;   11.06]    .             .     .       .
                       Gefitinib + chemotherapy:Rociletinib  0    0  2.08 [0.09;   48.68]      .              .   2.08 [0.09;   48.68]    .             .     .       .
                    Gefitinib + chemotherapy:antiangiogenesis  0    0  1.32 [0.27;    6.34]      .              .   1.32 [0.27;    6.34]    .             .     .       .
                                   Lazertinib:Osimertinib  1 0.81  1.44 [0.73;    2.83]   1.36 [0.64;   2.88]   1.84 [0.40;    8.52] 0.74 [0.13;  4.08] -0.35  0.7290
                      Lazertinib:Osimertinib + chemotherapy  0    0  0.54 [0.16;    1.87]      .              .   0.54 [0.16;    1.87]    .             .     .       .
                    Lazertinib:Osimertinib + antiangiogenesis  0    0  2.92 [0.46;   18.67]      .              .   2.92 [0.46;   18.67]    .             .     .       .
                                       Lazertinib:Placebo  0    0  2.18 [0.89;    5.39]      .              .   2.18 [0.89;    5.39]    .             .     .       .
                                   Lazertinib:Rociletinib  0    0  1.76 [0.09;   33.49]      .              .   1.76 [0.09;   33.49]    .             .     .       .
                                Lazertinib:antiangiogenesis  0    0  1.11 [0.37;    3.35]      .              .   1.11 [0.37;    3.35]    .             .     .       .
                     Osimertinib:Osimertinib + chemotherapy  1 1.00  0.37 [0.13;    1.07]   0.37 [0.13;   1.07]      .               .    .             .     .       .
                   Osimertinib:Osimertinib + antiangiogenesis  1 1.00  2.03 [0.36;   11.41]   2.03 [0.36;  11.41]      .               .    .             .     .       .
                                      Osimertinib:Placebo  2 0.48  1.52 [0.71;    3.22]   1.79 [0.61;   5.28]   1.30 [0.45;    3.70] 1.38 [0.31;  6.24]  0.42  0.6739
                                  Osimertinib:Rociletinib  0    0  1.22 [0.07;   22.34]      .              .   1.22 [0.07;   22.34]    .             .     .       .
                               Osimertinib:antiangiogenesis  0    0  0.77 [0.29;    2.08]      .              .   0.77 [0.29;    2.08]    .             .     .       .
      Osimertinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  5.41 [0.72;   40.77]      .              .   5.41 [0.72;   40.77]    .             .     .       .
                         Osimertinib + chemotherapy:Placebo  0    0  4.05 [1.12;   14.67]      .              .   4.05 [1.12;   14.67]    .             .     .       .
                     Osimertinib + chemotherapy:Rociletinib  0    0  3.26 [0.15;   71.56]      .              .   3.26 [0.15;   71.56]    .             .     .       .
                  Osimertinib + chemotherapy:antiangiogenesis  0    0  2.06 [0.49;    8.71]      .              .   2.06 [0.49;    8.71]    .             .     .       .
                       Osimertinib + antiangiogenesis:Placebo  0    0  0.75 [0.11;    4.92]      .              .   0.75 [0.11;    4.92]    .             .     .       .
                   Osimertinib + antiangiogenesis:Rociletinib  0    0  0.60 [0.02;   17.72]      .              .   0.60 [0.02;   17.72]    .             .     .       .
                Osimertinib + antiangiogenesis:antiangiogenesis  0    0  0.38 [0.05;    2.79]      .              .   0.38 [0.05;    2.79]    .             .     .       .
                                      Rociletinib:Placebo  0    0  1.24 [0.07;   21.37]      .              .   1.24 [0.07;   21.37]    .             .     .       .
                                   antiangiogenesis:Placebo  0    0  1.96 [0.88;    4.39]      .              .   1.96 [0.88;    4.39]    .             .     .       .
                               Rociletinib:antiangiogenesis  0    0  0.63 [0.04;   11.12]      .              .   0.63 [0.04;   11.12]    .             .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

total-arrhythmias

Random effects model: 

                                                comparison k prop   nma          95%-CI direct         95%-CI indir.            95%-CI    RoR           95%-CI     z p-value
                           Afatinib:Afatinib + Cetuximab 1 1.00  1.62 [0.51;    5.17]   1.62 [0.51;   5.17]      .                 .      .                .     .       .
                         Afatinib:Afatinib + HMGCR inhibitor 1 1.00  0.69 [0.18;    2.71]   0.69 [0.18;   2.71]      .                 .      .                .     .       .
                                     Afatinib:Almonertinib 0    0  1.34 [0.27;    6.76]      .              .   1.34 [0.27;      6.76]      .                .     .       .
                         Afatinib:Amivantamab  +  Lazertinib 0    0  0.55 [0.05;    5.89]      .              .   0.55 [0.05;      5.89]      .                .     .       .
                                     Afatinib:Chemotherapy 1 0.12  1.30 [0.43;    3.92]   0.16 [0.01;   3.97]   1.72 [0.53;      5.57]   0.09 [0.00;     2.83] -1.36  0.1731
                      Afatinib:Chemotherapy + antiangiogenesis 0    0  9.48 [0.39;  230.20]      .              .   9.48 [0.39;    230.20]      .                .     .       .
                                      Afatinib:Dacomitinib 0    0  2.94 [0.85;   10.19]      .              .   2.94 [0.85;     10.19]      .                .     .       .
                                   Afatinib:DHFR inhibitor 0    0  1.47 [0.16;   13.34]      .              .   1.47 [0.16;     13.34]      .                .     .       .
                                        Afatinib:Erlotinib 1 0.69  1.53 [0.58;    4.05]   2.56 [0.80;   8.23]   0.48 [0.08;      2.78]   5.29 [0.65;    43.45]  1.55  0.1207
                    Afatinib:Erlotinib + Autophagy inhibitor 0    0  1.53 [0.16;   14.33]      .              .   1.53 [0.16;     14.33]      .                .     .       .
                           Afatinib:Erlotinib + chemotherapy 0    0  0.91 [0.19;    4.29]      .              .   0.91 [0.19;      4.29]      .                .     .       .
                         Afatinib:Erlotinib + HER3 inhibitor 0    0  1.52 [0.21;   10.98]      .              .   1.52 [0.21;     10.98]      .                .     .       .
                          Afatinib:Erlotinib + HGF inhibitor 0    0 13.79 [0.36;  524.21]      .              .  13.79 [0.36;    524.21]      .                .     .       .
                          Afatinib:Erlotinib + IGF-1R inhibitor 0    0  2.51 [0.71;    8.86]      .              .   2.51 [0.71;      8.86]      .                .     .       .
                          Afatinib:Erlotinib + MET inhibitor 0    0  0.61 [0.17;    2.21]      .              .   0.61 [0.17;      2.21]      .                .     .       .
                          Afatinib:Erlotinib + MMP inhibitor 0    0  3.06 [0.23;   41.67]      .              .   3.06 [0.23;     41.67]      .                .     .       .
                         Afatinib:Erlotinib + antiangiogenesis 0    0  2.21 [0.75;    6.53]      .              .   2.21 [0.75;      6.53]      .                .     .       .
                                    Afatinib:Furmonertinib 0    0  1.21 [0.22;    6.59]      .              .   1.21 [0.22;      6.59]      .                .     .       .
                                        Afatinib:Gefitinib 1 0.23  1.40 [0.30;    6.45]   0.33 [0.01;   8.14]   2.14 [0.38;     12.15]   0.15 [0.00;     5.90] -1.01  0.3143
                              Afatinib:Gefitinib/Erlotinib 0    0  1.91 [0.45;    8.01]      .              .   1.91 [0.45;      8.01]      .                .     .       .
                           Afatinib:Gefitinib + chemotherapy 0    0  1.23 [0.13;   11.95]      .              .   1.23 [0.13;     11.95]      .                .     .       .
                                       Afatinib:Lazertinib 0    0  0.60 [0.06;    5.71]      .              .   0.60 [0.06;      5.71]      .                .     .       .
                                      Afatinib:Osimertinib 0    0  0.81 [0.22;    2.98]      .              .   0.81 [0.22;      2.98]      .                .     .       .
                         Afatinib:Osimertinib + chemotherapy 0    0  0.66 [0.16;    2.69]      .              .   0.66 [0.16;      2.69]      .                .     .       .
                       Afatinib:Osimertinib + antiangiogenesis 0    0  0.35 [0.08;    1.54]      .              .   0.35 [0.08;      1.54]      .                .     .       .
                                  Afatinib:PD-L1 inhibitor 0    0  3.28 [0.11;   96.93]      .              .   3.28 [0.11;     96.93]      .                .     .       .
                                          Afatinib:Placebo 1 0.32  2.92 [0.86;    9.96]   2.52 [0.29;  21.72]   3.14 [0.71;     13.95]   0.80 [0.06;    11.04] -0.16  0.8699
                                      Afatinib:Rociletinib 0    0  0.18 [0.04;    0.76]      .              .   0.18 [0.04;      0.76]      .                .     .       .
                                   Afatinib:antiangiogenesis 0    0  0.34 [0.09;    1.27]      .              .   0.34 [0.09;      1.27]      .                .     .       .
                                     Afatinib:Zorifertinib 0    0  1.68 [0.35;    7.94]      .              .   1.68 [0.35;      7.94]      .                .     .       .
           Afatinib + Cetuximab:Afatinib + HMGCR inhibitor 0    0  0.43 [0.07;    2.56]      .              .   0.43 [0.07;      2.56]      .                .     .       .
                       Afatinib + Cetuximab:Almonertinib 0    0  0.83 [0.11;    6.06]      .              .   0.83 [0.11;      6.06]      .                .     .       .
           Afatinib + Cetuximab:Amivantamab  +  Lazertinib 0    0  0.34 [0.02;    4.75]      .              .   0.34 [0.02;      4.75]      .                .     .       .
                       Afatinib + Cetuximab:Chemotherapy 0    0  0.80 [0.16;    3.98]      .              .   0.80 [0.16;      3.98]      .                .     .       .
        Afatinib + Cetuximab:Chemotherapy + antiangiogenesis 0    0  5.85 [0.20;  174.29]      .              .   5.85 [0.20;    174.29]      .                .     .       .
                        Afatinib + Cetuximab:Dacomitinib 0    0  1.82 [0.33;    9.94]      .              .   1.82 [0.33;      9.94]      .                .     .       .
                     Afatinib + Cetuximab:DHFR inhibitor 0    0  0.91 [0.08;   10.97]      .              .   0.91 [0.08;     10.97]      .                .     .       .
                          Afatinib + Cetuximab:Erlotinib 0    0  0.95 [0.21;    4.29]      .              .   0.95 [0.21;      4.29]      .                .     .       .
      Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor 0    0  0.95 [0.08;   11.74]      .              .   0.95 [0.08;     11.74]      .                .     .       .
             Afatinib + Cetuximab:Erlotinib + chemotherapy 0    0  0.56 [0.08;    3.89]      .              .   0.56 [0.08;      3.89]      .                .     .       .
           Afatinib + Cetuximab:Erlotinib + HER3 inhibitor 0    0  0.94 [0.09;    9.29]      .              .   0.94 [0.09;      9.29]      .                .     .       .
            Afatinib + Cetuximab:Erlotinib + HGF inhibitor 0    0  8.51 [0.19;  387.49]      .              .   8.51 [0.19;    387.49]      .                .     .       .
            Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor 0    0  1.55 [0.28;    8.60]      .              .   1.55 [0.28;      8.60]      .                .     .       .
            Afatinib + Cetuximab:Erlotinib + MET inhibitor 0    0  0.38 [0.07;    2.13]      .              .   0.38 [0.07;      2.13]      .                .     .       .
            Afatinib + Cetuximab:Erlotinib + MMP inhibitor 0    0  1.89 [0.11;   32.90]      .              .   1.89 [0.11;     32.90]      .                .     .       .
           Afatinib + Cetuximab:Erlotinib + antiangiogenesis 0    0  1.36 [0.28;    6.67]      .              .   1.36 [0.28;      6.67]      .                .     .       .
                      Afatinib + Cetuximab:Furmonertinib 0    0  0.75 [0.10;    5.83]      .              .   0.75 [0.10;      5.83]      .                .     .       .
                          Afatinib + Cetuximab:Gefitinib 0    0  0.86 [0.13;    5.89]      .              .   0.86 [0.13;      5.89]      .                .     .       .
                Afatinib + Cetuximab:Gefitinib/Erlotinib 0    0  1.18 [0.19;    7.45]      .              .   1.18 [0.19;      7.45]      .                .     .       .
             Afatinib + Cetuximab:Gefitinib + chemotherapy 0    0  0.76 [0.06;    9.75]      .              .   0.76 [0.06;      9.75]      .                .     .       .
                         Afatinib + Cetuximab:Lazertinib 0    0  0.37 [0.03;    4.67]      .              .   0.37 [0.03;      4.67]      .                .     .       .
                        Afatinib + Cetuximab:Osimertinib 0    0  0.50 [0.09;    2.86]      .              .   0.50 [0.09;      2.86]      .                .     .       .
           Afatinib + Cetuximab:Osimertinib + chemotherapy 0    0  0.41 [0.07;    2.53]      .              .   0.41 [0.07;      2.53]      .                .     .       .
         Afatinib + Cetuximab:Osimertinib + antiangiogenesis 0    0  0.22 [0.03;    1.41]      .              .   0.22 [0.03;      1.41]      .                .     .       .
                    Afatinib + Cetuximab:PD-L1 inhibitor 0    0  2.03 [0.06;   72.57]      .              .   2.03 [0.06;     72.57]      .                .     .       .
                            Afatinib + Cetuximab:Placebo 0    0  1.80 [0.33;    9.76]      .              .   1.80 [0.33;      9.76]      .                .     .       .
                        Afatinib + Cetuximab:Rociletinib 0    0  0.11 [0.02;    0.70]      .              .   0.11 [0.02;      0.70]      .                .     .       .
                     Afatinib + Cetuximab:antiangiogenesis 0    0  0.21 [0.04;    1.21]      .              .   0.21 [0.04;      1.21]      .                .     .       .
                       Afatinib + Cetuximab:Zorifertinib 0    0  1.03 [0.15;    7.20]      .              .   1.03 [0.15;      7.20]      .                .     .       .
                     Afatinib + HMGCR inhibitor:Almonertinib 0    0  1.95 [0.23;   16.16]      .              .   1.95 [0.23;     16.16]      .                .     .       .
         Afatinib + HMGCR inhibitor:Amivantamab  +  Lazertinib 0    0  0.80 [0.05;   12.30]      .              .   0.80 [0.05;     12.30]      .                .     .       .
                     Afatinib + HMGCR inhibitor:Chemotherapy 0    0  1.89 [0.33;   10.93]      .              .   1.89 [0.33;     10.93]      .                .     .       .
      Afatinib + HMGCR inhibitor:Chemotherapy + antiangiogenesis 0    0 13.73 [0.43;  441.49]      .              .  13.73 [0.43;    441.49]      .                .     .       .
                      Afatinib + HMGCR inhibitor:Dacomitinib 0    0  4.26 [0.67;   27.04]      .              .   4.26 [0.67;     27.04]      .                .     .       .
                   Afatinib + HMGCR inhibitor:DHFR inhibitor 0    0  2.13 [0.16;   28.52]      .              .   2.13 [0.16;     28.52]      .                .     .       .
                        Afatinib + HMGCR inhibitor:Erlotinib 0    0  2.22 [0.41;   11.88]      .              .   2.22 [0.41;     11.88]      .                .     .       .
    Afatinib + HMGCR inhibitor:Erlotinib + Autophagy inhibitor 0    0  2.22 [0.16;   30.50]      .              .   2.22 [0.16;     30.50]      .                .     .       .
           Afatinib + HMGCR inhibitor:Erlotinib + chemotherapy 0    0  1.32 [0.17;   10.42]      .              .   1.32 [0.17;     10.42]      .                .     .       .
         Afatinib + HMGCR inhibitor:Erlotinib + HER3 inhibitor 0    0  2.20 [0.20;   24.37]      .              .   2.20 [0.20;     24.37]      .                .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + HGF inhibitor 0    0 19.97 [0.41;  973.41]      .              .  19.97 [0.41;    973.41]      .                .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + IGF-1R inhibitor 0    0  3.64 [0.57;   23.37]      .              .   3.64 [0.57;     23.37]      .                .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + MET inhibitor 0    0  0.89 [0.14;    5.78]      .              .   0.89 [0.14;      5.78]      .                .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + MMP inhibitor 0    0  4.44 [0.23;   84.50]      .              .   4.44 [0.23;     84.50]      .                .     .       .
         Afatinib + HMGCR inhibitor:Erlotinib + antiangiogenesis 0    0  3.20 [0.56;   18.32]      .              .   3.20 [0.56;     18.32]      .                .     .       .
                    Afatinib + HMGCR inhibitor:Furmonertinib 0    0  1.76 [0.20;   15.47]      .              .   1.76 [0.20;     15.47]      .                .     .       .
                        Afatinib + HMGCR inhibitor:Gefitinib 0    0  2.03 [0.26;   15.76]      .              .   2.03 [0.26;     15.76]      .                .     .       .
              Afatinib + HMGCR inhibitor:Gefitinib/Erlotinib 0    0  2.76 [0.38;   20.05]      .              .   2.76 [0.38;     20.05]      .                .     .       .
           Afatinib + HMGCR inhibitor:Gefitinib + chemotherapy 0    0  1.79 [0.13;   25.32]      .              .   1.79 [0.13;     25.32]      .                .     .       .
                       Afatinib + HMGCR inhibitor:Lazertinib 0    0  0.87 [0.06;   12.12]      .              .   0.87 [0.06;     12.12]      .                .     .       .
                      Afatinib + HMGCR inhibitor:Osimertinib 0    0  1.18 [0.18;    7.77]      .              .   1.18 [0.18;      7.77]      .                .     .       .
         Afatinib + HMGCR inhibitor:Osimertinib + chemotherapy 0    0  0.96 [0.14;    6.81]      .              .   0.96 [0.14;      6.81]      .                .     .       .
       Afatinib + HMGCR inhibitor:Osimertinib + antiangiogenesis 0    0  0.51 [0.07;    3.80]      .              .   0.51 [0.07;      3.80]      .                .     .       .
                  Afatinib + HMGCR inhibitor:PD-L1 inhibitor 0    0  4.76 [0.12;  183.13]      .              .   4.76 [0.12;    183.13]      .                .     .       .
                          Afatinib + HMGCR inhibitor:Placebo 0    0  4.23 [0.67;   26.56]      .              .   4.23 [0.67;     26.56]      .                .     .       .
                      Afatinib + HMGCR inhibitor:Rociletinib 0    0  0.26 [0.03;    1.89]      .              .   0.26 [0.03;      1.89]      .                .     .       .
                   Afatinib + HMGCR inhibitor:antiangiogenesis 0    0  0.49 [0.07;    3.28]      .              .   0.49 [0.07;      3.28]      .                .     .       .
                     Afatinib + HMGCR inhibitor:Zorifertinib 0    0  2.43 [0.31;   19.26]      .              .   2.43 [0.31;     19.26]      .                .     .       .
                     Almonertinib:Amivantamab  +  Lazertinib 0    0  0.41 [0.04;    4.64]      .              .   0.41 [0.04;      4.64]      .                .     .       .
                                 Almonertinib:Chemotherapy 0    0  0.97 [0.24;    3.94]      .              .   0.97 [0.24;      3.94]      .                .     .       .
                  Almonertinib:Chemotherapy + antiangiogenesis 0    0  7.05 [0.25;  200.00]      .              .   7.05 [0.25;    200.00]      .                .     .       .
                                  Almonertinib:Dacomitinib 0    0  2.19 [0.42;   11.35]      .              .   2.19 [0.42;     11.35]      .                .     .       .
                               Almonertinib:DHFR inhibitor 0    0  1.09 [0.09;   12.74]      .              .   1.09 [0.09;     12.74]      .                .     .       .
                                    Almonertinib:Erlotinib 0    0  1.14 [0.27;    4.87]      .              .   1.14 [0.27;      4.87]      .                .     .       .
                Almonertinib:Erlotinib + Autophagy inhibitor 0    0  1.14 [0.10;   13.64]      .              .   1.14 [0.10;     13.64]      .                .     .       .
                       Almonertinib:Erlotinib + chemotherapy 0    0  0.68 [0.11;    4.36]      .              .   0.68 [0.11;      4.36]      .                .     .       .
                     Almonertinib:Erlotinib + HER3 inhibitor 0    0  1.13 [0.12;   10.76]      .              .   1.13 [0.12;     10.76]      .                .     .       .
                      Almonertinib:Erlotinib + HGF inhibitor 0    0 10.25 [0.23;  456.03]      .              .  10.25 [0.23;    456.03]      .                .     .       .
                      Almonertinib:Erlotinib + IGF-1R inhibitor 0    0  1.87 [0.36;    9.82]      .              .   1.87 [0.36;      9.82]      .                .     .       .
                      Almonertinib:Erlotinib + MET inhibitor 0    0  0.46 [0.09;    2.43]      .              .   0.46 [0.09;      2.43]      .                .     .       .
                      Almonertinib:Erlotinib + MMP inhibitor 0    0  2.28 [0.14;   38.40]      .              .   2.28 [0.14;     38.40]      .                .     .       .
                     Almonertinib:Erlotinib + antiangiogenesis 0    0  1.64 [0.36;    7.58]      .              .   1.64 [0.36;      7.58]      .                .     .       .
                                Almonertinib:Furmonertinib 0    0  0.90 [0.37;    2.22]      .              .   0.90 [0.37;      2.22]      .                .     .       .
                                    Almonertinib:Gefitinib 1 1.00  1.04 [0.62;    1.77]   1.04 [0.62;   1.77]      .                 .      .                .     .       .
                          Almonertinib:Gefitinib/Erlotinib 0    0  1.42 [0.25;    8.19]      .              .   1.42 [0.25;      8.19]      .                .     .       .
                       Almonertinib:Gefitinib + chemotherapy 0    0  0.92 [0.16;    5.35]      .              .   0.92 [0.16;      5.35]      .                .     .       .
                                   Almonertinib:Lazertinib 0    0  0.45 [0.05;    4.16]      .              .   0.45 [0.05;      4.16]      .                .     .       .
                                  Almonertinib:Osimertinib 0    0  0.61 [0.12;    3.13]      .              .   0.61 [0.12;      3.13]      .                .     .       .
                     Almonertinib:Osimertinib + chemotherapy 0    0  0.49 [0.09;    2.77]      .              .   0.49 [0.09;      2.77]      .                .     .       .
                   Almonertinib:Osimertinib + antiangiogenesis 0    0  0.26 [0.04;    1.56]      .              .   0.26 [0.04;      1.56]      .                .     .       .
                              Almonertinib:PD-L1 inhibitor 0    0  2.44 [0.07;   83.49]      .              .   2.44 [0.07;     83.49]      .                .     .       .
                                      Almonertinib:Placebo 0    0  2.17 [0.42;   11.18]      .              .   2.17 [0.42;     11.18]      .                .     .       .
                                  Almonertinib:Rociletinib 0    0  0.13 [0.02;    0.81]      .              .   0.13 [0.02;      0.81]      .                .     .       .
                               Almonertinib:antiangiogenesis 0    0  0.25 [0.05;    1.25]      .              .   0.25 [0.05;      1.25]      .                .     .       .
                                 Almonertinib:Zorifertinib 0    0  1.25 [0.20;    7.95]      .              .   1.25 [0.20;      7.95]      .                .     .       .
                     Amivantamab  +  Lazertinib:Chemotherapy 0    0  2.37 [0.25;   22.41]      .              .   2.37 [0.25;     22.41]      .                .     .       .
      Amivantamab  +  Lazertinib:Chemotherapy + antiangiogenesis 0    0 17.23 [0.48;  620.58]      .              .  17.23 [0.48;    620.58]      .                .     .       .
                      Amivantamab  +  Lazertinib:Dacomitinib 0    0  5.34 [0.50;   57.02]      .              .   5.34 [0.50;     57.02]      .                .     .       .
                   Amivantamab  +  Lazertinib:DHFR inhibitor 0    0  2.67 [0.13;   53.63]      .              .   2.67 [0.13;     53.63]      .                .     .       .
                        Amivantamab  +  Lazertinib:Erlotinib 0    0  2.78 [0.29;   26.50]      .              .   2.78 [0.29;     26.50]      .                .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor 0    0  2.78 [0.14;   57.15]      .              .   2.78 [0.14;     57.15]      .                .     .       .
           Amivantamab  +  Lazertinib:Erlotinib + chemotherapy 0    0  1.66 [0.13;   21.04]      .              .   1.66 [0.13;     21.04]      .                .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor 0    0  2.76 [0.16;   47.10]      .              .   2.76 [0.16;     47.10]      .                .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + HGF inhibitor 0    0 25.04 [0.39; 1617.40]      .              .  25.04 [0.39;   1617.40]      .                .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor 0    0  4.56 [0.42;   49.93]      .              .   4.56 [0.42;     49.93]      .                .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor 0    0  1.11 [0.10;   12.31]      .              .   1.11 [0.10;     12.31]      .                .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor 0    0  5.56 [0.20;  152.23]      .              .   5.56 [0.20;    152.23]      .                .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis 0    0  4.01 [0.40;   40.21]      .              .   4.01 [0.40;     40.21]      .                .     .       .
                    Amivantamab  +  Lazertinib:Furmonertinib 0    0  2.21 [0.18;   26.31]      .              .   2.21 [0.18;     26.31]      .                .     .       .
                        Amivantamab  +  Lazertinib:Gefitinib 0    0  2.55 [0.24;   27.23]      .              .   2.55 [0.24;     27.23]      .                .     .       .
              Amivantamab  +  Lazertinib:Gefitinib/Erlotinib 0    0  3.46 [0.39;   30.52]      .              .   3.46 [0.39;     30.52]      .                .     .       .
           Amivantamab  +  Lazertinib:Gefitinib + chemotherapy 0    0  2.24 [0.12;   40.97]      .              .   2.24 [0.12;     40.97]      .                .     .       .
                       Amivantamab  +  Lazertinib:Lazertinib 1 0.94  1.09 [0.19;    6.23]   0.76 [0.13;   4.57] 292.65 [0.26; 326136.12]   0.00 [0.00;     3.62] -1.61  0.1069
                      Amivantamab  +  Lazertinib:Osimertinib 1 0.85  1.48 [0.18;   11.93]   3.06 [0.32;  29.58]   0.03 [0.00;      5.42] 118.61 [0.36; 39423.38]  1.61  0.1069
         Amivantamab  +  Lazertinib:Osimertinib + chemotherapy 0    0  1.21 [0.14;   10.39]      .              .   1.21 [0.14;     10.39]      .                .     .       .
       Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis 0    0  0.63 [0.07;    5.76]      .              .   0.63 [0.07;      5.76]      .                .     .       .
                  Amivantamab  +  Lazertinib:PD-L1 inhibitor 0    0  5.97 [0.14;  256.01]      .              .   5.97 [0.14;    256.01]      .                .     .       .
                          Amivantamab  +  Lazertinib:Placebo 0    0  5.31 [0.60;   46.56]      .              .   5.31 [0.60;     46.56]      .                .     .       .
                      Amivantamab  +  Lazertinib:Rociletinib 0    0  0.32 [0.03;    3.92]      .              .   0.32 [0.03;      3.92]      .                .     .       .
                   Amivantamab  +  Lazertinib:antiangiogenesis 0    0  0.62 [0.06;    6.83]      .              .   0.62 [0.06;      6.83]      .                .     .       .
                     Amivantamab  +  Lazertinib:Zorifertinib 0    0  3.05 [0.32;   29.09]      .              .   3.05 [0.32;     29.09]      .                .     .       .
                  Chemotherapy:Chemotherapy + antiangiogenesis 0    0  7.27 [0.33;  162.05]      .              .   7.27 [0.33;    162.05]      .                .     .       .
                                  Chemotherapy:Dacomitinib 0    0  2.26 [0.80;    6.35]      .              .   2.26 [0.80;      6.35]      .                .     .       .
                               Chemotherapy:DHFR inhibitor 0    0  1.13 [0.14;    9.15]      .              .   1.13 [0.14;      9.15]      .                .     .       .
                                    Chemotherapy:Erlotinib 4 0.77  1.17 [0.59;    2.32]   1.10 [0.50;   2.38]   1.48 [0.36;      6.08]   0.74 [0.15;     3.73] -0.36  0.7183
                Chemotherapy:Erlotinib + Autophagy inhibitor 0    0  1.17 [0.14;    9.84]      .              .   1.17 [0.14;      9.84]      .                .     .       .
                       Chemotherapy:Erlotinib + chemotherapy 1 0.33  0.70 [0.19;    2.61]   0.97 [0.10;   9.58]   0.59 [0.12;      2.98]   1.64 [0.10;    26.94]  0.35  0.7278
                     Chemotherapy:Erlotinib + HER3 inhibitor 0    0  1.17 [0.18;    7.43]      .              .   1.17 [0.18;      7.43]      .                .     .       .
                      Chemotherapy:Erlotinib + HGF inhibitor 0    0 10.57 [0.30;  376.16]      .              .  10.57 [0.30;    376.16]      .                .     .       .
                      Chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  1.93 [0.67;    5.52]      .              .   1.93 [0.67;      5.52]      .                .     .       .
                      Chemotherapy:Erlotinib + MET inhibitor 0    0  0.47 [0.16;    1.38]      .              .   0.47 [0.16;      1.38]      .                .     .       .
                      Chemotherapy:Erlotinib + MMP inhibitor 0    0  2.35 [0.19;   29.10]      .              .   2.35 [0.19;     29.10]      .                .     .       .
                     Chemotherapy:Erlotinib + antiangiogenesis 0    0  1.70 [0.74;    3.90]      .              .   1.70 [0.74;      3.90]      .                .     .       .
                                Chemotherapy:Furmonertinib 0    0  0.93 [0.21;    4.13]      .              .   0.93 [0.21;      4.13]      .                .     .       .
                                    Chemotherapy:Gefitinib 2 0.60  1.08 [0.29;    3.94]   1.37 [0.26;   7.30]   0.75 [0.10;      5.87]   1.83 [0.13;    25.98]  0.44  0.6568
                          Chemotherapy:Gefitinib/Erlotinib 0    0  1.46 [0.43;    5.02]      .              .   1.46 [0.43;      5.02]      .                .     .       .
                       Chemotherapy:Gefitinib + chemotherapy 0    0  0.95 [0.11;    7.93]      .              .   0.95 [0.11;      7.93]      .                .     .       .
                                   Chemotherapy:Lazertinib 0    0  0.46 [0.06;    3.84]      .              .   0.46 [0.06;      3.84]      .                .     .       .
                                  Chemotherapy:Osimertinib 1 0.49  0.62 [0.21;    1.82]   0.40 [0.09;   1.86]   0.95 [0.21;      4.22]   0.42 [0.05;     3.59] -0.79  0.4300
                     Chemotherapy:Osimertinib + chemotherapy 0    0  0.51 [0.15;    1.68]      .              .   0.51 [0.15;      1.68]      .                .     .       .
                   Chemotherapy:Osimertinib + antiangiogenesis 0    0  0.27 [0.07;    0.97]      .              .   0.27 [0.07;      0.97]      .                .     .       .
                              Chemotherapy:PD-L1 inhibitor 0    0  2.52 [0.09;   68.58]      .              .   2.52 [0.09;     68.58]      .                .     .       .
                                      Chemotherapy:Placebo 0    0  2.24 [0.78;    6.47]      .              .   2.24 [0.78;      6.47]      .                .     .       .
                                  Chemotherapy:Rociletinib 0    0  0.14 [0.04;    0.49]      .              .   0.14 [0.04;      0.49]      .                .     .       .
                               Chemotherapy:antiangiogenesis 0    0  0.26 [0.09;    0.79]      .              .   0.26 [0.09;      0.79]      .                .     .       .
                                 Chemotherapy:Zorifertinib 0    0  1.29 [0.33;    5.06]      .              .   1.29 [0.33;      5.06]      .                .     .       .
                   Chemotherapy + antiangiogenesis:Dacomitinib 0    0  0.31 [0.01;    7.48]      .              .   0.31 [0.01;      7.48]      .                .     .       .
                Chemotherapy + antiangiogenesis:DHFR inhibitor 0    0  0.15 [0.00;    6.15]      .              .   0.15 [0.00;      6.15]      .                .     .       .
                     Chemotherapy + antiangiogenesis:Erlotinib 0    0  0.16 [0.01;    3.60]      .              .   0.16 [0.01;      3.60]      .                .     .       .
 Chemotherapy + antiangiogenesis:Erlotinib + Autophagy inhibitor 0    0  0.16 [0.00;    6.53]      .              .   0.16 [0.00;      6.53]      .                .     .       .
        Chemotherapy + antiangiogenesis:Erlotinib + chemotherapy 0    0  0.10 [0.00;    2.66]      .              .   0.10 [0.00;      2.66]      .                .     .       .
      Chemotherapy + antiangiogenesis:Erlotinib + HER3 inhibitor 0    0  0.16 [0.00;    5.57]      .              .   0.16 [0.00;      5.57]      .                .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + HGF inhibitor 0    0  1.45 [0.01;  156.96]      .              .   1.45 [0.01;    156.96]      .                .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + IGF-1R inhibitor 0    0  0.26 [0.01;    6.53]      .              .   0.26 [0.01;      6.53]      .                .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + MET inhibitor 0    0  0.06 [0.00;    1.61]      .              .   0.06 [0.00;      1.61]      .                .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + MMP inhibitor 0    0  0.32 [0.01;   16.55]      .              .   0.32 [0.01;     16.55]      .                .     .       .
      Chemotherapy + antiangiogenesis:Erlotinib + antiangiogenesis 0    0  0.23 [0.01;    5.38]      .              .   0.23 [0.01;      5.38]      .                .     .       .
                 Chemotherapy + antiangiogenesis:Furmonertinib 0    0  0.13 [0.00;    3.77]      .              .   0.13 [0.00;      3.77]      .                .     .       .
                     Chemotherapy + antiangiogenesis:Gefitinib 0    0  0.15 [0.01;    4.02]      .              .   0.15 [0.01;      4.02]      .                .     .       .
           Chemotherapy + antiangiogenesis:Gefitinib/Erlotinib 0    0  0.20 [0.01;    3.95]      .              .   0.20 [0.01;      3.95]      .                .     .       .
        Chemotherapy + antiangiogenesis:Gefitinib + chemotherapy 0    0  0.13 [0.00;    5.30]      .              .   0.13 [0.00;      5.30]      .                .     .       .
                    Chemotherapy + antiangiogenesis:Lazertinib 0    0  0.06 [0.00;    2.18]      .              .   0.06 [0.00;      2.18]      .                .     .       .
                   Chemotherapy + antiangiogenesis:Osimertinib 1 1.00  0.09 [0.00;    1.58]   0.09 [0.00;   1.58]      .                 .      .                .     .       .
      Chemotherapy + antiangiogenesis:Osimertinib + chemotherapy 0    0  0.07 [0.00;    1.35]      .              .   0.07 [0.00;      1.35]      .                .     .       .
    Chemotherapy + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.04 [0.00;    0.74]      .              .   0.04 [0.00;      0.74]      .                .     .       .
               Chemotherapy + antiangiogenesis:PD-L1 inhibitor 0    0  0.35 [0.00;   24.86]      .              .   0.35 [0.00;     24.86]      .                .     .       .
                       Chemotherapy + antiangiogenesis:Placebo 0    0  0.31 [0.02;    6.16]      .              .   0.31 [0.02;      6.16]      .                .     .       .
                   Chemotherapy + antiangiogenesis:Rociletinib 0    0  0.02 [0.00;    0.50]      .              .   0.02 [0.00;      0.50]      .                .     .       .
                Chemotherapy + antiangiogenesis:antiangiogenesis 0    0  0.04 [0.00;    0.90]      .              .   0.04 [0.00;      0.90]      .                .     .       .
                  Chemotherapy + antiangiogenesis:Zorifertinib 0    0  0.18 [0.01;    3.69]      .              .   0.18 [0.01;      3.69]      .                .     .       .
                                Dacomitinib:DHFR inhibitor 0    0  0.50 [0.06;    4.22]      .              .   0.50 [0.06;      4.22]      .                .     .       .
                                     Dacomitinib:Erlotinib 1 0.93  0.52 [0.23;    1.16]   0.55 [0.24;   1.27]   0.24 [0.01;      4.64]   2.34 [0.11;    51.24]  0.54  0.5902
                 Dacomitinib:Erlotinib + Autophagy inhibitor 0    0  0.52 [0.06;    4.54]      .              .   0.52 [0.06;      4.54]      .                .     .       .
                        Dacomitinib:Erlotinib + chemotherapy 0    0  0.31 [0.07;    1.33]      .              .   0.31 [0.07;      1.33]      .                .     .       .
                      Dacomitinib:Erlotinib + HER3 inhibitor 0    0  0.52 [0.08;    3.45]      .              .   0.52 [0.08;      3.45]      .                .     .       .
                       Dacomitinib:Erlotinib + HGF inhibitor 0    0  4.69 [0.13;  170.71]      .              .   4.69 [0.13;    170.71]      .                .     .       .
                       Dacomitinib:Erlotinib + IGF-1R inhibitor 0    0  0.85 [0.27;    2.65]      .              .   0.85 [0.27;      2.65]      .                .     .       .
                       Dacomitinib:Erlotinib + MET inhibitor 0    0  0.21 [0.07;    0.66]      .              .   0.21 [0.07;      0.66]      .                .     .       .
                       Dacomitinib:Erlotinib + MMP inhibitor 0    0  1.04 [0.08;   13.34]      .              .   1.04 [0.08;     13.34]      .                .     .       .
                      Dacomitinib:Erlotinib + antiangiogenesis 0    0  0.75 [0.30;    1.90]      .              .   0.75 [0.30;      1.90]      .                .     .       .
                                 Dacomitinib:Furmonertinib 0    0  0.41 [0.07;    2.30]      .              .   0.41 [0.07;      2.30]      .                .     .       .
                                     Dacomitinib:Gefitinib 0    0  0.48 [0.10;    2.26]      .              .   0.48 [0.10;      2.26]      .                .     .       .
                           Dacomitinib:Gefitinib/Erlotinib 0    0  0.65 [0.16;    2.68]      .              .   0.65 [0.16;      2.68]      .                .     .       .
                        Dacomitinib:Gefitinib + chemotherapy 0    0  0.42 [0.04;    4.15]      .              .   0.42 [0.04;      4.15]      .                .     .       .
                                    Dacomitinib:Lazertinib 0    0  0.20 [0.02;    1.94]      .              .   0.20 [0.02;      1.94]      .                .     .       .
                                   Dacomitinib:Osimertinib 0    0  0.28 [0.08;    1.00]      .              .   0.28 [0.08;      1.00]      .                .     .       .
                      Dacomitinib:Osimertinib + chemotherapy 0    0  0.23 [0.06;    0.90]      .              .   0.23 [0.06;      0.90]      .                .     .       .
                    Dacomitinib:Osimertinib + antiangiogenesis 0    0  0.12 [0.03;    0.51]      .              .   0.12 [0.03;      0.51]      .                .     .       .
                               Dacomitinib:PD-L1 inhibitor 0    0  1.12 [0.04;   32.72]      .              .   1.12 [0.04;     32.72]      .                .     .       .
                                       Dacomitinib:Placebo 1 0.19  0.99 [0.29;    3.35]   0.50 [0.03;   8.03]   1.17 [0.30;      4.52]   0.43 [0.02;     9.39] -0.54  0.5902
                                   Dacomitinib:Rociletinib 0    0  0.06 [0.02;    0.23]      .              .   0.06 [0.02;      0.23]      .                .     .       .
                                Dacomitinib:antiangiogenesis 0    0  0.12 [0.03;    0.39]      .              .   0.12 [0.03;      0.39]      .                .     .       .
                                  Dacomitinib:Zorifertinib 0    0  0.57 [0.12;    2.66]      .              .   0.57 [0.12;      2.66]      .                .     .       .
                                  DHFR inhibitor:Erlotinib 1 1.00  1.04 [0.14;    7.55]   1.04 [0.14;   7.55]      .                 .      .                .     .       .
              DHFR inhibitor:Erlotinib + Autophagy inhibitor 0    0  1.04 [0.06;   17.56]      .              .   1.04 [0.06;     17.56]      .                .     .       .
                     DHFR inhibitor:Erlotinib + chemotherapy 0    0  0.62 [0.06;    6.36]      .              .   0.62 [0.06;      6.36]      .                .     .       .
                   DHFR inhibitor:Erlotinib + HER3 inhibitor 0    0  1.03 [0.08;   14.27]      .              .   1.03 [0.08;     14.27]      .                .     .       .
                    DHFR inhibitor:Erlotinib + HGF inhibitor 0    0  9.38 [0.17;  525.87]      .              .   9.38 [0.17;    525.87]      .                .     .       .
                    DHFR inhibitor:Erlotinib + IGF-1R inhibitor 0    0  1.71 [0.20;   14.48]      .              .   1.71 [0.20;     14.48]      .                .     .       .
                    DHFR inhibitor:Erlotinib + MET inhibitor 0    0  0.42 [0.05;    3.57]      .              .   0.42 [0.05;      3.57]      .                .     .       .
                    DHFR inhibitor:Erlotinib + MMP inhibitor 0    0  2.08 [0.09;   47.62]      .              .   2.08 [0.09;     47.62]      .                .     .       .
                   DHFR inhibitor:Erlotinib + antiangiogenesis 0    0  1.50 [0.20;   11.53]      .              .   1.50 [0.20;     11.53]      .                .     .       .
                              DHFR inhibitor:Furmonertinib 0    0  0.83 [0.07;   10.12]      .              .   0.83 [0.07;     10.12]      .                .     .       .
                                  DHFR inhibitor:Gefitinib 0    0  0.95 [0.09;   10.49]      .              .   0.95 [0.09;     10.49]      .                .     .       .
                        DHFR inhibitor:Gefitinib/Erlotinib 0    0  1.30 [0.13;   13.35]      .              .   1.30 [0.13;     13.35]      .                .     .       .
                     DHFR inhibitor:Gefitinib + chemotherapy 0    0  0.84 [0.04;   15.70]      .              .   0.84 [0.04;     15.70]      .                .     .       .
                                 DHFR inhibitor:Lazertinib 0    0  0.41 [0.02;    7.49]      .              .   0.41 [0.02;      7.49]      .                .     .       .
                                DHFR inhibitor:Osimertinib 0    0  0.55 [0.06;    5.25]      .              .   0.55 [0.06;      5.25]      .                .     .       .
                   DHFR inhibitor:Osimertinib + chemotherapy 0    0  0.45 [0.04;    4.55]      .              .   0.45 [0.04;      4.55]      .                .     .       .
                 DHFR inhibitor:Osimertinib + antiangiogenesis 0    0  0.24 [0.02;    2.52]      .              .   0.24 [0.02;      2.52]      .                .     .       .
                            DHFR inhibitor:PD-L1 inhibitor 0    0  2.23 [0.05;  105.15]      .              .   2.23 [0.05;    105.15]      .                .     .       .
                                    DHFR inhibitor:Placebo 0    0  1.99 [0.22;   18.29]      .              .   1.99 [0.22;     18.29]      .                .     .       .
                                DHFR inhibitor:Rociletinib 0    0  0.12 [0.01;    1.15]      .              .   0.12 [0.01;      1.15]      .                .     .       .
                             DHFR inhibitor:antiangiogenesis 0    0  0.23 [0.03;    2.04]      .              .   0.23 [0.03;      2.04]      .                .     .       .
                               DHFR inhibitor:Zorifertinib 0    0  1.14 [0.10;   12.67]      .              .   1.14 [0.10;     12.67]      .                .     .       .
                   Erlotinib:Erlotinib + Autophagy inhibitor 1 1.00  1.00 [0.13;    7.49]   1.00 [0.13;   7.49]      .                 .      .                .     .       .
                          Erlotinib:Erlotinib + chemotherapy 2 0.83  0.60 [0.18;    2.02]   0.51 [0.13;   1.96]   1.25 [0.06;     25.32]   0.41 [0.02;    11.15] -0.53  0.5989
                        Erlotinib:Erlotinib + HER3 inhibitor 1 1.00  0.99 [0.18;    5.55]   0.99 [0.18;   5.55]      .                 .      .                .     .       .
                         Erlotinib:Erlotinib + HGF inhibitor 1 1.00  9.00 [0.27;  299.86]   9.00 [0.27; 299.86]      .                 .      .                .     .       .
                         Erlotinib:Erlotinib + IGF-1R inhibitor 2 1.00  1.64 [0.73;    3.66]   1.64 [0.73;   3.66]      .                 .      .                .     .       .
                         Erlotinib:Erlotinib + MET inhibitor 3 1.00  0.40 [0.17;    0.92]   0.40 [0.17;   0.92]      .                 .      .                .     .       .
                         Erlotinib:Erlotinib + MMP inhibitor 1 1.00  2.00 [0.18;   22.55]   2.00 [0.18;  22.55]      .                 .      .                .     .       .
                        Erlotinib:Erlotinib + antiangiogenesis 5 1.00  1.44 [0.89;    2.33]   1.44 [0.89;   2.33]      .                 .      .                .     .       .
                                   Erlotinib:Furmonertinib 0    0  0.79 [0.17;    3.68]      .              .   0.79 [0.17;      3.68]      .                .     .       .
                                       Erlotinib:Gefitinib 0    0  0.92 [0.24;    3.54]      .              .   0.92 [0.24;      3.54]      .                .     .       .
                             Erlotinib:Gefitinib/Erlotinib 0    0  1.24 [0.36;    4.27]      .              .   1.24 [0.36;      4.27]      .                .     .       .
                          Erlotinib:Gefitinib + chemotherapy 0    0  0.81 [0.09;    6.97]      .              .   0.81 [0.09;      6.97]      .                .     .       .
                                      Erlotinib:Lazertinib 0    0  0.39 [0.05;    3.30]      .              .   0.39 [0.05;      3.30]      .                .     .       .
                                     Erlotinib:Osimertinib 0    0  0.53 [0.18;    1.54]      .              .   0.53 [0.18;      1.54]      .                .     .       .
                        Erlotinib:Osimertinib + chemotherapy 0    0  0.43 [0.13;    1.43]      .              .   0.43 [0.13;      1.43]      .                .     .       .
                      Erlotinib:Osimertinib + antiangiogenesis 0    0  0.23 [0.06;    0.82]      .              .   0.23 [0.06;      0.82]      .                .     .       .
                                 Erlotinib:PD-L1 inhibitor 0    0  2.14 [0.08;   58.33]      .              .   2.14 [0.08;     58.33]      .                .     .       .
                                         Erlotinib:Placebo 3 0.39  1.91 [0.70;    5.20]   2.60 [0.52;  12.89]   1.56 [0.43;      5.66]   1.66 [0.21;    12.96]  0.48  0.6285
                                     Erlotinib:Rociletinib 1 1.00  0.12 [0.04;    0.34]   0.12 [0.04;   0.34]      .                 .      .                .     .       .
                                  Erlotinib:antiangiogenesis 2 0.92  0.22 [0.09;    0.55]   0.28 [0.11;   0.72]   0.02 [0.00;      0.44]  15.84 [0.55;   456.65]  1.61  0.1072
                                    Erlotinib:Zorifertinib 0    0  1.10 [0.28;    4.30]      .              .   1.10 [0.28;      4.30]      .                .     .       .
      Erlotinib + Autophagy inhibitor:Erlotinib + chemotherapy 0    0  0.60 [0.06;    6.28]      .              .   0.60 [0.06;      6.28]      .                .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + HER3 inhibitor 0    0  0.99 [0.07;   14.04]      .              .   0.99 [0.07;     14.04]      .                .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + HGF inhibitor 0    0  9.00 [0.16;  513.08]      .              .   9.00 [0.16;    513.08]      .                .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor 0    0  1.64 [0.19;   14.33]      .              .   1.64 [0.19;     14.33]      .                .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor 0    0  0.40 [0.05;    3.54]      .              .   0.40 [0.05;      3.54]      .                .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + MMP inhibitor 0    0  2.00 [0.09;   46.68]      .              .   2.00 [0.09;     46.68]      .                .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis 0    0  1.44 [0.18;   11.43]      .              .   1.44 [0.18;     11.43]      .                .     .       .
               Erlotinib + Autophagy inhibitor:Furmonertinib 0    0  0.79 [0.06;    9.98]      .              .   0.79 [0.06;      9.98]      .                .     .       .
                   Erlotinib + Autophagy inhibitor:Gefitinib 0    0  0.92 [0.08;   10.35]      .              .   0.92 [0.08;     10.35]      .                .     .       .
         Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib 0    0  1.24 [0.12;   13.19]      .              .   1.24 [0.12;     13.19]      .                .     .       .
      Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy 0    0  0.81 [0.04;   15.42]      .              .   0.81 [0.04;     15.42]      .                .     .       .
                  Erlotinib + Autophagy inhibitor:Lazertinib 0    0  0.39 [0.02;    7.36]      .              .   0.39 [0.02;      7.36]      .                .     .       .
                 Erlotinib + Autophagy inhibitor:Osimertinib 0    0  0.53 [0.05;    5.19]      .              .   0.53 [0.05;      5.19]      .                .     .       .
    Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy 0    0  0.43 [0.04;    4.50]      .              .   0.43 [0.04;      4.50]      .                .     .       .
  Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis 0    0  0.23 [0.02;    2.48]      .              .   0.23 [0.02;      2.48]      .                .     .       .
             Erlotinib + Autophagy inhibitor:PD-L1 inhibitor 0    0  2.14 [0.04;  102.67]      .              .   2.14 [0.04;    102.67]      .                .     .       .
                     Erlotinib + Autophagy inhibitor:Placebo 0    0  1.91 [0.20;   18.09]      .              .   1.91 [0.20;     18.09]      .                .     .       .
                 Erlotinib + Autophagy inhibitor:Rociletinib 0    0  0.12 [0.01;    1.14]      .              .   0.12 [0.01;      1.14]      .                .     .       .
              Erlotinib + Autophagy inhibitor:antiangiogenesis 0    0  0.22 [0.02;    2.02]      .              .   0.22 [0.02;      2.02]      .                .     .       .
                Erlotinib + Autophagy inhibitor:Zorifertinib 0    0  1.10 [0.10;   12.50]      .              .   1.10 [0.10;     12.50]      .                .     .       .
           Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor 0    0  1.67 [0.20;   13.78]      .              .   1.67 [0.20;     13.78]      .                .     .       .
            Erlotinib + chemotherapy:Erlotinib + HGF inhibitor 0    0 15.11 [0.37;  619.39]      .              .  15.11 [0.37;    619.39]      .                .     .       .
            Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  2.75 [0.64;   11.90]      .              .   2.75 [0.64;     11.90]      .                .     .       .
            Erlotinib + chemotherapy:Erlotinib + MET inhibitor 0    0  0.67 [0.15;    2.95]      .              .   0.67 [0.15;      2.95]      .                .     .       .
            Erlotinib + chemotherapy:Erlotinib + MMP inhibitor 0    0  3.36 [0.22;   50.66]      .              .   3.36 [0.22;     50.66]      .                .     .       .
           Erlotinib + chemotherapy:Erlotinib + antiangiogenesis 0    0  2.42 [0.65;    9.01]      .              .   2.42 [0.65;      9.01]      .                .     .       .
                      Erlotinib + chemotherapy:Furmonertinib 0    0  1.33 [0.19;    9.13]      .              .   1.33 [0.19;      9.13]      .                .     .       .
                          Erlotinib + chemotherapy:Gefitinib 0    0  1.54 [0.26;    9.14]      .              .   1.54 [0.26;      9.14]      .                .     .       .
                Erlotinib + chemotherapy:Gefitinib/Erlotinib 0    0  2.09 [0.38;   11.48]      .              .   2.09 [0.38;     11.48]      .                .     .       .
             Erlotinib + chemotherapy:Gefitinib + chemotherapy 0    0  1.35 [0.12;   15.69]      .              .   1.35 [0.12;     15.69]      .                .     .       .
                         Erlotinib + chemotherapy:Lazertinib 0    0  0.66 [0.06;    7.49]      .              .   0.66 [0.06;      7.49]      .                .     .       .
                        Erlotinib + chemotherapy:Osimertinib 0    0  0.89 [0.18;    4.37]      .              .   0.89 [0.18;      4.37]      .                .     .       .
           Erlotinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.73 [0.14;    3.88]      .              .   0.73 [0.14;      3.88]      .                .     .       .
         Erlotinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.38 [0.07;    2.19]      .              .   0.38 [0.07;      2.19]      .                .     .       .
                    Erlotinib + chemotherapy:PD-L1 inhibitor 0    0  3.60 [0.11;  120.03]      .              .   3.60 [0.11;    120.03]      .                .     .       .
                            Erlotinib + chemotherapy:Placebo 0    0  3.20 [0.68;   15.17]      .              .   3.20 [0.68;     15.17]      .                .     .       .
                        Erlotinib + chemotherapy:Rociletinib 0    0  0.19 [0.04;    0.99]      .              .   0.19 [0.04;      0.99]      .                .     .       .
                     Erlotinib + chemotherapy:antiangiogenesis 0    0  0.37 [0.08;    1.70]      .              .   0.37 [0.08;      1.70]      .                .     .       .
                       Erlotinib + chemotherapy:Zorifertinib 0    0  1.84 [0.30;   11.18]      .              .   1.84 [0.30;     11.18]      .                .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + HGF inhibitor 0    0  9.07 [0.18;  450.60]      .              .   9.07 [0.18;    450.60]      .                .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor 0    0  1.65 [0.25;   11.04]      .              .   1.65 [0.25;     11.04]      .                .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor 0    0  0.40 [0.06;    2.73]      .              .   0.40 [0.06;      2.73]      .                .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor 0    0  2.01 [0.10;   39.35]      .              .   2.01 [0.10;     39.35]      .                .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis 0    0  1.45 [0.24;    8.68]      .              .   1.45 [0.24;      8.68]      .                .     .       .
                    Erlotinib + HER3 inhibitor:Furmonertinib 0    0  0.80 [0.08;    8.02]      .              .   0.80 [0.08;      8.02]      .                .     .       .
                        Erlotinib + HER3 inhibitor:Gefitinib 0    0  0.92 [0.10;    8.23]      .              .   0.92 [0.10;      8.23]      .                .     .       .
              Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib 0    0  1.25 [0.15;   10.41]      .              .   1.25 [0.15;     10.41]      .                .     .       .
           Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy 0    0  0.81 [0.05;   12.83]      .              .   0.81 [0.05;     12.83]      .                .     .       .
                       Erlotinib + HER3 inhibitor:Lazertinib 0    0  0.40 [0.03;    6.12]      .              .   0.40 [0.03;      6.12]      .                .     .       .
                      Erlotinib + HER3 inhibitor:Osimertinib 0    0  0.54 [0.07;    4.06]      .              .   0.54 [0.07;      4.06]      .                .     .       .
         Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy 0    0  0.44 [0.05;    3.54]      .              .   0.44 [0.05;      3.54]      .                .     .       .
       Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis 0    0  0.23 [0.03;    1.97]      .              .   0.23 [0.03;      1.97]      .                .     .       .
                  Erlotinib + HER3 inhibitor:PD-L1 inhibitor 0    0  2.16 [0.05;   89.59]      .              .   2.16 [0.05;     89.59]      .                .     .       .
                          Erlotinib + HER3 inhibitor:Placebo 0    0  1.92 [0.26;   14.09]      .              .   1.92 [0.26;     14.09]      .                .     .       .
                      Erlotinib + HER3 inhibitor:Rociletinib 0    0  0.12 [0.02;    0.89]      .              .   0.12 [0.02;      0.89]      .                .     .       .
                   Erlotinib + HER3 inhibitor:antiangiogenesis 0    0  0.22 [0.03;    1.57]      .              .   0.22 [0.03;      1.57]      .                .     .       .
                     Erlotinib + HER3 inhibitor:Zorifertinib 0    0  1.10 [0.12;    9.95]      .              .   1.10 [0.12;      9.95]      .                .     .       .
           Erlotinib + HGF inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.18 [0.00;    6.65]      .              .   0.18 [0.00;      6.65]      .                .     .       .
           Erlotinib + HGF inhibitor:Erlotinib + MET inhibitor 0    0  0.04 [0.00;    1.63]      .              .   0.04 [0.00;      1.63]      .                .     .       .
           Erlotinib + HGF inhibitor:Erlotinib + MMP inhibitor 0    0  0.22 [0.00;   15.76]      .              .   0.22 [0.00;     15.76]      .                .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + antiangiogenesis 0    0  0.16 [0.00;    5.52]      .              .   0.16 [0.00;      5.52]      .                .     .       .
                     Erlotinib + HGF inhibitor:Furmonertinib 0    0  0.09 [0.00;    4.05]      .              .   0.09 [0.00;      4.05]      .                .     .       .
                         Erlotinib + HGF inhibitor:Gefitinib 0    0  0.10 [0.00;    4.36]      .              .   0.10 [0.00;      4.36]      .                .     .       .
               Erlotinib + HGF inhibitor:Gefitinib/Erlotinib 0    0  0.14 [0.00;    5.68]      .              .   0.14 [0.00;      5.68]      .                .     .       .
            Erlotinib + HGF inhibitor:Gefitinib + chemotherapy 0    0  0.09 [0.00;    5.49]      .              .   0.09 [0.00;      5.49]      .                .     .       .
                        Erlotinib + HGF inhibitor:Lazertinib 0    0  0.04 [0.00;    2.64]      .              .   0.04 [0.00;      2.64]      .                .     .       .
                       Erlotinib + HGF inhibitor:Osimertinib 0    0  0.06 [0.00;    2.31]      .              .   0.06 [0.00;      2.31]      .                .     .       .
          Erlotinib + HGF inhibitor:Osimertinib + chemotherapy 0    0  0.05 [0.00;    1.95]      .              .   0.05 [0.00;      1.95]      .                .     .       .
        Erlotinib + HGF inhibitor:Osimertinib + antiangiogenesis 0    0  0.03 [0.00;    1.06]      .              .   0.03 [0.00;      1.06]      .                .     .       .
                   Erlotinib + HGF inhibitor:PD-L1 inhibitor 0    0  0.24 [0.00;   29.45]      .              .   0.24 [0.00;     29.45]      .                .     .       .
                           Erlotinib + HGF inhibitor:Placebo 0    0  0.21 [0.01;    8.13]      .              .   0.21 [0.01;      8.13]      .                .     .       .
                       Erlotinib + HGF inhibitor:Rociletinib 0    0  0.01 [0.00;    0.50]      .              .   0.01 [0.00;      0.50]      .                .     .       .
                    Erlotinib + HGF inhibitor:antiangiogenesis 0    0  0.02 [0.00;    0.92]      .              .   0.02 [0.00;      0.92]      .                .     .       .
                      Erlotinib + HGF inhibitor:Zorifertinib 0    0  0.12 [0.00;    5.24]      .              .   0.12 [0.00;      5.24]      .                .     .       .
           Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor 0    0  0.24 [0.08;    0.78]      .              .   0.24 [0.08;      0.78]      .                .     .       .
           Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor 0    0  1.22 [0.10;   15.67]      .              .   1.22 [0.10;     15.67]      .                .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis 0    0  0.88 [0.35;    2.24]      .              .   0.88 [0.35;      2.24]      .                .     .       .
                     Erlotinib + IGF-1R inhibitor:Furmonertinib 0    0  0.48 [0.09;    2.74]      .              .   0.48 [0.09;      2.74]      .                .     .       .
                         Erlotinib + IGF-1R inhibitor:Gefitinib 0    0  0.56 [0.12;    2.69]      .              .   0.56 [0.12;      2.69]      .                .     .       .
               Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib 0    0  0.76 [0.17;    3.30]      .              .   0.76 [0.17;      3.30]      .                .     .       .
            Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy 0    0  0.49 [0.05;    4.92]      .              .   0.49 [0.05;      4.92]      .                .     .       .
                        Erlotinib + IGF-1R inhibitor:Lazertinib 0    0  0.24 [0.02;    2.33]      .              .   0.24 [0.02;      2.33]      .                .     .       .
                       Erlotinib + IGF-1R inhibitor:Osimertinib 0    0  0.32 [0.09;    1.23]      .              .   0.32 [0.09;      1.23]      .                .     .       .
          Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy 0    0  0.26 [0.06;    1.11]      .              .   0.26 [0.06;      1.11]      .                .     .       .
        Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis 0    0  0.14 [0.03;    0.63]      .              .   0.14 [0.03;      0.63]      .                .     .       .
                   Erlotinib + IGF-1R inhibitor:PD-L1 inhibitor 0    0  1.31 [0.04;   39.19]      .              .   1.31 [0.04;     39.19]      .                .     .       .
                           Erlotinib + IGF-1R inhibitor:Placebo 0    0  1.16 [0.32;    4.21]      .              .   1.16 [0.32;      4.21]      .                .     .       .
                       Erlotinib + IGF-1R inhibitor:Rociletinib 0    0  0.07 [0.02;    0.27]      .              .   0.07 [0.02;      0.27]      .                .     .       .
                    Erlotinib + IGF-1R inhibitor:antiangiogenesis 0    0  0.13 [0.04;    0.46]      .              .   0.13 [0.04;      0.46]      .                .     .       .
                      Erlotinib + IGF-1R inhibitor:Zorifertinib 0    0  0.67 [0.14;    3.27]      .              .   0.67 [0.14;      3.27]      .                .     .       .
           Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor 0    0  5.00 [0.39;   64.82]      .              .   5.00 [0.39;     64.82]      .                .     .       .
          Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis 0    0  3.61 [1.38;    9.44]      .              .   3.61 [1.38;      9.44]      .                .     .       .
                     Erlotinib + MET inhibitor:Furmonertinib 0    0  1.98 [0.35;   11.38]      .              .   1.98 [0.35;     11.38]      .                .     .       .
                         Erlotinib + MET inhibitor:Gefitinib 0    0  2.29 [0.47;   11.21]      .              .   2.29 [0.47;     11.21]      .                .     .       .
               Erlotinib + MET inhibitor:Gefitinib/Erlotinib 0    0  3.11 [0.70;   13.77]      .              .   3.11 [0.70;     13.77]      .                .     .       .
            Erlotinib + MET inhibitor:Gefitinib + chemotherapy 0    0  2.01 [0.20;   20.36]      .              .   2.01 [0.20;     20.36]      .                .     .       .
                        Erlotinib + MET inhibitor:Lazertinib 0    0  0.98 [0.10;    9.66]      .              .   0.98 [0.10;      9.66]      .                .     .       .
                       Erlotinib + MET inhibitor:Osimertinib 0    0  1.33 [0.34;    5.15]      .              .   1.33 [0.34;      5.15]      .                .     .       .
          Erlotinib + MET inhibitor:Osimertinib + chemotherapy 0    0  1.08 [0.25;    4.64]      .              .   1.08 [0.25;      4.64]      .                .     .       .
        Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis 0    0  0.57 [0.12;    2.64]      .              .   0.57 [0.12;      2.64]      .                .     .       .
                   Erlotinib + MET inhibitor:PD-L1 inhibitor 0    0  5.36 [0.18;  161.76]      .              .   5.36 [0.18;    161.76]      .                .     .       .
                           Erlotinib + MET inhibitor:Placebo 0    0  4.77 [1.29;   17.58]      .              .   4.77 [1.29;     17.58]      .                .     .       .
                       Erlotinib + MET inhibitor:Rociletinib 0    0  0.29 [0.07;    1.13]      .              .   0.29 [0.07;      1.13]      .                .     .       .
                    Erlotinib + MET inhibitor:antiangiogenesis 0    0  0.55 [0.16;    1.91]      .              .   0.55 [0.16;      1.91]      .                .     .       .
                      Erlotinib + MET inhibitor:Zorifertinib 0    0  2.74 [0.55;   13.59]      .              .   2.74 [0.55;     13.59]      .                .     .       .
          Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis 0    0  0.72 [0.06;    8.52]      .              .   0.72 [0.06;      8.52]      .                .     .       .
                     Erlotinib + MMP inhibitor:Furmonertinib 0    0  0.40 [0.02;    6.98]      .              .   0.40 [0.02;      6.98]      .                .     .       .
                         Erlotinib + MMP inhibitor:Gefitinib 0    0  0.46 [0.03;    7.33]      .              .   0.46 [0.03;      7.33]      .                .     .       .
               Erlotinib + MMP inhibitor:Gefitinib/Erlotinib 0    0  0.62 [0.04;    9.42]      .              .   0.62 [0.04;      9.42]      .                .     .       .
            Erlotinib + MMP inhibitor:Gefitinib + chemotherapy 0    0  0.40 [0.02;   10.33]      .              .   0.40 [0.02;     10.33]      .                .     .       .
                        Erlotinib + MMP inhibitor:Lazertinib 0    0  0.20 [0.01;    4.94]      .              .   0.20 [0.01;      4.94]      .                .     .       .
                       Erlotinib + MMP inhibitor:Osimertinib 0    0  0.27 [0.02;    3.75]      .              .   0.27 [0.02;      3.75]      .                .     .       .
          Erlotinib + MMP inhibitor:Osimertinib + chemotherapy 0    0  0.22 [0.01;    3.22]      .              .   0.22 [0.01;      3.22]      .                .     .       .
        Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis 0    0  0.11 [0.01;    1.77]      .              .   0.11 [0.01;      1.77]      .                .     .       .
                   Erlotinib + MMP inhibitor:PD-L1 inhibitor 0    0  1.07 [0.02;   64.46]      .              .   1.07 [0.02;     64.46]      .                .     .       .
                           Erlotinib + MMP inhibitor:Placebo 0    0  0.95 [0.07;   13.12]      .              .   0.95 [0.07;     13.12]      .                .     .       .
                       Erlotinib + MMP inhibitor:Rociletinib 0    0  0.06 [0.00;    0.82]      .              .   0.06 [0.00;      0.82]      .                .     .       .
                    Erlotinib + MMP inhibitor:antiangiogenesis 0    0  0.11 [0.01;    1.47]      .              .   0.11 [0.01;      1.47]      .                .     .       .
                      Erlotinib + MMP inhibitor:Zorifertinib 0    0  0.55 [0.03;    8.85]      .              .   0.55 [0.03;      8.85]      .                .     .       .
                    Erlotinib + antiangiogenesis:Furmonertinib 0    0  0.55 [0.11;    2.74]      .              .   0.55 [0.11;      2.74]      .                .     .       .
                        Erlotinib + antiangiogenesis:Gefitinib 0    0  0.63 [0.15;    2.66]      .              .   0.63 [0.15;      2.66]      .                .     .       .
              Erlotinib + antiangiogenesis:Gefitinib/Erlotinib 0    0  0.86 [0.23;    3.23]      .              .   0.86 [0.23;      3.23]      .                .     .       .
           Erlotinib + antiangiogenesis:Gefitinib + chemotherapy 0    0  0.56 [0.06;    5.09]      .              .   0.56 [0.06;      5.09]      .                .     .       .
                       Erlotinib + antiangiogenesis:Lazertinib 0    0  0.27 [0.03;    2.41]      .              .   0.27 [0.03;      2.41]      .                .     .       .
                      Erlotinib + antiangiogenesis:Osimertinib 0    0  0.37 [0.11;    1.19]      .              .   0.37 [0.11;      1.19]      .                .     .       .
         Erlotinib + antiangiogenesis:Osimertinib + chemotherapy 0    0  0.30 [0.08;    1.08]      .              .   0.30 [0.08;      1.08]      .                .     .       .
       Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.16 [0.04;    0.62]      .              .   0.16 [0.04;      0.62]      .                .     .       .
                  Erlotinib + antiangiogenesis:PD-L1 inhibitor 0    0  1.49 [0.05;   41.84]      .              .   1.49 [0.05;     41.84]      .                .     .       .
                          Erlotinib + antiangiogenesis:Placebo 0    0  1.32 [0.43;    4.02]      .              .   1.32 [0.43;      4.02]      .                .     .       .
                      Erlotinib + antiangiogenesis:Rociletinib 0    0  0.08 [0.02;    0.26]      .              .   0.08 [0.02;      0.26]      .                .     .       .
                   Erlotinib + antiangiogenesis:antiangiogenesis 0    0  0.15 [0.05;    0.43]      .              .   0.15 [0.05;      0.43]      .                .     .       .
                     Erlotinib + antiangiogenesis:Zorifertinib 0    0  0.76 [0.18;    3.23]      .              .   0.76 [0.18;      3.23]      .                .     .       .
                                   Furmonertinib:Gefitinib 1 1.00  1.15 [0.56;    2.39]   1.15 [0.56;   2.39]      .                 .      .                .     .       .
                         Furmonertinib:Gefitinib/Erlotinib 0    0  1.57 [0.25;    9.73]      .              .   1.57 [0.25;      9.73]      .                .     .       .
                      Furmonertinib:Gefitinib + chemotherapy 0    0  1.02 [0.16;    6.35]      .              .   1.02 [0.16;      6.35]      .                .     .       .
                                  Furmonertinib:Lazertinib 0    0  0.50 [0.05;    4.87]      .              .   0.50 [0.05;      4.87]      .                .     .       .
                                 Furmonertinib:Osimertinib 0    0  0.67 [0.12;    3.73]      .              .   0.67 [0.12;      3.73]      .                .     .       .
                    Furmonertinib:Osimertinib + chemotherapy 0    0  0.55 [0.09;    3.30]      .              .   0.55 [0.09;      3.30]      .                .     .       .
                  Furmonertinib:Osimertinib + antiangiogenesis 0    0  0.29 [0.04;    1.85]      .              .   0.29 [0.04;      1.85]      .                .     .       .
                             Furmonertinib:PD-L1 inhibitor 0    0  2.71 [0.08;   95.77]      .              .   2.71 [0.08;     95.77]      .                .     .       .
                                     Furmonertinib:Placebo 0    0  2.41 [0.43;   13.34]      .              .   2.41 [0.43;     13.34]      .                .     .       .
                                 Furmonertinib:Rociletinib 0    0  0.15 [0.02;    0.95]      .              .   0.15 [0.02;      0.95]      .                .     .       .
                              Furmonertinib:antiangiogenesis 0    0  0.28 [0.05;    1.50]      .              .   0.28 [0.05;      1.50]      .                .     .       .
                                Furmonertinib:Zorifertinib 0    0  1.38 [0.20;    9.41]      .              .   1.38 [0.20;      9.41]      .                .     .       .
                             Gefitinib:Gefitinib/Erlotinib 0    0  1.36 [0.26;    7.24]      .              .   1.36 [0.26;      7.24]      .                .     .       .
                          Gefitinib:Gefitinib + chemotherapy 2 1.00  0.88 [0.16;    4.73]   0.88 [0.16;   4.73]      .                 .      .                .     .       .
                                      Gefitinib:Lazertinib 1 0.46  0.43 [0.05;    3.75]   3.00 [0.12;  74.09]   0.08 [0.00;      1.58]  35.79 [0.46;  2771.17]  1.61  0.1069
                                     Gefitinib:Osimertinib 0    0  0.58 [0.12;    2.75]      .              .   0.58 [0.12;      2.75]      .                .     .       .
                        Gefitinib:Osimertinib + chemotherapy 0    0  0.47 [0.09;    2.45]      .              .   0.47 [0.09;      2.45]      .                .     .       .
                      Gefitinib:Osimertinib + antiangiogenesis 0    0  0.25 [0.04;    1.38]      .              .   0.25 [0.04;      1.38]      .                .     .       .
                                 Gefitinib:PD-L1 inhibitor 0    0  2.34 [0.07;   76.96]      .              .   2.34 [0.07;     76.96]      .                .     .       .
                                         Gefitinib:Placebo 0    0  2.08 [0.44;    9.83]      .              .   2.08 [0.44;      9.83]      .                .     .       .
                                     Gefitinib:Rociletinib 0    0  0.13 [0.02;    0.71]      .              .   0.13 [0.02;      0.71]      .                .     .       .
                                  Gefitinib:antiangiogenesis 1 0.28  0.24 [0.05;    1.10]   0.03 [0.00;   0.57]   0.53 [0.09;      3.18]   0.06 [0.00;     1.82] -1.61  0.1072
                                    Gefitinib:Zorifertinib 0    0  1.20 [0.20;    7.06]      .              .   1.20 [0.20;      7.06]      .                .     .       .
                Gefitinib/Erlotinib:Gefitinib + chemotherapy 0    0  0.65 [0.06;    6.94]      .              .   0.65 [0.06;      6.94]      .                .     .       .
                            Gefitinib/Erlotinib:Lazertinib 0    0  0.32 [0.04;    2.57]      .              .   0.32 [0.04;      2.57]      .                .     .       .
                           Gefitinib/Erlotinib:Osimertinib 1 1.00  0.43 [0.23;    0.79]   0.43 [0.23;   0.79]      .                 .      .                .     .       .
              Gefitinib/Erlotinib:Osimertinib + chemotherapy 0    0  0.35 [0.15;    0.78]      .              .   0.35 [0.15;      0.78]      .                .     .       .
            Gefitinib/Erlotinib:Osimertinib + antiangiogenesis 0    0  0.18 [0.07;    0.47]      .              .   0.18 [0.07;      0.47]      .                .     .       .
                       Gefitinib/Erlotinib:PD-L1 inhibitor 0    0  1.72 [0.07;   41.72]      .              .   1.72 [0.07;     41.72]      .                .     .       .
                               Gefitinib/Erlotinib:Placebo 0    0  1.53 [0.61;    3.87]      .              .   1.53 [0.61;      3.87]      .                .     .       .
                           Gefitinib/Erlotinib:Rociletinib 0    0  0.09 [0.02;    0.48]      .              .   0.09 [0.02;      0.48]      .                .     .       .
                        Gefitinib/Erlotinib:antiangiogenesis 0    0  0.18 [0.04;    0.81]      .              .   0.18 [0.04;      0.81]      .                .     .       .
                          Gefitinib/Erlotinib:Zorifertinib 1 1.00  0.88 [0.49;    1.60]   0.88 [0.49;   1.60]      .                 .      .                .     .       .
                         Gefitinib + chemotherapy:Lazertinib 0    0  0.49 [0.03;    7.56]      .              .   0.49 [0.03;      7.56]      .                .     .       .
                        Gefitinib + chemotherapy:Osimertinib 0    0  0.66 [0.07;    6.51]      .              .   0.66 [0.07;      6.51]      .                .     .       .
           Gefitinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.54 [0.05;    5.64]      .              .   0.54 [0.05;      5.64]      .                .     .       .
         Gefitinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.28 [0.03;    3.11]      .              .   0.28 [0.03;      3.11]      .                .     .       .
                    Gefitinib + chemotherapy:PD-L1 inhibitor 0    0  2.66 [0.06;  128.20]      .              .   2.66 [0.06;    128.20]      .                .     .       .
                            Gefitinib + chemotherapy:Placebo 0    0  2.37 [0.24;   23.29]      .              .   2.37 [0.24;     23.29]      .                .     .       .
                        Gefitinib + chemotherapy:Rociletinib 0    0  0.14 [0.01;    1.60]      .              .   0.14 [0.01;      1.60]      .                .     .       .
                     Gefitinib + chemotherapy:antiangiogenesis 0    0  0.27 [0.03;    2.64]      .              .   0.27 [0.03;      2.64]      .                .     .       .
                       Gefitinib + chemotherapy:Zorifertinib 0    0  1.36 [0.12;   15.66]      .              .   1.36 [0.12;     15.66]      .                .     .       .
                                    Lazertinib:Osimertinib 1 0.69  1.35 [0.18;   10.05]   4.05 [0.36;  44.89]   0.11 [0.00;      4.24]  35.79 [0.46;  2771.17]  1.61  0.1069
                       Lazertinib:Osimertinib + chemotherapy 0    0  1.10 [0.14;    8.77]      .              .   1.10 [0.14;      8.77]      .                .     .       .
                     Lazertinib:Osimertinib + antiangiogenesis 0    0  0.58 [0.07;    4.88]      .              .   0.58 [0.07;      4.88]      .                .     .       .
                                Lazertinib:PD-L1 inhibitor 0    0  5.46 [0.13;  223.94]      .              .   5.46 [0.13;    223.94]      .                .     .       .
                                        Lazertinib:Placebo 0    0  4.86 [0.61;   38.81]      .              .   4.86 [0.61;     38.81]      .                .     .       .
                                    Lazertinib:Rociletinib 0    0  0.29 [0.03;    3.21]      .              .   0.29 [0.03;      3.21]      .                .     .       .
                                 Lazertinib:antiangiogenesis 0    0  0.56 [0.06;    5.51]      .              .   0.56 [0.06;      5.51]      .                .     .       .
                                   Lazertinib:Zorifertinib 0    0  2.79 [0.32;   24.67]      .              .   2.79 [0.32;     24.67]      .                .     .       .
                      Osimertinib:Osimertinib + chemotherapy 2 1.00  0.82 [0.48;    1.38]   0.82 [0.48;   1.38]      .                 .      .                .     .       .
                    Osimertinib:Osimertinib + antiangiogenesis 2 1.00  0.43 [0.21;    0.88]   0.43 [0.21;   0.88]      .                 .      .                .     .       .
                               Osimertinib:PD-L1 inhibitor 1 1.00  4.03 [0.18;   91.91]   4.03 [0.18;  91.91]      .                 .      .                .     .       .
                                       Osimertinib:Placebo 2 0.88  3.59 [1.80;    7.16]   3.59 [1.72;   7.50]   3.58 [0.49;     26.14]   1.00 [0.12;     8.37]  0.00  0.9975
                                   Osimertinib:Rociletinib 0    0  0.22 [0.05;    0.99]      .              .   0.22 [0.05;      0.99]      .                .     .       .
                                Osimertinib:antiangiogenesis 0    0  0.42 [0.10;    1.66]      .              .   0.42 [0.10;      1.66]      .                .     .       .
                                  Osimertinib:Zorifertinib 0    0  2.06 [0.87;    4.85]      .              .   2.06 [0.87;      4.85]      .                .     .       .
       Osimertinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.53 [0.22;    1.28]      .              .   0.53 [0.22;      1.28]      .                .     .       .
                  Osimertinib + chemotherapy:PD-L1 inhibitor 0    0  4.95 [0.21;  117.89]      .              .   4.95 [0.21;    117.89]      .                .     .       .
                          Osimertinib + chemotherapy:Placebo 0    0  4.40 [1.84;   10.51]      .              .   4.40 [1.84;     10.51]      .                .     .       .
                      Osimertinib + chemotherapy:Rociletinib 0    0  0.27 [0.05;    1.33]      .              .   0.27 [0.05;      1.33]      .                .     .       .
                   Osimertinib + chemotherapy:antiangiogenesis 0    0  0.51 [0.12;    2.25]      .              .   0.51 [0.12;      2.25]      .                .     .       .
                     Osimertinib + chemotherapy:Zorifertinib 0    0  2.53 [0.92;    6.92]      .              .   2.53 [0.92;      6.92]      .                .     .       .
                Osimertinib + antiangiogenesis:PD-L1 inhibitor 0    0  9.41 [0.38;  232.58]      .              .   9.41 [0.38;    232.58]      .                .     .       .
                        Osimertinib + antiangiogenesis:Placebo 0    0  8.37 [3.09;   22.66]      .              .   8.37 [3.09;     22.66]      .                .     .       .
                    Osimertinib + antiangiogenesis:Rociletinib 0    0  0.51 [0.09;    2.72]      .              .   0.51 [0.09;      2.72]      .                .     .       .
                 Osimertinib + antiangiogenesis:antiangiogenesis 0    0  0.97 [0.20;    4.62]      .              .   0.97 [0.20;      4.62]      .                .     .       .
                   Osimertinib + antiangiogenesis:Zorifertinib 0    0  4.81 [1.57;   14.69]      .              .   4.81 [1.57;     14.69]      .                .     .       .
                                   PD-L1 inhibitor:Placebo 0    0  0.89 [0.04;   21.86]      .              .   0.89 [0.04;     21.86]      .                .     .       .
                               PD-L1 inhibitor:Rociletinib 0    0  0.05 [0.00;    1.74]      .              .   0.05 [0.00;      1.74]      .                .     .       .
                            PD-L1 inhibitor:antiangiogenesis 0    0  0.10 [0.00;    3.15]      .              .   0.10 [0.00;      3.15]      .                .     .       .
                              PD-L1 inhibitor:Zorifertinib 0    0  0.51 [0.02;   13.06]      .              .   0.51 [0.02;     13.06]      .                .     .       .
                                       Rociletinib:Placebo 0    0 16.48 [3.77;   71.98]      .              .  16.48 [3.77;     71.98]      .                .     .       .
                                    antiangiogenesis:Placebo 0    0  8.62 [2.25;   33.01]      .              .   8.62 [2.25;     33.01]      .                .     .       .
                                      Zorifertinib:Placebo 0    0  1.74 [0.58;    5.24]      .              .   1.74 [0.58;      5.24]      .                .     .       .
                                Rociletinib:antiangiogenesis 0    0  1.91 [0.46;    7.88]      .              .   1.91 [0.46;      7.88]      .                .     .       .
                                  Rociletinib:Zorifertinib 0    0  9.46 [1.66;   54.09]      .              .   9.46 [1.66;     54.09]      .                .     .       .
                               antiangiogenesis:Zorifertinib 0    0  4.95 [0.97;   25.26]      .              .   4.95 [0.97;     25.26]      .                .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

total-heart failure

Random effects model: 

                                          comparison k prop   nma          95%-CI direct        95%-CI    indir.               95%-CI    RoR            95%-CI     z p-value
                               Afatinib:Almonertinib 0    0  2.22 [0.03;  170.53]      .             .      2.22 [0.03; 1.705300e + 02]      .                 .     .       .
                   Afatinib:Amivantamab  +  Lazertinib 0    0  1.37 [0.14;   13.72]      .             .      1.37 [0.14; 1.372000e + 01]      .                 .     .       .
                               Afatinib:Chemotherapy 1 0.37  0.62 [0.09;    4.31]   0.16 [0.01;  3.87]      1.36 [0.12; 1.579000e + 01]   0.11 [0.00;      6.49] -1.05  0.2930
                                Afatinib:Dacomitinib 0    0  0.71 [0.03;   15.05]      .             .      0.71 [0.03; 1.505000e + 01]      .                 .     .       .
                                  Afatinib:Erlotinib 1 0.72  0.71 [0.20;    2.54]   0.75 [0.17;  3.39]      0.61 [0.05; 6.830000e + 00]   1.25 [0.07;     21.58]  0.15  0.8800
                     Afatinib:Erlotinib + chemotherapy 0    0  1.42 [0.09;   21.97]      .             .      1.42 [0.09; 2.197000e + 01]      .                 .     .       .
                   Afatinib:Erlotinib + HER3 inhibitor 0    0  0.28 [0.01;    7.55]      .             .      0.28 [0.01; 7.550000e + 00]      .                 .     .       .
                    Afatinib:Erlotinib + IGF-1R inhibitor 0    0  0.35 [0.04;    2.96]      .             .      0.35 [0.04; 2.960000e + 00]      .                 .     .       .
                    Afatinib:Erlotinib + MET inhibitor 0    0  0.48 [0.08;    2.89]      .             .      0.48 [0.08; 2.890000e + 00]      .                 .     .       .
                    Afatinib:Erlotinib + MMP inhibitor 0    0  0.23 [0.01;    7.33]      .             .      0.23 [0.01; 7.330000e + 00]      .                 .     .       .
                   Afatinib:Erlotinib + antiangiogenesis 0    0  0.39 [0.08;    1.85]      .             .      0.39 [0.08; 1.850000e + 00]      .                 .     .       .
                                  Afatinib:Gefitinib 0    0  0.74 [0.04;   13.80]      .             .      0.74 [0.04; 1.380000e + 01]      .                 .     .       .
                        Afatinib:Gefitinib/Erlotinib 0    0  4.32 [0.30;   62.28]      .             .      4.32 [0.30; 6.228000e + 01]      .                 .     .       .
                     Afatinib:Gefitinib + chemotherapy 0    0  1.01 [0.03;   41.16]      .             .      1.01 [0.03; 4.116000e + 01]      .                 .     .       .
                   Afatinib:Gefitinib + PARP inhibitor 0    0  0.24 [0.00;   18.85]      .             .      0.24 [0.00; 1.885000e + 01]      .                 .     .       .
                                   Afatinib:Icotinib 0    0  0.10 [0.00;    6.77]      .             .      0.10 [0.00; 6.770000e + 00]      .                 .     .       .
                                 Afatinib:Lazertinib 0    0  0.86 [0.07;   10.29]      .             .      0.86 [0.07; 1.029000e + 01]      .                 .     .       .
                                Afatinib:Osimertinib 0    0  0.61 [0.12;    3.15]      .             .      0.61 [0.12; 3.150000e + 00]      .                 .     .       .
                   Afatinib:Osimertinib + chemotherapy 0    0  0.10 [0.01;    1.46]      .             .      0.10 [0.01; 1.460000e + 00]      .                 .     .       .
                 Afatinib:Osimertinib + antiangiogenesis 0    0  0.04 [0.00;    0.60]      .             .      0.04 [0.00; 6.000000e-01]      .                 .     .       .
                                    Afatinib:Placebo 1 0.47  1.20 [0.27;    5.43]   2.01 [0.22; 18.11]      0.77 [0.10; 6.050000e + 00]   2.62 [0.13;     53.49]  0.63  0.5312
                             Afatinib:antiangiogenesis 0    0  0.13 [0.01;    1.59]      .             .      0.13 [0.01; 1.590000e + 00]      .                 .     .       .
               Almonertinib:Amivantamab  +  Lazertinib 0    0  0.61 [0.01;   51.19]      .             .      0.61 [0.01; 5.119000e + 01]      .                 .     .       .
                           Almonertinib:Chemotherapy 0    0  0.28 [0.00;   17.00]      .             .      0.28 [0.00; 1.700000e + 01]      .                 .     .       .
                            Almonertinib:Dacomitinib 0    0  0.32 [0.00;   54.21]      .             .      0.32 [0.00; 5.421000e + 01]      .                 .     .       .
                              Almonertinib:Erlotinib 0    0  0.32 [0.00;   24.01]      .             .      0.32 [0.00; 2.401000e + 01]      .                 .     .       .
                 Almonertinib:Erlotinib + chemotherapy 0    0  0.64 [0.00;   90.49]      .             .      0.64 [0.00; 9.049000e + 01]      .                 .     .       .
               Almonertinib:Erlotinib + HER3 inhibitor 0    0  0.12 [0.00;   24.66]      .             .      0.12 [0.00; 2.466000e + 01]      .                 .     .       .
                Almonertinib:Erlotinib + IGF-1R inhibitor 0    0  0.16 [0.00;   16.43]      .             .      0.16 [0.00; 1.643000e + 01]      .                 .     .       .
                Almonertinib:Erlotinib + MET inhibitor 0    0  0.21 [0.00;   19.37]      .             .      0.21 [0.00; 1.937000e + 01]      .                 .     .       .
                Almonertinib:Erlotinib + MMP inhibitor 0    0  0.10 [0.00;   22.62]      .             .      0.10 [0.00; 2.262000e + 01]      .                 .     .       .
               Almonertinib:Erlotinib + antiangiogenesis 0    0  0.18 [0.00;   14.49]      .             .      0.18 [0.00; 1.449000e + 01]      .                 .     .       .
                              Almonertinib:Gefitinib 1 1.00  0.33 [0.01;    8.23]   0.33 [0.01;  8.23]         .                    .      .                 .     .       .
                    Almonertinib:Gefitinib/Erlotinib 0    0  1.94 [0.02;  212.41]      .             .      1.94 [0.02; 2.124100e + 02]      .                 .     .       .
                 Almonertinib:Gefitinib + chemotherapy 0    0  0.46 [0.01;   23.21]      .             .      0.46 [0.01; 2.321000e + 01]      .                 .     .       .
               Almonertinib:Gefitinib + PARP inhibitor 0    0  0.11 [0.00;   10.29]      .             .      0.11 [0.00; 1.029000e + 01]      .                 .     .       .
                               Almonertinib:Icotinib 0    0  0.05 [0.00;    3.73]      .             .      0.05 [0.00; 3.730000e + 00]      .                 .     .       .
                             Almonertinib:Lazertinib 0    0  0.39 [0.01;   23.85]      .             .      0.39 [0.01; 2.385000e + 01]      .                 .     .       .
                            Almonertinib:Osimertinib 0    0  0.27 [0.00;   18.20]      .             .      0.27 [0.00; 1.820000e + 01]      .                 .     .       .
               Almonertinib:Osimertinib + chemotherapy 0    0  0.04 [0.00;    4.96]      .             .      0.04 [0.00; 4.960000e + 00]      .                 .     .       .
             Almonertinib:Osimertinib + antiangiogenesis 0    0  0.02 [0.00;    2.07]      .             .      0.02 [0.00; 2.070000e + 00]      .                 .     .       .
                                Almonertinib:Placebo 0    0  0.54 [0.01;   37.25]      .             .      0.54 [0.01; 3.725000e + 01]      .                 .     .       .
                         Almonertinib:antiangiogenesis 0    0  0.06 [0.00;    7.26]      .             .      0.06 [0.00; 7.260000e + 00]      .                 .     .       .
               Amivantamab  +  Lazertinib:Chemotherapy 0    0  0.45 [0.04;    5.31]      .             .      0.45 [0.04; 5.310000e + 00]      .                 .     .       .
                Amivantamab  +  Lazertinib:Dacomitinib 0    0  0.52 [0.01;   18.53]      .             .      0.52 [0.01; 1.853000e + 01]      .                 .     .       .
                  Amivantamab  +  Lazertinib:Erlotinib 0    0  0.52 [0.05;    4.95]      .             .      0.52 [0.05; 4.950000e + 00]      .                 .     .       .
     Amivantamab  +  Lazertinib:Erlotinib + chemotherapy 0    0  1.04 [0.04;   28.45]      .             .      1.04 [0.04; 2.845000e + 01]      .                 .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor 0    0  0.20 [0.00;    8.99]      .             .      0.20 [0.00; 8.990000e + 00]      .                 .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor 0    0  0.26 [0.02;    4.34]      .             .      0.26 [0.02; 4.340000e + 00]      .                 .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor 0    0  0.35 [0.03;    4.64]      .             .      0.35 [0.03; 4.640000e + 00]      .                 .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor 0    0  0.17 [0.00;    8.56]      .             .      0.17 [0.00; 8.560000e + 00]      .                 .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis 0    0  0.29 [0.03;    3.22]      .             .      0.29 [0.03; 3.220000e + 00]      .                 .     .       .
                  Amivantamab  +  Lazertinib:Gefitinib 0    0  0.54 [0.03;   11.39]      .             .      0.54 [0.03; 1.139000e + 01]      .                 .     .       .
        Amivantamab  +  Lazertinib:Gefitinib/Erlotinib 0    0  3.15 [0.22;   45.35]      .             .      3.15 [0.22; 4.535000e + 01]      .                 .     .       .
     Amivantamab  +  Lazertinib:Gefitinib + chemotherapy 0    0  0.74 [0.02;   33.13]      .             .      0.74 [0.02; 3.313000e + 01]      .                 .     .       .
   Amivantamab  +  Lazertinib:Gefitinib + PARP inhibitor 0    0  0.18 [0.00;   14.96]      .             .      0.18 [0.00; 1.496000e + 01]      .                 .     .       .
                   Amivantamab  +  Lazertinib:Icotinib 0    0  0.08 [0.00;    5.39]      .             .      0.08 [0.00; 5.390000e + 00]      .                 .     .       .
                 Amivantamab  +  Lazertinib:Lazertinib 1 0.91  0.63 [0.06;    6.28]   1.01 [0.09; 11.22]      0.00 [0.00; 1.077000e + 01] 222.99 [0.07; 761325.90]  1.30  0.1927
                Amivantamab  +  Lazertinib:Osimertinib 1 0.99  0.44 [0.09;    2.29]   0.40 [0.08;  2.09] 114324.16 [0.00; 1.698794e + 13]   0.00 [0.00;    563.94] -1.30  0.1927
   Amivantamab  +  Lazertinib:Osimertinib + chemotherapy 0    0  0.07 [0.00;    1.07]      .             .      0.07 [0.00; 1.070000e + 00]      .                 .     .       .
 Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis 0    0  0.03 [0.00;    0.44]      .             .      0.03 [0.00; 4.400000e-01]      .                 .     .       .
                    Amivantamab  +  Lazertinib:Placebo 0    0  0.88 [0.14;    5.42]      .             .      0.88 [0.14; 5.420000e + 00]      .                 .     .       .
             Amivantamab  +  Lazertinib:antiangiogenesis 0    0  0.09 [0.00;    2.14]      .             .      0.09 [0.00; 2.140000e + 00]      .                 .     .       .
                            Chemotherapy:Dacomitinib 0    0  1.15 [0.04;   33.68]      .             .      1.15 [0.04; 3.368000e + 01]      .                 .     .       .
                              Chemotherapy:Erlotinib 1 0.36  1.15 [0.17;    7.87]   2.77 [0.11; 68.50]      0.71 [0.06; 7.760000e + 00]   3.93 [0.07;    215.72]  0.67  0.5026
                 Chemotherapy:Erlotinib + chemotherapy 0    0  2.31 [0.10;   50.81]      .             .      2.31 [0.10; 5.081000e + 01]      .                 .     .       .
               Chemotherapy:Erlotinib + HER3 inhibitor 0    0  0.45 [0.01;   16.53]      .             .      0.45 [0.01; 1.653000e + 01]      .                 .     .       .
                Chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  0.57 [0.04;    7.44]      .             .      0.57 [0.04; 7.440000e + 00]      .                 .     .       .
                Chemotherapy:Erlotinib + MET inhibitor 0    0  0.77 [0.08;    7.75]      .             .      0.77 [0.08; 7.750000e + 00]      .                 .     .       .
                Chemotherapy:Erlotinib + MMP inhibitor 0    0  0.37 [0.01;   15.85]      .             .      0.37 [0.01; 1.585000e + 01]      .                 .     .       .
               Chemotherapy:Erlotinib + antiangiogenesis 0    0  0.64 [0.08;    5.26]      .             .      0.64 [0.08; 5.260000e + 00]      .                 .     .       .
                              Chemotherapy:Gefitinib 1 0.65  1.21 [0.09;   15.98]   0.34 [0.01;  8.44]     12.61 [0.16; 1.003940e + 03]   0.03 [0.00;      6.17] -1.30  0.1927
                    Chemotherapy:Gefitinib/Erlotinib 0    0  7.01 [0.41;  119.67]      .             .      7.01 [0.41; 1.196700e + 02]      .                 .     .       .
                 Chemotherapy:Gefitinib + chemotherapy 0    0  1.65 [0.05;   51.49]      .             .      1.65 [0.05; 5.149000e + 01]      .                 .     .       .
               Chemotherapy:Gefitinib + PARP inhibitor 0    0  0.40 [0.01;   24.56]      .             .      0.40 [0.01; 2.456000e + 01]      .                 .     .       .
                               Chemotherapy:Icotinib 0    0  0.17 [0.00;    8.74]      .             .      0.17 [0.00; 8.740000e + 00]      .                 .     .       .
                             Chemotherapy:Lazertinib 0    0  1.40 [0.12;   16.90]      .             .      1.40 [0.12; 1.690000e + 01]      .                 .     .       .
                            Chemotherapy:Osimertinib 1 0.39  0.99 [0.15;    6.64]   0.41 [0.02;  8.53]      1.75 [0.15; 2.012000e + 01]   0.23 [0.00;     11.51] -0.73  0.4636
               Chemotherapy:Osimertinib + chemotherapy 0    0  0.16 [0.01;    2.81]      .             .      0.16 [0.01; 2.810000e + 00]      .                 .     .       .
             Chemotherapy:Osimertinib + antiangiogenesis 0    0  0.07 [0.00;    1.15]      .             .      0.07 [0.00; 1.150000e + 00]      .                 .     .       .
                                Chemotherapy:Placebo 0    0  1.96 [0.29;   13.22]      .             .      1.96 [0.29; 1.322000e + 01]      .                 .     .       .
                         Chemotherapy:antiangiogenesis 0    0  0.21 [0.01;    3.78]      .             .      0.21 [0.01; 3.780000e + 00]      .                 .     .       .
                               Dacomitinib:Erlotinib 1 1.00  1.00 [0.06;   16.04]   1.00 [0.06; 16.04]         .                    .      .                 .     .       .
                  Dacomitinib:Erlotinib + chemotherapy 0    0  2.00 [0.05;   79.67]      .             .      2.00 [0.05; 7.967000e + 01]      .                 .     .       .
                Dacomitinib:Erlotinib + HER3 inhibitor 0    0  0.39 [0.01;   24.10]      .             .      0.39 [0.01; 2.410000e + 01]      .                 .     .       .
                 Dacomitinib:Erlotinib + IGF-1R inhibitor 0    0  0.49 [0.02;   12.85]      .             .      0.49 [0.02; 1.285000e + 01]      .                 .     .       .
                 Dacomitinib:Erlotinib + MET inhibitor 0    0  0.67 [0.03;   14.22]      .             .      0.67 [0.03; 1.422000e + 01]      .                 .     .       .
                 Dacomitinib:Erlotinib + MMP inhibitor 0    0  0.32 [0.00;   22.71]      .             .      0.32 [0.00; 2.271000e + 01]      .                 .     .       .
                Dacomitinib:Erlotinib + antiangiogenesis 0    0  0.55 [0.03;   10.15]      .             .      0.55 [0.03; 1.015000e + 01]      .                 .     .       .
                               Dacomitinib:Gefitinib 0    0  1.05 [0.02;   57.79]      .             .      1.05 [0.02; 5.779000e + 01]      .                 .     .       .
                     Dacomitinib:Gefitinib/Erlotinib 0    0  6.09 [0.13;  277.73]      .             .      6.09 [0.13; 2.777300e + 02]      .                 .     .       .
                  Dacomitinib:Gefitinib + chemotherapy 0    0  1.43 [0.01;  143.88]      .             .      1.43 [0.01; 1.438800e + 02]      .                 .     .       .
                Dacomitinib:Gefitinib + PARP inhibitor 0    0  0.34 [0.00;   58.89]      .             .      0.34 [0.00; 5.889000e + 01]      .                 .     .       .
                                Dacomitinib:Icotinib 0    0  0.15 [0.00;   21.77]      .             .      0.15 [0.00; 2.177000e + 01]      .                 .     .       .
                              Dacomitinib:Lazertinib 0    0  1.22 [0.03;   48.87]      .             .      1.22 [0.03; 4.887000e + 01]      .                 .     .       .
                             Dacomitinib:Osimertinib 0    0  0.86 [0.04;   20.82]      .             .      0.86 [0.04; 2.082000e + 01]      .                 .     .       .
                Dacomitinib:Osimertinib + chemotherapy 0    0  0.14 [0.00;    6.50]      .             .      0.14 [0.00; 6.500000e + 00]      .                 .     .       .
              Dacomitinib:Osimertinib + antiangiogenesis 0    0  0.06 [0.00;    2.69]      .             .      0.06 [0.00; 2.690000e + 00]      .                 .     .       .
                                 Dacomitinib:Placebo 0    0  1.70 [0.08;   38.42]      .             .      1.70 [0.08; 3.842000e + 01]      .                 .     .       .
                          Dacomitinib:antiangiogenesis 0    0  0.18 [0.01;    6.12]      .             .      0.18 [0.01; 6.120000e + 00]      .                 .     .       .
                    Erlotinib:Erlotinib + chemotherapy 1 1.00  2.00 [0.18;   22.59]   2.00 [0.18; 22.59]         .                    .      .                 .     .       .
                  Erlotinib:Erlotinib + HER3 inhibitor 1 1.00  0.39 [0.02;    8.24]   0.39 [0.02;  8.24]         .                    .      .                 .     .       .
                   Erlotinib:Erlotinib + IGF-1R inhibitor 1 1.00  0.49 [0.09;    2.72]   0.49 [0.09;  2.72]         .                    .      .                 .     .       .
                   Erlotinib:Erlotinib + MET inhibitor 2 1.00  0.67 [0.19;    2.39]   0.67 [0.19;  2.39]         .                    .      .                 .     .       .
                   Erlotinib:Erlotinib + MMP inhibitor 1 1.00  0.32 [0.01;    8.09]   0.32 [0.01;  8.09]         .                    .      .                 .     .       .
                  Erlotinib:Erlotinib + antiangiogenesis 6 1.00  0.55 [0.23;    1.33]   0.55 [0.23;  1.33]         .                    .      .                 .     .       .
                                 Erlotinib:Gefitinib 0    0  1.05 [0.06;   18.96]      .             .      1.05 [0.06; 1.896000e + 01]      .                 .     .       .
                       Erlotinib:Gefitinib/Erlotinib 0    0  6.09 [0.44;   84.12]      .             .      6.09 [0.44; 8.412000e + 01]      .                 .     .       .
                    Erlotinib:Gefitinib + chemotherapy 0    0  1.43 [0.04;   56.85]      .             .      1.43 [0.04; 5.685000e + 01]      .                 .     .       .
                  Erlotinib:Gefitinib + PARP inhibitor 0    0  0.34 [0.00;   26.11]      .             .      0.34 [0.00; 2.611000e + 01]      .                 .     .       .
                                  Erlotinib:Icotinib 0    0  0.15 [0.00;    9.37]      .             .      0.15 [0.00; 9.370000e + 00]      .                 .     .       .
                                Erlotinib:Lazertinib 0    0  1.22 [0.11;   13.92]      .             .      1.22 [0.11; 1.392000e + 01]      .                 .     .       .
                               Erlotinib:Osimertinib 0    0  0.86 [0.18;    4.14]      .             .      0.86 [0.18; 4.140000e + 00]      .                 .     .       .
                  Erlotinib:Osimertinib + chemotherapy 0    0  0.14 [0.01;    1.98]      .             .      0.14 [0.01; 1.980000e + 00]      .                 .     .       .
                Erlotinib:Osimertinib + antiangiogenesis 0    0  0.06 [0.00;    0.81]      .             .      0.06 [0.00; 8.100000e-01]      .                 .     .       .
                                   Erlotinib:Placebo 3 0.59  1.70 [0.41;    7.05]   2.50 [0.39; 15.87]      0.97 [0.10; 9.020000e + 00]   2.57 [0.14;     46.37]  0.64  0.5236
                            Erlotinib:antiangiogenesis 2 1.00  0.18 [0.02;    1.58]   0.18 [0.02;  1.58]         .                    .      .                 .     .       .
     Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor 0    0  0.20 [0.00;    9.60]      .             .      0.20 [0.00; 9.600000e + 00]      .                 .     .       .
      Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  0.25 [0.01;    4.79]      .             .      0.25 [0.01; 4.790000e + 00]      .                 .     .       .
      Erlotinib + chemotherapy:Erlotinib + MET inhibitor 0    0  0.34 [0.02;    5.19]      .             .      0.34 [0.02; 5.190000e + 00]      .                 .     .       .
      Erlotinib + chemotherapy:Erlotinib + MMP inhibitor 0    0  0.16 [0.00;    9.11]      .             .      0.16 [0.00; 9.110000e + 00]      .                 .     .       .
     Erlotinib + chemotherapy:Erlotinib + antiangiogenesis 0    0  0.28 [0.02;    3.64]      .             .      0.28 [0.02; 3.640000e + 00]      .                 .     .       .
                    Erlotinib + chemotherapy:Gefitinib 0    0  0.52 [0.01;   22.87]      .             .      0.52 [0.01; 2.287000e + 01]      .                 .     .       .
          Erlotinib + chemotherapy:Gefitinib/Erlotinib 0    0  3.04 [0.09;  108.51]      .             .      3.04 [0.09; 1.085100e + 02]      .                 .     .       .
       Erlotinib + chemotherapy:Gefitinib + chemotherapy 0    0  0.72 [0.01;   58.77]      .             .      0.72 [0.01; 5.877000e + 01]      .                 .     .       .
     Erlotinib + chemotherapy:Gefitinib + PARP inhibitor 0    0  0.17 [0.00;   24.58]      .             .      0.17 [0.00; 2.458000e + 01]      .                 .     .       .
                     Erlotinib + chemotherapy:Icotinib 0    0  0.07 [0.00;    9.03]      .             .      0.07 [0.00; 9.030000e + 00]      .                 .     .       .
                   Erlotinib + chemotherapy:Lazertinib 0    0  0.61 [0.02;   18.92]      .             .      0.61 [0.02; 1.892000e + 01]      .                 .     .       .
                  Erlotinib + chemotherapy:Osimertinib 0    0  0.43 [0.02;    7.71]      .             .      0.43 [0.02; 7.710000e + 00]      .                 .     .       .
     Erlotinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.07 [0.00;    2.54]      .             .      0.07 [0.00; 2.540000e + 00]      .                 .     .       .
   Erlotinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.03 [0.00;    1.05]      .             .      0.03 [0.00; 1.050000e + 00]      .                 .     .       .
                      Erlotinib + chemotherapy:Placebo 0    0  0.85 [0.05;   14.12]      .             .      0.85 [0.05; 1.412000e + 01]      .                 .     .       .
               Erlotinib + chemotherapy:antiangiogenesis 0    0  0.09 [0.00;    2.34]      .             .      0.09 [0.00; 2.340000e + 00]      .                 .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor 0    0  1.27 [0.04;   41.74]      .             .      1.27 [0.04; 4.174000e + 01]      .                 .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor 0    0  1.72 [0.06;   46.86]      .             .      1.72 [0.06; 4.686000e + 01]      .                 .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor 0    0  0.83 [0.01;   69.96]      .             .      0.83 [0.01; 6.996000e + 01]      .                 .     .       .
   Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis 0    0  1.42 [0.06;   33.83]      .             .      1.42 [0.06; 3.383000e + 01]      .                 .     .       .
                  Erlotinib + HER3 inhibitor:Gefitinib 0    0  2.68 [0.04;  179.94]      .             .      2.68 [0.04; 1.799400e + 02]      .                 .     .       .
        Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib 0    0 15.60 [0.28;  872.76]      .             .     15.60 [0.28; 8.727600e + 02]      .                 .     .       .
     Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy 0    0  3.67 [0.03;  437.21]      .             .      3.67 [0.03; 4.372100e + 02]      .                 .     .       .
   Erlotinib + HER3 inhibitor:Gefitinib + PARP inhibitor 0    0  0.88 [0.00;  175.93]      .             .      0.88 [0.00; 1.759300e + 02]      .                 .     .       .
                   Erlotinib + HER3 inhibitor:Icotinib 0    0  0.38 [0.00;   65.32]      .             .      0.38 [0.00; 6.532000e + 01]      .                 .     .       .
                 Erlotinib + HER3 inhibitor:Lazertinib 0    0  3.12 [0.06;  154.59]      .             .      3.12 [0.06; 1.545900e + 02]      .                 .     .       .
                Erlotinib + HER3 inhibitor:Osimertinib 0    0  2.20 [0.07;   67.94]      .             .      2.20 [0.07; 6.794000e + 01]      .                 .     .       .
   Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy 0    0  0.36 [0.01;   20.41]      .             .      0.36 [0.01; 2.041000e + 01]      .                 .     .       .
 Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis 0    0  0.15 [0.00;    8.47]      .             .      0.15 [0.00; 8.470000e + 00]      .                 .     .       .
                    Erlotinib + HER3 inhibitor:Placebo 0    0  4.35 [0.15;  126.02]      .             .      4.35 [0.15; 1.260200e + 02]      .                 .     .       .
             Erlotinib + HER3 inhibitor:antiangiogenesis 0    0  0.46 [0.01;   19.56]      .             .      0.46 [0.01; 1.956000e + 01]      .                 .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor 0    0  1.36 [0.16;   11.39]      .             .      1.36 [0.16; 1.139000e + 01]      .                 .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor 0    0  0.66 [0.02;   25.00]      .             .      0.66 [0.02; 2.500000e + 01]      .                 .     .       .
    Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis 0    0  1.12 [0.16;    7.60]      .             .      1.12 [0.16; 7.600000e + 00]      .                 .     .       .
                   Erlotinib + IGF-1R inhibitor:Gefitinib 0    0  2.11 [0.07;   60.99]      .             .      2.11 [0.07; 6.099000e + 01]      .                 .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib 0    0 12.30 [0.54;  281.71]      .             .     12.30 [0.54; 2.817100e + 02]      .                 .     .       .
      Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy 0    0  2.89 [0.05;  167.29]      .             .      2.89 [0.05; 1.672900e + 02]      .                 .     .       .
    Erlotinib + IGF-1R inhibitor:Gefitinib + PARP inhibitor 0    0  0.70 [0.01;   72.96]      .             .      0.70 [0.01; 7.296000e + 01]      .                 .     .       .
                    Erlotinib + IGF-1R inhibitor:Icotinib 0    0  0.30 [0.00;   26.53]      .             .      0.30 [0.00; 2.653000e + 01]      .                 .     .       .
                  Erlotinib + IGF-1R inhibitor:Lazertinib 0    0  2.46 [0.13;   48.13]      .             .      2.46 [0.13; 4.813000e + 01]      .                 .     .       .
                 Erlotinib + IGF-1R inhibitor:Osimertinib 0    0  1.73 [0.17;   17.64]      .             .      1.73 [0.17; 1.764000e + 01]      .                 .     .       .
    Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy 0    0  0.28 [0.01;    6.61]      .             .      0.28 [0.01; 6.610000e + 00]      .                 .     .       .
  Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis 0    0  0.12 [0.01;    2.72]      .             .      0.12 [0.01; 2.720000e + 00]      .                 .     .       .
                     Erlotinib + IGF-1R inhibitor:Placebo 0    0  3.43 [0.37;   31.64]      .             .      3.43 [0.37; 3.164000e + 01]      .                 .     .       .
              Erlotinib + IGF-1R inhibitor:antiangiogenesis 0    0  0.37 [0.02;    5.77]      .             .      0.37 [0.02; 5.770000e + 00]      .                 .     .       .
     Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor 0    0  0.48 [0.02;   15.33]      .             .      0.48 [0.02; 1.533000e + 01]      .                 .     .       .
    Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis 0    0  0.82 [0.18;    3.85]      .             .      0.82 [0.18; 3.850000e + 00]      .                 .     .       .
                   Erlotinib + MET inhibitor:Gefitinib 0    0  1.56 [0.07;   36.81]      .             .      1.56 [0.07; 3.681000e + 01]      .                 .     .       .
         Erlotinib + MET inhibitor:Gefitinib/Erlotinib 0    0  9.05 [0.49;  167.40]      .             .      9.05 [0.49; 1.674000e + 02]      .                 .     .       .
      Erlotinib + MET inhibitor:Gefitinib + chemotherapy 0    0  2.13 [0.04;  104.64]      .             .      2.13 [0.04; 1.046400e + 02]      .                 .     .       .
    Erlotinib + MET inhibitor:Gefitinib + PARP inhibitor 0    0  0.51 [0.01;   46.63]      .             .      0.51 [0.01; 4.663000e + 01]      .                 .     .       .
                    Erlotinib + MET inhibitor:Icotinib 0    0  0.22 [0.00;   16.87]      .             .      0.22 [0.00; 1.687000e + 01]      .                 .     .       .
                  Erlotinib + MET inhibitor:Lazertinib 0    0  1.81 [0.12;   28.26]      .             .      1.81 [0.12; 2.826000e + 01]      .                 .     .       .
                 Erlotinib + MET inhibitor:Osimertinib 0    0  1.27 [0.17;    9.64]      .             .      1.27 [0.17; 9.640000e + 00]      .                 .     .       .
    Erlotinib + MET inhibitor:Osimertinib + chemotherapy 0    0  0.21 [0.01;    3.93]      .             .      0.21 [0.01; 3.930000e + 00]      .                 .     .       .
  Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis 0    0  0.09 [0.00;    1.61]      .             .      0.09 [0.00; 1.610000e + 00]      .                 .     .       .
                     Erlotinib + MET inhibitor:Placebo 0    0  2.53 [0.38;   17.02]      .             .      2.53 [0.38; 1.702000e + 01]      .                 .     .       .
              Erlotinib + MET inhibitor:antiangiogenesis 0    0  0.27 [0.02;    3.32]      .             .      0.27 [0.02; 3.320000e + 00]      .                 .     .       .
    Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis 0    0  1.70 [0.06;   47.80]      .             .      1.70 [0.06; 4.780000e + 01]      .                 .     .       .
                   Erlotinib + MMP inhibitor:Gefitinib 0    0  3.22 [0.04;  244.72]      .             .      3.22 [0.04; 2.447200e + 02]      .                 .     .       .
         Erlotinib + MMP inhibitor:Gefitinib/Erlotinib 0    0 18.76 [0.29; 1193.37]      .             .     18.76 [0.29; 1.193370e + 03]      .                 .     .       .
      Erlotinib + MMP inhibitor:Gefitinib + chemotherapy 0    0  4.41 [0.03;  586.10]      .             .      4.41 [0.03; 5.861000e + 02]      .                 .     .       .
    Erlotinib + MMP inhibitor:Gefitinib + PARP inhibitor 0    0  1.06 [0.00;  233.44]      .             .      1.06 [0.00; 2.334400e + 02]      .                 .     .       .
                    Erlotinib + MMP inhibitor:Icotinib 0    0  0.46 [0.00;   86.90]      .             .      0.46 [0.00; 8.690000e + 01]      .                 .     .       .
                  Erlotinib + MMP inhibitor:Lazertinib 0    0  3.75 [0.07;  212.20]      .             .      3.75 [0.07; 2.122000e + 02]      .                 .     .       .
                 Erlotinib + MMP inhibitor:Osimertinib 0    0  2.64 [0.07;   94.90]      .             .      2.64 [0.07; 9.490000e + 01]      .                 .     .       .
    Erlotinib + MMP inhibitor:Osimertinib + chemotherapy 0    0  0.43 [0.01;   27.90]      .             .      0.43 [0.01; 2.790000e + 01]      .                 .     .       .
  Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis 0    0  0.19 [0.00;   11.58]      .             .      0.19 [0.00; 1.158000e + 01]      .                 .     .       .
                     Erlotinib + MMP inhibitor:Placebo 0    0  5.24 [0.16;  176.51]      .             .      5.24 [0.16; 1.765100e + 02]      .                 .     .       .
              Erlotinib + MMP inhibitor:antiangiogenesis 0    0  0.56 [0.01;   27.00]      .             .      0.56 [0.01; 2.700000e + 01]      .                 .     .       .
                  Erlotinib + antiangiogenesis:Gefitinib 0    0  1.89 [0.09;   39.06]      .             .      1.89 [0.09; 3.906000e + 01]      .                 .     .       .
        Erlotinib + antiangiogenesis:Gefitinib/Erlotinib 0    0 11.01 [0.69;  175.50]      .             .     11.01 [0.69; 1.755000e + 02]      .                 .     .       .
     Erlotinib + antiangiogenesis:Gefitinib + chemotherapy 0    0  2.59 [0.06;  114.01]      .             .      2.59 [0.06; 1.140100e + 02]      .                 .     .       .
   Erlotinib + antiangiogenesis:Gefitinib + PARP inhibitor 0    0  0.62 [0.01;   51.59]      .             .      0.62 [0.01; 5.159000e + 01]      .                 .     .       .
                   Erlotinib + antiangiogenesis:Icotinib 0    0  0.27 [0.00;   18.59]      .             .      0.27 [0.00; 1.859000e + 01]      .                 .     .       .
                 Erlotinib + antiangiogenesis:Lazertinib 0    0  2.20 [0.17;   29.34]      .             .      2.20 [0.17; 2.934000e + 01]      .                 .     .       .
                Erlotinib + antiangiogenesis:Osimertinib 0    0  1.55 [0.26;    9.40]      .             .      1.55 [0.26; 9.400000e + 00]      .                 .     .       .
   Erlotinib + antiangiogenesis:Osimertinib + chemotherapy 0    0  0.25 [0.02;    4.13]      .             .      0.25 [0.02; 4.130000e + 00]      .                 .     .       .
 Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.11 [0.01;    1.69]      .             .      0.11 [0.01; 1.690000e + 00]      .                 .     .       .
                    Erlotinib + antiangiogenesis:Placebo 0    0  3.07 [0.58;   16.35]      .             .      3.07 [0.58; 1.635000e + 01]      .                 .     .       .
             Erlotinib + antiangiogenesis:antiangiogenesis 0    0  0.33 [0.03;    3.39]      .             .      0.33 [0.03; 3.390000e + 00]      .                 .     .       .
                       Gefitinib:Gefitinib/Erlotinib 0    0  5.82 [0.19;  179.87]      .             .      5.82 [0.19; 1.798700e + 02]      .                 .     .       .
                    Gefitinib:Gefitinib + chemotherapy 2 1.00  1.37 [0.14;   13.27]   1.37 [0.14; 13.27]         .                    .      .                 .     .       .
                  Gefitinib:Gefitinib + PARP inhibitor 1 1.00  0.33 [0.01;    8.20]   0.33 [0.01;  8.20]         .                    .      .                 .     .       .
                                  Gefitinib:Icotinib 1 1.00  0.14 [0.01;    2.76]   0.14 [0.01;  2.76]         .                    .      .                 .     .       .
                                Gefitinib:Lazertinib 1 0.65  1.16 [0.09;   15.45]   0.33 [0.01;  8.15]     12.13 [0.15; 9.630200e + 02]   0.03 [0.00;      6.17] -1.30  0.1927
                               Gefitinib:Osimertinib 0    0  0.82 [0.05;   12.33]      .             .      0.82 [0.05; 1.233000e + 01]      .                 .     .       .
                  Gefitinib:Osimertinib + chemotherapy 0    0  0.13 [0.00;    4.21]      .             .      0.13 [0.00; 4.210000e + 00]      .                 .     .       .
                Gefitinib:Osimertinib + antiangiogenesis 0    0  0.06 [0.00;    1.74]      .             .      0.06 [0.00; 1.740000e + 00]      .                 .     .       .
                                   Gefitinib:Placebo 0    0  1.62 [0.10;   25.69]      .             .      1.62 [0.10; 2.569000e + 01]      .                 .     .       .
                            Gefitinib:antiangiogenesis 0    0  0.17 [0.00;    6.46]      .             .      0.17 [0.00; 6.460000e + 00]      .                 .     .       .
          Gefitinib/Erlotinib:Gefitinib + chemotherapy 0    0  0.24 [0.00;   14.40]      .             .      0.24 [0.00; 1.440000e + 01]      .                 .     .       .
        Gefitinib/Erlotinib:Gefitinib + PARP inhibitor 0    0  0.06 [0.00;    6.23]      .             .      0.06 [0.00; 6.230000e + 00]      .                 .     .       .
                        Gefitinib/Erlotinib:Icotinib 0    0  0.02 [0.00;    2.27]      .             .      0.02 [0.00; 2.270000e + 00]      .                 .     .       .
                      Gefitinib/Erlotinib:Lazertinib 0    0  0.20 [0.01;    3.58]      .             .      0.20 [0.01; 3.580000e + 00]      .                 .     .       .
                     Gefitinib/Erlotinib:Osimertinib 1 1.00  0.14 [0.02;    1.15]   0.14 [0.02;  1.15]         .                    .      .                 .     .       .
        Gefitinib/Erlotinib:Osimertinib + chemotherapy 0    0  0.02 [0.00;    0.46]      .             .      0.02 [0.00; 4.600000e-01]      .                 .     .       .
      Gefitinib/Erlotinib:Osimertinib + antiangiogenesis 0    0  0.01 [0.00;    0.19]      .             .      0.01 [0.00; 1.900000e-01]      .                 .     .       .
                         Gefitinib/Erlotinib:Placebo 0    0  0.28 [0.03;    2.64]      .             .      0.28 [0.03; 2.640000e + 00]      .                 .     .       .
                  Gefitinib/Erlotinib:antiangiogenesis 0    0  0.03 [0.00;    0.90]      .             .      0.03 [0.00; 9.000000e-01]      .                 .     .       .
     Gefitinib + chemotherapy:Gefitinib + PARP inhibitor 0    0  0.24 [0.00;   12.34]      .             .      0.24 [0.00; 1.234000e + 01]      .                 .     .       .
                     Gefitinib + chemotherapy:Icotinib 0    0  0.10 [0.00;    4.35]      .             .      0.10 [0.00; 4.350000e + 00]      .                 .     .       .
                   Gefitinib + chemotherapy:Lazertinib 0    0  0.85 [0.03;   26.58]      .             .      0.85 [0.03; 2.658000e + 01]      .                 .     .       .
                  Gefitinib + chemotherapy:Osimertinib 0    0  0.60 [0.02;   20.59]      .             .      0.60 [0.02; 2.059000e + 01]      .                 .     .       .
     Gefitinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.10 [0.00;    6.09]      .             .      0.10 [0.00; 6.090000e + 00]      .                 .     .       .
   Gefitinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.04 [0.00;    2.53]      .             .      0.04 [0.00; 2.530000e + 00]      .                 .     .       .
                      Gefitinib + chemotherapy:Placebo 0    0  1.19 [0.03;   42.39]      .             .      1.19 [0.03; 4.239000e + 01]      .                 .     .       .
               Gefitinib + chemotherapy:antiangiogenesis 0    0  0.13 [0.00;    9.08]      .             .      0.13 [0.00; 9.080000e + 00]      .                 .     .       .
                   Gefitinib + PARP inhibitor:Icotinib 0    0  0.43 [0.01;   34.10]      .             .      0.43 [0.01; 3.410000e + 01]      .                 .     .       .
                 Gefitinib + PARP inhibitor:Lazertinib 0    0  3.53 [0.06;  218.33]      .             .      3.53 [0.06; 2.183300e + 02]      .                 .     .       .
                Gefitinib + PARP inhibitor:Osimertinib 0    0  2.49 [0.04;  166.55]      .             .      2.49 [0.04; 1.665500e + 02]      .                 .     .       .
   Gefitinib + PARP inhibitor:Osimertinib + chemotherapy 0    0  0.41 [0.00;   45.36]      .             .      0.41 [0.00; 4.536000e + 01]      .                 .     .       .
 Gefitinib + PARP inhibitor:Osimertinib + antiangiogenesis 0    0  0.17 [0.00;   18.90]      .             .      0.17 [0.00; 1.890000e + 01]      .                 .     .       .
                    Gefitinib + PARP inhibitor:Placebo 0    0  4.93 [0.07;  340.93]      .             .      4.93 [0.07; 3.409300e + 02]      .                 .     .       .
             Gefitinib + PARP inhibitor:antiangiogenesis 0    0  0.53 [0.00;   66.40]      .             .      0.53 [0.00; 6.640000e + 01]      .                 .     .       .
                                 Icotinib:Lazertinib 0    0  8.23 [0.16;  422.09]      .             .      8.23 [0.16; 4.220900e + 02]      .                 .     .       .
                                Icotinib:Osimertinib 0    0  5.79 [0.10;  323.19]      .             .      5.79 [0.10; 3.231900e + 02]      .                 .     .       .
                   Icotinib:Osimertinib + chemotherapy 0    0  0.95 [0.01;   89.84]      .             .      0.95 [0.01; 8.984000e + 01]      .                 .     .       .
                 Icotinib:Osimertinib + antiangiogenesis 0    0  0.41 [0.00;   37.40]      .             .      0.41 [0.00; 3.740000e + 01]      .                 .     .       .
                                    Icotinib:Placebo 0    0 11.49 [0.20;  662.51]      .             .     11.49 [0.20; 6.625100e + 02]      .                 .     .       .
                             Icotinib:antiangiogenesis 0    0  1.22 [0.01;  132.11]      .             .      1.22 [0.01; 1.321100e + 02]      .                 .     .       .
                              Lazertinib:Osimertinib 1 0.84  0.70 [0.10;    5.08]   0.40 [0.05;  3.44]     14.67 [0.10; 2.130120e + 03]   0.03 [0.00;      6.17] -1.30  0.1927
                 Lazertinib:Osimertinib + chemotherapy 0    0  0.12 [0.01;    2.10]      .             .      0.12 [0.01; 2.100000e + 00]      .                 .     .       .
               Lazertinib:Osimertinib + antiangiogenesis 0    0  0.05 [0.00;    0.86]      .             .      0.05 [0.00; 8.600000e-01]      .                 .     .       .
                                  Lazertinib:Placebo 0    0  1.40 [0.17;   11.45]      .             .      1.40 [0.17; 1.145000e + 01]      .                 .     .       .
                           Lazertinib:antiangiogenesis 0    0  0.15 [0.01;    3.88]      .             .      0.15 [0.01; 3.880000e + 00]      .                 .     .       .
                Osimertinib:Osimertinib + chemotherapy 1 1.00  0.16 [0.02;    1.37]   0.16 [0.02;  1.37]         .                    .      .                 .     .       .
              Osimertinib:Osimertinib + antiangiogenesis 1 1.00  0.07 [0.01;    0.55]   0.07 [0.01;  0.55]         .                    .      .                 .     .       .
                                 Osimertinib:Placebo 2 0.95  1.98 [0.90;    4.39]   1.72 [0.76;  3.87]     41.52 [0.99; 1.734570e + 03]   0.04 [0.00;      1.88] -1.63  0.1021
                          Osimertinib:antiangiogenesis 0    0  0.21 [0.01;    3.08]      .             .      0.21 [0.01; 3.080000e + 00]      .                 .     .       .
 Osimertinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.43 [0.02;    8.27]      .             .      0.43 [0.02; 8.270000e + 00]      .                 .     .       .
                    Osimertinib + chemotherapy:Placebo 0    0 12.08 [1.25;  116.58]      .             .     12.08 [1.25; 1.165800e + 02]      .                 .     .       .
             Osimertinib + chemotherapy:antiangiogenesis 0    0  1.29 [0.04;   39.28]      .             .      1.29 [0.04; 3.928000e + 01]      .                 .     .       .
                  Osimertinib + antiangiogenesis:Placebo 0    0 28.26 [3.09;  258.73]      .             .     28.26 [3.09; 2.587300e + 02]      .                 .     .       .
           Osimertinib + antiangiogenesis:antiangiogenesis 0    0  3.01 [0.10;   88.76]      .             .      3.01 [0.10; 8.876000e + 01]      .                 .     .       .
                              antiangiogenesis:Placebo 0    0  9.39 [0.70;  125.51]      .             .      9.39 [0.70; 1.255100e + 02]      .                 .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

total-hypertension

Random effects model: 

                                               comparison k prop   nma          95%-CI direct        95%-CI indir.          95%-CI   RoR         95%-CI     z p-value
                          Afatinib:Afatinib + Cetuximab 1 1.00  1.65 [0.84;    3.28]   1.65 [0.84;  3.28]      .               .     .              .     .       .
                                    Afatinib:Almonertinib 0    0  0.57 [0.13;    2.56]      .             .   0.57 [0.13;    2.56]     .              .     .       .
                        Afatinib:Amivantamab  +  Lazertinib 0    0  0.92 [0.27;    3.09]      .             .   0.92 [0.27;    3.09]     .              .     .       .
                                    Afatinib:Chemotherapy 1 0.88  0.42 [0.20;    0.87]   0.45 [0.21;  0.98]   0.24 [0.03;    2.09]  1.85 [0.19;  18.21]  0.53  0.5970
                                     Afatinib:Dacomitinib 0    0  0.91 [0.22;    3.77]      .             .   0.91 [0.22;    3.77]     .              .     .       .
                                       Afatinib:Erlotinib 1 0.14  0.99 [0.29;    3.32]   0.34 [0.01;  8.25]   1.18 [0.32;    4.39]  0.28 [0.01;   9.02] -0.71  0.4748
                   Afatinib:Erlotinib + Autophagy inhibitor 0    0  1.88 [0.36;    9.89]      .             .   1.88 [0.36;    9.89]     .              .     .       .
                         Afatinib:Erlotinib + IGF-1R inhibitor 0    0  0.35 [0.07;    1.87]      .             .   0.35 [0.07;    1.87]     .              .     .       .
                         Afatinib:Erlotinib + MET inhibitor 0    0  0.33 [0.01;   10.15]      .             .   0.33 [0.01;   10.15]     .              .     .       .
                        Afatinib:Erlotinib + antiangiogenesis 0    0  0.20 [0.06;    0.70]      .             .   0.20 [0.06;    0.70]     .              .     .       .
                                       Afatinib:Gefitinib 1 0.16  0.72 [0.20;    2.62]   0.33 [0.01;  8.14]   0.84 [0.21;    3.44]  0.39 [0.01;  13.03] -0.52  0.6002
                             Afatinib:Gefitinib/Erlotinib 0    0  1.68 [0.45;    6.18]      .             .   1.68 [0.45;    6.18]     .              .     .       .
                          Afatinib:Gefitinib + chemotherapy 0    0  0.71 [0.18;    2.74]      .             .   0.71 [0.18;    2.74]     .              .     .       .
                        Afatinib:Gefitinib + antiangiogenesis 0    0  0.07 [0.02;    0.27]      .             .   0.07 [0.02;    0.27]     .              .     .       .
                                      Afatinib:Lazertinib 0    0  0.80 [0.24;    2.66]      .             .   0.80 [0.24;    2.66]     .              .     .       .
                                     Afatinib:Osimertinib 0    0  1.10 [0.38;    3.20]      .             .   1.10 [0.38;    3.20]     .              .     .       .
                        Afatinib:Osimertinib + chemotherapy 0    0  0.85 [0.24;    2.96]      .             .   0.85 [0.24;    2.96]     .              .     .       .
                      Afatinib:Osimertinib + antiangiogenesis 0    0  0.13 [0.04;    0.44]      .             .   0.13 [0.04;    0.44]     .              .     .       .
                                 Afatinib:PD-L1 inhibitor 0    0  2.50 [0.08;   78.99]      .             .   2.50 [0.08;   78.99]     .              .     .       .
                                         Afatinib:Placebo 1 0.16  0.78 [0.22;    2.82]   1.51 [0.06; 37.13]   0.69 [0.17;    2.80]  2.18 [0.07;  71.85]  0.44  0.6628
                                  Afatinib:antiangiogenesis 0    0  0.11 [0.03;    0.40]      .             .   0.11 [0.03;    0.40]     .              .     .       .
                      Afatinib + Cetuximab:Almonertinib 0    0  0.34 [0.07;    1.79]      .             .   0.34 [0.07;    1.79]     .              .     .       .
          Afatinib + Cetuximab:Amivantamab  +  Lazertinib 0    0  0.56 [0.14;    2.24]      .             .   0.56 [0.14;    2.24]     .              .     .       .
                      Afatinib + Cetuximab:Chemotherapy 0    0  0.25 [0.09;    0.69]      .             .   0.25 [0.09;    0.69]     .              .     .       .
                       Afatinib + Cetuximab:Dacomitinib 0    0  0.55 [0.11;    2.67]      .             .   0.55 [0.11;    2.67]     .              .     .       .
                         Afatinib + Cetuximab:Erlotinib 0    0  0.60 [0.15;    2.40]      .             .   0.60 [0.15;    2.40]     .              .     .       .
     Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor 0    0  1.14 [0.19;    6.84]      .             .   1.14 [0.19;    6.84]     .              .     .       .
           Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor 0    0  0.21 [0.03;    1.29]      .             .   0.21 [0.03;    1.29]     .              .     .       .
           Afatinib + Cetuximab:Erlotinib + MET inhibitor 0    0  0.20 [0.01;    6.57]      .             .   0.20 [0.01;    6.57]     .              .     .       .
          Afatinib + Cetuximab:Erlotinib + antiangiogenesis 0    0  0.12 [0.03;    0.50]      .             .   0.12 [0.03;    0.50]     .              .     .       .
                         Afatinib + Cetuximab:Gefitinib 0    0  0.44 [0.10;    1.88]      .             .   0.44 [0.10;    1.88]     .              .     .       .
               Afatinib + Cetuximab:Gefitinib/Erlotinib 0    0  1.01 [0.23;    4.42]      .             .   1.01 [0.23;    4.42]     .              .     .       .
            Afatinib + Cetuximab:Gefitinib + chemotherapy 0    0  0.43 [0.09;    1.95]      .             .   0.43 [0.09;    1.95]     .              .     .       .
          Afatinib + Cetuximab:Gefitinib + antiangiogenesis 0    0  0.04 [0.01;    0.19]      .             .   0.04 [0.01;    0.19]     .              .     .       .
                        Afatinib + Cetuximab:Lazertinib 0    0  0.49 [0.12;    1.93]      .             .   0.49 [0.12;    1.93]     .              .     .       .
                       Afatinib + Cetuximab:Osimertinib 0    0  0.66 [0.19;    2.36]      .             .   0.66 [0.19;    2.36]     .              .     .       .
          Afatinib + Cetuximab:Osimertinib + chemotherapy 0    0  0.51 [0.12;    2.13]      .             .   0.51 [0.12;    2.13]     .              .     .       .
        Afatinib + Cetuximab:Osimertinib + antiangiogenesis 0    0  0.08 [0.02;    0.32]      .             .   0.08 [0.02;    0.32]     .              .     .       .
                   Afatinib + Cetuximab:PD-L1 inhibitor 0    0  1.51 [0.04;   51.04]      .             .   1.51 [0.04;   51.04]     .              .     .       .
                           Afatinib + Cetuximab:Placebo 0    0  0.47 [0.11;    2.02]      .             .   0.47 [0.11;    2.02]     .              .     .       .
                    Afatinib + Cetuximab:antiangiogenesis 0    0  0.07 [0.02;    0.29]      .             .   0.07 [0.02;    0.29]     .              .     .       .
                    Almonertinib:Amivantamab  +  Lazertinib 0    0  1.62 [0.44;    6.05]      .             .   1.62 [0.44;    6.05]     .              .     .       .
                                Almonertinib:Chemotherapy 0    0  0.74 [0.18;    3.03]      .             .   0.74 [0.18;    3.03]     .              .     .       .
                                 Almonertinib:Dacomitinib 0    0  1.62 [0.61;    4.30]      .             .   1.62 [0.61;    4.30]     .              .     .       .
                                   Almonertinib:Erlotinib 0    0  1.74 [0.40;    7.69]      .             .   1.74 [0.40;    7.69]     .              .     .       .
               Almonertinib:Erlotinib + Autophagy inhibitor 0    0  3.32 [0.51;   21.49]      .             .   3.32 [0.51;   21.49]     .              .     .       .
                     Almonertinib:Erlotinib + IGF-1R inhibitor 0    0  0.62 [0.09;    4.05]      .             .   0.62 [0.09;    4.05]     .              .     .       .
                     Almonertinib:Erlotinib + MET inhibitor 0    0  0.58 [0.02;   19.92]      .             .   0.58 [0.02;   19.92]     .              .     .       .
                    Almonertinib:Erlotinib + antiangiogenesis 0    0  0.36 [0.08;    1.61]      .             .   0.36 [0.08;    1.61]     .              .     .       .
                                   Almonertinib:Gefitinib 1 1.00  1.28 [0.58;    2.79]   1.28 [0.58;  2.79]      .               .     .              .     .       .
                         Almonertinib:Gefitinib/Erlotinib 0    0  2.96 [0.67;   13.13]      .             .   2.96 [0.67;   13.13]     .              .     .       .
                      Almonertinib:Gefitinib + chemotherapy 0    0  1.25 [0.52;    3.03]      .             .   1.25 [0.52;    3.03]     .              .     .       .
                    Almonertinib:Gefitinib + antiangiogenesis 0    0  0.12 [0.05;    0.31]      .             .   0.12 [0.05;    0.31]     .              .     .       .
                                  Almonertinib:Lazertinib 0    0  1.42 [0.45;    4.53]      .             .   1.42 [0.45;    4.53]     .              .     .       .
                                 Almonertinib:Osimertinib 0    0  1.94 [0.54;    7.04]      .             .   1.94 [0.54;    7.04]     .              .     .       .
                    Almonertinib:Osimertinib + chemotherapy 0    0  1.50 [0.35;    6.33]      .             .   1.50 [0.35;    6.33]     .              .     .       .
                  Almonertinib:Osimertinib + antiangiogenesis 0    0  0.23 [0.05;    0.94]      .             .   0.23 [0.05;    0.94]     .              .     .       .
                             Almonertinib:PD-L1 inhibitor 0    0  4.42 [0.13;  150.26]      .             .   4.42 [0.13;  150.26]     .              .     .       .
                                     Almonertinib:Placebo 0    0  1.38 [0.30;    6.42]      .             .   1.38 [0.30;    6.42]     .              .     .       .
                              Almonertinib:antiangiogenesis 0    0  0.20 [0.04;    0.90]      .             .   0.20 [0.04;    0.90]     .              .     .       .
                    Amivantamab  +  Lazertinib:Chemotherapy 0    0  0.46 [0.16;    1.28]      .             .   0.46 [0.16;    1.28]     .              .     .       .
                     Amivantamab  +  Lazertinib:Dacomitinib 0    0  0.99 [0.30;    3.33]      .             .   0.99 [0.30;    3.33]     .              .     .       .
                       Amivantamab  +  Lazertinib:Erlotinib 0    0  1.07 [0.29;    3.99]      .             .   1.07 [0.29;    3.99]     .              .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor 0    0  2.04 [0.36;   11.58]      .             .   2.04 [0.36;   11.58]     .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor 0    0  0.38 [0.07;    2.18]      .             .   0.38 [0.07;    2.18]     .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor 0    0  0.36 [0.01;   11.45]      .             .   0.36 [0.01;   11.45]     .              .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis 0    0  0.22 [0.06;    0.84]      .             .   0.22 [0.06;    0.84]     .              .     .       .
                       Amivantamab  +  Lazertinib:Gefitinib 0    0  0.78 [0.27;    2.26]      .             .   0.78 [0.27;    2.26]     .              .     .       .
             Amivantamab  +  Lazertinib:Gefitinib/Erlotinib 0    0  1.82 [0.68;    4.90]      .             .   1.82 [0.68;    4.90]     .              .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + chemotherapy 0    0  0.77 [0.25;    2.39]      .             .   0.77 [0.25;    2.39]     .              .     .       .
        Amivantamab  +  Lazertinib:Gefitinib + antiangiogenesis 0    0  0.07 [0.02;    0.24]      .             .   0.07 [0.02;    0.24]     .              .     .       .
                      Amivantamab  +  Lazertinib:Lazertinib 1 0.96  0.87 [0.43;    1.76]   0.81 [0.40;  1.65]   7.17 [0.19;  278.20]  0.11 [0.00;   4.68] -1.15  0.2507
                     Amivantamab  +  Lazertinib:Osimertinib 1 0.98  1.20 [0.63;    2.28]   1.27 [0.66;  2.44]   0.11 [0.00;    6.87] 11.75 [0.18; 786.43]  1.15  0.2507
        Amivantamab  +  Lazertinib:Osimertinib + chemotherapy 0    0  0.92 [0.37;    2.30]      .             .   0.92 [0.37;    2.30]     .              .     .       .
      Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis 0    0  0.14 [0.06;    0.34]      .             .   0.14 [0.06;    0.34]     .              .     .       .
                 Amivantamab  +  Lazertinib:PD-L1 inhibitor 0    0  2.72 [0.10;   77.22]      .             .   2.72 [0.10;   77.22]     .              .     .       .
                         Amivantamab  +  Lazertinib:Placebo 0    0  0.85 [0.22;    3.34]      .             .   0.85 [0.22;    3.34]     .              .     .       .
                  Amivantamab  +  Lazertinib:antiangiogenesis 0    0  0.12 [0.03;    0.48]      .             .   0.12 [0.03;    0.48]     .              .     .       .
                                 Chemotherapy:Dacomitinib 0    0  2.18 [0.59;    8.06]      .             .   2.18 [0.59;    8.06]     .              .     .       .
                                   Chemotherapy:Erlotinib 3 0.49  2.35 [0.78;    7.10]   4.16 [0.86; 20.13]   1.36 [0.29;    6.38]  3.07 [0.34;  28.01]  0.99  0.3201
               Chemotherapy:Erlotinib + Autophagy inhibitor 0    0  4.48 [0.92;   21.79]      .             .   4.48 [0.92;   21.79]     .              .     .       .
                     Chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  0.83 [0.17;    4.11]      .             .   0.83 [0.17;    4.11]     .              .     .       .
                     Chemotherapy:Erlotinib + MET inhibitor 0    0  0.79 [0.03;   23.30]      .             .   0.79 [0.03;   23.30]     .              .     .       .
                    Chemotherapy:Erlotinib + antiangiogenesis 0    0  0.48 [0.16;    1.50]      .             .   0.48 [0.16;    1.50]     .              .     .       .
                                   Chemotherapy:Gefitinib 0    0  1.72 [0.53;    5.54]      .             .   1.72 [0.53;    5.54]     .              .     .       .
                         Chemotherapy:Gefitinib/Erlotinib 0    0  3.99 [1.29;   12.29]      .             .   3.99 [1.29;   12.29]     .              .     .       .
                      Chemotherapy:Gefitinib + chemotherapy 0    0  1.69 [0.49;    5.83]      .             .   1.69 [0.49;    5.83]     .              .     .       .
                    Chemotherapy:Gefitinib + antiangiogenesis 0    0  0.16 [0.05;    0.59]      .             .   0.16 [0.05;    0.59]     .              .     .       .
                                  Chemotherapy:Lazertinib 0    0  1.92 [0.69;    5.34]      .             .   1.92 [0.69;    5.34]     .              .     .       .
                                 Chemotherapy:Osimertinib 1 0.82  2.62 [1.13;    6.06]   2.38 [0.94;  6.00]   4.08 [0.56;   29.94]  0.58 [0.06;   5.26] -0.48  0.6313
                    Chemotherapy:Osimertinib + chemotherapy 0    0  2.02 [0.70;    5.83]      .             .   2.02 [0.70;    5.83]     .              .     .       .
                  Chemotherapy:Osimertinib + antiangiogenesis 0    0  0.30 [0.11;    0.87]      .             .   0.30 [0.11;    0.87]     .              .     .       .
                             Chemotherapy:PD-L1 inhibitor 0    0  5.95 [0.20;  176.48]      .             .   5.95 [0.20;  176.48]     .              .     .       .
                                     Chemotherapy:Placebo 0    0  1.86 [0.57;    6.12]      .             .   1.86 [0.57;    6.12]     .              .     .       .
                              Chemotherapy:antiangiogenesis 0    0  0.27 [0.08;    0.87]      .             .   0.27 [0.08;    0.87]     .              .     .       .
                                    Dacomitinib:Erlotinib 0    0  1.08 [0.27;    4.33]      .             .   1.08 [0.27;    4.33]     .              .     .       .
                Dacomitinib:Erlotinib + Autophagy inhibitor 0    0  2.06 [0.34;   12.35]      .             .   2.06 [0.34;   12.35]     .              .     .       .
                      Dacomitinib:Erlotinib + IGF-1R inhibitor 0    0  0.38 [0.06;    2.33]      .             .   0.38 [0.06;    2.33]     .              .     .       .
                      Dacomitinib:Erlotinib + MET inhibitor 0    0  0.36 [0.01;   11.86]      .             .   0.36 [0.01;   11.86]     .              .     .       .
                     Dacomitinib:Erlotinib + antiangiogenesis 0    0  0.22 [0.05;    0.91]      .             .   0.22 [0.05;    0.91]     .              .     .       .
                                    Dacomitinib:Gefitinib 1 1.00  0.79 [0.44;    1.42]   0.79 [0.44;  1.42]      .               .     .              .     .       .
                          Dacomitinib:Gefitinib/Erlotinib 0    0  1.83 [0.45;    7.40]      .             .   1.83 [0.45;    7.40]     .              .     .       .
                       Dacomitinib:Gefitinib + chemotherapy 0    0  0.77 [0.38;    1.58]      .             .   0.77 [0.38;    1.58]     .              .     .       .
                     Dacomitinib:Gefitinib + antiangiogenesis 0    0  0.07 [0.03;    0.16]      .             .   0.07 [0.03;    0.16]     .              .     .       .
                                   Dacomitinib:Lazertinib 0    0  0.88 [0.31;    2.48]      .             .   0.88 [0.31;    2.48]     .              .     .       .
                                  Dacomitinib:Osimertinib 0    0  1.20 [0.37;    3.90]      .             .   1.20 [0.37;    3.90]     .              .     .       .
                     Dacomitinib:Osimertinib + chemotherapy 0    0  0.93 [0.24;    3.56]      .             .   0.93 [0.24;    3.56]     .              .     .       .
                   Dacomitinib:Osimertinib + antiangiogenesis 0    0  0.14 [0.04;    0.53]      .             .   0.14 [0.04;    0.53]     .              .     .       .
                              Dacomitinib:PD-L1 inhibitor 0    0  2.73 [0.08;   89.46]      .             .   2.73 [0.08;   89.46]     .              .     .       .
                                      Dacomitinib:Placebo 0    0  0.86 [0.20;    3.63]      .             .   0.86 [0.20;    3.63]     .              .     .       .
                               Dacomitinib:antiangiogenesis 0    0  0.12 [0.03;    0.51]      .             .   0.12 [0.03;    0.51]     .              .     .       .
                  Erlotinib:Erlotinib + Autophagy inhibitor 1 1.00  1.90 [0.61;    5.91]   1.90 [0.61;  5.91]      .               .     .              .     .       .
                        Erlotinib:Erlotinib + IGF-1R inhibitor 1 1.00  0.35 [0.11;    1.12]   0.35 [0.11;  1.12]      .               .     .              .     .       .
                        Erlotinib:Erlotinib + MET inhibitor 1 1.00  0.33 [0.01;    8.23]   0.33 [0.01;  8.23]      .               .     .              .     .       .
                       Erlotinib:Erlotinib + antiangiogenesis 9 0.97  0.21 [0.16;    0.26]   0.21 [0.17;  0.27]   0.12 [0.03;    0.44]  1.82 [0.47;   7.06]  0.87  0.3854
                                      Erlotinib:Gefitinib 0    0  0.73 [0.21;    2.58]      .             .   0.73 [0.21;    2.58]     .              .     .       .
                            Erlotinib:Gefitinib/Erlotinib 0    0  1.70 [0.41;    7.03]      .             .   1.70 [0.41;    7.03]     .              .     .       .
                         Erlotinib:Gefitinib + chemotherapy 0    0  0.72 [0.19;    2.70]      .             .   0.72 [0.19;    2.70]     .              .     .       .
                       Erlotinib:Gefitinib + antiangiogenesis 0    0  0.07 [0.02;    0.27]      .             .   0.07 [0.02;    0.27]     .              .     .       .
                                     Erlotinib:Lazertinib 0    0  0.81 [0.23;    2.88]      .             .   0.81 [0.23;    2.88]     .              .     .       .
                                    Erlotinib:Osimertinib 0    0  1.11 [0.33;    3.72]      .             .   1.11 [0.33;    3.72]     .              .     .       .
                       Erlotinib:Osimertinib + chemotherapy 0    0  0.86 [0.22;    3.38]      .             .   0.86 [0.22;    3.38]     .              .     .       .
                     Erlotinib:Osimertinib + antiangiogenesis 0    0  0.13 [0.03;    0.50]      .             .   0.13 [0.03;    0.50]     .              .     .       .
                                Erlotinib:PD-L1 inhibitor 0    0  2.53 [0.08;   83.73]      .             .   2.53 [0.08;   83.73]     .              .     .       .
                                        Erlotinib:Placebo 1 0.92  0.79 [0.42;    1.49]   0.76 [0.40;  1.47]   1.22 [0.13;   11.25]  0.62 [0.06;   6.31] -0.40  0.6895
                                 Erlotinib:antiangiogenesis 2 0.83  0.12 [0.07;    0.18]   0.11 [0.07;  0.18]   0.15 [0.05;    0.45]  0.70 [0.22;   2.26] -0.60  0.5497
    Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.19 [0.04;    0.94]      .             .   0.19 [0.04;    0.94]     .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor 0    0  0.18 [0.01;    5.25]      .             .   0.18 [0.01;    5.25]     .              .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis 0    0  0.11 [0.03;    0.34]      .             .   0.11 [0.03;    0.34]     .              .     .       .
                  Erlotinib + Autophagy inhibitor:Gefitinib 0    0  0.38 [0.07;    2.09]      .             .   0.38 [0.07;    2.09]     .              .     .       .
        Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib 0    0  0.89 [0.14;    5.48]      .             .   0.89 [0.14;    5.48]     .              .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy 0    0  0.38 [0.07;    2.15]      .             .   0.38 [0.07;    2.15]     .              .     .       .
   Erlotinib + Autophagy inhibitor:Gefitinib + antiangiogenesis 0    0  0.04 [0.01;    0.21]      .             .   0.04 [0.01;    0.21]     .              .     .       .
                 Erlotinib + Autophagy inhibitor:Lazertinib 0    0  0.43 [0.08;    2.33]      .             .   0.43 [0.08;    2.33]     .              .     .       .
                Erlotinib + Autophagy inhibitor:Osimertinib 0    0  0.58 [0.11;    3.06]      .             .   0.58 [0.11;    3.06]     .              .     .       .
   Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy 0    0  0.45 [0.08;    2.67]      .             .   0.45 [0.08;    2.67]     .              .     .       .
 Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis 0    0  0.07 [0.01;    0.40]      .             .   0.07 [0.01;    0.40]     .              .     .       .
            Erlotinib + Autophagy inhibitor:PD-L1 inhibitor 0    0  1.33 [0.03;   52.55]      .             .   1.33 [0.03;   52.55]     .              .     .       .
                    Erlotinib + Autophagy inhibitor:Placebo 0    0  0.42 [0.11;    1.52]      .             .   0.42 [0.11;    1.52]     .              .     .       .
             Erlotinib + Autophagy inhibitor:antiangiogenesis 0    0  0.06 [0.02;    0.20]      .             .   0.06 [0.02;    0.20]     .              .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor 0    0  0.95 [0.03;   28.52]      .             .   0.95 [0.03;   28.52]     .              .     .       .
         Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis 0    0  0.58 [0.18;    1.89]      .             .   0.58 [0.18;    1.89]     .              .     .       .
                        Erlotinib + IGF-1R inhibitor:Gefitinib 0    0  2.07 [0.37;   11.44]      .             .   2.07 [0.37;   11.44]     .              .     .       .
              Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib 0    0  4.80 [0.77;   29.98]      .             .   4.80 [0.77;   29.98]     .              .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy 0    0  2.03 [0.35;   11.78]      .             .   2.03 [0.35;   11.78]     .              .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib + antiangiogenesis 0    0  0.20 [0.03;    1.17]      .             .   0.20 [0.03;    1.17]     .              .     .       .
                       Erlotinib + IGF-1R inhibitor:Lazertinib 0    0  2.31 [0.42;   12.78]      .             .   2.31 [0.42;   12.78]     .              .     .       .
                      Erlotinib + IGF-1R inhibitor:Osimertinib 0    0  3.15 [0.59;   16.77]      .             .   3.15 [0.59;   16.77]     .              .     .       .
         Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy 0    0  2.43 [0.40;   14.60]      .             .   2.43 [0.40;   14.60]     .              .     .       .
       Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis 0    0  0.37 [0.06;    2.18]      .             .   0.37 [0.06;    2.18]     .              .     .       .
                  Erlotinib + IGF-1R inhibitor:PD-L1 inhibitor 0    0  7.16 [0.18;  285.32]      .             .   7.16 [0.18;  285.32]     .              .     .       .
                          Erlotinib + IGF-1R inhibitor:Placebo 0    0  2.24 [0.60;    8.37]      .             .   2.24 [0.60;    8.37]     .              .     .       .
                   Erlotinib + IGF-1R inhibitor:antiangiogenesis 0    0  0.33 [0.09;    1.12]      .             .   0.33 [0.09;    1.12]     .              .     .       .
         Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis 0    0  0.62 [0.02;   15.27]      .             .   0.62 [0.02;   15.27]     .              .     .       .
                        Erlotinib + MET inhibitor:Gefitinib 0    0  2.18 [0.07;   68.27]      .             .   2.18 [0.07;   68.27]     .              .     .       .
              Erlotinib + MET inhibitor:Gefitinib/Erlotinib 0    0  5.07 [0.15;  168.57]      .             .   5.07 [0.15;  168.57]     .              .     .       .
           Erlotinib + MET inhibitor:Gefitinib + chemotherapy 0    0  2.14 [0.07;   68.64]      .             .   2.14 [0.07;   68.64]     .              .     .       .
         Erlotinib + MET inhibitor:Gefitinib + antiangiogenesis 0    0  0.21 [0.01;    6.72]      .             .   0.21 [0.01;    6.72]     .              .     .       .
                       Erlotinib + MET inhibitor:Lazertinib 0    0  2.43 [0.08;   76.19]      .             .   2.43 [0.08;   76.19]     .              .     .       .
                      Erlotinib + MET inhibitor:Osimertinib 0    0  3.33 [0.11;  102.05]      .             .   3.33 [0.11;  102.05]     .              .     .       .
         Erlotinib + MET inhibitor:Osimertinib + chemotherapy 0    0  2.57 [0.08;   83.62]      .             .   2.57 [0.08;   83.62]     .              .     .       .
       Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis 0    0  0.39 [0.01;   12.52]      .             .   0.39 [0.01;   12.52]     .              .     .       .
                  Erlotinib + MET inhibitor:PD-L1 inhibitor 0    0  7.56 [0.07;  868.66]      .             .   7.56 [0.07;  868.66]     .              .     .       .
                          Erlotinib + MET inhibitor:Placebo 0    0  2.37 [0.09;   62.01]      .             .   2.37 [0.09;   62.01]     .              .     .       .
                   Erlotinib + MET inhibitor:antiangiogenesis 0    0  0.34 [0.01;    8.73]      .             .   0.34 [0.01;    8.73]     .              .     .       .
                       Erlotinib + antiangiogenesis:Gefitinib 0    0  3.55 [0.99;   12.74]      .             .   3.55 [0.99;   12.74]     .              .     .       .
             Erlotinib + antiangiogenesis:Gefitinib/Erlotinib 0    0  8.24 [1.95;   34.70]      .             .   8.24 [1.95;   34.70]     .              .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + chemotherapy 0    0  3.48 [0.91;   13.33]      .             .   3.48 [0.91;   13.33]     .              .     .       .
        Erlotinib + antiangiogenesis:Gefitinib + antiangiogenesis 0    0  0.34 [0.08;    1.34]      .             .   0.34 [0.08;    1.34]     .              .     .       .
                      Erlotinib + antiangiogenesis:Lazertinib 0    0  3.96 [1.10;   14.26]      .             .   3.96 [1.10;   14.26]     .              .     .       .
                     Erlotinib + antiangiogenesis:Osimertinib 0    0  5.41 [1.59;   18.45]      .             .   5.41 [1.59;   18.45]     .              .     .       .
        Erlotinib + antiangiogenesis:Osimertinib + chemotherapy 0    0  4.17 [1.04;   16.71]      .             .   4.17 [1.04;   16.71]     .              .     .       .
      Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.63 [0.16;    2.49]      .             .   0.63 [0.16;    2.49]     .              .     .       .
                 Erlotinib + antiangiogenesis:PD-L1 inhibitor 0    0 12.29 [0.37;  409.34]      .             .  12.29 [0.37;  409.34]     .              .     .       .
                         Erlotinib + antiangiogenesis:Placebo 0    0  3.85 [1.97;    7.54]      .             .   3.85 [1.97;    7.54]     .              .     .       .
                  Erlotinib + antiangiogenesis:antiangiogenesis 1 0.29  0.56 [0.35;    0.90]   0.86 [0.35;  2.07]   0.47 [0.27;    0.83]  1.83 [0.64;   5.22]  1.13  0.2601
                            Gefitinib:Gefitinib/Erlotinib 0    0  2.32 [0.65;    8.24]      .             .   2.32 [0.65;    8.24]     .              .     .       .
                         Gefitinib:Gefitinib + chemotherapy 4 1.00  0.98 [0.65;    1.48]   0.98 [0.65;  1.48]      .               .     .              .     .       .
                       Gefitinib:Gefitinib + antiangiogenesis 2 1.00  0.09 [0.06;    0.16]   0.09 [0.06;  0.16]      .               .     .              .     .       .
                                     Gefitinib:Lazertinib 1 0.84  1.11 [0.47;    2.62]   1.39 [0.55;  3.53]   0.36 [0.04;    2.97]  3.88 [0.38;  39.14]  1.15  0.2507
                                    Gefitinib:Osimertinib 0    0  1.52 [0.55;    4.23]      .             .   1.52 [0.55;    4.23]     .              .     .       .
                       Gefitinib:Osimertinib + chemotherapy 0    0  1.17 [0.35;    3.94]      .             .   1.17 [0.35;    3.94]     .              .     .       .
                     Gefitinib:Osimertinib + antiangiogenesis 0    0  0.18 [0.05;    0.59]      .             .   0.18 [0.05;    0.59]     .              .     .       .
                                Gefitinib:PD-L1 inhibitor 0    0  3.46 [0.11;  107.89]      .             .   3.46 [0.11;  107.89]     .              .     .       .
                                        Gefitinib:Placebo 1 0.17  1.08 [0.29;    4.06]   0.32 [0.01;  7.99]   1.39 [0.33;    5.90]  0.23 [0.01;   7.86] -0.81  0.4175
                                 Gefitinib:antiangiogenesis 1 0.39  0.16 [0.04;    0.57]   0.06 [0.01;  0.50]   0.28 [0.05;    1.43]  0.23 [0.02;   3.20] -1.09  0.2742
               Gefitinib/Erlotinib:Gefitinib + chemotherapy 0    0  0.42 [0.11;    1.60]      .             .   0.42 [0.11;    1.60]     .              .     .       .
             Gefitinib/Erlotinib:Gefitinib + antiangiogenesis 0    0  0.04 [0.01;    0.16]      .             .   0.04 [0.01;    0.16]     .              .     .       .
                           Gefitinib/Erlotinib:Lazertinib 0    0  0.48 [0.17;    1.34]      .             .   0.48 [0.17;    1.34]     .              .     .       .
                          Gefitinib/Erlotinib:Osimertinib 1 1.00  0.66 [0.31;    1.39]   0.66 [0.31;  1.39]      .               .     .              .     .       .
             Gefitinib/Erlotinib:Osimertinib + chemotherapy 0    0  0.51 [0.19;    1.37]      .             .   0.51 [0.19;    1.37]     .              .     .       .
           Gefitinib/Erlotinib:Osimertinib + antiangiogenesis 0    0  0.08 [0.03;    0.20]      .             .   0.08 [0.03;    0.20]     .              .     .       .
                      Gefitinib/Erlotinib:PD-L1 inhibitor 0    0  1.49 [0.05;   43.33]      .             .   1.49 [0.05;   43.33]     .              .     .       .
                              Gefitinib/Erlotinib:Placebo 0    0  0.47 [0.11;    2.04]      .             .   0.47 [0.11;    2.04]     .              .     .       .
                       Gefitinib/Erlotinib:antiangiogenesis 0    0  0.07 [0.02;    0.29]      .             .   0.07 [0.02;    0.29]     .              .     .       .
          Gefitinib + chemotherapy:Gefitinib + antiangiogenesis 0    0  0.10 [0.05;    0.19]      .             .   0.10 [0.05;    0.19]     .              .     .       .
                        Gefitinib + chemotherapy:Lazertinib 0    0  1.14 [0.44;    2.93]      .             .   1.14 [0.44;    2.93]     .              .     .       .
                       Gefitinib + chemotherapy:Osimertinib 0    0  1.55 [0.52;    4.67]      .             .   1.55 [0.52;    4.67]     .              .     .       .
          Gefitinib + chemotherapy:Osimertinib + chemotherapy 0    0  1.20 [0.33;    4.30]      .             .   1.20 [0.33;    4.30]     .              .     .       .
        Gefitinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.18 [0.05;    0.64]      .             .   0.18 [0.05;    0.64]     .              .     .       .
                   Gefitinib + chemotherapy:PD-L1 inhibitor 0    0  3.53 [0.11;  112.68]      .             .   3.53 [0.11;  112.68]     .              .     .       .
                           Gefitinib + chemotherapy:Placebo 0    0  1.11 [0.28;    4.40]      .             .   1.11 [0.28;    4.40]     .              .     .       .
                    Gefitinib + chemotherapy:antiangiogenesis 0    0  0.16 [0.04;    0.62]      .             .   0.16 [0.04;    0.62]     .              .     .       .
                      Gefitinib + antiangiogenesis:Lazertinib 0    0 11.80 [4.32;   32.17]      .             .  11.80 [4.32;   32.17]     .              .     .       .
                     Gefitinib + antiangiogenesis:Osimertinib 0    0 16.12 [5.11;   50.89]      .             .  16.12 [5.11;   50.89]     .              .     .       .
        Gefitinib + antiangiogenesis:Osimertinib + chemotherapy 0    0 12.43 [3.32;   46.54]      .             .  12.43 [3.32;   46.54]     .              .     .       .
      Gefitinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  1.87 [0.50;    6.92]      .             .   1.87 [0.50;    6.92]     .              .     .       .
                 Gefitinib + antiangiogenesis:PD-L1 inhibitor 0    0 36.64 [1.13; 1188.60]      .             .  36.64 [1.13; 1188.60]     .              .     .       .
                         Gefitinib + antiangiogenesis:Placebo 0    0 11.48 [2.77;   47.53]      .             .  11.48 [2.77;   47.53]     .              .     .       .
                  Gefitinib + antiangiogenesis:antiangiogenesis 0    0  1.67 [0.42;    6.66]      .             .   1.67 [0.42;    6.66]     .              .     .       .
                                   Lazertinib:Osimertinib 1 0.90  1.37 [0.68;    2.76]   1.57 [0.75;  3.30]   0.41 [0.05;    3.62]  3.88 [0.38;  39.14]  1.15  0.2507
                      Lazertinib:Osimertinib + chemotherapy 0    0  1.05 [0.40;    2.74]      .             .   1.05 [0.40;    2.74]     .              .     .       .
                    Lazertinib:Osimertinib + antiangiogenesis 0    0  0.16 [0.06;    0.41]      .             .   0.16 [0.06;    0.41]     .              .     .       .
                               Lazertinib:PD-L1 inhibitor 0    0  3.11 [0.11;   89.28]      .             .   3.11 [0.11;   89.28]     .              .     .       .
                                       Lazertinib:Placebo 0    0  0.97 [0.26;    3.65]      .             .   0.97 [0.26;    3.65]     .              .     .       .
                                Lazertinib:antiangiogenesis 0    0  0.14 [0.04;    0.52]      .             .   0.14 [0.04;    0.52]     .              .     .       .
                     Osimertinib:Osimertinib + chemotherapy 2 1.00  0.77 [0.40;    1.48]   0.77 [0.40;  1.48]      .               .     .              .     .       .
                   Osimertinib:Osimertinib + antiangiogenesis 3 1.00  0.12 [0.06;    0.22]   0.12 [0.06;  0.22]      .               .     .              .     .       .
                              Osimertinib:PD-L1 inhibitor 1 1.00  2.27 [0.09;   60.64]   2.27 [0.09; 60.64]      .               .     .              .     .       .
                                      Osimertinib:Placebo 1 0.16  0.71 [0.20;    2.53]   3.06 [0.12; 75.44]   0.54 [0.14;    2.16]  5.64 [0.17; 184.44]  0.97  0.3313
                               Osimertinib:antiangiogenesis 0    0  0.10 [0.03;    0.36]      .             .   0.10 [0.03;    0.36]     .              .     .       .
      Osimertinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.15 [0.06;    0.37]      .             .   0.15 [0.06;    0.37]     .              .     .       .
                 Osimertinib + chemotherapy:PD-L1 inhibitor 0    0  2.95 [0.10;   83.82]      .             .   2.95 [0.10;   83.82]     .              .     .       .
                         Osimertinib + chemotherapy:Placebo 0    0  0.92 [0.22;    3.83]      .             .   0.92 [0.22;    3.83]     .              .     .       .
                  Osimertinib + chemotherapy:antiangiogenesis 0    0  0.13 [0.03;    0.55]      .             .   0.13 [0.03;    0.55]     .              .     .       .
               Osimertinib + antiangiogenesis:PD-L1 inhibitor 0    0 19.61 [0.69;  555.25]      .             .  19.61 [0.69;  555.25]     .              .     .       .
                       Osimertinib + antiangiogenesis:Placebo 0    0  6.14 [1.50;   25.25]      .             .   6.14 [1.50;   25.25]     .              .     .       .
                Osimertinib + antiangiogenesis:antiangiogenesis 0    0  0.89 [0.22;    3.61]      .             .   0.89 [0.22;    3.61]     .              .     .       .
                                  PD-L1 inhibitor:Placebo 0    0  0.31 [0.01;   10.58]      .             .   0.31 [0.01;   10.58]     .              .     .       .
                           PD-L1 inhibitor:antiangiogenesis 0    0  0.05 [0.00;    1.53]      .             .   0.05 [0.00;    1.53]     .              .     .       .
                                   antiangiogenesis:Placebo 0    0  6.89 [3.21;   14.78]      .             .   6.89 [3.21;   14.78]     .              .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

total-Vascular Toxicity

Random effects model: 

                                               comparison  k prop    nma           95%-CI direct         95%-CI indir.           95%-CI  RoR        95%-CI     z p-value
                          Afatinib:Afatinib + Cetuximab  1 1.00   0.97 [0.33;     2.91]   0.97 [0.33;   2.91]      .                .    .             .     .       .
                                    Afatinib:Almonertinib  0    0   0.06 [0.00;     1.01]      .              .   0.06 [0.00;     1.01]    .             .     .       .
                        Afatinib:Amivantamab  +  Lazertinib  0    0   0.14 [0.06;     0.32]      .              .   0.14 [0.06;     0.32]    .             .     .       .
                                    Afatinib:Chemotherapy  2 0.27   0.88 [0.48;     1.64]   0.58 [0.18;   1.92]   1.03 [0.50;     2.13] 0.57 [0.14;  2.29] -0.80  0.4234
                                     Afatinib:Dacomitinib  0    0   1.38 [0.61;     3.13]      .              .   1.38 [0.61;     3.13]    .             .     .       .
                                  Afatinib:DHFR inhibitor  0    0   1.17 [0.07;    19.97]      .              .   1.17 [0.07;    19.97]    .             .     .       .
                                       Afatinib:Erlotinib  1 0.57   1.22 [0.72;     2.08]   1.01 [0.50;   2.05]   1.56 [0.70;     3.51] 0.64 [0.22;  1.89] -0.80  0.4224
                   Afatinib:Erlotinib + Autophagy inhibitor  0    0   9.26 [0.44;   194.55]      .              .   9.26 [0.44;   194.55]    .             .     .       .
                          Afatinib:Erlotinib + chemotherapy  0    0   2.39 [0.83;     6.87]      .              .   2.39 [0.83;     6.87]    .             .     .       .
                        Afatinib:Erlotinib + COX2 inhibitor  0    0   3.80 [0.14;    99.62]      .              .   3.80 [0.14;    99.62]    .             .     .       .
                          Afatinib:Erlotinib + ER inhibitor  0    0   0.55 [0.20;     1.49]      .              .   0.55 [0.20;     1.49]    .             .     .       .
                        Afatinib:Erlotinib + HER3 inhibitor  0    0   1.84 [0.37;     9.27]      .              .   1.84 [0.37;     9.27]    .             .     .       .
                         Afatinib:Erlotinib + HGF inhibitor  0    0   1.52 [0.08;    29.29]      .              .   1.52 [0.08;    29.29]    .             .     .       .
                         Afatinib:Erlotinib + IGF-1R inhibitor  0    0   0.39 [0.13;     1.15]      .              .   0.39 [0.13;     1.15]    .             .     .       .
                         Afatinib:Erlotinib + MET inhibitor  0    0   1.25 [0.65;     2.40]      .              .   1.25 [0.65;     2.40]    .             .     .       .
                         Afatinib:Erlotinib + MMP inhibitor  0    0   2.97 [0.67;    13.22]      .              .   2.97 [0.67;    13.22]    .             .     .       .
                        Afatinib:Erlotinib + antiangiogenesis  0    0   0.94 [0.51;     1.71]      .              .   0.94 [0.51;     1.71]    .             .     .       .
                                       Afatinib:Gefitinib  1 0.43   1.48 [0.80;     2.75]   1.92 [0.75;   4.95]   1.22 [0.54;     2.77] 1.58 [0.45;  5.51]  0.71  0.4769
                             Afatinib:Gefitinib/Erlotinib  0    0   2.47 [0.67;     9.04]      .              .   2.47 [0.67;     9.04]    .             .     .       .
                          Afatinib:Gefitinib + chemotherapy  0    0   0.79 [0.27;     2.31]      .              .   0.79 [0.27;     2.31]    .             .     .       .
                          Afatinib:Gefitinib + ER inhibitor  0    0   0.34 [0.13;     0.87]      .              .   0.34 [0.13;     0.87]    .             .     .       .
                                      Afatinib:Lazertinib  0    0   0.67 [0.30;     1.47]      .              .   0.67 [0.30;     1.47]    .             .     .       .
                                     Afatinib:Osimertinib  0    0   0.93 [0.43;     2.01]      .              .   0.93 [0.43;     2.01]    .             .     .       .
                        Afatinib:Osimertinib + chemotherapy  0    0   0.45 [0.14;     1.51]      .              .   0.45 [0.14;     1.51]    .             .     .       .
                      Afatinib:Osimertinib + antiangiogenesis  0    0   1.88 [0.28;    12.48]      .              .   1.88 [0.28;    12.48]    .             .     .       .
                                 Afatinib:PD-L1 inhibitor  0    0   1.36 [0.10;    19.04]      .              .   1.36 [0.10;    19.04]    .             .     .       .
                                         Afatinib:Placebo  1 0.19   1.41 [0.74;     2.69]   3.33 [0.74;  14.89]   1.15 [0.56;     2.36] 2.89 [0.55; 15.21]  1.25  0.2113
                                     Afatinib:Rociletinib  0    0   1.19 [0.07;    20.67]      .              .   1.19 [0.07;    20.67]    .             .     .       .
                                  Afatinib:antiangiogenesis  0    0   0.71 [0.32;     1.58]      .              .   0.71 [0.32;     1.58]    .             .     .       .
                      Afatinib + Cetuximab:Almonertinib  0    0   0.06 [0.00;     1.27]      .              .   0.06 [0.00;     1.27]    .             .     .       .
          Afatinib + Cetuximab:Amivantamab  +  Lazertinib  0    0   0.15 [0.04;     0.57]      .              .   0.15 [0.04;     0.57]    .             .     .       .
                      Afatinib + Cetuximab:Chemotherapy  0    0   0.91 [0.26;     3.19]      .              .   0.91 [0.26;     3.19]    .             .     .       .
                       Afatinib + Cetuximab:Dacomitinib  0    0   1.42 [0.36;     5.56]      .              .   1.42 [0.36;     5.56]    .             .     .       .
                    Afatinib + Cetuximab:DHFR inhibitor  0    0   1.20 [0.06;    25.13]      .              .   1.20 [0.06;    25.13]    .             .     .       .
                         Afatinib + Cetuximab:Erlotinib  0    0   1.25 [0.37;     4.23]      .              .   1.25 [0.37;     4.23]    .             .     .       .
     Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor  0    0   9.50 [0.37;   241.61]      .              .   9.50 [0.37;   241.61]    .             .     .       .
            Afatinib + Cetuximab:Erlotinib + chemotherapy  0    0   2.45 [0.54;    11.23]      .              .   2.45 [0.54;    11.23]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + COX2 inhibitor  0    0   3.90 [0.12;   122.20]      .              .   3.90 [0.12;   122.20]    .             .     .       .
            Afatinib + Cetuximab:Erlotinib + ER inhibitor  0    0   0.56 [0.13;     2.48]      .              .   0.56 [0.13;     2.48]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + HER3 inhibitor  0    0   1.89 [0.27;    13.31]      .              .   1.89 [0.27;    13.31]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + HGF inhibitor  0    0   1.56 [0.07;    36.57]      .              .   1.56 [0.07;    36.57]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor  0    0   0.40 [0.09;     1.86]      .              .   0.40 [0.09;     1.86]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + MET inhibitor  0    0   1.28 [0.36;     4.58]      .              .   1.28 [0.36;     4.58]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + MMP inhibitor  0    0   3.05 [0.48;    19.41]      .              .   3.05 [0.48;    19.41]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + antiangiogenesis  0    0   0.96 [0.28;     3.35]      .              .   0.96 [0.28;     3.35]    .             .     .       .
                         Afatinib + Cetuximab:Gefitinib  0    0   1.52 [0.43;     5.35]      .              .   1.52 [0.43;     5.35]    .             .     .       .
               Afatinib + Cetuximab:Gefitinib/Erlotinib  0    0   2.53 [0.46;    13.83]      .              .   2.53 [0.46;    13.83]    .             .     .       .
            Afatinib + Cetuximab:Gefitinib + chemotherapy  0    0   0.81 [0.17;     3.75]      .              .   0.81 [0.17;     3.75]    .             .     .       .
            Afatinib + Cetuximab:Gefitinib + ER inhibitor  0    0   0.35 [0.08;     1.48]      .              .   0.35 [0.08;     1.48]    .             .     .       .
                        Afatinib + Cetuximab:Lazertinib  0    0   0.69 [0.18;     2.64]      .              .   0.69 [0.18;     2.64]    .             .     .       .
                       Afatinib + Cetuximab:Osimertinib  0    0   0.95 [0.25;     3.63]      .              .   0.95 [0.25;     3.63]    .             .     .       .
          Afatinib + Cetuximab:Osimertinib + chemotherapy  0    0   0.47 [0.09;     2.37]      .              .   0.47 [0.09;     2.37]    .             .     .       .
        Afatinib + Cetuximab:Osimertinib + antiangiogenesis  0    0   1.93 [0.22;    17.18]      .              .   1.93 [0.22;    17.18]    .             .     .       .
                   Afatinib + Cetuximab:PD-L1 inhibitor  0    0   1.40 [0.08;    24.30]      .              .   1.40 [0.08;    24.30]    .             .     .       .
                           Afatinib + Cetuximab:Placebo  0    0   1.44 [0.40;     5.14]      .              .   1.44 [0.40;     5.14]    .             .     .       .
                       Afatinib + Cetuximab:Rociletinib  0    0   1.23 [0.06;    25.98]      .              .   1.23 [0.06;    25.98]    .             .     .       .
                    Afatinib + Cetuximab:antiangiogenesis  0    0   0.72 [0.19;     2.82]      .              .   0.72 [0.19;     2.82]    .             .     .       .
                    Almonertinib:Amivantamab  +  Lazertinib  0    0   2.56 [0.14;    47.13]      .              .   2.56 [0.14;    47.13]    .             .     .       .
                                Almonertinib:Chemotherapy  0    0  15.87 [0.88;   287.25]      .              .  15.87 [0.88;   287.25]    .             .     .       .
                                 Almonertinib:Dacomitinib  0    0  24.84 [1.30;   473.73]      .              .  24.84 [1.30;   473.73]    .             .     .       .
                              Almonertinib:DHFR inhibitor  0    0  21.03 [0.38;  1165.31]      .              .  21.03 [0.38;  1165.31]    .             .     .       .
                                   Almonertinib:Erlotinib  0    0  21.91 [1.22;   394.51]      .              .  21.91 [1.22;   394.51]    .             .     .       .
               Almonertinib:Erlotinib + Autophagy inhibitor  0    0 166.30 [2.58; 10706.64]      .              . 166.30 [2.58; 10706.64]    .             .     .       .
                      Almonertinib:Erlotinib + chemotherapy  0    0  42.96 [2.07;   890.06]      .              .  42.96 [2.07;   890.06]    .             .     .       .
                    Almonertinib:Erlotinib + COX2 inhibitor  0    0  68.22 [0.90;  5178.60]      .              .  68.22 [0.90;  5178.60]    .             .     .       .
                      Almonertinib:Erlotinib + ER inhibitor  0    0   9.82 [0.50;   191.10]      .              .   9.82 [0.50;   191.10]    .             .     .       .
                    Almonertinib:Erlotinib + HER3 inhibitor  0    0  33.10 [1.26;   869.56]      .              .  33.10 [1.26;   869.56]    .             .     .       .
                     Almonertinib:Erlotinib + HGF inhibitor  0    0  27.38 [0.45;  1651.97]      .              .  27.38 [0.45;  1651.97]    .             .     .       .
                     Almonertinib:Erlotinib + IGF-1R inhibitor  0    0   6.97 [0.33;   145.92]      .              .   6.97 [0.33;   145.92]    .             .     .       .
                     Almonertinib:Erlotinib + MET inhibitor  0    0  22.46 [1.22;   414.33]      .              .  22.46 [1.22;   414.33]    .             .     .       .
                     Almonertinib:Erlotinib + MMP inhibitor  0    0  53.40 [2.16;  1322.17]      .              .  53.40 [2.16;  1322.17]    .             .     .       .
                    Almonertinib:Erlotinib + antiangiogenesis  0    0  16.80 [0.92;   306.66]      .              .  16.80 [0.92;   306.66]    .             .     .       .
                                   Almonertinib:Gefitinib  1 1.00  26.60 [1.57;   452.28]  26.60 [1.57; 452.28]      .                .    .             .     .       .
                         Almonertinib:Gefitinib/Erlotinib  0    0  44.31 [2.02;   974.33]      .              .  44.31 [2.02;   974.33]    .             .     .       .
                      Almonertinib:Gefitinib + chemotherapy  0    0  14.14 [0.73;   274.64]      .              .  14.14 [0.73;   274.64]    .             .     .       .
                      Almonertinib:Gefitinib + ER inhibitor  0    0   6.12 [0.32;   116.60]      .              .   6.12 [0.32;   116.60]    .             .     .       .
                                  Almonertinib:Lazertinib  0    0  12.01 [0.66;   218.50]      .              .  12.01 [0.66;   218.50]    .             .     .       .
                                 Almonertinib:Osimertinib  0    0  16.67 [0.91;   305.47]      .              .  16.67 [0.91;   305.47]    .             .     .       .
                    Almonertinib:Osimertinib + chemotherapy  0    0   8.15 [0.39;   172.27]      .              .   8.15 [0.39;   172.27]    .             .     .       .
                  Almonertinib:Osimertinib + antiangiogenesis  0    0  33.79 [1.15;   995.41]      .              .  33.79 [1.15;   995.41]    .             .     .       .
                             Almonertinib:PD-L1 inhibitor  0    0  24.45 [0.52;  1149.32]      .              .  24.45 [0.52;  1149.32]    .             .     .       .
                                     Almonertinib:Placebo  0    0  25.24 [1.38;   460.24]      .              .  25.24 [1.38;   460.24]    .             .     .       .
                                 Almonertinib:Rociletinib  0    0  21.46 [0.38;  1200.98]      .              .  21.46 [0.38;  1200.98]    .             .     .       .
                              Almonertinib:antiangiogenesis  0    0  12.68 [0.66;   242.98]      .              .  12.68 [0.66;   242.98]    .             .     .       .
                    Amivantamab  +  Lazertinib:Chemotherapy  0    0   6.20 [3.01;    12.77]      .              .   6.20 [3.01;    12.77]    .             .     .       .
                     Amivantamab  +  Lazertinib:Dacomitinib  0    0   9.71 [3.81;    24.78]      .              .   9.71 [3.81;    24.78]    .             .     .       .
                  Amivantamab  +  Lazertinib:DHFR inhibitor  0    0   8.22 [0.46;   146.73]      .              .   8.22 [0.46;   146.73]    .             .     .       .
                       Amivantamab  +  Lazertinib:Erlotinib  0    0   8.56 [4.09;    17.91]      .              .   8.56 [4.09;    17.91]    .             .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor  0    0  65.00 [2.96;  1425.11]      .              .  65.00 [2.96;  1425.11]    .             .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + chemotherapy  0    0  16.79 [5.20;    54.24]      .              .  16.79 [5.20;    54.24]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + COX2 inhibitor  0    0  26.67 [0.98;   727.62]      .              .  26.67 [0.98;   727.62]    .             .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + ER inhibitor  0    0   3.84 [1.31;    11.25]      .              .   3.84 [1.31;    11.25]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor  0    0  12.94 [2.38;    70.41]      .              .  12.94 [2.38;    70.41]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + HGF inhibitor  0    0  10.70 [0.53;   214.83]      .              .  10.70 [0.53;   214.83]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor  0    0   2.72 [0.82;     9.04]      .              .   2.72 [0.82;     9.04]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor  0    0   8.78 [3.84;    20.07]      .              .   8.78 [3.84;    20.07]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor  0    0  20.87 [4.31;   101.01]      .              .  20.87 [4.31;   101.01]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis  0    0   6.57 [2.98;    14.46]      .              .   6.57 [2.98;    14.46]    .             .     .       .
                       Amivantamab  +  Lazertinib:Gefitinib  0    0  10.40 [5.27;    20.52]      .              .  10.40 [5.27;    20.52]    .             .     .       .
             Amivantamab  +  Lazertinib:Gefitinib/Erlotinib  0    0  17.32 [5.74;    52.31]      .              .  17.32 [5.74;    52.31]    .             .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + chemotherapy  0    0   5.53 [1.82;    16.80]      .              .   5.53 [1.82;    16.80]    .             .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + ER inhibitor  0    0   2.39 [0.87;     6.59]      .              .   2.39 [0.87;     6.59]    .             .     .       .
                      Amivantamab  +  Lazertinib:Lazertinib  1 0.93   4.69 [3.07;     7.18]   4.84 [3.11;   7.53]   3.20 [0.67;    15.28] 1.51 [0.30;  7.69]  0.50  0.6172
                     Amivantamab  +  Lazertinib:Osimertinib  1 0.96   6.51 [4.55;     9.33]   6.39 [4.43;   9.23]  10.17 [1.71;    60.42] 0.63 [0.10;  3.88] -0.50  0.6172
        Amivantamab  +  Lazertinib:Osimertinib + chemotherapy  0    0   3.18 [1.18;     8.58]      .              .   3.18 [1.18;     8.58]    .             .     .       .
      Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis  0    0  13.21 [2.26;    77.15]      .              .  13.21 [2.26;    77.15]    .             .     .       .
                 Amivantamab  +  Lazertinib:PD-L1 inhibitor  0    0   9.55 [0.75;   122.23]      .              .   9.55 [0.75;   122.23]    .             .     .       .
                         Amivantamab  +  Lazertinib:Placebo  0    0   9.86 [4.66;    20.87]      .              .   9.86 [4.66;    20.87]    .             .     .       .
                     Amivantamab  +  Lazertinib:Rociletinib  0    0   8.39 [0.46;   151.81]      .              .   8.39 [0.46;   151.81]    .             .     .       .
                  Amivantamab  +  Lazertinib:antiangiogenesis  0    0   4.96 [1.91;    12.85]      .              .   4.96 [1.91;    12.85]    .             .     .       .
                                 Chemotherapy:Dacomitinib  0    0   1.57 [0.70;     3.49]      .              .   1.57 [0.70;     3.49]    .             .     .       .
                              Chemotherapy:DHFR inhibitor  0    0   1.32 [0.08;    22.48]      .              .   1.32 [0.08;    22.48]    .             .     .       .
                                   Chemotherapy:Erlotinib  6 0.63   1.38 [0.83;     2.29]   1.00 [0.53;   1.89]   2.39 [1.04;     5.47] 0.42 [0.15;  1.19] -1.63  0.1024
               Chemotherapy:Erlotinib + Autophagy inhibitor  0    0  10.48 [0.50;   219.09]      .              .  10.48 [0.50;   219.09]    .             .     .       .
                      Chemotherapy:Erlotinib + chemotherapy  0    0   2.71 [0.95;     7.67]      .              .   2.71 [0.95;     7.67]    .             .     .       .
                    Chemotherapy:Erlotinib + COX2 inhibitor  0    0   4.30 [0.16;   112.22]      .              .   4.30 [0.16;   112.22]    .             .     .       .
                      Chemotherapy:Erlotinib + ER inhibitor  0    0   0.62 [0.23;     1.67]      .              .   0.62 [0.23;     1.67]    .             .     .       .
                    Chemotherapy:Erlotinib + HER3 inhibitor  0    0   2.09 [0.42;    10.39]      .              .   2.09 [0.42;    10.39]    .             .     .       .
                     Chemotherapy:Erlotinib + HGF inhibitor  0    0   1.73 [0.09;    32.98]      .              .   1.73 [0.09;    32.98]    .             .     .       .
                     Chemotherapy:Erlotinib + IGF-1R inhibitor  0    0   0.44 [0.15;     1.28]      .              .   0.44 [0.15;     1.28]    .             .     .       .
                     Chemotherapy:Erlotinib + MET inhibitor  0    0   1.42 [0.76;     2.65]      .              .   1.42 [0.76;     2.65]    .             .     .       .
                     Chemotherapy:Erlotinib + MMP inhibitor  0    0   3.36 [0.76;    14.81]      .              .   3.36 [0.76;    14.81]    .             .     .       .
                    Chemotherapy:Erlotinib + antiangiogenesis  0    0   1.06 [0.59;     1.89]      .              .   1.06 [0.59;     1.89]    .             .     .       .
                                   Chemotherapy:Gefitinib  5 0.33   1.68 [0.92;     3.05]   2.01 [0.71;   5.68]   1.53 [0.74;     3.19] 1.31 [0.37;  4.67]  0.42  0.6764
                         Chemotherapy:Gefitinib/Erlotinib  0    0   2.79 [0.81;     9.67]      .              .   2.79 [0.81;     9.67]    .             .     .       .
                      Chemotherapy:Gefitinib + chemotherapy  0    0   0.89 [0.31;     2.58]      .              .   0.89 [0.31;     2.58]    .             .     .       .
                      Chemotherapy:Gefitinib + ER inhibitor  0    0   0.39 [0.15;     0.97]      .              .   0.39 [0.15;     0.97]    .             .     .       .
                                  Chemotherapy:Lazertinib  0    0   0.76 [0.37;     1.55]      .              .   0.76 [0.37;     1.55]    .             .     .       .
                                 Chemotherapy:Osimertinib  1 0.46   1.05 [0.54;     2.06]   1.46 [0.54;   3.92]   0.79 [0.32;     1.98] 1.85 [0.48;  7.11]  0.89  0.3729
                    Chemotherapy:Osimertinib + chemotherapy  0    0   0.51 [0.16;     1.61]      .              .   0.51 [0.16;     1.61]    .             .     .       .
                  Chemotherapy:Osimertinib + antiangiogenesis  0    0   2.13 [0.33;    13.59]      .              .   2.13 [0.33;    13.59]    .             .     .       .
                             Chemotherapy:PD-L1 inhibitor  0    0   1.54 [0.11;    20.97]      .              .   1.54 [0.11;    20.97]    .             .     .       .
                                     Chemotherapy:Placebo  0    0   1.59 [0.84;     3.02]      .              .   1.59 [0.84;     3.02]    .             .     .       .
                                 Chemotherapy:Rociletinib  0    0   1.35 [0.08;    23.26]      .              .   1.35 [0.08;    23.26]    .             .     .       .
                              Chemotherapy:antiangiogenesis  0    0   0.80 [0.36;     1.75]      .              .   0.80 [0.36;     1.75]    .             .     .       .
                               Dacomitinib:DHFR inhibitor  0    0   0.85 [0.05;    14.83]      .              .   0.85 [0.05;    14.83]    .             .     .       .
                                    Dacomitinib:Erlotinib  2 0.66   0.88 [0.46;     1.71]   0.64 [0.28;   1.44]   1.64 [0.53;     5.09] 0.39 [0.10;  1.58] -1.32  0.1866
                Dacomitinib:Erlotinib + Autophagy inhibitor  0    0   6.69 [0.31;   144.19]      .              .   6.69 [0.31;   144.19]    .             .     .       .
                       Dacomitinib:Erlotinib + chemotherapy  0    0   1.73 [0.56;     5.33]      .              .   1.73 [0.56;     5.33]    .             .     .       .
                     Dacomitinib:Erlotinib + COX2 inhibitor  0    0   2.75 [0.10;    73.71]      .              .   2.75 [0.10;    73.71]    .             .     .       .
                       Dacomitinib:Erlotinib + ER inhibitor  0    0   0.40 [0.13;     1.21]      .              .   0.40 [0.13;     1.21]    .             .     .       .
                     Dacomitinib:Erlotinib + HER3 inhibitor  0    0   1.33 [0.25;     7.02]      .              .   1.33 [0.25;     7.02]    .             .     .       .
                      Dacomitinib:Erlotinib + HGF inhibitor  0    0   1.10 [0.06;    21.73]      .              .   1.10 [0.06;    21.73]    .             .     .       .
                      Dacomitinib:Erlotinib + IGF-1R inhibitor  0    0   0.28 [0.09;     0.89]      .              .   0.28 [0.09;     0.89]    .             .     .       .
                      Dacomitinib:Erlotinib + MET inhibitor  0    0   0.90 [0.42;     1.93]      .              .   0.90 [0.42;     1.93]    .             .     .       .
                      Dacomitinib:Erlotinib + MMP inhibitor  0    0   2.15 [0.46;    10.05]      .              .   2.15 [0.46;    10.05]    .             .     .       .
                     Dacomitinib:Erlotinib + antiangiogenesis  0    0   0.68 [0.33;     1.39]      .              .   0.68 [0.33;     1.39]    .             .     .       .
                                    Dacomitinib:Gefitinib  1 0.11   1.07 [0.47;     2.42]   1.98 [0.18;  22.02]   0.99 [0.42;     2.35] 2.00 [0.16; 25.89]  0.53  0.5942
                          Dacomitinib:Gefitinib/Erlotinib  0    0   1.78 [0.45;     7.10]      .              .   1.78 [0.45;     7.10]    .             .     .       .
                       Dacomitinib:Gefitinib + chemotherapy  0    0   0.57 [0.17;     1.89]      .              .   0.57 [0.17;     1.89]    .             .     .       .
                       Dacomitinib:Gefitinib + ER inhibitor  0    0   0.25 [0.09;     0.71]      .              .   0.25 [0.09;     0.71]    .             .     .       .
                                   Dacomitinib:Lazertinib  0    0   0.48 [0.19;     1.22]      .              .   0.48 [0.19;     1.22]    .             .     .       .
                                  Dacomitinib:Osimertinib  0    0   0.67 [0.27;     1.65]      .              .   0.67 [0.27;     1.65]    .             .     .       .
                     Dacomitinib:Osimertinib + chemotherapy  0    0   0.33 [0.09;     1.19]      .              .   0.33 [0.09;     1.19]    .             .     .       .
                   Dacomitinib:Osimertinib + antiangiogenesis  0    0   1.36 [0.19;     9.56]      .              .   1.36 [0.19;     9.56]    .             .     .       .
                              Dacomitinib:PD-L1 inhibitor  0    0   0.98 [0.07;    14.35]      .              .   0.98 [0.07;    14.35]    .             .     .       .
                                      Dacomitinib:Placebo  1 0.40   1.02 [0.50;     2.08]   1.65 [0.53;   5.10]   0.73 [0.29;     1.86] 2.25 [0.52;  9.71]  1.08  0.2792
                                  Dacomitinib:Rociletinib  0    0   0.86 [0.05;    15.34]      .              .   0.86 [0.05;    15.34]    .             .     .       .
                               Dacomitinib:antiangiogenesis  0    0   0.51 [0.21;     1.25]      .              .   0.51 [0.21;     1.25]    .             .     .       .
                                 DHFR inhibitor:Erlotinib  1 1.00   1.04 [0.06;    16.89]   1.04 [0.06;  16.89]      .                .    .             .     .       .
             DHFR inhibitor:Erlotinib + Autophagy inhibitor  0    0   7.91 [0.13;   473.67]      .              .   7.91 [0.13;   473.67]    .             .     .       .
                    DHFR inhibitor:Erlotinib + chemotherapy  0    0   2.04 [0.11;    38.30]      .              .   2.04 [0.11;    38.30]    .             .     .       .
                  DHFR inhibitor:Erlotinib + COX2 inhibitor  0    0   3.24 [0.05;   229.75]      .              .   3.24 [0.05;   229.75]    .             .     .       .
                    DHFR inhibitor:Erlotinib + ER inhibitor  0    0   0.47 [0.02;     8.82]      .              .   0.47 [0.02;     8.82]    .             .     .       .
                  DHFR inhibitor:Erlotinib + HER3 inhibitor  0    0   1.57 [0.07;    37.70]      .              .   1.57 [0.07;    37.70]    .             .     .       .
                   DHFR inhibitor:Erlotinib + HGF inhibitor  0    0   1.30 [0.02;    73.00]      .              .   1.30 [0.02;    73.00]    .             .     .       .
                   DHFR inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.33 [0.02;     6.28]      .              .   0.33 [0.02;     6.28]    .             .     .       .
                   DHFR inhibitor:Erlotinib + MET inhibitor  0    0   1.07 [0.06;    17.75]      .              .   1.07 [0.06;    17.75]    .             .     .       .
                   DHFR inhibitor:Erlotinib + MMP inhibitor  0    0   2.54 [0.11;    57.22]      .              .   2.54 [0.11;    57.22]    .             .     .       .
                  DHFR inhibitor:Erlotinib + antiangiogenesis  0    0   0.80 [0.05;    13.14]      .              .   0.80 [0.05;    13.14]    .             .     .       .
                                 DHFR inhibitor:Gefitinib  0    0   1.27 [0.07;    21.75]      .              .   1.27 [0.07;    21.75]    .             .     .       .
                       DHFR inhibitor:Gefitinib/Erlotinib  0    0   2.11 [0.10;    44.74]      .              .   2.11 [0.10;    44.74]    .             .     .       .
                    DHFR inhibitor:Gefitinib + chemotherapy  0    0   0.67 [0.03;    13.20]      .              .   0.67 [0.03;    13.20]    .             .     .       .
                    DHFR inhibitor:Gefitinib + ER inhibitor  0    0   0.29 [0.02;     5.38]      .              .   0.29 [0.02;     5.38]    .             .     .       .
                                DHFR inhibitor:Lazertinib  0    0   0.57 [0.03;    10.16]      .              .   0.57 [0.03;    10.16]    .             .     .       .
                               DHFR inhibitor:Osimertinib  0    0   0.79 [0.04;    13.99]      .              .   0.79 [0.04;    13.99]    .             .     .       .
                  DHFR inhibitor:Osimertinib + chemotherapy  0    0   0.39 [0.02;     7.91]      .              .   0.39 [0.02;     7.91]    .             .     .       .
                DHFR inhibitor:Osimertinib + antiangiogenesis  0    0   1.61 [0.06;    45.85]      .              .   1.61 [0.06;    45.85]    .             .     .       .
                           DHFR inhibitor:PD-L1 inhibitor  0    0   1.16 [0.03;    53.14]      .              .   1.16 [0.03;    53.14]    .             .     .       .
                                   DHFR inhibitor:Placebo  0    0   1.20 [0.07;    20.35]      .              .   1.20 [0.07;    20.35]    .             .     .       .
                               DHFR inhibitor:Rociletinib  0    0   1.02 [0.02;    53.00]      .              .   1.02 [0.02;    53.00]    .             .     .       .
                            DHFR inhibitor:antiangiogenesis  0    0   0.60 [0.03;    10.43]      .              .   0.60 [0.03;    10.43]    .             .     .       .
                  Erlotinib:Erlotinib + Autophagy inhibitor  1 1.00   7.59 [0.38;   152.19]   7.59 [0.38; 152.19]      .                .    .             .     .       .
                         Erlotinib:Erlotinib + chemotherapy  3 1.00   1.96 [0.79;     4.88]   1.96 [0.79;   4.88]      .                .    .             .     .       .
                       Erlotinib:Erlotinib + COX2 inhibitor  1 1.00   3.11 [0.12;    78.18]   3.11 [0.12;  78.18]      .                .    .             .     .       .
                         Erlotinib:Erlotinib + ER inhibitor  1 0.63   0.45 [0.18;     1.14]   0.31 [0.09;   0.99]   0.87 [0.19;     4.09] 0.35 [0.05;  2.44] -1.06  0.2891
                       Erlotinib:Erlotinib + HER3 inhibitor  1 1.00   1.51 [0.33;     6.94]   1.51 [0.33;   6.94]      .                .    .             .     .       .
                        Erlotinib:Erlotinib + HGF inhibitor  1 1.00   1.25 [0.07;    22.88]   1.25 [0.07;  22.88]      .                .    .             .     .       .
                        Erlotinib:Erlotinib + IGF-1R inhibitor  3 1.00   0.32 [0.12;     0.82]   0.32 [0.12;   0.82]      .                .    .             .     .       .
                        Erlotinib:Erlotinib + MET inhibitor  5 1.00   1.03 [0.71;     1.49]   1.03 [0.71;   1.49]      .                .    .             .     .       .
                        Erlotinib:Erlotinib + MMP inhibitor  1 1.00   2.44 [0.61;     9.82]   2.44 [0.61;   9.82]      .                .    .             .     .       .
                       Erlotinib:Erlotinib + antiangiogenesis 12 0.99   0.77 [0.58;     1.01]   0.75 [0.57;   0.99]   9.03 [0.48;   168.45] 0.08 [0.00;  1.57] -1.66  0.0971
                                      Erlotinib:Gefitinib  1 0.21   1.21 [0.68;     2.16]   0.66 [0.19;   2.34]   1.42 [0.75;     2.71] 0.46 [0.11;  1.92] -1.06  0.2891
                            Erlotinib:Gefitinib/Erlotinib  0    0   2.02 [0.58;     7.09]      .              .   2.02 [0.58;     7.09]    .             .     .       .
                         Erlotinib:Gefitinib + chemotherapy  0    0   0.65 [0.23;     1.85]      .              .   0.65 [0.23;     1.85]    .             .     .       .
                         Erlotinib:Gefitinib + ER inhibitor  1 0.60   0.28 [0.12;     0.66]   0.19 [0.06;   0.58]   0.49 [0.13;     1.91] 0.39 [0.07;  2.24] -1.06  0.2891
                                     Erlotinib:Lazertinib  0    0   0.55 [0.27;     1.13]      .              .   0.55 [0.27;     1.13]    .             .     .       .
                                    Erlotinib:Osimertinib  0    0   0.76 [0.38;     1.52]      .              .   0.76 [0.38;     1.52]    .             .     .       .
                       Erlotinib:Osimertinib + chemotherapy  0    0   0.37 [0.12;     1.18]      .              .   0.37 [0.12;     1.18]    .             .     .       .
                     Erlotinib:Osimertinib + antiangiogenesis  0    0   1.54 [0.24;     9.93]      .              .   1.54 [0.24;     9.93]    .             .     .       .
                                Erlotinib:PD-L1 inhibitor  0    0   1.12 [0.08;    15.29]      .              .   1.12 [0.08;    15.29]    .             .     .       .
                                        Erlotinib:Placebo  3 0.58   1.15 [0.70;     1.90]   0.66 [0.34;   1.28]   2.48 [1.14;     5.37] 0.27 [0.10;  0.74] -2.55  0.0108
                                    Erlotinib:Rociletinib  1 1.00   0.98 [0.06;    16.11]   0.98 [0.06;  16.11]      .                .    .             .     .       .
                                 Erlotinib:antiangiogenesis  2 0.92   0.58 [0.32;     1.06]   0.64 [0.34;   1.20]   0.17 [0.02;     1.49] 3.69 [0.39; 34.46]  1.14  0.2527
     Erlotinib + Autophagy inhibitor:Erlotinib + chemotherapy  0    0   0.26 [0.01;     5.93]      .              .   0.26 [0.01;     5.93]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + COX2 inhibitor  0    0   0.41 [0.01;    33.47]      .              .   0.41 [0.01;    33.47]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + ER inhibitor  0    0   0.06 [0.00;     1.36]      .              .   0.06 [0.00;     1.36]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + HER3 inhibitor  0    0   0.20 [0.01;     5.75]      .              .   0.20 [0.01;     5.75]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + HGF inhibitor  0    0   0.16 [0.00;    10.72]      .              .   0.16 [0.00;    10.72]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.04 [0.00;     0.97]      .              .   0.04 [0.00;     0.97]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor  0    0   0.14 [0.01;     2.77]      .              .   0.14 [0.01;     2.77]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MMP inhibitor  0    0   0.32 [0.01;     8.76]      .              .   0.32 [0.01;     8.76]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis  0    0   0.10 [0.00;     2.05]      .              .   0.10 [0.00;     2.05]    .             .     .       .
                  Erlotinib + Autophagy inhibitor:Gefitinib  0    0   0.16 [0.01;     3.39]      .              .   0.16 [0.01;     3.39]    .             .     .       .
        Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib  0    0   0.27 [0.01;     6.87]      .              .   0.27 [0.01;     6.87]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy  0    0   0.09 [0.00;     2.04]      .              .   0.09 [0.00;     2.04]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + ER inhibitor  0    0   0.04 [0.00;     0.83]      .              .   0.04 [0.00;     0.83]    .             .     .       .
                 Erlotinib + Autophagy inhibitor:Lazertinib  0    0   0.07 [0.00;     1.58]      .              .   0.07 [0.00;     1.58]    .             .     .       .
                Erlotinib + Autophagy inhibitor:Osimertinib  0    0   0.10 [0.00;     2.18]      .              .   0.10 [0.00;     2.18]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy  0    0   0.05 [0.00;     1.22]      .              .   0.05 [0.00;     1.22]    .             .     .       .
 Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis  0    0   0.20 [0.01;     6.93]      .              .   0.20 [0.01;     6.93]    .             .     .       .
            Erlotinib + Autophagy inhibitor:PD-L1 inhibitor  0    0   0.15 [0.00;     7.86]      .              .   0.15 [0.00;     7.86]    .             .     .       .
                    Erlotinib + Autophagy inhibitor:Placebo  0    0   0.15 [0.01;     3.17]      .              .   0.15 [0.01;     3.17]    .             .     .       .
                Erlotinib + Autophagy inhibitor:Rociletinib  0    0   0.13 [0.00;     7.80]      .              .   0.13 [0.00;     7.80]    .             .     .       .
             Erlotinib + Autophagy inhibitor:antiangiogenesis  0    0   0.08 [0.00;     1.62]      .              .   0.08 [0.00;     1.62]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + COX2 inhibitor  0    0   1.59 [0.06;    45.24]      .              .   1.59 [0.06;    45.24]    .             .     .       .
            Erlotinib + chemotherapy:Erlotinib + ER inhibitor  0    0   0.23 [0.06;     0.84]      .              .   0.23 [0.06;     0.84]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor  0    0   0.77 [0.13;     4.55]      .              .   0.77 [0.13;     4.55]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + HGF inhibitor  0    0   0.64 [0.03;    13.41]      .              .   0.64 [0.03;    13.41]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor  0    0   0.16 [0.04;     0.60]      .              .   0.16 [0.04;     0.60]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + MET inhibitor  0    0   0.52 [0.20;     1.40]      .              .   0.52 [0.20;     1.40]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + MMP inhibitor  0    0   1.24 [0.24;     6.57]      .              .   1.24 [0.24;     6.57]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + antiangiogenesis  0    0   0.39 [0.15;     1.01]      .              .   0.39 [0.15;     1.01]    .             .     .       .
                         Erlotinib + chemotherapy:Gefitinib  0    0   0.62 [0.21;     1.82]      .              .   0.62 [0.21;     1.82]    .             .     .       .
               Erlotinib + chemotherapy:Gefitinib/Erlotinib  0    0   1.03 [0.22;     4.86]      .              .   1.03 [0.22;     4.86]    .             .     .       .
            Erlotinib + chemotherapy:Gefitinib + chemotherapy  0    0   0.33 [0.08;     1.32]      .              .   0.33 [0.08;     1.32]    .             .     .       .
            Erlotinib + chemotherapy:Gefitinib + ER inhibitor  0    0   0.14 [0.04;     0.50]      .              .   0.14 [0.04;     0.50]    .             .     .       .
                        Erlotinib + chemotherapy:Lazertinib  0    0   0.28 [0.09;     0.90]      .              .   0.28 [0.09;     0.90]    .             .     .       .
                       Erlotinib + chemotherapy:Osimertinib  0    0   0.39 [0.12;     1.22]      .              .   0.39 [0.12;     1.22]    .             .     .       .
          Erlotinib + chemotherapy:Osimertinib + chemotherapy  0    0   0.19 [0.04;     0.83]      .              .   0.19 [0.04;     0.83]    .             .     .       .
        Erlotinib + chemotherapy:Osimertinib + antiangiogenesis  0    0   0.79 [0.10;     6.25]      .              .   0.79 [0.10;     6.25]    .             .     .       .
                   Erlotinib + chemotherapy:PD-L1 inhibitor  0    0   0.57 [0.04;     9.09]      .              .   0.57 [0.04;     9.09]    .             .     .       .
                           Erlotinib + chemotherapy:Placebo  0    0   0.59 [0.21;     1.66]      .              .   0.59 [0.21;     1.66]    .             .     .       .
                       Erlotinib + chemotherapy:Rociletinib  0    0   0.50 [0.03;     9.49]      .              .   0.50 [0.03;     9.49]    .             .     .       .
                    Erlotinib + chemotherapy:antiangiogenesis  0    0   0.30 [0.10;     0.88]      .              .   0.30 [0.10;     0.88]    .             .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + ER inhibitor  0    0   0.14 [0.01;     4.12]      .              .   0.14 [0.01;     4.12]    .             .     .       .
        Erlotinib + COX2 inhibitor:Erlotinib + HER3 inhibitor  0    0   0.49 [0.01;    17.16]      .              .   0.49 [0.01;    17.16]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + HGF inhibitor  0    0   0.40 [0.01;    30.80]      .              .   0.40 [0.01;    30.80]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.10 [0.00;     2.94]      .              .   0.10 [0.00;     2.94]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + MET inhibitor  0    0   0.33 [0.01;     8.44]      .              .   0.33 [0.01;     8.44]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + MMP inhibitor  0    0   0.78 [0.02;    26.22]      .              .   0.78 [0.02;    26.22]    .             .     .       .
        Erlotinib + COX2 inhibitor:Erlotinib + antiangiogenesis  0    0   0.25 [0.01;     6.26]      .              .   0.25 [0.01;     6.26]    .             .     .       .
                       Erlotinib + COX2 inhibitor:Gefitinib  0    0   0.39 [0.01;    10.30]      .              .   0.39 [0.01;    10.30]    .             .     .       .
             Erlotinib + COX2 inhibitor:Gefitinib/Erlotinib  0    0   0.65 [0.02;    20.64]      .              .   0.65 [0.02;    20.64]    .             .     .       .
          Erlotinib + COX2 inhibitor:Gefitinib + chemotherapy  0    0   0.21 [0.01;     6.15]      .              .   0.21 [0.01;     6.15]    .             .     .       .
          Erlotinib + COX2 inhibitor:Gefitinib + ER inhibitor  0    0   0.09 [0.00;     2.52]      .              .   0.09 [0.00;     2.52]    .             .     .       .
                      Erlotinib + COX2 inhibitor:Lazertinib  0    0   0.18 [0.01;     4.79]      .              .   0.18 [0.01;     4.79]    .             .     .       .
                     Erlotinib + COX2 inhibitor:Osimertinib  0    0   0.24 [0.01;     6.60]      .              .   0.24 [0.01;     6.60]    .             .     .       .
        Erlotinib + COX2 inhibitor:Osimertinib + chemotherapy  0    0   0.12 [0.00;     3.66]      .              .   0.12 [0.00;     3.66]    .             .     .       .
      Erlotinib + COX2 inhibitor:Osimertinib + antiangiogenesis  0    0   0.50 [0.01;    20.49]      .              .   0.50 [0.01;    20.49]    .             .     .       .
                 Erlotinib + COX2 inhibitor:PD-L1 inhibitor  0    0   0.36 [0.01;    22.77]      .              .   0.36 [0.01;    22.77]    .             .     .       .
                         Erlotinib + COX2 inhibitor:Placebo  0    0   0.37 [0.01;     9.65]      .              .   0.37 [0.01;     9.65]    .             .     .       .
                     Erlotinib + COX2 inhibitor:Rociletinib  0    0   0.31 [0.00;    22.49]      .              .   0.31 [0.00;    22.49]    .             .     .       .
                  Erlotinib + COX2 inhibitor:antiangiogenesis  0    0   0.19 [0.01;     4.93]      .              .   0.19 [0.01;     4.93]    .             .     .       .
          Erlotinib + ER inhibitor:Erlotinib + HER3 inhibitor  0    0   3.37 [0.56;    20.17]      .              .   3.37 [0.56;    20.17]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + HGF inhibitor  0    0   2.79 [0.13;    59.12]      .              .   2.79 [0.13;    59.12]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.71 [0.19;     2.68]      .              .   0.71 [0.19;     2.68]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MET inhibitor  0    0   2.29 [0.84;     6.26]      .              .   2.29 [0.84;     6.26]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MMP inhibitor  0    0   5.44 [1.02;    29.13]      .              .   5.44 [1.02;    29.13]    .             .     .       .
          Erlotinib + ER inhibitor:Erlotinib + antiangiogenesis  0    0   1.71 [0.65;     4.54]      .              .   1.71 [0.65;     4.54]    .             .     .       .
                         Erlotinib + ER inhibitor:Gefitinib  1 0.82   2.71 [1.12;     6.58]   2.17 [0.81;   5.77]   7.56 [0.93;    61.34] 0.29 [0.03;  2.89] -1.06  0.2891
               Erlotinib + ER inhibitor:Gefitinib/Erlotinib  0    0   4.51 [1.02;    19.95]      .              .   4.51 [1.02;    19.95]    .             .     .       .
            Erlotinib + ER inhibitor:Gefitinib + chemotherapy  0    0   1.44 [0.41;     5.02]      .              .   1.44 [0.41;     5.02]    .             .     .       .
            Erlotinib + ER inhibitor:Gefitinib + ER inhibitor  1 1.00   0.62 [0.29;     1.36]   0.62 [0.29;   1.36]      .                .    .             .     .       .
                        Erlotinib + ER inhibitor:Lazertinib  0    0   1.22 [0.43;     3.50]      .              .   1.22 [0.43;     3.50]    .             .     .       .
                       Erlotinib + ER inhibitor:Osimertinib  0    0   1.70 [0.59;     4.88]      .              .   1.70 [0.59;     4.88]    .             .     .       .
          Erlotinib + ER inhibitor:Osimertinib + chemotherapy  0    0   0.83 [0.20;     3.38]      .              .   0.83 [0.20;     3.38]    .             .     .       .
        Erlotinib + ER inhibitor:Osimertinib + antiangiogenesis  0    0   3.44 [0.45;    26.09]      .              .   3.44 [0.45;    26.09]    .             .     .       .
                   Erlotinib + ER inhibitor:PD-L1 inhibitor  0    0   2.49 [0.16;    38.40]      .              .   2.49 [0.16;    38.40]    .             .     .       .
                           Erlotinib + ER inhibitor:Placebo  0    0   2.57 [0.94;     7.03]      .              .   2.57 [0.94;     7.03]    .             .     .       .
                       Erlotinib + ER inhibitor:Rociletinib  0    0   2.19 [0.11;    41.86]      .              .   2.19 [0.11;    41.86]    .             .     .       .
                    Erlotinib + ER inhibitor:antiangiogenesis  0    0   1.29 [0.42;     3.93]      .              .   1.29 [0.42;     3.93]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + HGF inhibitor  0    0   0.83 [0.03;    22.05]      .              .   0.83 [0.03;    22.05]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.21 [0.03;     1.27]      .              .   0.21 [0.03;     1.27]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor  0    0   0.68 [0.14;     3.26]      .              .   0.68 [0.14;     3.26]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor  0    0   1.61 [0.20;    12.73]      .              .   1.61 [0.20;    12.73]    .             .     .       .
        Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis  0    0   0.51 [0.11;     2.39]      .              .   0.51 [0.11;     2.39]    .             .     .       .
                       Erlotinib + HER3 inhibitor:Gefitinib  0    0   0.80 [0.16;     4.10]      .              .   0.80 [0.16;     4.10]    .             .     .       .
             Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib  0    0   1.34 [0.19;     9.65]      .              .   1.34 [0.19;     9.65]    .             .     .       .
          Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy  0    0   0.43 [0.07;     2.72]      .              .   0.43 [0.07;     2.72]    .             .     .       .
          Erlotinib + HER3 inhibitor:Gefitinib + ER inhibitor  0    0   0.18 [0.03;     1.07]      .              .   0.18 [0.03;     1.07]    .             .     .       .
                      Erlotinib + HER3 inhibitor:Lazertinib  0    0   0.36 [0.07;     1.96]      .              .   0.36 [0.07;     1.96]    .             .     .       .
                     Erlotinib + HER3 inhibitor:Osimertinib  0    0   0.50 [0.09;     2.69]      .              .   0.50 [0.09;     2.69]    .             .     .       .
        Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy  0    0   0.25 [0.04;     1.67]      .              .   0.25 [0.04;     1.67]    .             .     .       .
      Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis  0    0   1.02 [0.09;    11.33]      .              .   1.02 [0.09;    11.33]    .             .     .       .
                 Erlotinib + HER3 inhibitor:PD-L1 inhibitor  0    0   0.74 [0.04;    15.27]      .              .   0.74 [0.04;    15.27]    .             .     .       .
                         Erlotinib + HER3 inhibitor:Placebo  0    0   0.76 [0.15;     3.80]      .              .   0.76 [0.15;     3.80]    .             .     .       .
                     Erlotinib + HER3 inhibitor:Rociletinib  0    0   0.65 [0.03;    15.72]      .              .   0.65 [0.03;    15.72]    .             .     .       .
                  Erlotinib + HER3 inhibitor:antiangiogenesis  0    0   0.38 [0.07;     1.97]      .              .   0.38 [0.07;     1.97]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.25 [0.01;     5.41]      .              .   0.25 [0.01;     5.41]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MET inhibitor  0    0   0.82 [0.04;    15.38]      .              .   0.82 [0.04;    15.38]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MMP inhibitor  0    0   1.95 [0.08;    49.00]      .              .   1.95 [0.08;    49.00]    .             .     .       .
         Erlotinib + HGF inhibitor:Erlotinib + antiangiogenesis  0    0   0.61 [0.03;    11.38]      .              .   0.61 [0.03;    11.38]    .             .     .       .
                        Erlotinib + HGF inhibitor:Gefitinib  0    0   0.97 [0.05;    18.81]      .              .   0.97 [0.05;    18.81]    .             .     .       .
              Erlotinib + HGF inhibitor:Gefitinib/Erlotinib  0    0   1.62 [0.07;    38.39]      .              .   1.62 [0.07;    38.39]    .             .     .       .
           Erlotinib + HGF inhibitor:Gefitinib + chemotherapy  0    0   0.52 [0.02;    11.36]      .              .   0.52 [0.02;    11.36]    .             .     .       .
           Erlotinib + HGF inhibitor:Gefitinib + ER inhibitor  0    0   0.22 [0.01;     4.64]      .              .   0.22 [0.01;     4.64]    .             .     .       .
                       Erlotinib + HGF inhibitor:Lazertinib  0    0   0.44 [0.02;     8.77]      .              .   0.44 [0.02;     8.77]    .             .     .       .
                      Erlotinib + HGF inhibitor:Osimertinib  0    0   0.61 [0.03;    12.09]      .              .   0.61 [0.03;    12.09]    .             .     .       .
         Erlotinib + HGF inhibitor:Osimertinib + chemotherapy  0    0   0.30 [0.01;     6.79]      .              .   0.30 [0.01;     6.79]    .             .     .       .
       Erlotinib + HGF inhibitor:Osimertinib + antiangiogenesis  0    0   1.23 [0.04;    38.97]      .              .   1.23 [0.04;    38.97]    .             .     .       .
                  Erlotinib + HGF inhibitor:PD-L1 inhibitor  0    0   0.89 [0.02;    44.62]      .              .   0.89 [0.02;    44.62]    .             .     .       .
                          Erlotinib + HGF inhibitor:Placebo  0    0   0.92 [0.05;    17.61]      .              .   0.92 [0.05;    17.61]    .             .     .       .
                      Erlotinib + HGF inhibitor:Rociletinib  0    0   0.78 [0.01;    44.37]      .              .   0.78 [0.01;    44.37]    .             .     .       .
                   Erlotinib + HGF inhibitor:antiangiogenesis  0    0   0.46 [0.02;     9.02]      .              .   0.46 [0.02;     9.02]    .             .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor  0    0   3.22 [1.17;     8.91]      .              .   3.22 [1.17;     8.91]    .             .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor  0    0   7.66 [1.42;    41.29]      .              .   7.66 [1.42;    41.29]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis  0    0   2.41 [0.90;     6.46]      .              .   2.41 [0.90;     6.46]    .             .     .       .
                        Erlotinib + IGF-1R inhibitor:Gefitinib  0    0   3.82 [1.26;    11.55]      .              .   3.82 [1.26;    11.55]    .             .     .       .
              Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib  0    0   6.36 [1.32;    30.61]      .              .   6.36 [1.32;    30.61]    .             .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy  0    0   2.03 [0.49;     8.34]      .              .   2.03 [0.49;     8.34]    .             .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + ER inhibitor  0    0   0.88 [0.24;     3.16]      .              .   0.88 [0.24;     3.16]    .             .     .       .
                       Erlotinib + IGF-1R inhibitor:Lazertinib  0    0   1.72 [0.52;     5.67]      .              .   1.72 [0.52;     5.67]    .             .     .       .
                      Erlotinib + IGF-1R inhibitor:Osimertinib  0    0   2.39 [0.74;     7.73]      .              .   2.39 [0.74;     7.73]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy  0    0   1.17 [0.26;     5.20]      .              .   1.17 [0.26;     5.20]    .             .     .       .
       Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis  0    0   4.85 [0.60;    39.15]      .              .   4.85 [0.60;    39.15]    .             .     .       .
                  Erlotinib + IGF-1R inhibitor:PD-L1 inhibitor  0    0   3.51 [0.22;    56.71]      .              .   3.51 [0.22;    56.71]    .             .     .       .
                          Erlotinib + IGF-1R inhibitor:Placebo  0    0   3.62 [1.24;    10.57]      .              .   3.62 [1.24;    10.57]    .             .     .       .
                      Erlotinib + IGF-1R inhibitor:Rociletinib  0    0   3.08 [0.16;    59.17]      .              .   3.08 [0.16;    59.17]    .             .     .       .
                   Erlotinib + IGF-1R inhibitor:antiangiogenesis  0    0   1.82 [0.59;     5.58]      .              .   1.82 [0.59;     5.58]    .             .     .       .
          Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor  0    0   2.38 [0.56;    10.06]      .              .   2.38 [0.56;    10.06]    .             .     .       .
         Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis  0    0   0.75 [0.47;     1.19]      .              .   0.75 [0.47;     1.19]    .             .     .       .
                        Erlotinib + MET inhibitor:Gefitinib  0    0   1.18 [0.60;     2.35]      .              .   1.18 [0.60;     2.35]    .             .     .       .
              Erlotinib + MET inhibitor:Gefitinib/Erlotinib  0    0   1.97 [0.53;     7.30]      .              .   1.97 [0.53;     7.30]    .             .     .       .
           Erlotinib + MET inhibitor:Gefitinib + chemotherapy  0    0   0.63 [0.21;     1.92]      .              .   0.63 [0.21;     1.92]    .             .     .       .
           Erlotinib + MET inhibitor:Gefitinib + ER inhibitor  0    0   0.27 [0.11;     0.70]      .              .   0.27 [0.11;     0.70]    .             .     .       .
                       Erlotinib + MET inhibitor:Lazertinib  0    0   0.53 [0.24;     1.21]      .              .   0.53 [0.24;     1.21]    .             .     .       .
                      Erlotinib + MET inhibitor:Osimertinib  0    0   0.74 [0.34;     1.63]      .              .   0.74 [0.34;     1.63]    .             .     .       .
         Erlotinib + MET inhibitor:Osimertinib + chemotherapy  0    0   0.36 [0.11;     1.22]      .              .   0.36 [0.11;     1.22]    .             .     .       .
       Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis  0    0   1.50 [0.23;    10.05]      .              .   1.50 [0.23;    10.05]    .             .     .       .
                  Erlotinib + MET inhibitor:PD-L1 inhibitor  0    0   1.09 [0.08;    15.30]      .              .   1.09 [0.08;    15.30]    .             .     .       .
                          Erlotinib + MET inhibitor:Placebo  0    0   1.12 [0.60;     2.10]      .              .   1.12 [0.60;     2.10]    .             .     .       .
                      Erlotinib + MET inhibitor:Rociletinib  0    0   0.96 [0.06;    16.11]      .              .   0.96 [0.06;    16.11]    .             .     .       .
                   Erlotinib + MET inhibitor:antiangiogenesis  0    0   0.56 [0.28;     1.15]      .              .   0.56 [0.28;     1.15]    .             .     .       .
         Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis  0    0   0.31 [0.08;     1.30]      .              .   0.31 [0.08;     1.30]    .             .     .       .
                        Erlotinib + MMP inhibitor:Gefitinib  0    0   0.50 [0.11;     2.25]      .              .   0.50 [0.11;     2.25]    .             .     .       .
              Erlotinib + MMP inhibitor:Gefitinib/Erlotinib  0    0   0.83 [0.13;     5.41]      .              .   0.83 [0.13;     5.41]    .             .     .       .
           Erlotinib + MMP inhibitor:Gefitinib + chemotherapy  0    0   0.26 [0.05;     1.52]      .              .   0.26 [0.05;     1.52]    .             .     .       .
           Erlotinib + MMP inhibitor:Gefitinib + ER inhibitor  0    0   0.11 [0.02;     0.59]      .              .   0.11 [0.02;     0.59]    .             .     .       .
                       Erlotinib + MMP inhibitor:Lazertinib  0    0   0.22 [0.05;     1.08]      .              .   0.22 [0.05;     1.08]    .             .     .       .
                      Erlotinib + MMP inhibitor:Osimertinib  0    0   0.31 [0.07;     1.48]      .              .   0.31 [0.07;     1.48]    .             .     .       .
         Erlotinib + MMP inhibitor:Osimertinib + chemotherapy  0    0   0.15 [0.02;     0.93]      .              .   0.15 [0.02;     0.93]    .             .     .       .
       Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis  0    0   0.63 [0.06;     6.48]      .              .   0.63 [0.06;     6.48]    .             .     .       .
                  Erlotinib + MMP inhibitor:PD-L1 inhibitor  0    0   0.46 [0.02;     8.88]      .              .   0.46 [0.02;     8.88]    .             .     .       .
                          Erlotinib + MMP inhibitor:Placebo  0    0   0.47 [0.11;     2.08]      .              .   0.47 [0.11;     2.08]    .             .     .       .
                      Erlotinib + MMP inhibitor:Rociletinib  0    0   0.40 [0.02;     9.17]      .              .   0.40 [0.02;     9.17]    .             .     .       .
                   Erlotinib + MMP inhibitor:antiangiogenesis  0    0   0.24 [0.05;     1.08]      .              .   0.24 [0.05;     1.08]    .             .     .       .
                       Erlotinib + antiangiogenesis:Gefitinib  0    0   1.58 [0.84;     3.00]      .              .   1.58 [0.84;     3.00]    .             .     .       .
             Erlotinib + antiangiogenesis:Gefitinib/Erlotinib  0    0   2.64 [0.73;     9.54]      .              .   2.64 [0.73;     9.54]    .             .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + chemotherapy  0    0   0.84 [0.28;     2.50]      .              .   0.84 [0.28;     2.50]    .             .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + ER inhibitor  0    0   0.36 [0.15;     0.90]      .              .   0.36 [0.15;     0.90]    .             .     .       .
                      Erlotinib + antiangiogenesis:Lazertinib  0    0   0.71 [0.33;     1.55]      .              .   0.71 [0.33;     1.55]    .             .     .       .
                     Erlotinib + antiangiogenesis:Osimertinib  0    0   0.99 [0.47;     2.10]      .              .   0.99 [0.47;     2.10]    .             .     .       .
        Erlotinib + antiangiogenesis:Osimertinib + chemotherapy  0    0   0.48 [0.15;     1.59]      .              .   0.48 [0.15;     1.59]    .             .     .       .
      Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0   2.01 [0.31;    13.22]      .              .   2.01 [0.31;    13.22]    .             .     .       .
                 Erlotinib + antiangiogenesis:PD-L1 inhibitor  0    0   1.46 [0.10;    20.23]      .              .   1.46 [0.10;    20.23]    .             .     .       .
                         Erlotinib + antiangiogenesis:Placebo  0    0   1.50 [0.85;     2.67]      .              .   1.50 [0.85;     2.67]    .             .     .       .
                     Erlotinib + antiangiogenesis:Rociletinib  0    0   1.28 [0.08;    21.31]      .              .   1.28 [0.08;    21.31]    .             .     .       .
                  Erlotinib + antiangiogenesis:antiangiogenesis  1 0.16   0.75 [0.39;     1.45]   0.25 [0.05;   1.31]   0.92 [0.45;     1.88] 0.28 [0.05;  1.65] -1.41  0.1574
                            Gefitinib:Gefitinib/Erlotinib  0    0   1.67 [0.48;     5.72]      .              .   1.67 [0.48;     5.72]    .             .     .       .
                         Gefitinib:Gefitinib + chemotherapy  4 1.00   0.53 [0.22;     1.28]   0.53 [0.22;   1.28]      .                .    .             .     .       .
                         Gefitinib:Gefitinib + ER inhibitor  1 0.79   0.23 [0.10;     0.52]   0.29 [0.12;   0.72]   0.10 [0.02;     0.58] 2.95 [0.40; 21.74]  1.06  0.2891
                                     Gefitinib:Lazertinib  1 0.66   0.45 [0.24;     0.84]   0.40 [0.19;   0.87]   0.56 [0.19;     1.63] 0.72 [0.19;  2.66] -0.50  0.6172
                                    Gefitinib:Osimertinib  0    0   0.63 [0.32;     1.21]      .              .   0.63 [0.32;     1.21]    .             .     .       .
                       Gefitinib:Osimertinib + chemotherapy  0    0   0.31 [0.10;     0.95]      .              .   0.31 [0.10;     0.95]    .             .     .       .
                     Gefitinib:Osimertinib + antiangiogenesis  0    0   1.27 [0.20;     8.07]      .              .   1.27 [0.20;     8.07]    .             .     .       .
                                Gefitinib:PD-L1 inhibitor  0    0   0.92 [0.07;    12.46]      .              .   0.92 [0.07;    12.46]    .             .     .       .
                                        Gefitinib:Placebo  2 0.23   0.95 [0.50;     1.79]   1.82 [0.49;   6.78]   0.78 [0.38;     1.61] 2.34 [0.52; 10.49]  1.11  0.2683
                                    Gefitinib:Rociletinib  0    0   0.81 [0.05;    14.06]      .              .   0.81 [0.05;    14.06]    .             .     .       .
                                 Gefitinib:antiangiogenesis  0    0   0.48 [0.21;     1.10]      .              .   0.48 [0.21;     1.10]    .             .     .       .
               Gefitinib/Erlotinib:Gefitinib + chemotherapy  0    0   0.32 [0.07;     1.45]      .              .   0.32 [0.07;     1.45]    .             .     .       .
               Gefitinib/Erlotinib:Gefitinib + ER inhibitor  0    0   0.14 [0.03;     0.58]      .              .   0.14 [0.03;     0.58]    .             .     .       .
                           Gefitinib/Erlotinib:Lazertinib  0    0   0.27 [0.09;     0.85]      .              .   0.27 [0.09;     0.85]    .             .     .       .
                          Gefitinib/Erlotinib:Osimertinib  1 1.00   0.38 [0.13;     1.07]   0.38 [0.13;   1.07]      .                .    .             .     .       .
             Gefitinib/Erlotinib:Osimertinib + chemotherapy  0    0   0.18 [0.05;     0.74]      .              .   0.18 [0.05;     0.74]    .             .     .       .
           Gefitinib/Erlotinib:Osimertinib + antiangiogenesis  0    0   0.76 [0.10;     5.75]      .              .   0.76 [0.10;     5.75]    .             .     .       .
                      Gefitinib/Erlotinib:PD-L1 inhibitor  0    0   0.55 [0.04;     8.47]      .              .   0.55 [0.04;     8.47]    .             .     .       .
                              Gefitinib/Erlotinib:Placebo  0    0   0.57 [0.16;     2.01]      .              .   0.57 [0.16;     2.01]    .             .     .       .
                          Gefitinib/Erlotinib:Rociletinib  0    0   0.48 [0.02;    10.42]      .              .   0.48 [0.02;    10.42]    .             .     .       .
                       Gefitinib/Erlotinib:antiangiogenesis  0    0   0.29 [0.07;     1.15]      .              .   0.29 [0.07;     1.15]    .             .     .       .
            Gefitinib + chemotherapy:Gefitinib + ER inhibitor  0    0   0.43 [0.13;     1.43]      .              .   0.43 [0.13;     1.43]    .             .     .       .
                        Gefitinib + chemotherapy:Lazertinib  0    0   0.85 [0.29;     2.50]      .              .   0.85 [0.29;     2.50]    .             .     .       .
                       Gefitinib + chemotherapy:Osimertinib  0    0   1.18 [0.39;     3.53]      .              .   1.18 [0.39;     3.53]    .             .     .       .
          Gefitinib + chemotherapy:Osimertinib + chemotherapy  0    0   0.58 [0.14;     2.42]      .              .   0.58 [0.14;     2.42]    .             .     .       .
        Gefitinib + chemotherapy:Osimertinib + antiangiogenesis  0    0   2.39 [0.31;    18.51]      .              .   2.39 [0.31;    18.51]    .             .     .       .
                   Gefitinib + chemotherapy:PD-L1 inhibitor  0    0   1.73 [0.11;    27.10]      .              .   1.73 [0.11;    27.10]    .             .     .       .
                           Gefitinib + chemotherapy:Placebo  0    0   1.79 [0.60;     5.28]      .              .   1.79 [0.60;     5.28]    .             .     .       .
                       Gefitinib + chemotherapy:Rociletinib  0    0   1.52 [0.08;    30.21]      .              .   1.52 [0.08;    30.21]    .             .     .       .
                    Gefitinib + chemotherapy:antiangiogenesis  0    0   0.90 [0.27;     3.01]      .              .   0.90 [0.27;     3.01]    .             .     .       .
                        Gefitinib + ER inhibitor:Lazertinib  0    0   1.96 [0.73;     5.26]      .              .   1.96 [0.73;     5.26]    .             .     .       .
                       Gefitinib + ER inhibitor:Osimertinib  0    0   2.72 [1.01;     7.35]      .              .   2.72 [1.01;     7.35]    .             .     .       .
          Gefitinib + ER inhibitor:Osimertinib + chemotherapy  0    0   1.33 [0.34;     5.16]      .              .   1.33 [0.34;     5.16]    .             .     .       .
        Gefitinib + ER inhibitor:Osimertinib + antiangiogenesis  0    0   5.52 [0.75;    40.50]      .              .   5.52 [0.75;    40.50]    .             .     .       .
                   Gefitinib + ER inhibitor:PD-L1 inhibitor  0    0   3.99 [0.27;    60.12]      .              .   3.99 [0.27;    60.12]    .             .     .       .
                           Gefitinib + ER inhibitor:Placebo  0    0   4.12 [1.61;    10.55]      .              .   4.12 [1.61;    10.55]    .             .     .       .
                       Gefitinib + ER inhibitor:Rociletinib  0    0   3.51 [0.19;    65.65]      .              .   3.51 [0.19;    65.65]    .             .     .       .
                    Gefitinib + ER inhibitor:antiangiogenesis  0    0   2.07 [0.72;     5.93]      .              .   2.07 [0.72;     5.93]    .             .     .       .
                                   Lazertinib:Osimertinib  1 0.85   1.39 [0.87;     2.21]   1.32 [0.80;   2.19]   1.85 [0.55;     6.21] 0.72 [0.19;  2.66] -0.50  0.6172
                      Lazertinib:Osimertinib + chemotherapy  0    0   0.68 [0.24;     1.91]      .              .   0.68 [0.24;     1.91]    .             .     .       .
                    Lazertinib:Osimertinib + antiangiogenesis  0    0   2.81 [0.47;    16.85]      .              .   2.81 [0.47;    16.85]    .             .     .       .
                               Lazertinib:PD-L1 inhibitor  0    0   2.04 [0.16;    26.50]      .              .   2.04 [0.16;    26.50]    .             .     .       .
                                       Lazertinib:Placebo  0    0   2.10 [1.00;     4.42]      .              .   2.10 [1.00;     4.42]    .             .     .       .
                                   Lazertinib:Rociletinib  0    0   1.79 [0.10;    32.23]      .              .   1.79 [0.10;    32.23]    .             .     .       .
                                Lazertinib:antiangiogenesis  0    0   1.06 [0.41;     2.71]      .              .   1.06 [0.41;     2.71]    .             .     .       .
                     Osimertinib:Osimertinib + chemotherapy  1 1.00   0.49 [0.19;     1.23]   0.49 [0.19;   1.23]      .                .    .             .     .       .
                   Osimertinib:Osimertinib + antiangiogenesis  1 1.00   2.03 [0.36;    11.41]   2.03 [0.36;  11.41]      .                .    .             .     .       .
                              Osimertinib:PD-L1 inhibitor  1 1.00   1.47 [0.12;    18.29]   1.47 [0.12;  18.29]      .                .    .             .     .       .
                                      Osimertinib:Placebo  2 0.42   1.51 [0.75;     3.05]   1.79 [0.61;   5.28]   1.34 [0.53;     3.37] 1.34 [0.32;  5.53]  0.40  0.6901
                                  Osimertinib:Rociletinib  0    0   1.29 [0.07;    23.05]      .              .   1.29 [0.07;    23.05]    .             .     .       .
                               Osimertinib:antiangiogenesis  0    0   0.76 [0.30;     1.91]      .              .   0.76 [0.30;     1.91]    .             .     .       .
      Osimertinib + chemotherapy:Osimertinib + antiangiogenesis  0    0   4.15 [0.58;    29.42]      .              .   4.15 [0.58;    29.42]    .             .     .       .
                 Osimertinib + chemotherapy:PD-L1 inhibitor  0    0   3.00 [0.20;    44.07]      .              .   3.00 [0.20;    44.07]    .             .     .       .
                         Osimertinib + chemotherapy:Placebo  0    0   3.10 [0.97;     9.87]      .              .   3.10 [0.97;     9.87]    .             .     .       .
                     Osimertinib + chemotherapy:Rociletinib  0    0   2.63 [0.13;    54.47]      .              .   2.63 [0.13;    54.47]    .             .     .       .
                  Osimertinib + chemotherapy:antiangiogenesis  0    0   1.56 [0.42;     5.73]      .              .   1.56 [0.42;     5.73]    .             .     .       .
               Osimertinib + antiangiogenesis:PD-L1 inhibitor  0    0   0.72 [0.03;    15.40]      .              .   0.72 [0.03;    15.40]    .             .     .       .
                       Osimertinib + antiangiogenesis:Placebo  0    0   0.75 [0.12;     4.82]      .              .   0.75 [0.12;     4.82]    .             .     .       .
                   Osimertinib + antiangiogenesis:Rociletinib  0    0   0.64 [0.02;    18.34]      .              .   0.64 [0.02;    18.34]    .             .     .       .
                Osimertinib + antiangiogenesis:antiangiogenesis  0    0   0.38 [0.05;     2.66]      .              .   0.38 [0.05;     2.66]    .             .     .       .
                                  PD-L1 inhibitor:Placebo  0    0   1.03 [0.08;    14.17]      .              .   1.03 [0.08;    14.17]    .             .     .       .
                              PD-L1 inhibitor:Rociletinib  0    0   0.88 [0.02;    40.55]      .              .   0.88 [0.02;    40.55]    .             .     .       .
                           PD-L1 inhibitor:antiangiogenesis  0    0   0.52 [0.04;     7.61]      .              .   0.52 [0.04;     7.61]    .             .     .       .
                                      Rociletinib:Placebo  0    0   1.18 [0.07;    20.23]      .              .   1.18 [0.07;    20.23]    .             .     .       .
                                   antiangiogenesis:Placebo  0    0   1.99 [0.91;     4.36]      .              .   1.99 [0.91;     4.36]    .             .     .       .
                               Rociletinib:antiangiogenesis  0    0   0.59 [0.03;    10.36]      .              .   0.59 [0.03;    10.36]    .             .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
